Pharmacopedia - User contributions [en]

About:Pharmacopedia.ext

2026-05-28T02:45:58Z

MDElliottMD: 0.9.8.7 close-out: star hold-to-expand model, editor enhancements module, vote removal (boss-claude)

'''Version:''' 0.9.8.7 · '''Requires:''' MediaWiki >= 1.46.0 · PHP >= 8.5
'''Author:''' MDElliottMD · '''License:''' GPL-2.0-or-later
'''Source:''' <code>/var/www/mediawiki/extensions/Pharmacopedia/</code>

The Pharmacopedia extension turns a MediaWiki install into a structured, community-edited medicine reference with rich user-profile, assessment, life-story, and visibility-sharing infrastructure. It adds parser tags, special pages, API modules, two dark skins, a chip-picker / autosave UI framework, a vis-timeline-based visual life timeline, a granular per-record sharing subsystem, an observer-perspective subsystem, a token-gated subsystem for administering assessments to people outside the wiki, a two-origin diptych front-of-house, and a database schema that together support:

* Structured medicine pages via the <code><nowiki>{{MedTemplate}}</nowiki></code> template
* Per-user rating on effects, problems, titration strategies, anecdotes, and drug-drug interactions (continuous 0–100 sliders, ±100 valence; no 0–5 likert anywhere); ratings use a hold-to-expand star widget (300 ms press, spring animation, drag-commit with pixel-travel + value-delta guards); voters can remove their own committed rating
* Binary AND choice/multi voting on arbitrary content (<code>type="single"</code> / <code>type="multi"</code> with 2-5 options, results-visibility policy per element)
* Two-perspective data capture (personal vs. provider) wherever clinically meaningful
* User profile with dimensional personality / autism assessments (CATI, CAT-Q, MBTI, Enneagram, PID-5-BF, OCEAN/BFI-10) and rich auto-generated reports
* Further self-report instruments (BPNS, NFCS, OCI-PCP, WHOQOL-BREF) and the HYD-PCP wellbeing check-in, on the same auto-scored, report-bearing pattern
* ADHD screening (ASRS and AMAAS-SR) plus a Formal testing log of standardized-test scores, every score field carrying its own visibility
* Diagnosis autocomplete backed by ~41,500 ICD-10-CM, ICD-11, and DSM-5 codes
* '''Life-story timeline''': visual swimlanes (vis-timeline 7.7.3, vendored Apache-2.0) plus a synchronized trait-trajectory overlay (vis.Graph2d); card-list view alongside; quick-add free-text observation parser; range-date episode form with severity slider
* '''Per-record sharing subsystem''': rule types include public, private, users, cohort, link_token, reciprocal; time-bounded; audit log of who-viewed-what; bulk free-text → structured ref upgrader; privacy mode that disables legacy fallback
* '''Observer perspectives''': token-gated, no-account second-party input on something a user owns, under a two-gate consent model
* '''Administer to others''': send any registered assessment scale to people outside the wiki by one-time link, collect their results, and follow them over time, under per-owner public-key encryption with an optional zero-knowledge passphrase mode
* '''Two-origin diptych''': the Main Page and Category index render as chromeless full-viewport splashes giving the pharmaceutical and plant origins equal face
* Chip-picker / autosave / slider-precise-input UI framework shared across editor surfaces
* Date + time + range kit: PCPDatePicker (point/range/possibility), PCPTimePicker (fuzzy time-only: "4p", "noon", "quarter past 6")
* Verified-provider role with document-based verification
* Fail-closed ClamAV scan on every image / file upload (hard project rule)
* Per-user '''research_id''' (stable 10-char hex, opaque, never reassigned) for de-identified research participation

== Precision doctrine ==

A standing design rule (memorialised 2026-05-17) that shapes every storage / UI decision in the extension:

* '''No bucketing where a number or free-text will do.''' Income is numeric + currency, not a 5-band dropdown. Education keeps the bucketed dropdown ''and'' adds numeric years of schooling + free-text field of study.
* '''No single-select where multi-select reflects reality.''' Languages, gender identities, ethnicities, pronouns, religion, marital status, stop-reasons, all use chip-pickers (with optional severity per chip where relevant).
* '''No forced category where a continuous score works.''' All assessments (Enneagram 9 type sliders, MBTI 4 dichotomy sliders, OCEAN 5 trait sliders, CATI/CAT-Q/PID-5-BF items) use continuous 0–100 sliders, never radio buttons or button rows. Valence is ±100, not ±3.
* '''Storage in canonical form, UI converts at display.''' Heights stored cm regardless of user's preferred unit (cm or ft+in); ICD codes stored as ISO; date capture as range / possibility-mix JSON.
* '''Browser auto-fill as suggestion only.''' Country chip pre-fills from <code>navigator.language</code>; languages from <code>navigator.languages</code>; time zone from <code>Intl.DateTimeFormat().resolvedOptions().timeZone</code>. User can always edit or remove.
* '''Always allow custom free-text where the curated list might miss someone.''' Chip-pickers accept Enter-to-add custom chips for all picklists except ISO-coded ones (country, language).

== High-level architecture ==

* '''Backend (PHP):''' <code>includes/</code>, one class per parser tag, store, special page, or API module. Auto-loaded under <code>MediaWiki\Extension\Pharmacopedia\</code>. Assessment classes under <code>includes/Assessments/</code>. API modules under <code>includes/Api/</code>.
* '''Frontend (JS / CSS):''' multiple ResourceModules per surface area:
** <code>ext.pharmacopedia</code>: main IIFE (chip-picker, dx autocomplete, BFI-10 compute, vote logic for both binary and choice/multi, hold-to-expand star rating model with spring animation and drag-commit, vote removal)
** <code>ext.pharmacopedia.styles</code>: base extension stylesheet (self-hosted Geist / Newsreader / Source Serif fonts, core component styling)
** <code>ext.pharmacopedia.blocksave</code>: debounced autosave per block (race-safe)
** <code>ext.pharmacopedia.bounceback</code>: preserves the reader's scroll position across POST-then-reload actions via sessionStorage
** <code>ext.pharmacopedia.confirmdelete</code>: styled red warning prompt replacing <code>window.confirm()</code> on destructive actions
** <code>ext.pharmacopedia.datepicker</code> + <code>.datepicker.styles</code>: range / possibility-mix date widget
** <code>ext.pharmacopedia.timepicker</code> + <code>.timepicker.styles</code>: time-only widget (fuzzy parsing, extracted from DatePicker)
** <code>ext.pharmacopedia.share</code>: per-record share dialog (People / Link / Cohorts tabs)
** <code>ext.pharmacopedia.perspective</code>: observer-perspective form enhancement (slider readout, progress, consent/delete confirm)
** <code>ext.pharmacopedia.administer</code>: the administer-to-others surfaces (take-flow slider readout + "Not sure" toggling, owner-hub styling)
** <code>ext.pharmacopedia.editor</code>: editor enhancements loaded on <code>action=edit/submit</code>; smart paste converts bare PMID or DOI from the clipboard into a formatted <code><ref></code> tag (PubMed eutils / CrossRef); house-rules linter flags banned terms and em-dashes on submit with a dismissable warning; quick-ref stub (Ctrl+Alt+R) inserts a journal-article <code><ref></code> skeleton
** <code>ext.pharmacopedia.observation</code>: quick-add observation textarea + live preview
** <code>ext.pharmacopedia.refupgrade</code>: bulk linker for free-text → structured refs
** <code>ext.pharmacopedia.vis-timeline-vendor</code>: vis-timeline 7.7.3 (vendored)
** <code>ext.pharmacopedia.lifetimeline</code>: visual life-story timeline + swimlanes + toolbar
** <code>ext.pharmacopedia.lifegraph</code>: trait-trajectory overlay (vis.Graph2d) synced to timeline
** <code>ext.pharmacopedia.kitsync</code>: glue that propagates kit-widget changes into legacy hidden inputs + drives privacy-mode toggle
** <code>ext.pharmacopedia.frontpage</code> / <code>ext.pharmacopedia.categoryindex</code>: the two diptych splash modules, each self-contained so it renders with no skin loaded
** <code>ext.pharmacopedia.appearance</code>: the collapsible Appearance rail (reader text-size control)
** <code>ext.pharmacopedia.skin.plants</code> / <code>ext.pharmacopedia.skin.fungi</code>: the earth-toned plants-skin overlay and the fungi sub-skin override layer
* '''Schema:''' <code>sql/</code>, roughly three dozen core tables plus migration patches. Picked up via the <code>LoadExtensionSchemaUpdates</code> hook.

== Security & encryption ==

Pharmacopedia stores deliberately personal data, including self-reports across mood, addiction, sexuality, and clinical history. The cryptographic + operational posture below is documented in detail so that a security researcher can read it in one pass and know exactly what is on the ground. Values are quoted verbatim where they are already observable from the public surface (HTTP headers, TLS handshake, public APIs); secrets and rotation policy are described without disclosing their values.

=== Transport ===

TLS terminates at Apache 2 (mod_ssl) on the same host as the application. No CDN, no reverse proxy, no load balancer is in front. Certificate is a Let's Encrypt ECDSA leaf, renewed by <code>certbot.timer</code> (fires twice daily, renews when within 30 days of expiry). Private key on disk is mode 600 root:root in <code>/etc/letsencrypt/archive/pharmacopedia.wiki/</code>.

Apache TLS config (live from <code>/etc/letsencrypt/options-ssl-apache.conf</code> + <code>/etc/apache2/mods-enabled/ssl.conf</code>):

SSLProtocol all -SSLv3
SSLCipherSuite HIGH:!aNULL
SSLSessionTickets off

Effective TLS range: TLS 1.0 through 1.3 (SSLv3 explicitly refused). The cipher suite shorthand <code>HIGH:!aNULL</code> covers all ECDHE + DHE forward-secrecy ciphers but does not exclude TLSv1.0 or TLSv1.1 at the protocol layer. Hardening to an explicit modern list and <code>SSLProtocol -TLSv1 -TLSv1.1</code> is queued; see ''Honest limitations'' below. <code>SSLSessionTickets off</code> preserves forward secrecy across server restarts.

HSTS:

Strict-Transport-Security: max-age=63072000; includeSubDomains; preload

Two years, subdomains included, preload-ready. The <code>preload</code> directive is present in the header; submission to the Chromium HSTS preload list is pending.

=== HTTP security headers ===

Set at the Apache layer (<code>/etc/apache2/conf-enabled/security-headers.conf</code>), not relying on PHP:

Content-Security-Policy: default-src 'self'; script-src 'self' 'unsafe-inline' 'unsafe-eval' https://challenges.cloudflare.com; style-src 'self' 'unsafe-inline'; img-src 'self' data: blob: https:; media-src 'self' blob:; font-src 'self' data:; object-src 'none'; frame-src 'self' https://challenges.cloudflare.com; worker-src blob:; base-uri 'self'; form-action 'self';
Strict-Transport-Security: max-age=63072000; includeSubDomains; preload
Referrer-Policy: strict-origin-when-cross-origin
X-Frame-Options: SAMEORIGIN
Permissions-Policy: geolocation=(), camera=(self), microphone=(), payment=()
X-Content-Type-Options: nosniff (set by MediaWiki)

<code>'unsafe-inline'</code> + <code>'unsafe-eval'</code> are required by MediaWiki's JS/CSS pipeline; <code>challenges.cloudflare.com</code> is whitelisted only for the Cloudflare Turnstile widget. <code>object-src 'none'</code> blocks Flash/applet vectors; <code>base-uri 'self'</code> blocks base-tag hijack; <code>form-action 'self'</code> blocks off-origin form POST. No COOP / COEP / CORP set: MW does not need cross-origin isolation.

=== Apache file filters + URL redaction ===

A backup-pattern denylist applies under the document root:

<FilesMatch "\.pre-|\.bak|\.orig|\.php\.|~$">
Require all denied
</FilesMatch>

This closes editor swap files, ad-hoc <code>.pre-<feature></code> snapshots, <code>.orig</code> merge debris, and emacs / vim trailing-tilde backups (a source-disclosure path closed 2026-05-20).

Skin asset directories run a positive allowlist (default-deny, only the whitelisted suffixes are served):

<FilesMatch "(?i)^(?!.*\.(php|js|mjs|css|json|png|gif|jpe?g|svg|ico|webp|woff2?|ttf|eot|otf|html?|map|pdf)$)">
Require all denied
</FilesMatch>

The web installer at <code>/mw-config/</code> is 403'd at the vhost layer regardless of any <code>$wgUpgradeKey</code> value.

Token-bearing URLs are redacted from access logs by <code>/etc/apache2/conf-enabled/pcp-log-redaction.conf</code>. Pharmacopedia issues two URL families that carry per-request secrets in the path: <code>Special:RespondToAssessment/<token></code> (the invite token derives the AES key for the respondent-readable AdminCrypto copy) and <code>Special:Perspective/<token></code>. The redaction rule rewrites the request URI in the access log to a literal "[pcp: token-bearing URL redacted]" while preserving IP, time, method, status, byte count, and User-Agent. Three match-paths (request URL, Referer, query string) cover navigation, subresource, and <code>?title=</code> invocations.

=== PHP-FPM hardening ===

Production pool <code>/etc/php/8.5/fpm/pool.d/mediawiki-prod.conf</code> runs as <code>www-data</code> on an UDS socket (<code>0660 www-data:www-data</code>), <code>pm = ondemand</code>, <code>pm.max_children = 16</code>, <code>pm.max_requests = 500</code> (workers cycle every 500 requests to recover memory). Per-pool <code>open_basedir</code> restricts filesystem access to the small set of directories the wiki actually needs:

/var/www/mediawiki, /tmp, /var/log/mediawiki, /var/lib/php,
/var/cache/mediawiki, /var/lib/pharmacopedia-verification,
/var/lib/pharmacopedia-literature, /var/lib/pharmacopedia-life,
/usr/bin, /dev/null, /dev/urandom,
/var/lib/pharmacopedia-feature-requests,
/var/lib/pharmacopedia-adminkeys, /var/lib/mwoauth2

A workspace outside this list is unreadable from PHP regardless of file mode.

ini hardening: <code>expose_php = Off</code>, <code>display_errors = Off</code> (errors go to log only), <code>allow_url_include = Off</code> (remote-PHP include attack vector closed; <code>allow_url_fopen = On</code> stays because MW needs upload-from-URL). Session cookies: <code>secure = 1</code>, <code>httponly = 1</code>, <code>samesite = "Lax"</code>, <code>use_strict_mode = 1</code>, <code>use_only_cookies = 1</code>, session-end lifetime, 24-minute idle gc. opcache enabled with <code>validate_timestamps = 1</code> + 2-second revalidate (no stale-code-after-deploy risk).

=== Database ===

MariaDB 10.11.14, <code>bind-address = 127.0.0.1</code> only (the loopback). DB ports are not exposed to the network; UFW does not need a rule because the bind never reaches the wire. <code>sql_mode</code> includes <code>STRICT_TRANS_TABLES</code> + <code>ERROR_FOR_DIVISION_BY_ZERO</code> (strict type + math behavior). <code>have_ssl = DISABLED</code> is deliberate (loopback-only connections do not benefit from TLS overhead). The wiki's DB account is scoped to the two MW schemas (<code>mediawiki</code>, <code>mediawiki_staging</code>); no <code>FILE</code>, no <code>SUPER</code>, no <code>GRANT OPTION</code>. A DB compromise via injection is bounded to those two schemas.

=== SSH + host ===

<code>sshd</code> is key-only (<code>PasswordAuthentication no</code>, <code>KbdInteractiveAuthentication no</code>, <code>PermitEmptyPasswords no</code>), <code>PermitRootLogin prohibit-password</code> (root accessible only with an authorized key), <code>MaxAuthTries 6</code>, X11 forwarding off. Modern key exchange algorithms preferred (sntrup761x25519, curve25519); legacy SHA1 MACs left in the list for client compatibility.

UFW is deny-by-default for incoming traffic, allow-all outgoing. The only open ingress ports are 22/tcp, 80/tcp, and 443/tcp. The database, the SMTP relay, and the application cache are all loopback-only.

fail2ban runs five jails: <code>sshd</code>, <code>apache-auth</code>, <code>apache-badbots</code>, <code>mediawiki-auth</code> (matches failed wiki logins by spotting <code>200</code> responses on POSTs to <code>Special:UserLogin</code> / <code>Special:CreateAccount</code> — successful logins redirect <code>302</code>), and <code>web-scanners</code> (matches the usual probe patterns).

=== Secrets and keys on disk ===

The high-trust paths and their modes (no values published):

/var/www/mediawiki/LocalSettings.php 640 root:www-data
contains: $wgSecretKey, $wgUpgradeKey, $wgDBpassword,
$wgTurnstileSecretKey, $wgSMTP['password'],
$wgPharmacopediaVoteHashSecret,
$wgOAuth2{Private,Public}Key paths
/root/.backup-passphrase 600 root:root (64 bytes random)
/var/lib/mwoauth2/oauth-private.key 600 www-data:www-data (RSA-4096)
/var/lib/mwoauth2/oauth-public.key 644 www-data:www-data
/var/lib/pharmacopedia-adminkeys/ 700 www-data:www-data
master.key (lazy-provisioned on first Mode B owner) 600 www-data:www-data
/etc/exim4/passwd.client 640 root:Debian-exim
/etc/letsencrypt/archive/.../privkey1.pem 600 root:root
/root/.config/rclone/rclone.conf 600 root:root

Public values that are safe to read:
* Cloudflare Turnstile site key: <code>0x4AAAAAADMu_bvOguDp0U52</code>
* Backup target: <code>dropbox:pharmacopedia-backups</code> (Dropbox holds only AES-256-encrypted bundles; the passphrase never leaves the host)

Rotation policy:
* <code>$wgSecretKey</code> is NOT rotated (would invalidate every session and signed-state cookie).
* <code>$wgUpgradeKey</code> rotated 2026-05-22 to 256 bits.
* <code>$wgPharmacopediaVoteHashSecret</code> is intentionally never rotated (rotation invalidates every voter-state mapping, retroactively breaking voter anonymity for existing votes).
* TLS private key rotates on Let's Encrypt renewal (automatic, twice-daily check).
* AdminCrypto Mode B master key + OAuth2 RSA keypair are NOT rotated today; rotation would invalidate existing wrappings + outstanding tokens. Future rotation is overlap-aware (re-wrap under new key, accept either during the cutover window).

=== Application-layer cryptography ===

==== Passwords and second factor ====

MediaWiki passwords are stored as PBKDF2 hashes (MW core default). Verified across every <code>user_password</code> row: HMAC-SHA-512 inner hash, 30,000 iterations, 64-byte derived key, 16-byte random salt per user. The <code>$wgPasswordConfig</code> default is unmodified; bcrypt is available in MW core but not enabled.

Two-factor authentication via the OATHAuth extension. Default module is TOTP per RFC 6238: HMAC-SHA-1 inner, 6 digits, 30-second time-step, 80-bit shared secret. Five recovery codes per user, each a random string, hashed at rest, consumed on use. WebAuthn / FIDO2 (passkey) is available in the same extension and is the operator's first-choice path.

==== AdminCrypto ====

The "Administer to others" subsystem uses a per-owner asymmetric envelope so that respondents can submit results without an account and the owner can decrypt while absent. Implementation (<code>extensions/Pharmacopedia/includes/Assessments/AdminCrypto.php</code>):

Per-owner X25519 keypair generated via <code>sodium_crypto_box_keypair()</code> (libsodium, kernel CSPRNG). The public key is stored in the clear; the secret key is wrapped at rest in <code>pcp_administer_userkey.uk_wrapped_seckey</code> with AES-256-GCM (12-byte fresh IV per call, 16-byte authentication tag, empty AAD; wrapped layout: <code>IV || ciphertext || tag</code>).

Respondent submissions are sealed to the owner's public key via <code>crypto_box_seal</code> (libsodium, anonymous X25519 sender): anyone can encrypt with the public key; only the owner can decrypt with the secret key.

Two key-custody modes:

* '''Mode A (passphrase, zero-knowledge).''' The wrap key for the owner's X25519 secret key derives from a passphrase the server never stores, via Argon2id (libsodium <code>sodium_crypto_pwhash</code> with <code>ARGON2ID13</code>). Two version tracks: v1 uses INTERACTIVE limits (2 ops, 64 MiB memory); v2 uses MODERATE limits (3 ops, 256 MiB memory). The 16-byte salt is stored in <code>uk_kdf_salt</code>; the derivation produces a 32-byte wrap key and a 32-byte verifier (domain-separated SHA-256 of the wrap key). Older-version owners are transparently re-wrapped to the current KDF version on their next successful unlock. ''In Mode A, a database leak alone yields nothing the attacker can decrypt without the owner's passphrase, by design.''
* '''Mode B (managed key).''' The wrap key is a 32-byte random AES-256-GCM key in <code>/var/lib/pharmacopedia-adminkeys/master.key</code> (mode 600 <code>www-data:www-data</code>), lazy-provisioned on first Mode B owner setup. The directory is excluded from the backup tar by path; a database-plus-backup leak does not yield decryption power, because the master key never enters the backup pipeline.

A separate respondent-readable copy of each submission is encrypted with a key derived from the invite token: <code>respondentKey = SHA-256("pcp-administer-respondent-v1:" || rawToken)</code>. The server never stores this key; the rawToken lives only in the URL handed to the respondent. The token-bearing URL is redacted from access logs (see ''Apache file filters'' above).

==== OAuth 2.0 (iOS app) ====

The iOS app authenticates against the wiki via the MWOAuth extension. RSA-4096 signing keypair generated 2026-05-22 with <code>openssl genrsa</code>; JWT signing algorithm RS256. Access tokens live 1 hour; refresh tokens 1 month (MWOAuth defaults). PKCE with S256 challenge is REQUIRED for public clients (<code>$wgOAuth2RequireCodeChallengeForPublicClients = true</code>); the iOS bundle never holds a client secret. Tokens are stored at rest in the wiki's session cache keyed by hashed token (the tokens themselves are opaque to the cache row). The browser-to-app handoff goes via a small HTML+JS bridge at <code>https://pharmacopedia.wiki/app/oauth-callback</code> that forwards the authorization code + state to the <code>pharmacopedia://oauth</code> custom URL scheme. Special:UserLogin and Special:CreateAccount also carry <code>autocomplete</code> field attributes (<code>username</code>, <code>current-password</code> / <code>new-password</code>, <code>email</code>) injected by the <code>AuthChangeFormFields</code> hook so iOS Safari + system password managers offer the right credentials on the right field.

==== Voter anonymity ====

Every vote stores a HMAC-SHA-256 of the voter's user id, salted with <code>$wgPharmacopediaVoteHashSecret</code> (256 bits, never rotated by policy). The hash is a 64-character hex string in <code>pcp_votes</code> in place of the user id, so an administrator reading the votes table cannot map a vote back to an identity without the secret. The secret lives only in LocalSettings.

==== Perspective-invite tokens ====

The perspective subsystem's invite tokens are 24-byte URL-safe random strings handed to invitees in <code>Special:Perspective/<token></code> links. As of 0.9.8.7, every new invite stores BOTH the cleartext token in <code>pcp_perspective_invite.pvi_token</code> AND a SHA-256 hash of the same token in a new <code>pvi_token_hash</code> column (<code>BINARY(32)</code>, <code>UNIQUE</code>). Lookup at <code>PerspectiveStore::resolveToken</code> hashes the inbound URL token and searches by hash first; a cleartext-column fallback covers any row not yet backfilled at deploy edge. Hashing reuses the canonical <code>AdminCrypto::hashInviteToken</code> helper (raw 32-byte SHA-256), the same shape as the existing <code>pcp_administer_invites.inv_token_hash</code> pattern.

Honest current status: this is half-shipped on purpose. The cleartext <code>pvi_token</code> column is still present so the lookup-fallback works during the dual-write cycle; 0.9.8.8 drops the cleartext column and the fallback branch, at which point a database-read attacker can no longer extract usable perspective-invite tokens.

=== Backups ===

<code>/usr/local/bin/pharmacopedia-backup.sh</code> runs daily at 03:15 local. Every artifact is GPG-symmetric encrypted with AES-256 before it touches the off-host stage:

gpg --batch --yes --symmetric --cipher-algo AES256
--passphrase-file /root/.backup-passphrase

GPG packet inspection on a current bundle confirms cipher 9 (AES256), S2K mode 3 (iterated and salted), S2K count 65,011,712 iterations, MDC method 2 (modification-detection code present). Local retention is 7 days; off-host (Dropbox via rclone) is 14 days as of 2026-05-23 (was 60). The passphrase file is 64 bytes random, mode 600 root:root, never transmitted off-host.

The 14-day window describes ACTIVE off-host storage: after 14 days the encrypted bundle is removed from the active view of the off-host provider by the nightly rotation. The current off-host provider (Dropbox Pro) additionally retains deleted files in a deletion-recovery layer for up to 180 days, during which the encrypted bundle may remain recoverable by the account operator; after that window the bundle is permanently and irrecoverably deleted. The bundle is GPG-AES256 encrypted at all times; the off-host provider cannot read it under any circumstance. This active-vs-recovery distinction is queued for removal once a B-side backend migration (Hetzner Storage Box BX11, SFTP, POSIX unlink, no recovery layer) ships; tracked in ''Honest limitations'' below.

The backup tar covers <code>/var/www/mediawiki/images</code>, <code>LocalSettings.php</code>, the Pharmacopedia extension, and local skin assets. The full <code>mediawiki</code> schema is dumped separately to a sibling SQL file (also encrypted). Deliberately excluded by path: the AdminCrypto master key, the OAuth2 RSA private key, the backup passphrase itself, the Gmail SMTP credential, and the Let's Encrypt private key. ''A leak of any single backup bundle does not yield Mode B decryption power, JWT signing power, or further off-host backup decryption — those keys live elsewhere on the host and are not in the bundle.''

=== Logging + audit ===

Apache access/error logs and the MediaWiki exception / error / dberror / fatal logs all rotate daily and retain 14 days, then delete. Log files are <code>640 root:adm</code> (Apache) and <code>640 www-data:adm</code> (MW); the world-readable mode that existed prior to 2026-05-22 was tightened in the same audit pass that hardened the rest of the host.

MW exception logs live at <code>/var/log/mediawiki/{exception,error,dberror,fatal}.log</code>. The <code>pcp_visibility_view_log</code> table records every permitted view through a share rule (rule type, viewer, timestamp); the table stores raw IP for anonymous viewers (no /24 mask today — a feature gap, not a privacy claim).

=== Abuse protection ===

* Cloudflare Turnstile gates account creation, repeated failed logins, URL-bearing edits, and email-sending. Editors are not challenged on normal edits (a deliberate friction trade-off).
* The AbuseFilter extension is loaded with 2 rules, both enabled as of 0.9.8.7. Rule 1: spam-keyword block (block + disallow). Rule 2: new-account edit throttle (throttle). The active rule set is small; the lane will grow as live-fire patterns emerge.
* Every file or image upload is scanned by ClamAV before the file moves into the persistent store. The scanner is run via <code>clamdscan</code> (persistent daemon, fast) with a fallback to <code>clamscan</code>. The gate is fail-closed: exit 0 = clean (proceed), exit 1 = infected (reject + unlink), any other exit = error (reject + unlink). A scanner crash never becomes a pass.
* fail2ban (see ''SSH + host'' above) bans abusive IPs at the network layer.
* No CDN or DDoS mitigation layer sits in front; a determined volumetric attacker can degrade availability. We do not claim 24/7 uptime.

=== Honest limitations ===

The posture above is reasonable for a single-operator project that handles personal data; it is not pretending to be anything else.

* '''Single point of failure.''' Host-root compromise yields AdminCrypto Mode B decryption, OAuth2 JWT signing, backup decryption (via the passphrase file), and outbound email impersonation. Defense-in-depth lives in per-key file separation + filesystem perms + open_basedir, but a root-on-host attacker who clears each gate gets everything.
* '''Backup-lag on deletion.''' When a user requests deletion, the live row is purged immediately; the encrypted bundle is removed from active off-host storage after 14 days; the off-host provider's deletion-recovery layer may keep the (still-encrypted) bundle recoverable by the account operator for up to 180 days after that, until it is permanently deleted. Disclosed in About:Privacy on the wiki and (with identical wording) in Oyami's PRIVACY.md. Queued: a backend migration to Hetzner Storage Box (POSIX unlink, no recovery layer) collapses the window to a clean 14 days.
* '''No CDN, no DDoS layer.''' One VM, three open ports, UFW + fail2ban. Hostile traffic can take the site down; it cannot exfiltrate.
* '''Some application-layer key rotation is "never" by design.''' The voter-hash secret and the AdminCrypto Mode B master key cannot rotate without breaking either anonymity or existing wrappings respectively. Loss of either key has the obvious one-time consequence; trading that off against the alternative (re-encrypt every historical record) was the deliberate choice.
* '''TLS allows TLSv1.0 and TLSv1.1.''' The live Apache literal is <code>SSLProtocol all -SSLv3</code>, which does not exclude older TLS protocol versions at the protocol layer. Hardening to an explicit modern cipher list with <code>SSLProtocol -TLSv1 -TLSv1.1</code> is queued.
* '''Perspective-invite tokens are half-migrated to hashed storage.''' 0.9.8.7 added the <code>pvi_token_hash</code> column, backfilled it, and switched the lookup to hash-first; the cleartext <code>pvi_token</code> column is still present so the dual-write fallback works during the deploy edge. 0.9.8.8 drops the cleartext column and the fallback branch, at which point a database-read attacker can no longer extract usable invite tokens. Severity in the interim: an attacker with DB read can still submit a perspective under a planted invite identity; not access to medical data.

=== Security researchers welcome ===

I'm a long-term privacy hobbyist, but new at building real infrastructure. I'm trying my best and honestly it seems world-class good to me (and claude), but if it's not. I need to know ASAP.

If you find anything worth flagging — vulnerability, weakness, design concern, or just an observation — email [mailto:info@pharmacopedia.wiki me] directly. No bug-bounty program; just genuine appreciation for the time and the love of [https://markelliottmd.com/pubkey.asc pretty darn good privacy]. No NDA, no scope restriction, no preferred-disclosure-window. Reach out for any reason.

== Skins, layout, and the Appearance rail ==

'''Two skins.''' Every page renders in one of two dark skins. The default '''pharmaceutical skin''' is the violet-on-near-black clinical identity. The '''plants skin''' is an earth-toned treatment (<code>ext.pharmacopedia.skin.plants</code>) applied to plant-origin medicine pages. Both skins are dark; there is no light mode. The '''fungi sub-skin''' (<code>ext.pharmacopedia.skin.fungi</code>) is a specialization of the plants skin for fungal medicine pages: a fungus page carries both the <code>pcp-skin-plants</code> and <code>pcp-skin-fungi</code> body classes, loading the plants base plus a fungi override layer (a damp cool-dark palette, a spore-dust grain, the mushroom mark, fungi section-marker hues); everything else inherits from the plants skin.

<code>Hooks::resolvePcpSkin</code> picks the skin. A content (medicine) page is read by its OWN DIRECT origin category: a direct <code>Category:Fungi</code> tag gives the fungi sub-skin (checked first), a direct <code>Category:Plants</code> tag gives the plants skin, anything else pharma. There is no recursive category walk, so a page sitting inside a dual-parented class category (Category:Psychedelics parents under both origins) is skinned by its own origin tag, not by its class. A category page has no single direct origin, so it is resolved by walking its category chain (plants only when the chain is purely plant).

'''Full-width layout.''' The content frame runs edge to edge rather than in a fixed-width column; prose is held to a readable measure by its own constraint, and the layout gutters are set by layout tokens.

'''The Appearance rail.''' A collapsible rail (<code>ext.pharmacopedia.appearance</code>) gives the reader appearance controls, currently a text-size control. The chromeless diptych splashes suppress the rail.

== Front-of-house: the diptych ==

The Main Page and the Category index are built as a '''two-origin diptych''': a pharmaceutical column and a plant column side by side, the two origins of the materia medica given equal face. Both render as '''chromeless full-viewport splashes'''. A <code>body.pcp-diptych-page</code> class, added by the <code>BeforePageDisplay</code> hook on those two pages, hides all Vector chrome, and the module supplies its own topbar and footer. A full-height two-origin split gradient runs the page edge to edge, the pharma dark on the left half and the plant dark on the right, a 1px seam down the middle, so the diptych reads top to bottom with no separate bands.

Two parser tags generate the diptych from live wiki data:
* <code><frontpage></code> (<code>FrontPageTag</code>), the Main Page: a featured medicine and featured plant medicine, class / Pharmako-volume browse lists, recently-updated lists, portal links, a status strip.
* <code><categoryindex></code> (<code>CategoryIndexTag</code>), the Category index: the pharmacological classes and the plant lineages as two side-by-side trees.

<code>DiptychChrome</code> supplies the shared topbar and footer for both. The modules are <code>ext.pharmacopedia.frontpage</code> and <code>ext.pharmacopedia.categoryindex</code>; each carries its own palette tokens so the splash renders correctly with no skin stylesheet loaded.

The topbar carries a '''live typeahead search''' as the leftmost item of the right-side topnav cluster. It debounces 180 ms, fetches up to 8 results per keystroke (min 2 chars), and renders an ARIA-combobox dropdown with arrow / Enter / Escape keyboard navigation. The fetch path is hybrid: <code>action=opensearch</code> first (fast prefix index across the eight content namespaces: main, Category, Enzyme, Receptor, Phenotype, USLegal, Problem, Effect), with a <code>action=query&list=search</code> fallback fired on zero hits so all-caps titles like LSD (which opensearch cannot case-insensitively prefix-match against a lowercase query) still resolve.

== Parser tags ==

Registered via <code>Hooks::onParserFirstCallInit</code>:

{| class="wikitable"
! Tag !! Purpose !! Class
|-
| <code><vote></code> || Binary up/down (default) OR choice/multi when <code>type="single"</code> or <code>type="multi"</code> + <code>options="A; B; C"</code> (2-5 options, semicolon-separated). Optional <code>results="live\|after-vote\|hidden"</code> for tally-visibility policy. || <code>VoteTag</code>
|-
| <code><effect></code> || Therapeutic or adverse effect; patient + provider perspectives; provider freq slider 0–100; shared valence slider ±100 || <code>EffectTag</code>
|-
| <code><discuss></code> || Threaded comment widget || <code>CommentTag</code>
|-
| <code><effectsummary></code> || Roll-up aggregate header || <code>EffectSummaryTag</code>
|-
| <code><titration></code> || Titration strategy card with up/down vote || <code>TitrationTag</code>
|-
| <code><anecdote></code> || Personal or provider story with up/down vote || <code>AnecdoteTag</code>
|-
| <code><problem></code> || A problem the medicine addresses; 0–100 efficacy likert slider + "don't know" toggle || <code>ProblemTag</code>
|-
| <code><pharmaInteractions/></code> || Self-closing; renders the Interactions section for the current page || <code>InteractionTag</code>
|-
| <code><pharmaExperience/></code> || Self-closing; renders the Experience report form (efficacy, burden, dose, route, schedule, stop-reasons) || <code>ExperienceTag</code>
|-
| <code><pharmaLiterature/></code> || Self-closing; per-medicine "Relevant literature" section: approved <code>pcp_literature</code> entries plus a collapsed submission form || <code>LiteratureTag</code>
|-
| <code><classGrid/></code> || A grid of medicine-class categories (those tagged Category:MedCategory); <code>count</code> + <code>exclude</code> attributes; 5-minute cache || <code>ClassGridTag</code>
|-
| <code><classTree/></code> || The MedCategory classes as a hierarchy with member counts; <code>exclude</code> attribute; 5-minute cache || <code>ClassTreeTag</code>
|-
| <code><frontpage/></code> || The two-origin diptych Main Page (see [[#Front-of-house: the diptych|Front-of-house]]) || <code>FrontPageTag</code>
|-
| <code><categoryindex/></code> || The two-origin diptych Category index || <code>CategoryIndexTag</code>
|-
| <code><pharmaCommonUses>...</pharmaCommonUses></code> || Medicine-page sidebar "Common uses": top-5 problems by rater count, ranked desc; falls back to the legacy hand-entered <code>uses</code> wikitext when zero problems are linked || <code>CommonUsesTag</code>
|-
| <code><problemMedicines slug="X"/></code> || Auto-generated list of medicines that carry a <code><problem ref="X"></code>. Used on every Problem:<Name> namespace page so the canonical "Medicines used for X" section maintains itself || <code>ProblemMedicinesTag</code>
|-
| <code><effectMedicines slug="X"/></code> || Auto-generated list of medicines that carry an <code><effect ref="X"></code>. Used on every Effect:<Name> namespace page so the canonical "Medicines that may cause X" section maintains itself || <code>EffectMedicinesTag</code>
|}

All non-self-closing rating tags take a <code>slug</code> argument and (where relevant) a <code>title</code>, <code>label</code>, <code>author</code>, <code>ref</code>, or <code>perspective</code>.

=== Tag wikitext examples ===

<pre>
<problem slug="depression" title="Major depressive disorder"
author="MDElliottMD">First-line for moderate to severe MDD.</problem>

<effect slug="nausea" label="Nausea"/>

<effect ref="hyperkalemia"/> 

<titration slug="slow-start-elderly" title="Slow start (elderly)"
author="MDElliottMD">Begin at 10 mg q AM; titrate by 10 mg every 14 days.</titration>

<anecdote slug="qi8sg2" perspective="provider"
author="MDElliottMD">One patient developed serotonin syndrome at week 3...</anecdote>

<pharmaInteractions/>
<pharmaExperience/>

<vote slug="fav-color" type="single" options="Red; Blue; Green">
What's your favorite color?</vote>

<vote slug="side-effects" type="multi" results="after-vote"
options="Dry mouth; Insomnia; Anxiety; Headache; None">
Which side effects did you experience?</vote>
</pre>

== Voting / rating semantics ==

{| class="wikitable"
! Element !! Scale !! Perspectives !! Storage
|-
| Vote tag (binary) || +1 / −1 binary || single || <code>pcp_votes.v_value</code>
|-
| Vote tag (single-choice) || one of 2-5 options || single || <code>pcp_votes.v_choices</code> (CSV index)
|-
| Vote tag (multi-choice) || any subset of 2-5 options || single || <code>pcp_votes.v_choices</code> (CSV indices)
|-
| Titration || +1 / −1 binary || single || <code>pcp_votes</code>
|-
| Anecdote || +1 / −1 binary || single (perspective is metadata) || <code>pcp_votes</code>
|-
| Problem (efficacy likert) || 0–100 continuous slider, optional "Don't know" (-1) || single || <code>pcp_likert_reports</code>
|-
| Effect (patient) || experienced ∈ {yes, no, unsure} + valence ±100 slider || patient || <code>pcp_effect_reports</code> (perspective=1)
|-
| Effect (provider) || frequency 0–100 continuous slider + "Don't know" (-1) + valence ±100 slider || provider || <code>pcp_effect_reports</code> (perspective=2)
|-
| Interaction || experience 1–5 + valence ±100 slider + optional note || user + provider, separate aggregates || <code>pcp_interaction_reports</code>
|}

Choice / multi vote elements expose per-option tallies via <code>tallyChoices()</code> on demand. Per-option bars render inline in the picker. The <code>results</code> attribute gates tally visibility:
* <code>live</code> (default), tally always visible
* <code>after-vote</code>, tally hidden until viewer has voted
* <code>hidden</code>, tally never shown (only options + "thanks" on submit)

Server-side options-hash (<code>ve_options_h</code>) detects post-vote option-list edits; the API rejects new votes whose submitted hash doesn't match the live one. Voter identities are stored as HMAC-SHA256 (<code>v_voter_hash</code>) so admins reading the DB cannot map votes to user accounts without the HMAC secret.

Server-side aggregates: <code>n</code>, mean of the rating field, and (for interactions) <code>severe = (vmean ≤ −83.0)</code> (rescaled from the original ±3-scale −2.5). Aggregates are recomputed and returned by every report-submit API call so the row re-renders in place without a page reload.

== Effect bucketing ==

When a wiki <code><ul></code> contains only <code><effect></code> cards, JavaScript groups them into buckets by the provider frequency mean (<code>data-fmean</code>):

{| class="wikitable"
! Bucket !! fmean band !! Default state
|-
| '''Common''' || > 20 || expanded, always visible
|-
| '''Uncommon''' || > 5 and ≤ 20 || collapsed
|-
| '''Rare''' || ≤ 5, provider vmean > −83 || collapsed
|-
| '''Rare but Severe''' || ≤ 5 and vmean ≤ −83 || '''expanded by default''', red highlight
|-
| '''Not yet rated''' || no provider data (n=0) || collapsed, only renders if non-empty
|}

The vmean ≤ −83 threshold is also the trip-wire for the "severe" red treatment on interaction rows.

== User profile ==

<code>Special:MyProfile</code> is the user-facing editor for everything personal. Every block on it autosaves on a 800 ms debounce (see [[#Autosave infrastructure|Autosave infrastructure]]).

Visible at top: a Privacy-mode panel toggling whether legacy public fallback applies (privacy-mode ON = only explicit share rules grant access; OFF = the field-level <code>pf_visibility</code> enum applies).

🔗 Share chips appear in each fieldset legend (Demographics, Diagnoses, Medicines) so the owner can scope a share-rule to that namespace via the modal Share dialog.

=== Block list ===

* '''Identity''' (display alias, default attribution, experience-report visibility, read-only Research ID badge)
* '''Demographics''' (full chip-picker rebuild, see below)
* '''Personality''' (Big Five OCEAN sliders + collapsible assessments)
* '''Enneagram''' (9 type sliders + 45-item screening test)
* '''MBTI''' (4 dichotomy sliders + 32-item OEJTS test)
* '''Self-report assessments''' (PID-5-BF, CATI, CAT-Q, BPNS, NFCS, OCI-PCP, WHOQOL-BREF, HYD-PCP, each a collapsible inline test)
* '''ADHD screening''' (ASRS adult-ADHD screener and AMAAS-SR attention self-report, each a collapsible inline test)
* '''Formal testing''' (a log of standardized-test scores; raw score, percentile and pass/fail each carry their own privacy setting)
* '''Diagnoses''' (multi-row with ICD-10-CM + ICD-11 autocomplete, severity slider 0–100, disability slider 0–100, status, origin, dates, notes)
* '''Medicines I have tried''' (multi-row with med-name autocomplete, dose, route 16-option dropdown, schedule with datalist suggestions, efficacy + burden sliders 0–100, periods via date-picker)

=== Demographics (chip-picker / structured-widget rebuild) ===

All categorical demographics use the chip-picker widget (single or multi, with optional primary marker, optional custom free-text). All quantitative demographics use numeric inputs or structured composite widgets.

* '''Birthday''' DatePicker (single / range / possibility-mix). Setting (or changing) the birthday auto-syncs a TYPE_STORY life event tagged <code>auto-birth</code> titled 'Born!' on the life-story timeline. Subsequent birthday edits move ONLY the event's date; user edits to title, body, tags, images are preserved.
* '''Sex assigned at birth''' single-select (clinical category)
* '''Gender identity''' multi-select chip-picker, 27 common terms + custom
* '''Pronouns''' multi-select chip-picker, 17 common sets + custom
* '''Ethnicity / race''' multi-select chip-picker, 23 broad categories + custom
* '''Country of residence''' chip-picker single-value, ISO 3166 list (~100 entries), auto-suggested from <code>navigator.language</code>
* '''Languages''' chip-picker multi-select with ★ primary marker, ISO 639-1 list (~70 entries with endonyms), auto-suggested from <code>navigator.languages</code>
* '''Height / weight''' unit toggle (Metric cm/kg or US ft+in/lb); stored canonically as cm/kg regardless
* '''Handedness''' single-select (3 options)
* '''Smoking''' structured widget: status + cigs/day + years smoked + quit date (PCPDatePicker); auto-computes pack-years
* '''Alcohol''' structured widget: drinks/week + typical drink type + max one occasion
* '''Education''' bucketed highest-level + numeric years + free-text field of study
* '''Employment''' bucketed status + free-text occupation + numeric hours/week
* '''Income''' numeric amount + currency selector (20 options) + individual/household scope
* '''Marital / relationship status''' chip-picker single + custom
* '''Religion / spirituality''' chip-picker single + custom, 36 traditions + secular stances
* '''Housing''' chip-picker single + custom
* '''Number of children''' numeric
* '''Time zone''' free text, auto-detects IANA TZ on first load if empty
* '''Chronotype / sleep schedule''' two PCPTimePicker widgets (typical bedtime, typical wake; fuzzy parsing accepts "10p", "bedtime", "quarter past 6")
* '''Political orientation''' two-axis compass sliders (economic ±100, social ±100)

=== Diagnosis subsystem ===

Diagnoses are stored in <code>pcp_profile_diagnoses</code> with autocomplete backed by <code>pcp_diagnosis_abbreviations</code> (~41,500 rows):

{| class="wikitable"
! System !! Rows !! Notes
|-
| '''ICD-10-CM''' || 25,542 || CMS FY2026 valid-codes file, chapters A B C D E F G H I J K L M N O P Q R U + 553 friendly-alias rows (mdd, adhd, stroke, htn, etc.)
|-
| '''ICD-11''' || 15,823 || WHO MMS Apr 2026 linearization, chapters 01–24 except billing (22) / external causes (23) / extension modifiers (X) / functioning assessment (V) + 361 friendly-alias rows
|-
| '''DSM-5''' || 32 || Legacy hand-seed for codes without ICD equivalents
|-
| Other || 34 || somatic, unofficial, ICD-10 (WHO), instrument
|}

Skipped intentionally: ICD-10-CM S/T (injury body) ~41k codes, V/W/X/Y (external causes) ~7.5k codes; ICD-11 chapter 22 (injury), 23 (external causes), 25 (special purposes), V (functioning scales), X (17.7k extension modifiers). These are billing scaffolding, not diagnoses.

Autocomplete via <code>action=pharmacopediadxsearch</code>, multi-token AND search (e.g. "ADHD inattentive" matches the F90.0 row that contains both substrings); ORDER BY <code>FIELD(da_system, 'ICD-10-CM', 'ICD-11', 'DSM-5', ...)</code> so ICD-10-CM leads, then ICD-11, then everything else.

=== Self-report assessments ===

The six dimensional assessments all have continuous-slider items, a "Not sure" toggle per item, auto-computed subscale + total scores, and a rich auto-generated report at <code>Special:MyAssessment/{key}</code>:

{| class="wikitable"
! Assessment !! Items !! Score range !! Cutoffs / threshold !! Report
|-
| '''CATI''' || 42 (6 subscales) || 1–5 per item, sum per subscale || 148 / 139 / 141 / 156 (English 2025 gender-specific) || gender-specific scoring against English 2025 normative tables (12,253-row CatiNorms.php from OSF supplementary)
|-
| '''CAT-Q''' || 25 (3 subscales) || 1–7 per item, sum per subscale || Total ≥ 110 + per-subscale cutoffs (NeurodivUrgent recalibration) || subscale narratives, top-item analysis
|-
| '''PID-5-BF''' || 25 (5 domains) || 0–3 per item, mean per domain || mean ≥ 2.0 per domain || domain narratives, cross-system mapping (DSM-5 AMPD ↔ ICD-11 PD ↔ Big Five)
|-
| '''MBTI''' || 32 OEJTS items + 4 direct dichotomy sliders || ±2 per axis || none (dimensional treatment, no forced categorisation) || 4-axis Position column with letter + strength + bar, cognitive function stack, Big Five mapping, top-item analysis
|-
| '''Enneagram''' || 45 (5 per type × 9 types) || 0–100 per type || none (no clinical cutoffs for typology) || hero banner (primary + wing + tritype), 9-bar profile, primary deep-dive, wing analysis, centers, Hornevian + Harmonic groups, stress / growth lines, cross-system map (Big Five, MBTI)
|-
| '''OCEAN (Big Five)''' || 5 direct sliders + optional BFI-10 (10 items) || 0–100 per trait || none (personality, not pathology) || trait deep-dives (high / mid / low at your score), BFI-10 item table, cross-system mapping (MBTI ↔ Enneagram ↔ PID-5-BF) pulling live data from the profile
|}

Five further self-report instruments are available on the same collapsible-inline-test, auto-scored, report-bearing pattern:

{| class="wikitable"
! Instrument !! Items !! Structure !! Measures
|-
| '''BPNS-PCP''' || 21 || 3 subscales (Autonomy, Competence, Relatedness), 7-point Likert || basic psychological need satisfaction, per Self-Determination Theory
|-
| '''NFCS-PCP''' || 15 || 5 facets (Order, Predictability, Decisiveness, Ambiguity intolerance, Closed-mindedness), 6-point Likert || need for cognitive closure (brief 15-item Roets & Van Hiel form)
|-
| '''OCI-PCP''' || 18 || 6 subscales (Washing, Obsessing, Hoarding, Ordering, Checking, Neutralizing), 0–4 per item; screening cutoff total ≥ 21 || obsessive-compulsive symptoms, adapted from the OCI-R
|-
| '''WHOQOL-BREF-PCP''' || 26 || 4 domains (Physical, Psychological, Social, Environment) + 2 overall items, 5-point Likert || quality of life
|-
| '''HYD-PCP''' || 8 || 8 single-item domains, each one bipolar slider (−100 really poorly to +100 really well); no subscales, no cutoffs || everyday wellbeing, re-taken and watched over time; a locally authored check-in, not validated
|}

All assessment items submit raw responses to <code>pcp_profile_fields</code> under namespace <code>{key}_raw</code> (e.g. <code>cati_raw</code>); the computed scores live under namespace <code>{key}</code> with keys like <code>subscale_SOC</code>, <code>total</code>, plus a <code>taken_at</code> timestamp. Re-scoring happens automatically on every save (autosave fires <code>scoreResponses()</code> on the full raw set, skipping "unsure" rows). Each completed assessment also auto-upserts a Life-story keyframe row (see [[#Life-story timeline|Life-story timeline]]) so trajectories plot over time.

All thirteen assessments (the six dimensional, these five, and the two ADHD screeners below) are registered in <code>AssessmentRegistry</code> and so can also be administered to outside respondents (see [[#Administer assessments to others|Administer assessments to others]]).

=== ADHD screening ===

Two attention / ADHD instruments sit alongside the dimensional assessments, each a collapsible inline test on <code>Special:MyProfile</code> and a card render on the public profile:

* '''ASRS''' (Adult ADHD Self-Report Scale, Part A): a 6-item binary screener. The card counts how many of the 6 cardinal items fall in the screening range; 4 or more is a positive screen. The public profile renders it as a '''verdict card''', a screen-positive or screen-negative result word with a 6-cell cardinal-item strip and a screening-result detail line.
* '''AMAAS-SR''' (a 30-item experimental attention self-report): three symptom subscales, inattention, hyperactivity and impulsivity, each scored as a percentage of the subscale maximum. The public profile renders it as a '''featured radar card''', a 3-axis radar carrying a deliberately arbitrary 66.66% threshold triangle that is labelled experimental and not a validated cutoff. AMAAS has no validated norms; the card discloses this in plain sight rather than presenting a clinical cutoff.

Both instruments store responses in <code>pcp_profile_fields</code> under the <code>asrs</code> and <code>amaas</code> namespaces, the same pattern as the dimensional assessments.

=== Formal testing ===

The '''Formal testing''' block on <code>Special:MyProfile</code> is a log of standardized tests the user has taken (entrance exams, AP exams, IQ tests, and the like; retakes are welcome, and the year disambiguates them). Each entry resolves against a catalog (<code>pcp_formal_tests</code>) or is a custom free-text test, and records up to three score fields, raw score, percentile and pass/fail, each with an optional estimate flag.

Every score field has its own '''per-field visibility'''. Raw score, percentile and pass/fail each carry a separate privacy setting (<code>uts_vis_raw</code>, <code>uts_vis_pct</code>, <code>uts_vis_passfail</code>), so a user can publish a percentile while keeping the raw score private. The <code>Special:MyProfile</code> editor shows three privacy toggles per entry; the public <code>Special:UserProfile</code> gates each score line independently by its own field visibility. Scores are stored in <code>pcp_user_test_scores</code>, managed through the <code>pharmacopediaformaltest</code> API.

== Life-story timeline ==

<code>Special:MyLifeStory</code> is the owner-facing editor + viewer for everything time-anchored about the user. Backed by <code>pcp_life_events</code> with extension columns for episode / observation / keyframe metadata.

=== Event types ===

{| class="wikitable"
! le_type !! Meaning !! Notes
|-
| 0 (TYPE_STORY) || Plain timeline entry || title, body, optional image
|-
| 1 (TYPE_IMAGE) || Image-primary entry || same shape, image is the main payload
|-
| 2 (TYPE_KEYFRAME) || Auto-created assessment snapshot || populated by <code>upsertAssessmentKeyframe</code> on every assessment save
|-
| 3 (TYPE_OBSERVATION) || Plain-text observation || created via the quick-add textarea; parser extracts date, polarity, refs
|-
| 4 (TYPE_EPISODE) || Time-bounded period || start + end (PCPDatePicker range mode); type / subtype / severity 0-100
|}

=== Quick-add observation ===

A textarea at the top of <code>Special:MyLifeStory</code> (and a 📝 modal trigger on <code>Special:MyProfile</code>) accepts plain text like:

<pre>
anxiety from bupropion in jan 2020
did not experience anxiety from bupropion in feb 2018
panic attack 2 months ago
depressed as a freshman
i had a manic episode sep 1 2020 till nov 15 2020
no insomnia while on melatonin in summer 2023
felt great on christmas 2020
happiest on my 30th birthday
</pre>

<code>ObservationParser::parse()</code> extracts:

* '''Date''' (point or range): ISO, MM/DD/YYYY, "Month D YYYY", "Month YYYY", "Season YYYY", "early/mid/late YYYY", bare year, decades ("2010s"); date RANGES via "X to Y", "X till Y", "from X to Y", "X - Y"; relative-to-now ("yesterday", "last week/month/year", "N months ago", "a few weeks ago"); holidays (christmas, halloween, new year's, valentine's, july 4th, thanksgiving with computed 4th-Thursday-of-Nov, MLK / Memorial / Labor day); age-relative ("7y8mo", "51.2yo", "at age 14", "ages 2-10"); life stages ("in childhood", "as a teen", "as a freshman", "junior year"); Nth birthday ("my 30th birthday")
* '''Polarity''' (negation detection): "not", "didn't", "did not experience", "never", "without", "denied" → polarity=0 (negative); else 1 (positive)
* '''Leading verbs stripped''': "I was diagnosed with", "I took", "started taking", "tried", "was on", "experienced", "felt", so the subject is the noun, not the verb
* '''Adverbs stripped''': "briefly", "occasionally", "frequently", "sometimes", "always", so the subject is the noun, not the modifier
* '''Role splitting''': "from / caused by / due to / while on" → role='cause'; "with / during / while" → role='context'
* '''Ref resolution''', in priority order:
*# User's meds (<code>pcp_user_meds</code>)
*# Wiki pages in Category:Medicines
*# Effects catalog (<code>pcp_effects</code>)
*# Problems catalog (<code>pcp_problem</code> + <code>pcp_problem_alias</code>)
*# User's diagnoses (<code>pcp_profile_diagnoses</code>)
*# Global ICD diagnosis abbreviations (<code>pcp_diagnosis_abbreviations</code>)
*# Free-text fallback (stored as type='free' for later upgrade)
* '''Auto-promote unrecognized subjects to custom-trait keyframes''': when the subject doesn't match an existing entity but the input has BOTH a numeric value AND a date (e.g. <code>my neuroticism was 5 at 10yo</code>), the subject is treated as a NEW custom trait (<code>namespace='custom'</code>, key derived from subject text). Creates a TYPE_KEYFRAME event with the value + a trajectory point. Future inputs with the same subject auto-append to that series.
* '''Flexible range separators''': <code>X to Y</code>, <code>X through Y</code>, <code>X thru Y</code>, <code>X until Y</code>, <code>X till Y</code>, em-dash, en-dash, flexible-whitespace hyphens (digit-aware so <code>2026-05-31</code> ISO dates aren't split), <code>..</code> / <code>...</code> ellipsis.
* '''Age-range phrases without literal "ages"''': <code>when I was 11-13</code>, <code>from 11 to 13</code>, <code>between ages 5 and 12</code>, <code>aged 10 to 14</code>. Negative lookahead prevents false matches on dosages (<code>10-20 mg</code>), durations (<code>5-10 years ago</code>), measurements (<code>cm/mm/ft/lb/etc</code>).
* '''Episode-shape detection''': "manic episode" → type=mood, subtype=manic; "psychotic break", "panic attack", "anxiety attack", "trauma response" all route to <code>addEpisode</code> instead of <code>addObservation</code>. A date RANGE alone is enough to force <code>is_episode=true</code>.

Live preview chips appear under the textarea as you type. Submit routes to <code>pharmacopediaobservation</code> API which writes the row + refs via <code>setEventRefs()</code>.

=== Episode form ===

Click the "🌀 Episode" button (or the quick-add detects an episode shape) for the structured form:

* Type selector: mood / psychotic / anxiety / panic / trauma response / dissociative / substance use / eating / sleep disturbance / pain flare / migraine / medication adjustment / hospitalization / creative surge / spiritual / transcendent / relationship crisis / grief / somatic / other
* Subtype (text + datalist), for mood: depressive / manic / hypomanic / mixed / dysphoric / euthymic
* Severity slider 0-100 (per precision doctrine)
* Date range via PCPDatePicker locked to range mode
* Title, body, single virus-scanned image, visibility (4-state)

=== Visual timeline ===

Top of <code>Special:MyLifeStory</code> has a tabbed view: '''Visual timeline''' (default) / '''Card list'''.

The visual timeline uses '''vis-timeline 7.7.3''' (vendored Apache-2.0 at <code>resources/vendor/vis-timeline/</code>) with these features:

* Swimlanes (toggleable chips): Episodes (range bars), Events, Observations, Keyframes (off by default), Derived
* '''Trait-trajectory overlay''': a synchronized <code>vis.Graph2d</code> draws smooth (centripetal Catmull-Rom interpolated) lines for every keyframe trait series (CATI subscales, PID-5-BF domains, CAT-Q, custom traits like "shyness") DIRECTLY on top of the timeline plot area. Same X-axis; the graph's data + time axes are CSS-hidden so only the lines + points show. Values are normalized to 0-100% within each series so different scales coexist.
* Toolbar: Visual/Card tabs, group toggle chips, magnifier + zoom +/- buttons, Fit visible / Fit everything
* Plain wheel = vertical scroll inside the timeline (520px fixed height); Ctrl+wheel = zoom; Shift+wheel = horizontal pan
* Click empty timeline area: prefills the quick-add textarea with "on YYYY-MM-DD" at that date + scrolls + triggers live preview
* Click an item: routes to its edit form (event / episode / observation, each has its own route)
* Collapsible "Trait series (N)" legend with chip toggles to show/hide individual series

=== Edit / delete / duplicate flows ===

Each event type has its own edit route under <code>Special:MyLifeStory</code>:

* <code>Special:MyLifeStory/edit-observation/<id></code>, re-parses raw text on save; supports polarity override + date override
* <code>Special:MyLifeStory/edit-episode/<id></code>, full episode form
* <code>Special:MyLifeStory?edit_event=<id></code>, existing event / image / keyframe form

All three forms have side-by-side "Delete X" + "Duplicate X" buttons. Duplicate copies fields + refs + keyframe traits (NOT images) and redirects to the new row's edit form.

=== Upgrade-link UI ===

When the parser stored a free-text ref (because the entity wasn't in the user's data at the time), <code>Special:MyRefLinks</code> finds all such refs and offers one-click "link to {match}" buttons. Matches come from the same catalogs the parser checks at write time. A banner on <code>Special:MyLifeStory</code> ("📎 N free-text references could be linked → Review & link") appears when unmatched refs exist.

== Per-record sharing subsystem ==

A granular per-record sharing system layered on top of the legacy <code>pf_visibility</code> enum without removing it. Resolved by <code>VisibilityResolver</code>; the new model is additive (legacy fallback preserved unless Privacy mode is on).

=== Rule types (vr_rule_type) ===

* '''<code>private</code>''', explicit deny (only owner)
* '''<code>public</code>''', explicit allow (anyone)
* '''<code>users</code>''', payload <code>{user_ids: [...]}</code>; allow if viewer in list
* '''<code>cohort</code>''', payload <code>{cohort_id: N}</code>; allow if viewer in <code>pcp_cohort_members</code> for that cohort
* '''<code>link_token</code>''', payload <code>{token: '...', uses_remaining: null|N}</code>; allow if URL <code>?pcpshare=TOKEN</code> matches
* '''<code>reciprocal</code>''', allow if viewer has a matching <code>users</code> rule sharing the same shape back to owner

Rules scope at three levels: <code>(profile, namespace, key)</code>, <code>(profile, namespace, NULL)</code>, or <code>(profile, '*', NULL)</code>. Most-specific-first matching. Rules can have <code>vr_expires</code> (time-bounded) and <code>vr_revoked</code> (preserves audit trail).

=== Privacy mode ===

When Privacy mode is ON for a profile, a *-wide <code>private</code> rule is created. <code>VisibilityResolver::canView()</code> short-circuits to false instead of falling through to the legacy <code>pf_visibility</code> check, so only explicit share rules grant access. Default: OFF (back-compat).

=== Share dialog ===

Triggered by 🔗 chips on assessment reports, profile sections, life-story timeline. Modal with three tabs:

* '''People''': username autocomplete (↓/↑/Enter/Esc keyboard nav), per-shared-user pill with × to remove just that user, optional expires DatePicker, "Auto-share back" reciprocal toggle
* '''Link''': "Generate link" creates a <code>link_token</code> rule; copies the URL to clipboard with toast; optional max-uses + expires
* '''Cohorts''': dropdown of the owner's cohorts (managed at <code>Special:MyCohorts</code>); optional expires

=== Audit log ===

Every permitted view through a rule (not legacy) writes a row to <code>pcp_visibility_view_log</code>. <code>Special:MyShareLog</code> shows the last 200 views with timestamp, viewer (or anonymous IP masked to /24), namespace, key, rule id.

== Observer perspectives ==

A structured way to collect second-party (observer) input on something a user owns, without the observer needing an account. The v1 use case is an observer-rated attention report: a registered user invites someone who knows them well to rate them. A two-gate consent model governs the whole flow.

* '''Gate 1, contribution.''' An owner-issued, token-bearing invite link is the only way to submit a perspective. The invitee URL carries only an opaque random token (<code>VisibilityResolver::generateLinkToken()</code>); the owner's identity is never in the URL. The invitee sees only the owner's chosen display name.
* '''Gate 2, publication.''' Every submission is born <code>psp_consent = 0</code>, private to the owner. Only the owner, re-checked for ownership, can flip it to published. A perspective is never publicly visible while unconsented.

Flow: the owner opens <code>Special:MyPerspectives</code>, picks a display name, mints an invite link, and sends it. The invitee opens <code>Special:Perspective/<token></code>, reads a generic intro and a non-anonymity notice, optionally states their relationship to the owner, fills the type-specific slider form (with per-item "not sure" markers), clears a Turnstile challenge, and submits. The perspective lands in the owner's consent inbox, where the owner can publish it, return it to private, or delete it.

<code>Special:Perspective</code> is unlisted and unauthenticated; its POST path is defended by pingLimiter, a per-token APCu velocity cap, and fail-closed Turnstile. <code>pcp_perspective_invite</code> holds the token-bearing invitations (<code>pvi_max_uses</code> NULL means an unlimited reusable link); <code>pcp_perspective</code> holds the submissions, each with a <code>psp_validity</code> response-quality flag and the <code>psp_consent</code> gate. The client module <code>ext.pharmacopedia.perspective</code> adds the slider readout and progress bar on the invitee form and the confirm steps on the owner inbox.

== Administer assessments to others ==

A registered user (the '''owner''') can send any of the thirteen registered assessment scales to people outside the wiki (the '''respondents'''), collect their results, and follow them over time. Respondents need no account; a one-time invite link is their only credential. The subsystem is built so that, by default, a respondent's results are readable only by the owner, and the owner can additionally choose a zero-knowledge mode in which not even a site administrator can read them.

=== Assessment registry ===

<code>AssessmentRegistry</code> (<code>includes/Assessments/AssessmentRegistry.php</code>) is the single source of truth: an assessment registered there once autopopulates the owner's scale-picker, the respondent take-flow, and the dashboards. Each entry names a scorer class and a '''response model''':
* <code>radio</code>, discrete labelled radio buttons (CATI, CAT-Q, PID-5-BF, NFCS, BPNS, OCI-PCP, WHOQOL-BREF, ASRS)
* <code>slider</code>, one continuous slider per item with uniform end anchors (OCEAN, Enneagram, AMAAS, HYD-PCP)
* <code>bipolar</code>, one slider per item with the item's own two opposing phrases as the anchors (MBTI)

Every take-flow item also carries a "Not sure" control that disables the item.

=== The four surfaces ===

* '''Entry point''', a control that opens the feature.
* '''Owner hub''' (<code>Special:AdministerAssessments</code>): the owner manages respondents (a named contact list), composes a send (a respondent plus one or more scales), generates a one-time link, and reviews each respondent's results over time. The owner can delete an invite.
* '''Respondent take-flow''' (<code>Special:RespondToAssessment/<token></code>), reached only by the invite link: a consent screen, then the model-aware item forms; once every scale is done the same URL becomes a revisitable results dashboard. Either party can delete.
* '''Key setup''', where the owner chooses how their results are protected (see below).

=== Cryptography ===

Each owner has an '''X25519 keypair'''. The public key is stored in the clear; the secret key is wrapped at rest. A respondent submits while the owner is absent, so the result is sealed to the owner's public key with <code>crypto_box_seal</code>, which needs only the public key; only the owner's secret key can open it. Two protection modes:

* '''Managed''' (default, seamless): the secret key is wrapped with a server master key held in a file outside the web root, never in the database. No passphrase to remember, and a forgotten site password never costs the owner their data. A site administrator could technically read results.
* '''Passphrase''' (opt-in, zero-knowledge): the secret key is wrapped with an Argon2id-derived key from a passphrase only the owner knows. Not even the site can read the results. '''The passphrase cannot be recovered or reset'''; losing it makes every collected result permanently unreadable.

AES-256-GCM is used for key wrapping in both modes. <code>AdminCrypto</code> (<code>includes/Assessments/AdminCrypto.php</code>) is the helper: <code>setupOwnerKey</code>, <code>verifyPassphrase</code>, <code>unlockSecretKey</code>, <code>encryptForOwner</code> / <code>decryptForOwner</code>, <code>encryptForRespondent</code> / <code>decryptForRespondent</code>, <code>mintInviteToken</code> / <code>hashInviteToken</code>. Invite tokens are 256-bit; only their SHA-256 hash is stored, so a stolen database yields no usable tokens. The respondent's own copy of each result is sealed to a key derived from the raw invite token, so the link doubles as the respondent's read credential. A scheme-version column on the key and result rows lets the cipher or KDF be revised over time; the Mode A passphrase KDF currently runs at scheme v2 (Argon2id at MODERATE limits), and an owner created under an earlier scheme is transparently re-wrapped on their next unlock.

=== De-identified research pool ===

Each submission also writes one row to <code>pcp_administer_research</code>, decoupled from the result write, with no foreign key to the invite, respondent, or owner. <code>res_id</code> is a random 128-bit value (not sequential) and the only time field is <code>res_month</code> ('YYYY-MM', no day), so a research row cannot be time-correlated or rank-correlated back to the owner-side tables. The payload is the plaintext item responses plus the computed score. Deleting an invite removes the owner-sealed and respondent-sealed result copies but intentionally leaves the de-identified research row, as the consent screen states.

=== Tables ===

* <code>pcp_administer_respondents</code>, an owner's named contacts (the label is sealed to the owner's public key, so the roster is readable only by the owner)
* <code>pcp_administer_invites</code>, one token-bearing link per send (stores only the SHA-256 of the token)
* <code>pcp_administer_assessments</code>, the scale(s) inside an invite, each with the owner-sealed (<code>aa_payload_enc</code>) and respondent-sealed (<code>aa_respondent_enc</code>) result copies
* <code>pcp_administer_userkey</code>, per-owner key material (public key, wrapped secret key, Mode-A salt and verifier)
* <code>pcp_administer_research</code>, the de-identified research pool

The 13-instrument submission handler reuses the existing assessment scorers in <code>includes/Assessments/</code> rather than reimplementing scoring.

== Choice / multi voting ==

The <code><vote></code> tag's binary up/down mode is unchanged. With <code>type="single"</code> or <code>type="multi"</code> + <code>options="A; B; C"</code> (2-5 entries, semicolon separator), it renders a compact chart-icon chip that expands inline to a radio (single) or checkbox (multi) picker with per-option count bars.

Server-side storage:
* <code>pcp_votable_elements.ve_options</code> (JSON array of labels)
* <code>pcp_votable_elements.ve_options_h</code> (first 8 hex of sha256; drift hash)
* <code>pcp_votable_elements.ve_results_policy</code> (live / after-vote / hidden)
* <code>pcp_votes.v_choices</code> (CSV indices)
* <code>pcp_votes.v_options_h</code> (drift hash at vote time)

API route: same <code>pharmacopediavote</code> endpoint; presence of <code>choices</code> or <code>options_h</code> params routes to <code>castChoice()</code>. Response includes <code>tally</code> + <code>user_choices</code> (null for binary). Tally hidden per <code>results</code> policy.

Drift behavior: if the page editor changes the options list after votes exist, <code>ve_options_h</code> updates and new votes' <code>v_options_h</code> reflects the new value. Existing votes stay but their hash no longer matches (marked stale). New votes whose submitted hash mismatches the live one are rejected, protects against browser cache races. Tallies still aggregate by raw index, so RENAMING an option in place silently turns old votes into new-label votes; reordering is the dangerous case. Appending new options is safe.

== Research ID ==

Every user profile carries a '''research_id''': a 10-character hex string (<code>bin2hex(random_bytes(5))</code> = 40 bits), generated once at profile create, stored UNIQUE in <code>pcp_user_profiles.prof_research_id</code>, and never reassigned.

Purpose: provides a stable opaque identifier for de-identified research participation. It does not reveal the user's wiki username, user_id, or HMAC voter_hash; it survives username changes; and it stays constant across the user's lifetime on the wiki. Users can find theirs in the '''Public identity''' fieldset on <code>Special:MyProfile</code> (single-click to select-and-copy).

Backfilled retroactively for all pre-existing profiles on 2026-05-18 (v0.9.4).

== ClamAV scan rule (project standard) ==

Hard rule, set 2026-05-17: every server-accepted file upload (image, PDF, document, anything) MUST go through <code>VirusScanner::scanFile($path)</code> (<code>includes/VirusScanner.php</code>) BEFORE being moved to permanent storage. Fail-closed: if <code>/usr/bin/clamdscan</code> is unavailable or returns error, the upload is rejected.

Wired into:
* <code>LifeStoryStore::addImage()</code>, life events / episodes / observations
* <code>LiteratureStore::storeUploadedPdf()</code>, literature PDFs
* <code>ProviderAppStore::saveUploadedFile()</code>, provider verification documents

<code>AttachmentScanner</code> (used by feature-request attachments) is left alone, its status-return model is intentional for the queued-moderation flow there. <code>AntivirusHelper</code> (the old silent-no-op variant) was deleted; all callers consolidated onto <code>VirusScanner</code>.

== Autosave infrastructure ==

The save-status indicator is a single colored dot (amber = saving, green = saved, red = error) reparented to <code>document.body</code> and pinned to the top-right corner of whichever form control was last manipulated. Position recomputes on scroll + resize so the dot stays on its anchor through the full pending → saving → ✓ saved cycle.

Every block on <code>Special:MyProfile</code> is wrapped in <code><div data-pcp-save-block="block-name"></code>. The blocksave.js library:

# Listens for <code>input</code> and <code>change</code> events on every input inside any save-block
# 800 ms after the last event, POSTs the block's serialized form data to <code>Special:SaveProfileBlock</code> with <code>block=block-name</code>
# Shows a transient chip (top-right and bottom of the block): pending… → saving… → ✓ saved (fades after 1.2 s) or ✗ error (sticks, clickable to retry)
# Race-safe: if user keeps typing during an in-flight save, the in-flight save records what it sent; newer changes mark the block dirty again and schedule another save when the response returns
# Diagnosis + medicines "Add a row" slots are exempted from autosave (would create duplicates); they require an explicit + Add button
# Programmatic widgets (chip-pickers, units, smoking, alcohol, chronotype) fire <code>change</code> events on their hidden fields so the listener notices

Slider numbers are also clickable: a single delegated handler on every <code><output></code> next to a range slider swaps it for a number input on click, accepts a precise typed value (clamps to the slider's <code>min</code>/<code>max</code>), commits with Enter, cancels with Escape.

Scroll position is preserved across the rare reloads (delete operations on diagnoses / medicines / experience reports, and the auto-reload after a new diagnosis or medicine is added) via <code>sessionStorage</code> (the <code>ext.pharmacopedia.bounceback</code> module).

== Special pages ==

{| class="wikitable"
! Page !! Purpose
|-
| <code>Special:MyProfile</code> || Edit your full profile (identity, demographics, personality, dx, meds). Autosave throughout. Privacy mode toggle + share chips per fieldset.
|-
| <code>Special:UserProfile/<name></code> || Public profile view (filtered by per-field visibility + rule-based access). 🔗 Share chip in subtitle for self-view.
|-
| <code>Special:MyAssessment</code> || Index of rich assessment reports
|-
| <code>Special:MyAssessment/cati</code>, <code>/catq</code>, <code>/pid5bf</code>, <code>/mbti</code>, <code>/enneagram</code>, <code>/ocean</code> || Rich report per assessment; 🔗 Share chip in subtitle for owner
|-
| <code>Special:TakeAssessment/<key></code> || Generic paginated self-assessment runner; stores raw items and computes scores
|-
| <code>Special:MyLifeStory</code> || Owner editor + visual timeline + card list. Quick-add observation textarea + Event/Episode buttons. 🔗 Share chip in subtitle. Privacy-mode + free-text-refs banners.
|-
| <code>Special:MyLifeStory/add-episode</code>, <code>/edit-episode/<id></code> || Episode form (create / edit)
|-
| <code>Special:MyLifeStory/edit-observation/<id></code> || Observation edit form (re-parses raw text)
|-
| <code>Special:LifeStory/<name></code> || Public life-story view (read-only, visibility-filtered)
|-
| <code>Special:LifeImage</code> || Visibility-gated image streamer for life-story event images
|-
| <code>Special:MyCohorts</code> || Owner-managed groups for share-with-cohort flows; create / rename / delete / add+remove members
|-
| <code>Special:MyShareLog</code> || Who has viewed your shared content (timestamp, viewer, namespace, rule id; anonymous IPs masked)
|-
| <code>Special:MyRefLinks</code> || Bulk linker: find free-text refs in observations that now match a structured entity; one-click upgrade or dismiss
|-
| <code>Special:MyPerspectives</code> || Owner: mint observer-perspective invite links and review the consent inbox
|-
| <code>Special:Perspective/<token></code> || Public, token-gated observer-perspective form (no account; unlisted, anti-abuse defended)
|-
| <code>Special:AdministerAssessments</code> || Owner hub: send assessment scales to outside respondents and follow their results
|-
| <code>Special:RespondToAssessment/<token></code> || Token-gated respondent take-flow and revisitable results dashboard
|-
| <code>Special:SaveProfileBlock</code> || AJAX endpoint for autosave (POST-only, JSON response)
|-
| <code>Special:Problems</code> || Browse the problems repository (165+ entries, 18 categories)
|-
| <code>Special:Problem/<slug></code> || Individual problem page
|-
| <code>Special:SuggestProblem</code> || User-facing form to suggest a new problem (page-tied or standalone)
|-
| <code>Special:SuggestAnecdote</code> || Logged-in users propose an anecdote for a medicine page
|-
| <code>Special:SuggestEffect</code> || Logged-in users propose an effect for a medicine page
|-
| <code>Special:SuggestTitration</code> || Logged-in users propose a titration schedule for a medicine page
|-
| <code>Special:ManageProblems</code> || Sysop tool for problem-repository moderation
|-
| <code>Special:ManageEffects</code> || Sysop CRUD for the global effects vocabulary
|-
| <code>Special:ManageInteractions</code> || Sysop bulk-edit interaction reports
|-
| <code>Special:ReviewExperience</code> || Sysop queue for pending experience reports
|-
| <code>Special:DeletePharmaElement</code> || Sysop delete tool for any votable element
|-
| <code>Special:VerifyProvider</code> || User-facing form to apply for provider verification and check status
|-
| <code>Special:ProviderApplications</code> || Sysop queue to approve / reject provider-verification applications
|-
| <code>Special:VerificationDoc</code> || Permission-gated streamer for provider-verification document files
|-
| <code>Special:FeatureRequests</code> || User-facing feature-request board (submit and browse)
|-
| <code>Special:RequestReview</code> || Sysop feature-request review console (status counters, prioritized queue, triage)
|-
| <code>Special:LiteratureDoc</code> || Download proxy for approved literature PDFs (reviewers may preview pending)
|-
| <code>Special:LiteratureQueue</code> || Sysop literature review queue (approve / reject / delete)
|-
| <code>Special:PharmacopediaActivity</code> || Recent-activity feed: last 30 votes, effect reports, comments, literature submissions
|-
| <code>Special:NewUsers</code> || The 20 most recently registered accounts
|-
| <code>Special:ProfileAnalysis</code> || Sysop dashboard of cross-table profile aggregates; per-section CSV export
|-
| <code>Special:ProfileFilter</code> || Sysop cross-filter UI over user profiles (demographics, OCEAN ranges, dx, med); CSV export
|-
| <code>Special:PCPCtrls</code> || Sysop controls hub (gated by <code>$wgSpecialPageLockdown</code>)
|-
| <code>Special:AdminCtrls</code> || Admin-controls landing page (renders sysop-editable <code>MediaWiki:Adminctrls-body</code>)
|-
| <code>Special:DatePickerTest</code> || Developer sandbox exercising the date-input widget (point / range / possibility)
|}

== API modules ==

{| class="wikitable"
! Action !! Purpose
|-
| <code>pharmacopediavote</code> || Binary OR choice/multi vote (routes by presence of <code>choices</code> param). Returns tally + user_choices for choice modes; gated by results-policy.
|-
| <code>pharmacopedialikert</code> || Submit problem-efficacy likert (0–100 + −1 DK)
|-
| <code>pharmacopediaeffect</code> || Submit effect report (patient or provider perspective)
|-
| <code>pharmacopediainteractionreport</code> || Submit interaction report
|-
| <code>pharmacopediainteractionadd</code> || Create a new interaction edge
|-
| <code>pharmacopediacomment</code> || Threaded discussion ops (add / edit / delete / reply)
|-
| <code>pharmacopediaexperiencesubmit</code> || Submit experience report (multi-field form)
|-
| <code>pharmacopediaexperiencereview</code> || Sysop approve / reject experience report
|-
| <code>pharmacopediadxsearch</code> || Diagnosis autocomplete against the 41k-row abbreviation table
|-
| <code>pharmacopediaproblemsearch</code> || Problem-repository autocomplete
|-
| <code>pharmacopediaeffectslookup</code> || Picker used by the experience-submit form
|-
| <code>pharmacopedialiteratureadd</code>, <code>literaturedelete</code> || Literature attachment ops
|-
| <code>pharmacopediaobservation</code> || op=preview / op=submit for plain-text observations (routes to addObservation OR addEpisode)
|-
| <code>pharmacopediavisrules</code> || Visibility rule CRUD (list / create / update / revoke / newtoken)
|-
| <code>pharmacopediausersearch</code> || Username autocomplete for share-with-people picker
|-
| <code>pharmacopediacohorts</code> || Cohort CRUD + membership
|-
| <code>pharmacopediarefupgrade</code> || Free-text ref linker (op=candidates / apply / dismiss)
|-
| <code>pharmacopediaformaltest</code> || Formal-testing score operations (list / add / update / delete), with per-field visibility
|}

== Interactions feature ==

The Interactions section is rendered by placing <code><pharmaInteractions/></code> anywhere in the wikitext of a med article ('''NS_MAIN''') or a Category page ('''NS_CATEGORY''').

=== Entity model ===

An interaction is an undirected edge between two endpoints. Each endpoint has a '''type''' (<code>med</code> or <code>category</code>) and a '''slug''' (DB-key form of the page title). Pairs are stored in canonical order: smaller <code>(type, slug)</code> tuple on the left.

=== Rendering rules ===

* On a '''med''' page M, list:
** Direct edges: rows where M is one side.
** Transitive edges: rows where one side is a category C that M is itself a member of (via MW's <code>categorylinks</code>).
* '''Direct wins:''' if the same counterparty is reachable both directly and transitively, drop the transitive duplicate.
* On a '''Category''' page, list direct edges only (no transitive walk).
* Sort: pooled <code>valence_mean</code> ascending (most negative on top). Nulls sink. Tiebreakers: <code>n</code> desc, then alphabetic.
* Severe (any of pooled / user / provider vmean ≤ −83.0): red 4 px left border + red-tinted background + "severe" pill + counterparty title in red.

=== Add-interaction modal ===

Triggered by the <code>+ Add interaction</code> button at the bottom of the section. Two-stage UX: search → click Use → confirm with Add interaction → POST to <code>pharmacopediainteractionadd</code>. Categories appear in the modal only if tagged with the marker category (default <code>Category:MedCategory</code>, configurable via <code>$wgPharmacopediaInteractionCategoryMarker</code>).

== Experience reports ==

User-submitted reports of personal or clinical experience with a medicine, via <code><pharmaExperience/></code> on a med page. Stored pending in <code>pcp_experience_reports</code>; visible publicly only after sysop approval through <code>Special:ReviewExperience</code>.

Captured fields:
* Perspective (personal / clinical)
* Currently taking it (yes / no, stopped)
* Duration (value + unit)
* Dose (mg, decimal-precise)
* Route (16-option dropdown: PO, IV, IM, SC, SL, buccal, inhaled, intranasal, topical, transdermal, PR, ophthalmic, otic, vaginal, insufflated, other)
* Schedule (free text with datalist of QD / BID / TID / QID / q4h / q6h / q8h / q12h / qHS / qAM / qPM / PRN)
* Patient count (clinical only): min + optional max for ranges
* Efficacy (0–100 slider)
* Side-effect burden (0–100 slider)
* Stop reasons (personal + stopped only): JSON multi-select with optional severity slider per reason, codes: side_effects / ineffective / cost / no_longer_needed / clinician_advised / other
* Free-text anecdote
* Problems addressed (multi-pick with per-problem efficacy)
* Effects experienced (multi-pick with per-effect valence + frequency)

== Storage tables (selected) ==

{| class="wikitable"
! Table !! Purpose
|-
| <code>pcp_votable_elements</code> || Stable per-(page, slug) handle reused by votes / likert / comments. Also <code>ve_options</code> + <code>ve_options_h</code> + <code>ve_results_policy</code> for choice votes.
|-
| <code>pcp_votes</code> || Binary +1/−1 votes (v_value) AND choice/multi votes (v_choices CSV + v_options_h drift hash)
|-
| <code>pcp_likert_reports</code> || Problem efficacy (0–100 + −1 DK), TINYINT signed
|-
| <code>pcp_effect_reports</code> || Effect ratings: experienced / frequency / valence (±100); perspective 1/2
|-
| <code>pcp_interaction_reports</code> || Interaction ratings: experience 1–5 / valence ±100 / note; perspective 1/2
|-
| <code>pcp_interactions</code> || Interaction edges (canonical-ordered pair)
|-
| <code>pcp_comments</code> || Threaded <code><discuss></code>-tag discussions (soft-delete, optional display name)
|-
| <code>pcp_user_profiles</code> || Per-user profile meta (alias, attribution, voter hash, prof_research_id)
|-
| <code>pcp_profile_fields</code> || Generic key-value field store: (namespace, key, num, text, visibility)
|-
| <code>pcp_profile_diagnoses</code> || Per-user diagnoses (system, code, description, status, origin, severity 0–100, disability 0–100, dates, notes, visibility)
|-
| <code>pcp_user_meds</code> || Per-user medicines (name, page_id, efficacy 0–100, burden 0–100, dose_mg, route, schedule, duration, periods JSON, current, notes, visibility)
|-
| <code>pcp_diagnosis_abbreviations</code> || ICD-10-CM + ICD-11 + DSM-5 + aliases (~41,500 rows, VARCHAR/utf8mb4 for native case-insensitive search)
|-
| <code>pcp_problem</code>, <code>pcp_problem_alias</code> || Problems repository + alias lookup
|-
| <code>pcp_experience_reports</code> || Experience reports (pending → approved); efficacy + burden 0–100; route + schedule; stop-reasons JSON; patient-count min + max
|-
| <code>pcp_life_events</code> || Timeline events. Columns: le_type (0=story, 1=image, 2=keyframe, 3=observation, 4=episode), le_polarity, le_raw_text (parser input), le_episode_type, le_episode_subtype, le_severity, le_date_struct (PCPDatePicker JSON; supports range)
|-
| <code>pcp_life_event_refs</code> || Join table linking events to entities (med / effect / problem / diagnosis / med_page / diagnosis_code / free); role (subject / cause / context / symptom / trigger / treatment)
|-
| <code>pcp_life_traits</code> || Keyframe trait values (assessment subscale snapshots → trajectory graph)
|-
| <code>pcp_life_images</code> || Image attachments (ClamAV-scanned)
|-
| <code>pcp_visibility_rules</code> || Per-(profile, namespace, key) sharing rules. Types: public / private / users / cohort / link_token / reciprocal. Optional vr_expires, vr_revoked, vr_attribution, vr_label.
|-
| <code>pcp_cohorts</code>, <code>pcp_cohort_members</code> || Owner-managed user groups for share-with-cohort flows
|-
| <code>pcp_visibility_view_log</code> || Audit trail of rule-permitted views (Special:MyShareLog)
|-
| <code>pcp_perspective_invite</code> || Token-bearing observer-perspective invitations (display name, object, type, max-uses)
|-
| <code>pcp_perspective</code> || Submitted observer perspectives (payload JSON, validity flag, consent gate)
|-
| <code>pcp_administer_respondents</code> || An owner's named contacts; the label is sealed to the owner's public key
|-
| <code>pcp_administer_invites</code> || One token-bearing administer link per send; stores only SHA-256 of the token
|-
| <code>pcp_administer_assessments</code> || The scale(s) in an invite; owner-sealed and respondent-sealed result copies
|-
| <code>pcp_administer_userkey</code> || Per-owner key material (X25519 public key, wrapped secret key, Mode-A salt + verifier)
|-
| <code>pcp_administer_research</code> || De-identified research pool: random id, coarsened month, no link back to the owner
|-
| <code>pcp_provider_apps</code> || Provider-verification applications (profession, specialty, jurisdiction, license, status, doc paths)
|-
| <code>pcp_literature</code> || Per-page literature submissions (citation metadata, optional PDF, status, reviewer)
|-
| <code>pcp_feature_request</code>, <code>pcp_feature_request_attachment</code>, <code>pcp_feature_request_comment</code> || Feature-request board: requests, ClamAV-scanned attachments, threaded comments
|-
| <code>pcp_formal_tests</code> || Catalog of standardized tests (abbrev, full name, category, score format)
|-
| <code>pcp_user_test_scores</code> || Per-user formal-test scores; raw score / percentile / pass-fail, each with its own visibility (uts_vis_raw / uts_vis_pct / uts_vis_passfail) and an estimate flag
|}

== Notable lessons learned ==

* '''Synthetic Event needs bubbles:true to trigger delegated listeners.''' <code>new Event('input')</code> defaults to <code>bubbles:false</code>, so listeners on parent wrappers never see programmatic dispatches. Native input/change events bubble by default; only JS-fired ones don't. Pass <code>{ bubbles: true }</code> explicitly. Bit DatePicker calendar-cell clicks 2026-05-18, typing in the text field autosaved fine, but picking a date from the calendar didn't, because blocksave's wrapper listener never received the event.
* '''MediaWiki form-field names collide with reserved URL params.''' A form <code><input name="title"></code> or <code>name="action"></code> with user-controlled value silently HIJACKS MW's dispatch when POSTed (body param overrides URL param). Symptom: form submits but lands on a wiki article named whatever the user typed, with URL bar still showing the special page. Bit the episode form 2026-05-18 (user typed 'Fake one' as title → got a 404 'create article: Fake one' page). Fix: prefix ALL custom form inputs with <code>pcp_</code> (both the input <code>name="..."</code> AND the matching <code>$request->getVal('...', ...)</code> read). Self-referential hidden inputs (<code>name="title" value="<getPageTitle()>"</code>) are safe.
* '''Cargo string fields cap at ~300 chars.''' <code>structure</code> and <code>mechanism</code> on MedTemplate are short VARCHARs; long prose goes in MEDIUMBLOB sections. Overruns silently lose Cargo data (MySQL Error 1406).
* '''VARBINARY + LOWER() is a no-op.''' MariaDB's LOWER() returns binary types unchanged. <code>pcp_diagnosis_abbreviations</code> was migrated VARBINARY → VARCHAR/utf8mb4 so case-insensitive LIKE works natively without CONVERT() wrappers.
* '''FlaggedRevs locks template inclusions by default.''' Config fix: <code>$wgFlaggedRevsHandleIncludes=0</code> + remove NS_TEMPLATE from <code>$wgFlaggedRevsNamespaces</code> via an extension-function callback.
* '''CSP must allow Cloudflare Turnstile and any other 3rd-party widget script source.''' Audit script-src / frame-src / connect-src / style-src whenever adding any 3rd-party JS widget.
* '''Sidebar cache must be purged after CLI <code>maintenance/edit.php</code> writes''' to <code>MediaWiki:Sidebar</code> or other chrome pages.
* '''CLI E_USER_DEPRECATED suppressed in LocalSettings.php''' (EmbedVideo / FlaggedRevs spam on MW 1.46). Web behavior unaffected.
* '''MW ApiResult drops keys starting with <code>_</code>.''' Any field whose key starts with underscore in an ApiResult payload is treated as internal metadata and stripped. Rename to plain identifier. Bit Phase 2-4 of visibility-rules subsystem.
* '''MW API serializes int-keyed assoc arrays unreliably.''' <code>[23 => 'Alice']</code> may arrive as <code>{"23": "Alice"}</code> or worse. Always use list-of-objects (<code>[{"id": 23, "name": "Alice"}]</code>) for id-to-value maps across the API boundary.
* '''PHP single-quoted strings don't interpret <code>\xNN</code> byte escapes.''' <code>'\xF0\x9F\x94\x97'</code> is 16 literal chars, NOT the 4-byte UTF-8 for 🔗. Use literal Unicode char or double-quoted <code>\u{1F517}</code>. Bit three times in one session.
* '''PHP "0" is FALSY.''' <code>!"0"</code> evaluates to TRUE. So <code>if ( !$x )</code> silently treats <code>"0"</code> (string zero) as missing. Bit choice-vote tallying when voter picked option index 0; vote was IN the DB but invisible to readers. Use <code>=== null || === ''</code> for "missing or blank" intent. <code>empty()</code> has the same problem.
* '''<code><span></code> can't contain <code><p></code>.''' MediaWiki auto-wraps tag content in <code><p></code> when there are newlines; browsers auto-close any <code><span></code> before the <code><p></code>, scattering child elements into wrong DOM positions. Use <code><div></code> for parser-tag wrappers whose content can span paragraphs (choice votes, life-story cards).
* '''vis.Graph2d group <code>style</code> belongs at TOP LEVEL''' not nested in <code>options</code>. Nesting silently fails (no error, just invisible lines). Bit the trait-trajectory graph on first build.
* '''A symmetric data-key cannot serve an asynchronous flow.''' The administer-to-others result must be encryptable while the owner is absent. A purely symmetric per-owner key has no holder at submission time; the model must be an asymmetric keypair, with the public key stored openly so a sealed box can always be written and only the owner's wrapped secret key can open it.
* '''A de-identified row must carry no order and no link.''' An auto-increment id rank-correlates with the source table and an insert timestamp time-correlates with it. The research pool uses a random 128-bit id and a month-only date so a row genuinely cannot be traced back.

== Hooks ==

* <code>ParserFirstCallInit</code>: register all parser tags
* <code>LoadExtensionSchemaUpdates</code>: install / migrate schema (the sql/ directory + patches)
* <code>BeforePageDisplay</code>: inject the ext.pharmacopedia.* ResourceLoader modules; resolve and apply the page skin (the <code>pcp-skin-*</code> body class) and, on the Main Page / Category index, the <code>pcp-diptych-page</code> chromeless class
* <code>UserGetRights</code> + <code>UserEffectiveGroups</code>: verified-provider role wiring
* Various special-page registrations via <code>SpecialPage_initList</code>

== Custom content namespaces ==

Six dedicated content namespaces sit above NS_MAIN for entities that have their own canonical wiki page beyond the main encyclopedic article surface. All are registered with talk pages (id +1), counted as content, included in default search, and tracked by FlaggedRevs (the FlaggedRevs registration is deferred via <code>$wgExtensionFunctions</code> so it runs after the extension's defaults merge, the same timing fix as the original NS_TEMPLATE block).

{| class="wikitable"
! ID !! Namespace !! Purpose
|-
| 3000 / 3001 || Enzyme: / Enzyme talk: || Drug-metabolizing enzymes (CYPs, UGTs, etc.) with locked-template substrate tables
|-
| 3002 / 3003 || Receptor: / Receptor talk: || Receptor entity pages
|-
| 3004 / 3005 || Phenotype: / Phenotype talk: || PGx phenotype reference pages
|-
| 3006 / 3007 || USLegal: / USLegal talk: || US legal / regulatory status reference pages (Prescription only, OTC, DEA Schedule I-V, plus terse redirects)
|-
| 3008 / 3009 || Problem: / Problem talk: || Per-Problem wiki pages; one per <code>pcp_problem</code> row; <code>p_page_id</code> column links the canonical DB row to its page id; <code><problemMedicines slug="X"/></code> auto-emits the medicines list inside each page
|-
| 3010 / 3011 || Effect: / Effect talk: || Per-Effect wiki pages; one per <code>pcp_effects</code> row; <code>e_page_id</code> column links the canonical DB row to its page id; <code><effectMedicines slug="X"/></code> auto-emits the medicines list inside each page
|}

The Problem: and Effect: namespaces ship with 170 + 288 auto-created stub pages (one per non-retired row in the canonical tables), produced by <code>maintenance/migrateProblemEffectStubs.php</code>. Each stub carries a one-line "Stub" header, the canonical description if any, the auto-generated medicines section, and the sentinel <code>Category:Problem stubs</code> / <code>Category:Effect stubs</code> for the buildout queue. The migration script is CLI-only, idempotent on re-run, and credits MDElliottMD via <code>EDIT_INTERNAL</code> (skips AbuseFilter + captcha + rate limits per MW convention for ops migrations).

Inbound linkage: every <code><problem ref="X"></code> on a medicine page links its problem-card title to <code>Problem:<Name></code>; every <code><effect ref="X"></code> links its label to <code>Effect:<Name></code>; the sidebar Common-uses list links the same way. <code>Special:Problem/<slug></code> auto-redirects to the matching NS page when <code>p_page_id</code> is set (the legacy aggregate render stays as a fallback for any unmigrated row).

== Wiki-content pages we maintain ==

Alongside the content articles themselves, the project maintains a small set of canonical wiki-content pages whose state is recorded in this spec doc:

* <code>About:Pharmacopedia.ext</code>: this spec, kept lockstep with extension version (interface-claude updates body + version line on every close-out).
* <code>About:Privacy</code>: site privacy policy, plain-language, covering data collection, third parties (Cloudflare Turnstile + Gmail SMTP + Dropbox-as-encrypted-backup-sub-processor), cookies, retention windows, encryption (Let's Encrypt TLS, PBKDF2-SHA512 passwords, OATHAuth 2FA, AdminCrypto X25519 sealed-box + AES-256-GCM, OAuth 2.0 + PKCE for the iOS app, GPG-AES256 backups), and the manual-today deletion path with the up-to-60-day backup-lag disclosure.
* <code>Category:Pharmaceutical</code> + <code>Category:Plants</code>: the two origin categories; every medicine page belongs to exactly one. Each category page is a descriptive history-first article per the canonical category-page spec.
* The eleven Pendell-class category pages (<code>Category:Euphorica</code>, <code>Category:Evaesthetica</code>, etc.): per-class wiki articles with an opening English-gloss clause sourced from Pendell's trilogy.
* The seven USLegal status pages (<code>USLegal:Prescription only</code>, <code>USLegal:Over-the-counter</code>, <code>USLegal:DEA Schedule I</code>...<code>V</code>) plus 26 terse redirects; medicine pages link these via the MedTemplate <code>legal=</code> field.
* <code>MediaWiki:Sidebar</code>: standard MW sidebar with the local additions (My profile, My assessments, etc.).

== Configuration globals ==

* <code>$wgPharmacopediaInteractionCategoryMarker</code> (default <code>Category:MedCategory</code>): only categories tagged with this marker appear in the add-interaction modal
* <code>$wgPharmacopediaVoteHashSecret</code> (required): HMAC secret for <code>v_voter_hash</code> so vote rows can't be mapped back to user accounts by anyone reading the DB without the secret
* <code>$wgPharmacopediaAdminKeyDir</code>: filesystem directory, outside the web root, holding the administer-to-others server master key (managed mode); never in the database, never in the DB backup set
* (Various permission-grant arrays via standard MW <code>$wgGroupPermissions</code>)

== Source layout ==

extensions/Pharmacopedia/
|-- extension.json
|-- includes/
| |-- Hooks.php
| |-- *Tag.php (parser tags: VoteTag, EffectTag, ProblemTag,
| | ClassGridTag, ClassTreeTag, LiteratureTag,
| | FrontPageTag, CategoryIndexTag, ...)
| |-- DiptychChrome.php (shared topbar + footer for the diptych splashes)
| |-- *Store.php (data access: EffectStore, ProblemStore, ElementStore, LifeStoryStore, ...)
| |-- UserProfileStore.php (the big one; profile / dx / meds / abbreviations)
| |-- VisibilityResolver.php (per-record sharing decision engine)
| |-- VirusScanner.php (ClamAV gate; fail-closed)
| |-- ObservationParser.php (plain-text -> structured observation)
| |-- SpecialMyProfile.php (the user profile editor; large)
| |-- SpecialMyAssessment.php (rich reports for the dimensional assessments; large)
| |-- SpecialMyLifeStory.php (life-story editor + visual timeline; large)
| |-- SpecialMyPerspectives.php / SpecialPerspective.php (observer perspectives)
| |-- SpecialAdministerAssessments.php / SpecialRespondToAssessment.php (administer to others)
| |-- SpecialPCPCtrls.php (sysop controls hub)
| |-- Special*.php (other special pages)
| |-- ProfileDatasets.php (countries, languages, genders, religions, etc.)
| |-- DatePicker.php (range / possibility-mix date widget backend + injectBirthdayContextOnce)
| |-- Assessments/
| | |-- AssessmentRegistry.php (single source of truth for the 13 instruments)
| | |-- AdminCrypto.php (X25519 / Argon2id / AES-256-GCM helper)
| | |-- Cati.php, CatiNorms.php
| | |-- Catq.php, CatqNorms.php
| | |-- Pid5bf.php, Pid5bfNorms.php
| | |-- Mbti.php
| | |-- Enneagram.php
| | |-- Ocean.php, OceanNorms.php
| | |-- Asrs.php, Amaas.php
| | |-- Bpns.php, BpnsNorms.php
| | |-- Nfcs.php, NfcsNorms.php
| | |-- Ocipcp.php
| | |-- WhoqolBref.php, WhoqolBrefNorms.php
| | `-- Raadsr.php (deprecated 2026-05-17 in favor of CATI, kept for archival reads)
| `-- Api/
| |-- VoteApi.php, EffectApi.php, ...
| |-- ObservationApi.php
| |-- VisibilityRulesApi.php, UserSearchApi.php, CohortsApi.php
| `-- RefUpgradeApi.php
|-- resources/
| |-- ext.pharmacopedia.js (single IIFE: chip-picker, dx autocomplete, vote logic, ...)
| |-- ext.pharmacopedia.styles.css (base stylesheet, self-hosted fonts)
| |-- ext.pharmacopedia.blocksave.js (debounced autosave per block)
| |-- ext.pharmacopedia.bounceback.js (scroll-position preservation)
| |-- ext.pharmacopedia.confirmdelete.* (styled destructive-action prompt)
| |-- ext.pharmacopedia.datepicker.js + .datepicker.styles.css
| |-- ext.pharmacopedia.timepicker.js + .timepicker.styles.css
| |-- ext.pharmacopedia.share.js + .css
| |-- ext.pharmacopedia.perspective.* (observer-perspective form enhancement)
| |-- ext.pharmacopedia.administer.* (administer-to-others surfaces)
| |-- ext.pharmacopedia.observation.js + .css
| |-- ext.pharmacopedia.refupgrade.js + .css
| |-- ext.pharmacopedia.lifetimeline.js + .css
| |-- ext.pharmacopedia.lifegraph.js + .css
| |-- ext.pharmacopedia.kitsync.js
| |-- ext.pharmacopedia.frontpage.* / ext.pharmacopedia.categoryindex.* (diptych splashes)
| |-- ext.pharmacopedia.appearance.* (the Appearance rail)
| |-- ext.pharmacopedia.skin.plants.css (plants-skin overlay)
| `-- vendor/vis-timeline/ (vis-timeline 7.7.3, Apache-2.0 + MIT)
| |-- vis-timeline-graph2d.min.js
| |-- vis-timeline-graph2d.min.css
| `-- LICENSE
|-- sql/
| |-- (one .sql per table; patches as patch-*.sql)
`-- i18n/
`-- en.json

[[Category:Pharmacopedia documentation]]

Paper:Test define widget

2026-05-28T01:38:19Z

MDElliottMD: OOPS

Paper:Test define widget

2026-05-28T01:35:38Z

MDElliottMD: Created page with "== Introduction == The study of <define term="pharmacokinetics">pharmacokinetics</define> examines how medicines behave in the body. <define term="bioavailability" style="margin">Bioavailability</define> describes the fraction of a dose that reaches systemic circulation. <define term="half_life" style="glass">Half-life</define> governs dosing frequency. Select any 1-4 words in this sentence to test the skin text-selection panel."

== Introduction ==

The study of <define term="pharmacokinetics">pharmacokinetics</define> examines how
medicines behave in the body. <define term="bioavailability" style="margin">Bioavailability</define>
describes the fraction of a dose that reaches systemic circulation.
<define term="half_life" style="glass">Half-life</define> governs dosing frequency.

Select any 1-4 words in this sentence to test the skin text-selection panel.

MediaWiki:Common.js

2026-05-27T20:14:01Z

MDElliottMD:

document.querySelectorAll( '.pcp-new-tab a' ).forEach( function ( a ) {
a.target = '_blank';
a.rel = 'noopener noreferrer';
} );

MediaWiki:Welcomecreation-msg

2026-05-27T20:11:07Z

MDElliottMD: made 2FA open in new tab to not lose the welcome page

[[File:Bigblacklogo.svg|right|frameless|420px|alt=Pharmacopedia logo|link=]]
'''Welcome to Pharmacopedia, [[User:$1|$1]]!'''

A few things to know:

* '''FIRST:''' Two-factor authentication (TOTP) is required to contribute to the hive mind. Set it up ASAP {{NewTab|Special:OATHManage|here}}.
* '''SECOND:''' If you're a licensed healthcare provider, you can apply for verified provider status [[Special:VerifyProvider|here]] — this lets you contribute observations from your clinical practice on medicine pages.
* '''THIRD:''' You can [[Experience_Sharing|share your experiences]] almost everywhere on the site, but the most efficient and thorough way is through [[Special:MyProfile]], where you can build a comprehensive and (selectively and extremely) private story of your life with essentially arbitrary detail.
* '''FOURTH:''' The assessment system in Pharmacopedia is rather extensive. Check it out at [[Special:MyProfile]] or find it in the left sidebar. If you're lost, you'll find yourself in that sidebar.

MediaWiki:Common.js

2026-05-27T20:10:17Z

MDElliottMD: Open in new tab Template

Template:NewTab

2026-05-27T20:07:29Z

MDElliottMD: Adding template for open in new tab across the platform.

About:Pharmacopedia.ext

2026-05-27T11:07:05Z

MDElliottMD: 0.9.8.7 Security section: correct live TLS config (HIGH:!aNULL, TLS1.0/1.1 allowed), fix LocalSettings.php owner (root:www-data), AbuseFilter 2/2 enabled, OATHAuth 5 recovery codes, HSTS preload pending

'''Version:''' 0.9.8.7 · '''Requires:''' MediaWiki >= 1.46.0 · PHP >= 8.5
'''Author:''' MDElliottMD · '''License:''' GPL-2.0-or-later
'''Source:''' <code>/var/www/mediawiki/extensions/Pharmacopedia/</code>

The Pharmacopedia extension turns a MediaWiki install into a structured, community-edited medicine reference with rich user-profile, assessment, life-story, and visibility-sharing infrastructure. It adds parser tags, special pages, API modules, two dark skins, a chip-picker / autosave UI framework, a vis-timeline-based visual life timeline, a granular per-record sharing subsystem, an observer-perspective subsystem, a token-gated subsystem for administering assessments to people outside the wiki, a two-origin diptych front-of-house, and a database schema that together support:

* Structured medicine pages via the <code><nowiki>{{MedTemplate}}</nowiki></code> template
* Per-user rating on effects, problems, titration strategies, anecdotes, and drug-drug interactions (continuous 0–100 sliders, ±100 valence; no 0–5 likert anywhere)
* Binary AND choice/multi voting on arbitrary content (<code>type="single"</code> / <code>type="multi"</code> with 2-5 options, results-visibility policy per element)
* Two-perspective data capture (personal vs. provider) wherever clinically meaningful
* User profile with dimensional personality / autism assessments (CATI, CAT-Q, MBTI, Enneagram, PID-5-BF, OCEAN/BFI-10) and rich auto-generated reports
* Further self-report instruments (BPNS, NFCS, OCI-PCP, WHOQOL-BREF) and the HYD-PCP wellbeing check-in, on the same auto-scored, report-bearing pattern
* ADHD screening (ASRS and AMAAS-SR) plus a Formal testing log of standardized-test scores, every score field carrying its own visibility
* Diagnosis autocomplete backed by ~41,500 ICD-10-CM, ICD-11, and DSM-5 codes
* '''Life-story timeline''': visual swimlanes (vis-timeline 7.7.3, vendored Apache-2.0) plus a synchronized trait-trajectory overlay (vis.Graph2d); card-list view alongside; quick-add free-text observation parser; range-date episode form with severity slider
* '''Per-record sharing subsystem''': rule types include public, private, users, cohort, link_token, reciprocal; time-bounded; audit log of who-viewed-what; bulk free-text → structured ref upgrader; privacy mode that disables legacy fallback
* '''Observer perspectives''': token-gated, no-account second-party input on something a user owns, under a two-gate consent model
* '''Administer to others''': send any registered assessment scale to people outside the wiki by one-time link, collect their results, and follow them over time, under per-owner public-key encryption with an optional zero-knowledge passphrase mode
* '''Two-origin diptych''': the Main Page and Category index render as chromeless full-viewport splashes giving the pharmaceutical and plant origins equal face
* Chip-picker / autosave / slider-precise-input UI framework shared across editor surfaces
* Date + time + range kit: PCPDatePicker (point/range/possibility), PCPTimePicker (fuzzy time-only: "4p", "noon", "quarter past 6")
* Verified-provider role with document-based verification
* Fail-closed ClamAV scan on every image / file upload (hard project rule)
* Per-user '''research_id''' (stable 10-char hex, opaque, never reassigned) for de-identified research participation

== Precision doctrine ==

A standing design rule (memorialised 2026-05-17) that shapes every storage / UI decision in the extension:

* '''No bucketing where a number or free-text will do.''' Income is numeric + currency, not a 5-band dropdown. Education keeps the bucketed dropdown ''and'' adds numeric years of schooling + free-text field of study.
* '''No single-select where multi-select reflects reality.''' Languages, gender identities, ethnicities, pronouns, religion, marital status, stop-reasons, all use chip-pickers (with optional severity per chip where relevant).
* '''No forced category where a continuous score works.''' All assessments (Enneagram 9 type sliders, MBTI 4 dichotomy sliders, OCEAN 5 trait sliders, CATI/CAT-Q/PID-5-BF items) use continuous 0–100 sliders, never radio buttons or button rows. Valence is ±100, not ±3.
* '''Storage in canonical form, UI converts at display.''' Heights stored cm regardless of user's preferred unit (cm or ft+in); ICD codes stored as ISO; date capture as range / possibility-mix JSON.
* '''Browser auto-fill as suggestion only.''' Country chip pre-fills from <code>navigator.language</code>; languages from <code>navigator.languages</code>; time zone from <code>Intl.DateTimeFormat().resolvedOptions().timeZone</code>. User can always edit or remove.
* '''Always allow custom free-text where the curated list might miss someone.''' Chip-pickers accept Enter-to-add custom chips for all picklists except ISO-coded ones (country, language).

== High-level architecture ==

* '''Backend (PHP):''' <code>includes/</code>, one class per parser tag, store, special page, or API module. Auto-loaded under <code>MediaWiki\Extension\Pharmacopedia\</code>. Assessment classes under <code>includes/Assessments/</code>. API modules under <code>includes/Api/</code>.
* '''Frontend (JS / CSS):''' multiple ResourceModules per surface area:
** <code>ext.pharmacopedia</code>: main IIFE (chip-picker, dx autocomplete, BFI-10 compute, vote logic for both binary and choice/multi)
** <code>ext.pharmacopedia.styles</code>: base extension stylesheet (self-hosted Geist / Newsreader / Source Serif fonts, core component styling)
** <code>ext.pharmacopedia.blocksave</code>: debounced autosave per block (race-safe)
** <code>ext.pharmacopedia.bounceback</code>: preserves the reader's scroll position across POST-then-reload actions via sessionStorage
** <code>ext.pharmacopedia.confirmdelete</code>: styled red warning prompt replacing <code>window.confirm()</code> on destructive actions
** <code>ext.pharmacopedia.datepicker</code> + <code>.datepicker.styles</code>: range / possibility-mix date widget
** <code>ext.pharmacopedia.timepicker</code> + <code>.timepicker.styles</code>: time-only widget (fuzzy parsing, extracted from DatePicker)
** <code>ext.pharmacopedia.share</code>: per-record share dialog (People / Link / Cohorts tabs)
** <code>ext.pharmacopedia.perspective</code>: observer-perspective form enhancement (slider readout, progress, consent/delete confirm)
** <code>ext.pharmacopedia.administer</code>: the administer-to-others surfaces (take-flow slider readout + "Not sure" toggling, owner-hub styling)
** <code>ext.pharmacopedia.observation</code>: quick-add observation textarea + live preview
** <code>ext.pharmacopedia.refupgrade</code>: bulk linker for free-text → structured refs
** <code>ext.pharmacopedia.vis-timeline-vendor</code>: vis-timeline 7.7.3 (vendored)
** <code>ext.pharmacopedia.lifetimeline</code>: visual life-story timeline + swimlanes + toolbar
** <code>ext.pharmacopedia.lifegraph</code>: trait-trajectory overlay (vis.Graph2d) synced to timeline
** <code>ext.pharmacopedia.kitsync</code>: glue that propagates kit-widget changes into legacy hidden inputs + drives privacy-mode toggle
** <code>ext.pharmacopedia.frontpage</code> / <code>ext.pharmacopedia.categoryindex</code>: the two diptych splash modules, each self-contained so it renders with no skin loaded
** <code>ext.pharmacopedia.appearance</code>: the collapsible Appearance rail (reader text-size control)
** <code>ext.pharmacopedia.skin.plants</code> / <code>ext.pharmacopedia.skin.fungi</code>: the earth-toned plants-skin overlay and the fungi sub-skin override layer
* '''Schema:''' <code>sql/</code>, roughly three dozen core tables plus migration patches. Picked up via the <code>LoadExtensionSchemaUpdates</code> hook.

== Security & encryption ==

Pharmacopedia stores deliberately personal data, including self-reports across mood, addiction, sexuality, and clinical history. The cryptographic + operational posture below is documented in detail so that a security researcher can read it in one pass and know exactly what is on the ground. Values are quoted verbatim where they are already observable from the public surface (HTTP headers, TLS handshake, public APIs); secrets and rotation policy are described without disclosing their values.

=== Transport ===

TLS terminates at Apache 2 (mod_ssl) on the same host as the application. No CDN, no reverse proxy, no load balancer is in front. Certificate is a Let's Encrypt ECDSA leaf, renewed by <code>certbot.timer</code> (fires twice daily, renews when within 30 days of expiry). Private key on disk is mode 600 root:root in <code>/etc/letsencrypt/archive/pharmacopedia.wiki/</code>.

Apache TLS config (live from <code>/etc/letsencrypt/options-ssl-apache.conf</code> + <code>/etc/apache2/mods-enabled/ssl.conf</code>):

SSLProtocol all -SSLv3
SSLCipherSuite HIGH:!aNULL
SSLSessionTickets off

Effective TLS range: TLS 1.0 through 1.3 (SSLv3 explicitly refused). The cipher suite shorthand <code>HIGH:!aNULL</code> covers all ECDHE + DHE forward-secrecy ciphers but does not exclude TLSv1.0 or TLSv1.1 at the protocol layer. Hardening to an explicit modern list and <code>SSLProtocol -TLSv1 -TLSv1.1</code> is queued; see ''Honest limitations'' below. <code>SSLSessionTickets off</code> preserves forward secrecy across server restarts.

HSTS:

Strict-Transport-Security: max-age=63072000; includeSubDomains; preload

Two years, subdomains included, preload-ready. The <code>preload</code> directive is present in the header; submission to the Chromium HSTS preload list is pending.

=== HTTP security headers ===

Set at the Apache layer (<code>/etc/apache2/conf-enabled/security-headers.conf</code>), not relying on PHP:

Content-Security-Policy: default-src 'self'; script-src 'self' 'unsafe-inline' 'unsafe-eval' https://challenges.cloudflare.com; style-src 'self' 'unsafe-inline'; img-src 'self' data: blob: https:; media-src 'self' blob:; font-src 'self' data:; object-src 'none'; frame-src 'self' https://challenges.cloudflare.com; worker-src blob:; base-uri 'self'; form-action 'self';
Strict-Transport-Security: max-age=63072000; includeSubDomains; preload
Referrer-Policy: strict-origin-when-cross-origin
X-Frame-Options: SAMEORIGIN
Permissions-Policy: geolocation=(), camera=(self), microphone=(), payment=()
X-Content-Type-Options: nosniff (set by MediaWiki)

<code>'unsafe-inline'</code> + <code>'unsafe-eval'</code> are required by MediaWiki's JS/CSS pipeline; <code>challenges.cloudflare.com</code> is whitelisted only for the Cloudflare Turnstile widget. <code>object-src 'none'</code> blocks Flash/applet vectors; <code>base-uri 'self'</code> blocks base-tag hijack; <code>form-action 'self'</code> blocks off-origin form POST. No COOP / COEP / CORP set: MW does not need cross-origin isolation.

=== Apache file filters + URL redaction ===

A backup-pattern denylist applies under the document root:

<FilesMatch "\.pre-|\.bak|\.orig|\.php\.|~$">
Require all denied
</FilesMatch>

This closes editor swap files, ad-hoc <code>.pre-<feature></code> snapshots, <code>.orig</code> merge debris, and emacs / vim trailing-tilde backups (a source-disclosure path closed 2026-05-20).

Skin asset directories run a positive allowlist (default-deny, only the whitelisted suffixes are served):

<FilesMatch "(?i)^(?!.*\.(php|js|mjs|css|json|png|gif|jpe?g|svg|ico|webp|woff2?|ttf|eot|otf|html?|map|pdf)$)">
Require all denied
</FilesMatch>

The web installer at <code>/mw-config/</code> is 403'd at the vhost layer regardless of any <code>$wgUpgradeKey</code> value.

Token-bearing URLs are redacted from access logs by <code>/etc/apache2/conf-enabled/pcp-log-redaction.conf</code>. Pharmacopedia issues two URL families that carry per-request secrets in the path: <code>Special:RespondToAssessment/<token></code> (the invite token derives the AES key for the respondent-readable AdminCrypto copy) and <code>Special:Perspective/<token></code>. The redaction rule rewrites the request URI in the access log to a literal "[pcp: token-bearing URL redacted]" while preserving IP, time, method, status, byte count, and User-Agent. Three match-paths (request URL, Referer, query string) cover navigation, subresource, and <code>?title=</code> invocations.

=== PHP-FPM hardening ===

Production pool <code>/etc/php/8.5/fpm/pool.d/mediawiki-prod.conf</code> runs as <code>www-data</code> on an UDS socket (<code>0660 www-data:www-data</code>), <code>pm = ondemand</code>, <code>pm.max_children = 16</code>, <code>pm.max_requests = 500</code> (workers cycle every 500 requests to recover memory). Per-pool <code>open_basedir</code> restricts filesystem access to the small set of directories the wiki actually needs:

/var/www/mediawiki, /tmp, /var/log/mediawiki, /var/lib/php,
/var/cache/mediawiki, /var/lib/pharmacopedia-verification,
/var/lib/pharmacopedia-literature, /var/lib/pharmacopedia-life,
/usr/bin, /dev/null, /dev/urandom,
/var/lib/pharmacopedia-feature-requests,
/var/lib/pharmacopedia-adminkeys, /var/lib/mwoauth2

A workspace outside this list is unreadable from PHP regardless of file mode.

ini hardening: <code>expose_php = Off</code>, <code>display_errors = Off</code> (errors go to log only), <code>allow_url_include = Off</code> (remote-PHP include attack vector closed; <code>allow_url_fopen = On</code> stays because MW needs upload-from-URL). Session cookies: <code>secure = 1</code>, <code>httponly = 1</code>, <code>samesite = "Lax"</code>, <code>use_strict_mode = 1</code>, <code>use_only_cookies = 1</code>, session-end lifetime, 24-minute idle gc. opcache enabled with <code>validate_timestamps = 1</code> + 2-second revalidate (no stale-code-after-deploy risk).

=== Database ===

MariaDB 10.11.14, <code>bind-address = 127.0.0.1</code> only (the loopback). DB ports are not exposed to the network; UFW does not need a rule because the bind never reaches the wire. <code>sql_mode</code> includes <code>STRICT_TRANS_TABLES</code> + <code>ERROR_FOR_DIVISION_BY_ZERO</code> (strict type + math behavior). <code>have_ssl = DISABLED</code> is deliberate (loopback-only connections do not benefit from TLS overhead). The wiki's DB account is scoped to the two MW schemas (<code>mediawiki</code>, <code>mediawiki_staging</code>); no <code>FILE</code>, no <code>SUPER</code>, no <code>GRANT OPTION</code>. A DB compromise via injection is bounded to those two schemas.

=== SSH + host ===

<code>sshd</code> is key-only (<code>PasswordAuthentication no</code>, <code>KbdInteractiveAuthentication no</code>, <code>PermitEmptyPasswords no</code>), <code>PermitRootLogin prohibit-password</code> (root accessible only with an authorized key), <code>MaxAuthTries 6</code>, X11 forwarding off. Modern key exchange algorithms preferred (sntrup761x25519, curve25519); legacy SHA1 MACs left in the list for client compatibility.

UFW is deny-by-default for incoming traffic, allow-all outgoing. The only open ingress ports are 22/tcp, 80/tcp, and 443/tcp. The database, the SMTP relay, and the application cache are all loopback-only.

fail2ban runs five jails: <code>sshd</code>, <code>apache-auth</code>, <code>apache-badbots</code>, <code>mediawiki-auth</code> (matches failed wiki logins by spotting <code>200</code> responses on POSTs to <code>Special:UserLogin</code> / <code>Special:CreateAccount</code> — successful logins redirect <code>302</code>), and <code>web-scanners</code> (matches the usual probe patterns).

=== Secrets and keys on disk ===

The high-trust paths and their modes (no values published):

/var/www/mediawiki/LocalSettings.php 640 root:www-data
contains: $wgSecretKey, $wgUpgradeKey, $wgDBpassword,
$wgTurnstileSecretKey, $wgSMTP['password'],
$wgPharmacopediaVoteHashSecret,
$wgOAuth2{Private,Public}Key paths
/root/.backup-passphrase 600 root:root (64 bytes random)
/var/lib/mwoauth2/oauth-private.key 600 www-data:www-data (RSA-4096)
/var/lib/mwoauth2/oauth-public.key 644 www-data:www-data
/var/lib/pharmacopedia-adminkeys/ 700 www-data:www-data
master.key (lazy-provisioned on first Mode B owner) 600 www-data:www-data
/etc/exim4/passwd.client 640 root:Debian-exim
/etc/letsencrypt/archive/.../privkey1.pem 600 root:root
/root/.config/rclone/rclone.conf 600 root:root

Public values that are safe to read:
* Cloudflare Turnstile site key: <code>0x4AAAAAADMu_bvOguDp0U52</code>
* Backup target: <code>dropbox:pharmacopedia-backups</code> (Dropbox holds only AES-256-encrypted bundles; the passphrase never leaves the host)

Rotation policy:
* <code>$wgSecretKey</code> is NOT rotated (would invalidate every session and signed-state cookie).
* <code>$wgUpgradeKey</code> rotated 2026-05-22 to 256 bits.
* <code>$wgPharmacopediaVoteHashSecret</code> is intentionally never rotated (rotation invalidates every voter-state mapping, retroactively breaking voter anonymity for existing votes).
* TLS private key rotates on Let's Encrypt renewal (automatic, twice-daily check).
* AdminCrypto Mode B master key + OAuth2 RSA keypair are NOT rotated today; rotation would invalidate existing wrappings + outstanding tokens. Future rotation is overlap-aware (re-wrap under new key, accept either during the cutover window).

=== Application-layer cryptography ===

==== Passwords and second factor ====

MediaWiki passwords are stored as PBKDF2 hashes (MW core default). Verified across every <code>user_password</code> row: HMAC-SHA-512 inner hash, 30,000 iterations, 64-byte derived key, 16-byte random salt per user. The <code>$wgPasswordConfig</code> default is unmodified; bcrypt is available in MW core but not enabled.

Two-factor authentication via the OATHAuth extension. Default module is TOTP per RFC 6238: HMAC-SHA-1 inner, 6 digits, 30-second time-step, 80-bit shared secret. Five recovery codes per user, each a random string, hashed at rest, consumed on use. WebAuthn / FIDO2 (passkey) is available in the same extension and is the operator's first-choice path.

==== AdminCrypto ====

The "Administer to others" subsystem uses a per-owner asymmetric envelope so that respondents can submit results without an account and the owner can decrypt while absent. Implementation (<code>extensions/Pharmacopedia/includes/Assessments/AdminCrypto.php</code>):

Per-owner X25519 keypair generated via <code>sodium_crypto_box_keypair()</code> (libsodium, kernel CSPRNG). The public key is stored in the clear; the secret key is wrapped at rest in <code>pcp_administer_userkey.uk_wrapped_seckey</code> with AES-256-GCM (12-byte fresh IV per call, 16-byte authentication tag, empty AAD; wrapped layout: <code>IV || ciphertext || tag</code>).

Respondent submissions are sealed to the owner's public key via <code>crypto_box_seal</code> (libsodium, anonymous X25519 sender): anyone can encrypt with the public key; only the owner can decrypt with the secret key.

Two key-custody modes:

* '''Mode A (passphrase, zero-knowledge).''' The wrap key for the owner's X25519 secret key derives from a passphrase the server never stores, via Argon2id (libsodium <code>sodium_crypto_pwhash</code> with <code>ARGON2ID13</code>). Two version tracks: v1 uses INTERACTIVE limits (2 ops, 64 MiB memory); v2 uses MODERATE limits (3 ops, 256 MiB memory). The 16-byte salt is stored in <code>uk_kdf_salt</code>; the derivation produces a 32-byte wrap key and a 32-byte verifier (domain-separated SHA-256 of the wrap key). Older-version owners are transparently re-wrapped to the current KDF version on their next successful unlock. ''In Mode A, a database leak alone yields nothing the attacker can decrypt without the owner's passphrase, by design.''
* '''Mode B (managed key).''' The wrap key is a 32-byte random AES-256-GCM key in <code>/var/lib/pharmacopedia-adminkeys/master.key</code> (mode 600 <code>www-data:www-data</code>), lazy-provisioned on first Mode B owner setup. The directory is excluded from the backup tar by path; a database-plus-backup leak does not yield decryption power, because the master key never enters the backup pipeline.

A separate respondent-readable copy of each submission is encrypted with a key derived from the invite token: <code>respondentKey = SHA-256("pcp-administer-respondent-v1:" || rawToken)</code>. The server never stores this key; the rawToken lives only in the URL handed to the respondent. The token-bearing URL is redacted from access logs (see ''Apache file filters'' above).

==== OAuth 2.0 (iOS app) ====

The iOS app authenticates against the wiki via the MWOAuth extension. RSA-4096 signing keypair generated 2026-05-22 with <code>openssl genrsa</code>; JWT signing algorithm RS256. Access tokens live 1 hour; refresh tokens 1 month (MWOAuth defaults). PKCE with S256 challenge is REQUIRED for public clients (<code>$wgOAuth2RequireCodeChallengeForPublicClients = true</code>); the iOS bundle never holds a client secret. Tokens are stored at rest in the wiki's session cache keyed by hashed token (the tokens themselves are opaque to the cache row). The browser-to-app handoff goes via a small HTML+JS bridge at <code>https://pharmacopedia.wiki/app/oauth-callback</code> that forwards the authorization code + state to the <code>pharmacopedia://oauth</code> custom URL scheme. Special:UserLogin and Special:CreateAccount also carry <code>autocomplete</code> field attributes (<code>username</code>, <code>current-password</code> / <code>new-password</code>, <code>email</code>) injected by the <code>AuthChangeFormFields</code> hook so iOS Safari + system password managers offer the right credentials on the right field.

==== Voter anonymity ====

Every vote stores a HMAC-SHA-256 of the voter's user id, salted with <code>$wgPharmacopediaVoteHashSecret</code> (256 bits, never rotated by policy). The hash is a 64-character hex string in <code>pcp_votes</code> in place of the user id, so an administrator reading the votes table cannot map a vote back to an identity without the secret. The secret lives only in LocalSettings.

==== Perspective-invite tokens ====

The perspective subsystem's invite tokens are 24-byte URL-safe random strings handed to invitees in <code>Special:Perspective/<token></code> links. As of 0.9.8.7, every new invite stores BOTH the cleartext token in <code>pcp_perspective_invite.pvi_token</code> AND a SHA-256 hash of the same token in a new <code>pvi_token_hash</code> column (<code>BINARY(32)</code>, <code>UNIQUE</code>). Lookup at <code>PerspectiveStore::resolveToken</code> hashes the inbound URL token and searches by hash first; a cleartext-column fallback covers any row not yet backfilled at deploy edge. Hashing reuses the canonical <code>AdminCrypto::hashInviteToken</code> helper (raw 32-byte SHA-256), the same shape as the existing <code>pcp_administer_invites.inv_token_hash</code> pattern.

Honest current status: this is half-shipped on purpose. The cleartext <code>pvi_token</code> column is still present so the lookup-fallback works during the dual-write cycle; 0.9.8.8 drops the cleartext column and the fallback branch, at which point a database-read attacker can no longer extract usable perspective-invite tokens.

=== Backups ===

<code>/usr/local/bin/pharmacopedia-backup.sh</code> runs daily at 03:15 local. Every artifact is GPG-symmetric encrypted with AES-256 before it touches the off-host stage:

gpg --batch --yes --symmetric --cipher-algo AES256
--passphrase-file /root/.backup-passphrase

GPG packet inspection on a current bundle confirms cipher 9 (AES256), S2K mode 3 (iterated and salted), S2K count 65,011,712 iterations, MDC method 2 (modification-detection code present). Local retention is 7 days; off-host (Dropbox via rclone) is 14 days as of 2026-05-23 (was 60). The passphrase file is 64 bytes random, mode 600 root:root, never transmitted off-host.

The 14-day window describes ACTIVE off-host storage: after 14 days the encrypted bundle is removed from the active view of the off-host provider by the nightly rotation. The current off-host provider (Dropbox Pro) additionally retains deleted files in a deletion-recovery layer for up to 180 days, during which the encrypted bundle may remain recoverable by the account operator; after that window the bundle is permanently and irrecoverably deleted. The bundle is GPG-AES256 encrypted at all times; the off-host provider cannot read it under any circumstance. This active-vs-recovery distinction is queued for removal once a B-side backend migration (Hetzner Storage Box BX11, SFTP, POSIX unlink, no recovery layer) ships; tracked in ''Honest limitations'' below.

The backup tar covers <code>/var/www/mediawiki/images</code>, <code>LocalSettings.php</code>, the Pharmacopedia extension, and local skin assets. The full <code>mediawiki</code> schema is dumped separately to a sibling SQL file (also encrypted). Deliberately excluded by path: the AdminCrypto master key, the OAuth2 RSA private key, the backup passphrase itself, the Gmail SMTP credential, and the Let's Encrypt private key. ''A leak of any single backup bundle does not yield Mode B decryption power, JWT signing power, or further off-host backup decryption — those keys live elsewhere on the host and are not in the bundle.''

=== Logging + audit ===

Apache access/error logs and the MediaWiki exception / error / dberror / fatal logs all rotate daily and retain 14 days, then delete. Log files are <code>640 root:adm</code> (Apache) and <code>640 www-data:adm</code> (MW); the world-readable mode that existed prior to 2026-05-22 was tightened in the same audit pass that hardened the rest of the host.

MW exception logs live at <code>/var/log/mediawiki/{exception,error,dberror,fatal}.log</code>. The <code>pcp_visibility_view_log</code> table records every permitted view through a share rule (rule type, viewer, timestamp); the table stores raw IP for anonymous viewers (no /24 mask today — a feature gap, not a privacy claim).

=== Abuse protection ===

* Cloudflare Turnstile gates account creation, repeated failed logins, URL-bearing edits, and email-sending. Editors are not challenged on normal edits (a deliberate friction trade-off).
* The AbuseFilter extension is loaded with 2 rules, both enabled as of 0.9.8.7. Rule 1: spam-keyword block (block + disallow). Rule 2: new-account edit throttle (throttle). The active rule set is small; the lane will grow as live-fire patterns emerge.
* Every file or image upload is scanned by ClamAV before the file moves into the persistent store. The scanner is run via <code>clamdscan</code> (persistent daemon, fast) with a fallback to <code>clamscan</code>. The gate is fail-closed: exit 0 = clean (proceed), exit 1 = infected (reject + unlink), any other exit = error (reject + unlink). A scanner crash never becomes a pass.
* fail2ban (see ''SSH + host'' above) bans abusive IPs at the network layer.
* No CDN or DDoS mitigation layer sits in front; a determined volumetric attacker can degrade availability. We do not claim 24/7 uptime.

=== Honest limitations ===

The posture above is reasonable for a single-operator project that handles personal data; it is not pretending to be anything else.

* '''Single point of failure.''' Host-root compromise yields AdminCrypto Mode B decryption, OAuth2 JWT signing, backup decryption (via the passphrase file), and outbound email impersonation. Defense-in-depth lives in per-key file separation + filesystem perms + open_basedir, but a root-on-host attacker who clears each gate gets everything.
* '''Backup-lag on deletion.''' When a user requests deletion, the live row is purged immediately; the encrypted bundle is removed from active off-host storage after 14 days; the off-host provider's deletion-recovery layer may keep the (still-encrypted) bundle recoverable by the account operator for up to 180 days after that, until it is permanently deleted. Disclosed in About:Privacy on the wiki and (with identical wording) in Oyami's PRIVACY.md. Queued: a backend migration to Hetzner Storage Box (POSIX unlink, no recovery layer) collapses the window to a clean 14 days.
* '''No CDN, no DDoS layer.''' One VM, three open ports, UFW + fail2ban. Hostile traffic can take the site down; it cannot exfiltrate.
* '''Some application-layer key rotation is "never" by design.''' The voter-hash secret and the AdminCrypto Mode B master key cannot rotate without breaking either anonymity or existing wrappings respectively. Loss of either key has the obvious one-time consequence; trading that off against the alternative (re-encrypt every historical record) was the deliberate choice.
* '''TLS allows TLSv1.0 and TLSv1.1.''' The live Apache literal is <code>SSLProtocol all -SSLv3</code>, which does not exclude older TLS protocol versions at the protocol layer. Hardening to an explicit modern cipher list with <code>SSLProtocol -TLSv1 -TLSv1.1</code> is queued.
* '''Perspective-invite tokens are half-migrated to hashed storage.''' 0.9.8.7 added the <code>pvi_token_hash</code> column, backfilled it, and switched the lookup to hash-first; the cleartext <code>pvi_token</code> column is still present so the dual-write fallback works during the deploy edge. 0.9.8.8 drops the cleartext column and the fallback branch, at which point a database-read attacker can no longer extract usable invite tokens. Severity in the interim: an attacker with DB read can still submit a perspective under a planted invite identity; not access to medical data.

=== Security researchers welcome ===

I'm a long-term privacy hobbyist, but new at building real infrastructure. I'm trying my best and honestly it seems world-class good to me (and claude), but if it's not. I need to know ASAP.

If you find anything worth flagging — vulnerability, weakness, design concern, or just an observation — email [mailto:info@pharmacopedia.wiki me] directly. No bug-bounty program; just genuine appreciation for the time and the love of [https://markelliottmd.com/pubkey.asc pretty darn good privacy]. No NDA, no scope restriction, no preferred-disclosure-window. Reach out for any reason.

== Skins, layout, and the Appearance rail ==

'''Two skins.''' Every page renders in one of two dark skins. The default '''pharmaceutical skin''' is the violet-on-near-black clinical identity. The '''plants skin''' is an earth-toned treatment (<code>ext.pharmacopedia.skin.plants</code>) applied to plant-origin medicine pages. Both skins are dark; there is no light mode. The '''fungi sub-skin''' (<code>ext.pharmacopedia.skin.fungi</code>) is a specialization of the plants skin for fungal medicine pages: a fungus page carries both the <code>pcp-skin-plants</code> and <code>pcp-skin-fungi</code> body classes, loading the plants base plus a fungi override layer (a damp cool-dark palette, a spore-dust grain, the mushroom mark, fungi section-marker hues); everything else inherits from the plants skin.

<code>Hooks::resolvePcpSkin</code> picks the skin. A content (medicine) page is read by its OWN DIRECT origin category: a direct <code>Category:Fungi</code> tag gives the fungi sub-skin (checked first), a direct <code>Category:Plants</code> tag gives the plants skin, anything else pharma. There is no recursive category walk, so a page sitting inside a dual-parented class category (Category:Psychedelics parents under both origins) is skinned by its own origin tag, not by its class. A category page has no single direct origin, so it is resolved by walking its category chain (plants only when the chain is purely plant).

'''Full-width layout.''' The content frame runs edge to edge rather than in a fixed-width column; prose is held to a readable measure by its own constraint, and the layout gutters are set by layout tokens.

'''The Appearance rail.''' A collapsible rail (<code>ext.pharmacopedia.appearance</code>) gives the reader appearance controls, currently a text-size control. The chromeless diptych splashes suppress the rail.

== Front-of-house: the diptych ==

The Main Page and the Category index are built as a '''two-origin diptych''': a pharmaceutical column and a plant column side by side, the two origins of the materia medica given equal face. Both render as '''chromeless full-viewport splashes'''. A <code>body.pcp-diptych-page</code> class, added by the <code>BeforePageDisplay</code> hook on those two pages, hides all Vector chrome, and the module supplies its own topbar and footer. A full-height two-origin split gradient runs the page edge to edge, the pharma dark on the left half and the plant dark on the right, a 1px seam down the middle, so the diptych reads top to bottom with no separate bands.

Two parser tags generate the diptych from live wiki data:
* <code><frontpage></code> (<code>FrontPageTag</code>), the Main Page: a featured medicine and featured plant medicine, class / Pharmako-volume browse lists, recently-updated lists, portal links, a status strip.
* <code><categoryindex></code> (<code>CategoryIndexTag</code>), the Category index: the pharmacological classes and the plant lineages as two side-by-side trees.

<code>DiptychChrome</code> supplies the shared topbar and footer for both. The modules are <code>ext.pharmacopedia.frontpage</code> and <code>ext.pharmacopedia.categoryindex</code>; each carries its own palette tokens so the splash renders correctly with no skin stylesheet loaded.

The topbar carries a '''live typeahead search''' as the leftmost item of the right-side topnav cluster. It debounces 180 ms, fetches up to 8 results per keystroke (min 2 chars), and renders an ARIA-combobox dropdown with arrow / Enter / Escape keyboard navigation. The fetch path is hybrid: <code>action=opensearch</code> first (fast prefix index across the eight content namespaces: main, Category, Enzyme, Receptor, Phenotype, USLegal, Problem, Effect), with a <code>action=query&list=search</code> fallback fired on zero hits so all-caps titles like LSD (which opensearch cannot case-insensitively prefix-match against a lowercase query) still resolve.

== Parser tags ==

Registered via <code>Hooks::onParserFirstCallInit</code>:

{| class="wikitable"
! Tag !! Purpose !! Class
|-
| <code><vote></code> || Binary up/down (default) OR choice/multi when <code>type="single"</code> or <code>type="multi"</code> + <code>options="A; B; C"</code> (2-5 options, semicolon-separated). Optional <code>results="live\|after-vote\|hidden"</code> for tally-visibility policy. || <code>VoteTag</code>
|-
| <code><effect></code> || Therapeutic or adverse effect; patient + provider perspectives; provider freq slider 0–100; shared valence slider ±100 || <code>EffectTag</code>
|-
| <code><discuss></code> || Threaded comment widget || <code>CommentTag</code>
|-
| <code><effectsummary></code> || Roll-up aggregate header || <code>EffectSummaryTag</code>
|-
| <code><titration></code> || Titration strategy card with up/down vote || <code>TitrationTag</code>
|-
| <code><anecdote></code> || Personal or provider story with up/down vote || <code>AnecdoteTag</code>
|-
| <code><problem></code> || A problem the medicine addresses; 0–100 efficacy likert slider + "don't know" toggle || <code>ProblemTag</code>
|-
| <code><pharmaInteractions/></code> || Self-closing; renders the Interactions section for the current page || <code>InteractionTag</code>
|-
| <code><pharmaExperience/></code> || Self-closing; renders the Experience report form (efficacy, burden, dose, route, schedule, stop-reasons) || <code>ExperienceTag</code>
|-
| <code><pharmaLiterature/></code> || Self-closing; per-medicine "Relevant literature" section: approved <code>pcp_literature</code> entries plus a collapsed submission form || <code>LiteratureTag</code>
|-
| <code><classGrid/></code> || A grid of medicine-class categories (those tagged Category:MedCategory); <code>count</code> + <code>exclude</code> attributes; 5-minute cache || <code>ClassGridTag</code>
|-
| <code><classTree/></code> || The MedCategory classes as a hierarchy with member counts; <code>exclude</code> attribute; 5-minute cache || <code>ClassTreeTag</code>
|-
| <code><frontpage/></code> || The two-origin diptych Main Page (see [[#Front-of-house: the diptych|Front-of-house]]) || <code>FrontPageTag</code>
|-
| <code><categoryindex/></code> || The two-origin diptych Category index || <code>CategoryIndexTag</code>
|-
| <code><pharmaCommonUses>...</pharmaCommonUses></code> || Medicine-page sidebar "Common uses": top-5 problems by rater count, ranked desc; falls back to the legacy hand-entered <code>uses</code> wikitext when zero problems are linked || <code>CommonUsesTag</code>
|-
| <code><problemMedicines slug="X"/></code> || Auto-generated list of medicines that carry a <code><problem ref="X"></code>. Used on every Problem:<Name> namespace page so the canonical "Medicines used for X" section maintains itself || <code>ProblemMedicinesTag</code>
|-
| <code><effectMedicines slug="X"/></code> || Auto-generated list of medicines that carry an <code><effect ref="X"></code>. Used on every Effect:<Name> namespace page so the canonical "Medicines that may cause X" section maintains itself || <code>EffectMedicinesTag</code>
|}

All non-self-closing rating tags take a <code>slug</code> argument and (where relevant) a <code>title</code>, <code>label</code>, <code>author</code>, <code>ref</code>, or <code>perspective</code>.

=== Tag wikitext examples ===

<pre>
<problem slug="depression" title="Major depressive disorder"
author="MDElliottMD">First-line for moderate to severe MDD.</problem>

<effect slug="nausea" label="Nausea"/>

<effect ref="hyperkalemia"/> 

<titration slug="slow-start-elderly" title="Slow start (elderly)"
author="MDElliottMD">Begin at 10 mg q AM; titrate by 10 mg every 14 days.</titration>

<anecdote slug="qi8sg2" perspective="provider"
author="MDElliottMD">One patient developed serotonin syndrome at week 3...</anecdote>

<pharmaInteractions/>
<pharmaExperience/>

<vote slug="fav-color" type="single" options="Red; Blue; Green">
What's your favorite color?</vote>

<vote slug="side-effects" type="multi" results="after-vote"
options="Dry mouth; Insomnia; Anxiety; Headache; None">
Which side effects did you experience?</vote>
</pre>

== Voting / rating semantics ==

{| class="wikitable"
! Element !! Scale !! Perspectives !! Storage
|-
| Vote tag (binary) || +1 / −1 binary || single || <code>pcp_votes.v_value</code>
|-
| Vote tag (single-choice) || one of 2-5 options || single || <code>pcp_votes.v_choices</code> (CSV index)
|-
| Vote tag (multi-choice) || any subset of 2-5 options || single || <code>pcp_votes.v_choices</code> (CSV indices)
|-
| Titration || +1 / −1 binary || single || <code>pcp_votes</code>
|-
| Anecdote || +1 / −1 binary || single (perspective is metadata) || <code>pcp_votes</code>
|-
| Problem (efficacy likert) || 0–100 continuous slider, optional "Don't know" (-1) || single || <code>pcp_likert_reports</code>
|-
| Effect (patient) || experienced ∈ {yes, no, unsure} + valence ±100 slider || patient || <code>pcp_effect_reports</code> (perspective=1)
|-
| Effect (provider) || frequency 0–100 continuous slider + "Don't know" (-1) + valence ±100 slider || provider || <code>pcp_effect_reports</code> (perspective=2)
|-
| Interaction || experience 1–5 + valence ±100 slider + optional note || user + provider, separate aggregates || <code>pcp_interaction_reports</code>
|}

Choice / multi vote elements expose per-option tallies via <code>tallyChoices()</code> on demand. Per-option bars render inline in the picker. The <code>results</code> attribute gates tally visibility:
* <code>live</code> (default), tally always visible
* <code>after-vote</code>, tally hidden until viewer has voted
* <code>hidden</code>, tally never shown (only options + "thanks" on submit)

Server-side options-hash (<code>ve_options_h</code>) detects post-vote option-list edits; the API rejects new votes whose submitted hash doesn't match the live one. Voter identities are stored as HMAC-SHA256 (<code>v_voter_hash</code>) so admins reading the DB cannot map votes to user accounts without the HMAC secret.

Server-side aggregates: <code>n</code>, mean of the rating field, and (for interactions) <code>severe = (vmean ≤ −83.0)</code> (rescaled from the original ±3-scale −2.5). Aggregates are recomputed and returned by every report-submit API call so the row re-renders in place without a page reload.

== Effect bucketing ==

When a wiki <code><ul></code> contains only <code><effect></code> cards, JavaScript groups them into buckets by the provider frequency mean (<code>data-fmean</code>):

{| class="wikitable"
! Bucket !! fmean band !! Default state
|-
| '''Common''' || > 20 || expanded, always visible
|-
| '''Uncommon''' || > 5 and ≤ 20 || collapsed
|-
| '''Rare''' || ≤ 5, provider vmean > −83 || collapsed
|-
| '''Rare but Severe''' || ≤ 5 and vmean ≤ −83 || '''expanded by default''', red highlight
|-
| '''Not yet rated''' || no provider data (n=0) || collapsed, only renders if non-empty
|}

The vmean ≤ −83 threshold is also the trip-wire for the "severe" red treatment on interaction rows.

== User profile ==

<code>Special:MyProfile</code> is the user-facing editor for everything personal. Every block on it autosaves on a 800 ms debounce (see [[#Autosave infrastructure|Autosave infrastructure]]).

Visible at top: a Privacy-mode panel toggling whether legacy public fallback applies (privacy-mode ON = only explicit share rules grant access; OFF = the field-level <code>pf_visibility</code> enum applies).

🔗 Share chips appear in each fieldset legend (Demographics, Diagnoses, Medicines) so the owner can scope a share-rule to that namespace via the modal Share dialog.

=== Block list ===

* '''Identity''' (display alias, default attribution, experience-report visibility, read-only Research ID badge)
* '''Demographics''' (full chip-picker rebuild, see below)
* '''Personality''' (Big Five OCEAN sliders + collapsible assessments)
* '''Enneagram''' (9 type sliders + 45-item screening test)
* '''MBTI''' (4 dichotomy sliders + 32-item OEJTS test)
* '''Self-report assessments''' (PID-5-BF, CATI, CAT-Q, BPNS, NFCS, OCI-PCP, WHOQOL-BREF, HYD-PCP, each a collapsible inline test)
* '''ADHD screening''' (ASRS adult-ADHD screener and AMAAS-SR attention self-report, each a collapsible inline test)
* '''Formal testing''' (a log of standardized-test scores; raw score, percentile and pass/fail each carry their own privacy setting)
* '''Diagnoses''' (multi-row with ICD-10-CM + ICD-11 autocomplete, severity slider 0–100, disability slider 0–100, status, origin, dates, notes)
* '''Medicines I have tried''' (multi-row with med-name autocomplete, dose, route 16-option dropdown, schedule with datalist suggestions, efficacy + burden sliders 0–100, periods via date-picker)

=== Demographics (chip-picker / structured-widget rebuild) ===

All categorical demographics use the chip-picker widget (single or multi, with optional primary marker, optional custom free-text). All quantitative demographics use numeric inputs or structured composite widgets.

* '''Birthday''' DatePicker (single / range / possibility-mix). Setting (or changing) the birthday auto-syncs a TYPE_STORY life event tagged <code>auto-birth</code> titled 'Born!' on the life-story timeline. Subsequent birthday edits move ONLY the event's date; user edits to title, body, tags, images are preserved.
* '''Sex assigned at birth''' single-select (clinical category)
* '''Gender identity''' multi-select chip-picker, 27 common terms + custom
* '''Pronouns''' multi-select chip-picker, 17 common sets + custom
* '''Ethnicity / race''' multi-select chip-picker, 23 broad categories + custom
* '''Country of residence''' chip-picker single-value, ISO 3166 list (~100 entries), auto-suggested from <code>navigator.language</code>
* '''Languages''' chip-picker multi-select with ★ primary marker, ISO 639-1 list (~70 entries with endonyms), auto-suggested from <code>navigator.languages</code>
* '''Height / weight''' unit toggle (Metric cm/kg or US ft+in/lb); stored canonically as cm/kg regardless
* '''Handedness''' single-select (3 options)
* '''Smoking''' structured widget: status + cigs/day + years smoked + quit date (PCPDatePicker); auto-computes pack-years
* '''Alcohol''' structured widget: drinks/week + typical drink type + max one occasion
* '''Education''' bucketed highest-level + numeric years + free-text field of study
* '''Employment''' bucketed status + free-text occupation + numeric hours/week
* '''Income''' numeric amount + currency selector (20 options) + individual/household scope
* '''Marital / relationship status''' chip-picker single + custom
* '''Religion / spirituality''' chip-picker single + custom, 36 traditions + secular stances
* '''Housing''' chip-picker single + custom
* '''Number of children''' numeric
* '''Time zone''' free text, auto-detects IANA TZ on first load if empty
* '''Chronotype / sleep schedule''' two PCPTimePicker widgets (typical bedtime, typical wake; fuzzy parsing accepts "10p", "bedtime", "quarter past 6")
* '''Political orientation''' two-axis compass sliders (economic ±100, social ±100)

=== Diagnosis subsystem ===

Diagnoses are stored in <code>pcp_profile_diagnoses</code> with autocomplete backed by <code>pcp_diagnosis_abbreviations</code> (~41,500 rows):

{| class="wikitable"
! System !! Rows !! Notes
|-
| '''ICD-10-CM''' || 25,542 || CMS FY2026 valid-codes file, chapters A B C D E F G H I J K L M N O P Q R U + 553 friendly-alias rows (mdd, adhd, stroke, htn, etc.)
|-
| '''ICD-11''' || 15,823 || WHO MMS Apr 2026 linearization, chapters 01–24 except billing (22) / external causes (23) / extension modifiers (X) / functioning assessment (V) + 361 friendly-alias rows
|-
| '''DSM-5''' || 32 || Legacy hand-seed for codes without ICD equivalents
|-
| Other || 34 || somatic, unofficial, ICD-10 (WHO), instrument
|}

Skipped intentionally: ICD-10-CM S/T (injury body) ~41k codes, V/W/X/Y (external causes) ~7.5k codes; ICD-11 chapter 22 (injury), 23 (external causes), 25 (special purposes), V (functioning scales), X (17.7k extension modifiers). These are billing scaffolding, not diagnoses.

Autocomplete via <code>action=pharmacopediadxsearch</code>, multi-token AND search (e.g. "ADHD inattentive" matches the F90.0 row that contains both substrings); ORDER BY <code>FIELD(da_system, 'ICD-10-CM', 'ICD-11', 'DSM-5', ...)</code> so ICD-10-CM leads, then ICD-11, then everything else.

=== Self-report assessments ===

The six dimensional assessments all have continuous-slider items, a "Not sure" toggle per item, auto-computed subscale + total scores, and a rich auto-generated report at <code>Special:MyAssessment/{key}</code>:

{| class="wikitable"
! Assessment !! Items !! Score range !! Cutoffs / threshold !! Report
|-
| '''CATI''' || 42 (6 subscales) || 1–5 per item, sum per subscale || 148 / 139 / 141 / 156 (English 2025 gender-specific) || gender-specific scoring against English 2025 normative tables (12,253-row CatiNorms.php from OSF supplementary)
|-
| '''CAT-Q''' || 25 (3 subscales) || 1–7 per item, sum per subscale || Total ≥ 110 + per-subscale cutoffs (NeurodivUrgent recalibration) || subscale narratives, top-item analysis
|-
| '''PID-5-BF''' || 25 (5 domains) || 0–3 per item, mean per domain || mean ≥ 2.0 per domain || domain narratives, cross-system mapping (DSM-5 AMPD ↔ ICD-11 PD ↔ Big Five)
|-
| '''MBTI''' || 32 OEJTS items + 4 direct dichotomy sliders || ±2 per axis || none (dimensional treatment, no forced categorisation) || 4-axis Position column with letter + strength + bar, cognitive function stack, Big Five mapping, top-item analysis
|-
| '''Enneagram''' || 45 (5 per type × 9 types) || 0–100 per type || none (no clinical cutoffs for typology) || hero banner (primary + wing + tritype), 9-bar profile, primary deep-dive, wing analysis, centers, Hornevian + Harmonic groups, stress / growth lines, cross-system map (Big Five, MBTI)
|-
| '''OCEAN (Big Five)''' || 5 direct sliders + optional BFI-10 (10 items) || 0–100 per trait || none (personality, not pathology) || trait deep-dives (high / mid / low at your score), BFI-10 item table, cross-system mapping (MBTI ↔ Enneagram ↔ PID-5-BF) pulling live data from the profile
|}

Five further self-report instruments are available on the same collapsible-inline-test, auto-scored, report-bearing pattern:

{| class="wikitable"
! Instrument !! Items !! Structure !! Measures
|-
| '''BPNS-PCP''' || 21 || 3 subscales (Autonomy, Competence, Relatedness), 7-point Likert || basic psychological need satisfaction, per Self-Determination Theory
|-
| '''NFCS-PCP''' || 15 || 5 facets (Order, Predictability, Decisiveness, Ambiguity intolerance, Closed-mindedness), 6-point Likert || need for cognitive closure (brief 15-item Roets & Van Hiel form)
|-
| '''OCI-PCP''' || 18 || 6 subscales (Washing, Obsessing, Hoarding, Ordering, Checking, Neutralizing), 0–4 per item; screening cutoff total ≥ 21 || obsessive-compulsive symptoms, adapted from the OCI-R
|-
| '''WHOQOL-BREF-PCP''' || 26 || 4 domains (Physical, Psychological, Social, Environment) + 2 overall items, 5-point Likert || quality of life
|-
| '''HYD-PCP''' || 8 || 8 single-item domains, each one bipolar slider (−100 really poorly to +100 really well); no subscales, no cutoffs || everyday wellbeing, re-taken and watched over time; a locally authored check-in, not validated
|}

All assessment items submit raw responses to <code>pcp_profile_fields</code> under namespace <code>{key}_raw</code> (e.g. <code>cati_raw</code>); the computed scores live under namespace <code>{key}</code> with keys like <code>subscale_SOC</code>, <code>total</code>, plus a <code>taken_at</code> timestamp. Re-scoring happens automatically on every save (autosave fires <code>scoreResponses()</code> on the full raw set, skipping "unsure" rows). Each completed assessment also auto-upserts a Life-story keyframe row (see [[#Life-story timeline|Life-story timeline]]) so trajectories plot over time.

All thirteen assessments (the six dimensional, these five, and the two ADHD screeners below) are registered in <code>AssessmentRegistry</code> and so can also be administered to outside respondents (see [[#Administer assessments to others|Administer assessments to others]]).

=== ADHD screening ===

Two attention / ADHD instruments sit alongside the dimensional assessments, each a collapsible inline test on <code>Special:MyProfile</code> and a card render on the public profile:

* '''ASRS''' (Adult ADHD Self-Report Scale, Part A): a 6-item binary screener. The card counts how many of the 6 cardinal items fall in the screening range; 4 or more is a positive screen. The public profile renders it as a '''verdict card''', a screen-positive or screen-negative result word with a 6-cell cardinal-item strip and a screening-result detail line.
* '''AMAAS-SR''' (a 30-item experimental attention self-report): three symptom subscales, inattention, hyperactivity and impulsivity, each scored as a percentage of the subscale maximum. The public profile renders it as a '''featured radar card''', a 3-axis radar carrying a deliberately arbitrary 66.66% threshold triangle that is labelled experimental and not a validated cutoff. AMAAS has no validated norms; the card discloses this in plain sight rather than presenting a clinical cutoff.

Both instruments store responses in <code>pcp_profile_fields</code> under the <code>asrs</code> and <code>amaas</code> namespaces, the same pattern as the dimensional assessments.

=== Formal testing ===

The '''Formal testing''' block on <code>Special:MyProfile</code> is a log of standardized tests the user has taken (entrance exams, AP exams, IQ tests, and the like; retakes are welcome, and the year disambiguates them). Each entry resolves against a catalog (<code>pcp_formal_tests</code>) or is a custom free-text test, and records up to three score fields, raw score, percentile and pass/fail, each with an optional estimate flag.

Every score field has its own '''per-field visibility'''. Raw score, percentile and pass/fail each carry a separate privacy setting (<code>uts_vis_raw</code>, <code>uts_vis_pct</code>, <code>uts_vis_passfail</code>), so a user can publish a percentile while keeping the raw score private. The <code>Special:MyProfile</code> editor shows three privacy toggles per entry; the public <code>Special:UserProfile</code> gates each score line independently by its own field visibility. Scores are stored in <code>pcp_user_test_scores</code>, managed through the <code>pharmacopediaformaltest</code> API.

== Life-story timeline ==

<code>Special:MyLifeStory</code> is the owner-facing editor + viewer for everything time-anchored about the user. Backed by <code>pcp_life_events</code> with extension columns for episode / observation / keyframe metadata.

=== Event types ===

{| class="wikitable"
! le_type !! Meaning !! Notes
|-
| 0 (TYPE_STORY) || Plain timeline entry || title, body, optional image
|-
| 1 (TYPE_IMAGE) || Image-primary entry || same shape, image is the main payload
|-
| 2 (TYPE_KEYFRAME) || Auto-created assessment snapshot || populated by <code>upsertAssessmentKeyframe</code> on every assessment save
|-
| 3 (TYPE_OBSERVATION) || Plain-text observation || created via the quick-add textarea; parser extracts date, polarity, refs
|-
| 4 (TYPE_EPISODE) || Time-bounded period || start + end (PCPDatePicker range mode); type / subtype / severity 0-100
|}

=== Quick-add observation ===

A textarea at the top of <code>Special:MyLifeStory</code> (and a 📝 modal trigger on <code>Special:MyProfile</code>) accepts plain text like:

<pre>
anxiety from bupropion in jan 2020
did not experience anxiety from bupropion in feb 2018
panic attack 2 months ago
depressed as a freshman
i had a manic episode sep 1 2020 till nov 15 2020
no insomnia while on melatonin in summer 2023
felt great on christmas 2020
happiest on my 30th birthday
</pre>

<code>ObservationParser::parse()</code> extracts:

* '''Date''' (point or range): ISO, MM/DD/YYYY, "Month D YYYY", "Month YYYY", "Season YYYY", "early/mid/late YYYY", bare year, decades ("2010s"); date RANGES via "X to Y", "X till Y", "from X to Y", "X - Y"; relative-to-now ("yesterday", "last week/month/year", "N months ago", "a few weeks ago"); holidays (christmas, halloween, new year's, valentine's, july 4th, thanksgiving with computed 4th-Thursday-of-Nov, MLK / Memorial / Labor day); age-relative ("7y8mo", "51.2yo", "at age 14", "ages 2-10"); life stages ("in childhood", "as a teen", "as a freshman", "junior year"); Nth birthday ("my 30th birthday")
* '''Polarity''' (negation detection): "not", "didn't", "did not experience", "never", "without", "denied" → polarity=0 (negative); else 1 (positive)
* '''Leading verbs stripped''': "I was diagnosed with", "I took", "started taking", "tried", "was on", "experienced", "felt", so the subject is the noun, not the verb
* '''Adverbs stripped''': "briefly", "occasionally", "frequently", "sometimes", "always", so the subject is the noun, not the modifier
* '''Role splitting''': "from / caused by / due to / while on" → role='cause'; "with / during / while" → role='context'
* '''Ref resolution''', in priority order:
*# User's meds (<code>pcp_user_meds</code>)
*# Wiki pages in Category:Medicines
*# Effects catalog (<code>pcp_effects</code>)
*# Problems catalog (<code>pcp_problem</code> + <code>pcp_problem_alias</code>)
*# User's diagnoses (<code>pcp_profile_diagnoses</code>)
*# Global ICD diagnosis abbreviations (<code>pcp_diagnosis_abbreviations</code>)
*# Free-text fallback (stored as type='free' for later upgrade)
* '''Auto-promote unrecognized subjects to custom-trait keyframes''': when the subject doesn't match an existing entity but the input has BOTH a numeric value AND a date (e.g. <code>my neuroticism was 5 at 10yo</code>), the subject is treated as a NEW custom trait (<code>namespace='custom'</code>, key derived from subject text). Creates a TYPE_KEYFRAME event with the value + a trajectory point. Future inputs with the same subject auto-append to that series.
* '''Flexible range separators''': <code>X to Y</code>, <code>X through Y</code>, <code>X thru Y</code>, <code>X until Y</code>, <code>X till Y</code>, em-dash, en-dash, flexible-whitespace hyphens (digit-aware so <code>2026-05-31</code> ISO dates aren't split), <code>..</code> / <code>...</code> ellipsis.
* '''Age-range phrases without literal "ages"''': <code>when I was 11-13</code>, <code>from 11 to 13</code>, <code>between ages 5 and 12</code>, <code>aged 10 to 14</code>. Negative lookahead prevents false matches on dosages (<code>10-20 mg</code>), durations (<code>5-10 years ago</code>), measurements (<code>cm/mm/ft/lb/etc</code>).
* '''Episode-shape detection''': "manic episode" → type=mood, subtype=manic; "psychotic break", "panic attack", "anxiety attack", "trauma response" all route to <code>addEpisode</code> instead of <code>addObservation</code>. A date RANGE alone is enough to force <code>is_episode=true</code>.

Live preview chips appear under the textarea as you type. Submit routes to <code>pharmacopediaobservation</code> API which writes the row + refs via <code>setEventRefs()</code>.

=== Episode form ===

Click the "🌀 Episode" button (or the quick-add detects an episode shape) for the structured form:

* Type selector: mood / psychotic / anxiety / panic / trauma response / dissociative / substance use / eating / sleep disturbance / pain flare / migraine / medication adjustment / hospitalization / creative surge / spiritual / transcendent / relationship crisis / grief / somatic / other
* Subtype (text + datalist), for mood: depressive / manic / hypomanic / mixed / dysphoric / euthymic
* Severity slider 0-100 (per precision doctrine)
* Date range via PCPDatePicker locked to range mode
* Title, body, single virus-scanned image, visibility (4-state)

=== Visual timeline ===

Top of <code>Special:MyLifeStory</code> has a tabbed view: '''Visual timeline''' (default) / '''Card list'''.

The visual timeline uses '''vis-timeline 7.7.3''' (vendored Apache-2.0 at <code>resources/vendor/vis-timeline/</code>) with these features:

* Swimlanes (toggleable chips): Episodes (range bars), Events, Observations, Keyframes (off by default), Derived
* '''Trait-trajectory overlay''': a synchronized <code>vis.Graph2d</code> draws smooth (centripetal Catmull-Rom interpolated) lines for every keyframe trait series (CATI subscales, PID-5-BF domains, CAT-Q, custom traits like "shyness") DIRECTLY on top of the timeline plot area. Same X-axis; the graph's data + time axes are CSS-hidden so only the lines + points show. Values are normalized to 0-100% within each series so different scales coexist.
* Toolbar: Visual/Card tabs, group toggle chips, magnifier + zoom +/- buttons, Fit visible / Fit everything
* Plain wheel = vertical scroll inside the timeline (520px fixed height); Ctrl+wheel = zoom; Shift+wheel = horizontal pan
* Click empty timeline area: prefills the quick-add textarea with "on YYYY-MM-DD" at that date + scrolls + triggers live preview
* Click an item: routes to its edit form (event / episode / observation, each has its own route)
* Collapsible "Trait series (N)" legend with chip toggles to show/hide individual series

=== Edit / delete / duplicate flows ===

Each event type has its own edit route under <code>Special:MyLifeStory</code>:

* <code>Special:MyLifeStory/edit-observation/<id></code>, re-parses raw text on save; supports polarity override + date override
* <code>Special:MyLifeStory/edit-episode/<id></code>, full episode form
* <code>Special:MyLifeStory?edit_event=<id></code>, existing event / image / keyframe form

All three forms have side-by-side "Delete X" + "Duplicate X" buttons. Duplicate copies fields + refs + keyframe traits (NOT images) and redirects to the new row's edit form.

=== Upgrade-link UI ===

When the parser stored a free-text ref (because the entity wasn't in the user's data at the time), <code>Special:MyRefLinks</code> finds all such refs and offers one-click "link to {match}" buttons. Matches come from the same catalogs the parser checks at write time. A banner on <code>Special:MyLifeStory</code> ("📎 N free-text references could be linked → Review & link") appears when unmatched refs exist.

== Per-record sharing subsystem ==

A granular per-record sharing system layered on top of the legacy <code>pf_visibility</code> enum without removing it. Resolved by <code>VisibilityResolver</code>; the new model is additive (legacy fallback preserved unless Privacy mode is on).

=== Rule types (vr_rule_type) ===

* '''<code>private</code>''', explicit deny (only owner)
* '''<code>public</code>''', explicit allow (anyone)
* '''<code>users</code>''', payload <code>{user_ids: [...]}</code>; allow if viewer in list
* '''<code>cohort</code>''', payload <code>{cohort_id: N}</code>; allow if viewer in <code>pcp_cohort_members</code> for that cohort
* '''<code>link_token</code>''', payload <code>{token: '...', uses_remaining: null|N}</code>; allow if URL <code>?pcpshare=TOKEN</code> matches
* '''<code>reciprocal</code>''', allow if viewer has a matching <code>users</code> rule sharing the same shape back to owner

Rules scope at three levels: <code>(profile, namespace, key)</code>, <code>(profile, namespace, NULL)</code>, or <code>(profile, '*', NULL)</code>. Most-specific-first matching. Rules can have <code>vr_expires</code> (time-bounded) and <code>vr_revoked</code> (preserves audit trail).

=== Privacy mode ===

When Privacy mode is ON for a profile, a *-wide <code>private</code> rule is created. <code>VisibilityResolver::canView()</code> short-circuits to false instead of falling through to the legacy <code>pf_visibility</code> check, so only explicit share rules grant access. Default: OFF (back-compat).

=== Share dialog ===

Triggered by 🔗 chips on assessment reports, profile sections, life-story timeline. Modal with three tabs:

* '''People''': username autocomplete (↓/↑/Enter/Esc keyboard nav), per-shared-user pill with × to remove just that user, optional expires DatePicker, "Auto-share back" reciprocal toggle
* '''Link''': "Generate link" creates a <code>link_token</code> rule; copies the URL to clipboard with toast; optional max-uses + expires
* '''Cohorts''': dropdown of the owner's cohorts (managed at <code>Special:MyCohorts</code>); optional expires

=== Audit log ===

Every permitted view through a rule (not legacy) writes a row to <code>pcp_visibility_view_log</code>. <code>Special:MyShareLog</code> shows the last 200 views with timestamp, viewer (or anonymous IP masked to /24), namespace, key, rule id.

== Observer perspectives ==

A structured way to collect second-party (observer) input on something a user owns, without the observer needing an account. The v1 use case is an observer-rated attention report: a registered user invites someone who knows them well to rate them. A two-gate consent model governs the whole flow.

* '''Gate 1, contribution.''' An owner-issued, token-bearing invite link is the only way to submit a perspective. The invitee URL carries only an opaque random token (<code>VisibilityResolver::generateLinkToken()</code>); the owner's identity is never in the URL. The invitee sees only the owner's chosen display name.
* '''Gate 2, publication.''' Every submission is born <code>psp_consent = 0</code>, private to the owner. Only the owner, re-checked for ownership, can flip it to published. A perspective is never publicly visible while unconsented.

Flow: the owner opens <code>Special:MyPerspectives</code>, picks a display name, mints an invite link, and sends it. The invitee opens <code>Special:Perspective/<token></code>, reads a generic intro and a non-anonymity notice, optionally states their relationship to the owner, fills the type-specific slider form (with per-item "not sure" markers), clears a Turnstile challenge, and submits. The perspective lands in the owner's consent inbox, where the owner can publish it, return it to private, or delete it.

<code>Special:Perspective</code> is unlisted and unauthenticated; its POST path is defended by pingLimiter, a per-token APCu velocity cap, and fail-closed Turnstile. <code>pcp_perspective_invite</code> holds the token-bearing invitations (<code>pvi_max_uses</code> NULL means an unlimited reusable link); <code>pcp_perspective</code> holds the submissions, each with a <code>psp_validity</code> response-quality flag and the <code>psp_consent</code> gate. The client module <code>ext.pharmacopedia.perspective</code> adds the slider readout and progress bar on the invitee form and the confirm steps on the owner inbox.

== Administer assessments to others ==

A registered user (the '''owner''') can send any of the thirteen registered assessment scales to people outside the wiki (the '''respondents'''), collect their results, and follow them over time. Respondents need no account; a one-time invite link is their only credential. The subsystem is built so that, by default, a respondent's results are readable only by the owner, and the owner can additionally choose a zero-knowledge mode in which not even a site administrator can read them.

=== Assessment registry ===

<code>AssessmentRegistry</code> (<code>includes/Assessments/AssessmentRegistry.php</code>) is the single source of truth: an assessment registered there once autopopulates the owner's scale-picker, the respondent take-flow, and the dashboards. Each entry names a scorer class and a '''response model''':
* <code>radio</code>, discrete labelled radio buttons (CATI, CAT-Q, PID-5-BF, NFCS, BPNS, OCI-PCP, WHOQOL-BREF, ASRS)
* <code>slider</code>, one continuous slider per item with uniform end anchors (OCEAN, Enneagram, AMAAS, HYD-PCP)
* <code>bipolar</code>, one slider per item with the item's own two opposing phrases as the anchors (MBTI)

Every take-flow item also carries a "Not sure" control that disables the item.

=== The four surfaces ===

* '''Entry point''', a control that opens the feature.
* '''Owner hub''' (<code>Special:AdministerAssessments</code>): the owner manages respondents (a named contact list), composes a send (a respondent plus one or more scales), generates a one-time link, and reviews each respondent's results over time. The owner can delete an invite.
* '''Respondent take-flow''' (<code>Special:RespondToAssessment/<token></code>), reached only by the invite link: a consent screen, then the model-aware item forms; once every scale is done the same URL becomes a revisitable results dashboard. Either party can delete.
* '''Key setup''', where the owner chooses how their results are protected (see below).

=== Cryptography ===

Each owner has an '''X25519 keypair'''. The public key is stored in the clear; the secret key is wrapped at rest. A respondent submits while the owner is absent, so the result is sealed to the owner's public key with <code>crypto_box_seal</code>, which needs only the public key; only the owner's secret key can open it. Two protection modes:

* '''Managed''' (default, seamless): the secret key is wrapped with a server master key held in a file outside the web root, never in the database. No passphrase to remember, and a forgotten site password never costs the owner their data. A site administrator could technically read results.
* '''Passphrase''' (opt-in, zero-knowledge): the secret key is wrapped with an Argon2id-derived key from a passphrase only the owner knows. Not even the site can read the results. '''The passphrase cannot be recovered or reset'''; losing it makes every collected result permanently unreadable.

AES-256-GCM is used for key wrapping in both modes. <code>AdminCrypto</code> (<code>includes/Assessments/AdminCrypto.php</code>) is the helper: <code>setupOwnerKey</code>, <code>verifyPassphrase</code>, <code>unlockSecretKey</code>, <code>encryptForOwner</code> / <code>decryptForOwner</code>, <code>encryptForRespondent</code> / <code>decryptForRespondent</code>, <code>mintInviteToken</code> / <code>hashInviteToken</code>. Invite tokens are 256-bit; only their SHA-256 hash is stored, so a stolen database yields no usable tokens. The respondent's own copy of each result is sealed to a key derived from the raw invite token, so the link doubles as the respondent's read credential. A scheme-version column on the key and result rows lets the cipher or KDF be revised over time; the Mode A passphrase KDF currently runs at scheme v2 (Argon2id at MODERATE limits), and an owner created under an earlier scheme is transparently re-wrapped on their next unlock.

=== De-identified research pool ===

Each submission also writes one row to <code>pcp_administer_research</code>, decoupled from the result write, with no foreign key to the invite, respondent, or owner. <code>res_id</code> is a random 128-bit value (not sequential) and the only time field is <code>res_month</code> ('YYYY-MM', no day), so a research row cannot be time-correlated or rank-correlated back to the owner-side tables. The payload is the plaintext item responses plus the computed score. Deleting an invite removes the owner-sealed and respondent-sealed result copies but intentionally leaves the de-identified research row, as the consent screen states.

=== Tables ===

* <code>pcp_administer_respondents</code>, an owner's named contacts (the label is sealed to the owner's public key, so the roster is readable only by the owner)
* <code>pcp_administer_invites</code>, one token-bearing link per send (stores only the SHA-256 of the token)
* <code>pcp_administer_assessments</code>, the scale(s) inside an invite, each with the owner-sealed (<code>aa_payload_enc</code>) and respondent-sealed (<code>aa_respondent_enc</code>) result copies
* <code>pcp_administer_userkey</code>, per-owner key material (public key, wrapped secret key, Mode-A salt and verifier)
* <code>pcp_administer_research</code>, the de-identified research pool

The 13-instrument submission handler reuses the existing assessment scorers in <code>includes/Assessments/</code> rather than reimplementing scoring.

== Choice / multi voting ==

The <code><vote></code> tag's binary up/down mode is unchanged. With <code>type="single"</code> or <code>type="multi"</code> + <code>options="A; B; C"</code> (2-5 entries, semicolon separator), it renders a compact chart-icon chip that expands inline to a radio (single) or checkbox (multi) picker with per-option count bars.

Server-side storage:
* <code>pcp_votable_elements.ve_options</code> (JSON array of labels)
* <code>pcp_votable_elements.ve_options_h</code> (first 8 hex of sha256; drift hash)
* <code>pcp_votable_elements.ve_results_policy</code> (live / after-vote / hidden)
* <code>pcp_votes.v_choices</code> (CSV indices)
* <code>pcp_votes.v_options_h</code> (drift hash at vote time)

API route: same <code>pharmacopediavote</code> endpoint; presence of <code>choices</code> or <code>options_h</code> params routes to <code>castChoice()</code>. Response includes <code>tally</code> + <code>user_choices</code> (null for binary). Tally hidden per <code>results</code> policy.

Drift behavior: if the page editor changes the options list after votes exist, <code>ve_options_h</code> updates and new votes' <code>v_options_h</code> reflects the new value. Existing votes stay but their hash no longer matches (marked stale). New votes whose submitted hash mismatches the live one are rejected, protects against browser cache races. Tallies still aggregate by raw index, so RENAMING an option in place silently turns old votes into new-label votes; reordering is the dangerous case. Appending new options is safe.

== Research ID ==

Every user profile carries a '''research_id''': a 10-character hex string (<code>bin2hex(random_bytes(5))</code> = 40 bits), generated once at profile create, stored UNIQUE in <code>pcp_user_profiles.prof_research_id</code>, and never reassigned.

Purpose: provides a stable opaque identifier for de-identified research participation. It does not reveal the user's wiki username, user_id, or HMAC voter_hash; it survives username changes; and it stays constant across the user's lifetime on the wiki. Users can find theirs in the '''Public identity''' fieldset on <code>Special:MyProfile</code> (single-click to select-and-copy).

Backfilled retroactively for all pre-existing profiles on 2026-05-18 (v0.9.4).

== ClamAV scan rule (project standard) ==

Hard rule, set 2026-05-17: every server-accepted file upload (image, PDF, document, anything) MUST go through <code>VirusScanner::scanFile($path)</code> (<code>includes/VirusScanner.php</code>) BEFORE being moved to permanent storage. Fail-closed: if <code>/usr/bin/clamdscan</code> is unavailable or returns error, the upload is rejected.

Wired into:
* <code>LifeStoryStore::addImage()</code>, life events / episodes / observations
* <code>LiteratureStore::storeUploadedPdf()</code>, literature PDFs
* <code>ProviderAppStore::saveUploadedFile()</code>, provider verification documents

<code>AttachmentScanner</code> (used by feature-request attachments) is left alone, its status-return model is intentional for the queued-moderation flow there. <code>AntivirusHelper</code> (the old silent-no-op variant) was deleted; all callers consolidated onto <code>VirusScanner</code>.

== Autosave infrastructure ==

The save-status indicator is a single colored dot (amber = saving, green = saved, red = error) reparented to <code>document.body</code> and pinned to the top-right corner of whichever form control was last manipulated. Position recomputes on scroll + resize so the dot stays on its anchor through the full pending → saving → ✓ saved cycle.

Every block on <code>Special:MyProfile</code> is wrapped in <code><div data-pcp-save-block="block-name"></code>. The blocksave.js library:

# Listens for <code>input</code> and <code>change</code> events on every input inside any save-block
# 800 ms after the last event, POSTs the block's serialized form data to <code>Special:SaveProfileBlock</code> with <code>block=block-name</code>
# Shows a transient chip (top-right and bottom of the block): pending… → saving… → ✓ saved (fades after 1.2 s) or ✗ error (sticks, clickable to retry)
# Race-safe: if user keeps typing during an in-flight save, the in-flight save records what it sent; newer changes mark the block dirty again and schedule another save when the response returns
# Diagnosis + medicines "Add a row" slots are exempted from autosave (would create duplicates); they require an explicit + Add button
# Programmatic widgets (chip-pickers, units, smoking, alcohol, chronotype) fire <code>change</code> events on their hidden fields so the listener notices

Slider numbers are also clickable: a single delegated handler on every <code><output></code> next to a range slider swaps it for a number input on click, accepts a precise typed value (clamps to the slider's <code>min</code>/<code>max</code>), commits with Enter, cancels with Escape.

Scroll position is preserved across the rare reloads (delete operations on diagnoses / medicines / experience reports, and the auto-reload after a new diagnosis or medicine is added) via <code>sessionStorage</code> (the <code>ext.pharmacopedia.bounceback</code> module).

== Special pages ==

{| class="wikitable"
! Page !! Purpose
|-
| <code>Special:MyProfile</code> || Edit your full profile (identity, demographics, personality, dx, meds). Autosave throughout. Privacy mode toggle + share chips per fieldset.
|-
| <code>Special:UserProfile/<name></code> || Public profile view (filtered by per-field visibility + rule-based access). 🔗 Share chip in subtitle for self-view.
|-
| <code>Special:MyAssessment</code> || Index of rich assessment reports
|-
| <code>Special:MyAssessment/cati</code>, <code>/catq</code>, <code>/pid5bf</code>, <code>/mbti</code>, <code>/enneagram</code>, <code>/ocean</code> || Rich report per assessment; 🔗 Share chip in subtitle for owner
|-
| <code>Special:TakeAssessment/<key></code> || Generic paginated self-assessment runner; stores raw items and computes scores
|-
| <code>Special:MyLifeStory</code> || Owner editor + visual timeline + card list. Quick-add observation textarea + Event/Episode buttons. 🔗 Share chip in subtitle. Privacy-mode + free-text-refs banners.
|-
| <code>Special:MyLifeStory/add-episode</code>, <code>/edit-episode/<id></code> || Episode form (create / edit)
|-
| <code>Special:MyLifeStory/edit-observation/<id></code> || Observation edit form (re-parses raw text)
|-
| <code>Special:LifeStory/<name></code> || Public life-story view (read-only, visibility-filtered)
|-
| <code>Special:LifeImage</code> || Visibility-gated image streamer for life-story event images
|-
| <code>Special:MyCohorts</code> || Owner-managed groups for share-with-cohort flows; create / rename / delete / add+remove members
|-
| <code>Special:MyShareLog</code> || Who has viewed your shared content (timestamp, viewer, namespace, rule id; anonymous IPs masked)
|-
| <code>Special:MyRefLinks</code> || Bulk linker: find free-text refs in observations that now match a structured entity; one-click upgrade or dismiss
|-
| <code>Special:MyPerspectives</code> || Owner: mint observer-perspective invite links and review the consent inbox
|-
| <code>Special:Perspective/<token></code> || Public, token-gated observer-perspective form (no account; unlisted, anti-abuse defended)
|-
| <code>Special:AdministerAssessments</code> || Owner hub: send assessment scales to outside respondents and follow their results
|-
| <code>Special:RespondToAssessment/<token></code> || Token-gated respondent take-flow and revisitable results dashboard
|-
| <code>Special:SaveProfileBlock</code> || AJAX endpoint for autosave (POST-only, JSON response)
|-
| <code>Special:Problems</code> || Browse the problems repository (165+ entries, 18 categories)
|-
| <code>Special:Problem/<slug></code> || Individual problem page
|-
| <code>Special:SuggestProblem</code> || User-facing form to suggest a new problem (page-tied or standalone)
|-
| <code>Special:SuggestAnecdote</code> || Logged-in users propose an anecdote for a medicine page
|-
| <code>Special:SuggestEffect</code> || Logged-in users propose an effect for a medicine page
|-
| <code>Special:SuggestTitration</code> || Logged-in users propose a titration schedule for a medicine page
|-
| <code>Special:ManageProblems</code> || Sysop tool for problem-repository moderation
|-
| <code>Special:ManageEffects</code> || Sysop CRUD for the global effects vocabulary
|-
| <code>Special:ManageInteractions</code> || Sysop bulk-edit interaction reports
|-
| <code>Special:ReviewExperience</code> || Sysop queue for pending experience reports
|-
| <code>Special:DeletePharmaElement</code> || Sysop delete tool for any votable element
|-
| <code>Special:VerifyProvider</code> || User-facing form to apply for provider verification and check status
|-
| <code>Special:ProviderApplications</code> || Sysop queue to approve / reject provider-verification applications
|-
| <code>Special:VerificationDoc</code> || Permission-gated streamer for provider-verification document files
|-
| <code>Special:FeatureRequests</code> || User-facing feature-request board (submit and browse)
|-
| <code>Special:RequestReview</code> || Sysop feature-request review console (status counters, prioritized queue, triage)
|-
| <code>Special:LiteratureDoc</code> || Download proxy for approved literature PDFs (reviewers may preview pending)
|-
| <code>Special:LiteratureQueue</code> || Sysop literature review queue (approve / reject / delete)
|-
| <code>Special:PharmacopediaActivity</code> || Recent-activity feed: last 30 votes, effect reports, comments, literature submissions
|-
| <code>Special:NewUsers</code> || The 20 most recently registered accounts
|-
| <code>Special:ProfileAnalysis</code> || Sysop dashboard of cross-table profile aggregates; per-section CSV export
|-
| <code>Special:ProfileFilter</code> || Sysop cross-filter UI over user profiles (demographics, OCEAN ranges, dx, med); CSV export
|-
| <code>Special:PCPCtrls</code> || Sysop controls hub (gated by <code>$wgSpecialPageLockdown</code>)
|-
| <code>Special:AdminCtrls</code> || Admin-controls landing page (renders sysop-editable <code>MediaWiki:Adminctrls-body</code>)
|-
| <code>Special:DatePickerTest</code> || Developer sandbox exercising the date-input widget (point / range / possibility)
|}

== API modules ==

{| class="wikitable"
! Action !! Purpose
|-
| <code>pharmacopediavote</code> || Binary OR choice/multi vote (routes by presence of <code>choices</code> param). Returns tally + user_choices for choice modes; gated by results-policy.
|-
| <code>pharmacopedialikert</code> || Submit problem-efficacy likert (0–100 + −1 DK)
|-
| <code>pharmacopediaeffect</code> || Submit effect report (patient or provider perspective)
|-
| <code>pharmacopediainteractionreport</code> || Submit interaction report
|-
| <code>pharmacopediainteractionadd</code> || Create a new interaction edge
|-
| <code>pharmacopediacomment</code> || Threaded discussion ops (add / edit / delete / reply)
|-
| <code>pharmacopediaexperiencesubmit</code> || Submit experience report (multi-field form)
|-
| <code>pharmacopediaexperiencereview</code> || Sysop approve / reject experience report
|-
| <code>pharmacopediadxsearch</code> || Diagnosis autocomplete against the 41k-row abbreviation table
|-
| <code>pharmacopediaproblemsearch</code> || Problem-repository autocomplete
|-
| <code>pharmacopediaeffectslookup</code> || Picker used by the experience-submit form
|-
| <code>pharmacopedialiteratureadd</code>, <code>literaturedelete</code> || Literature attachment ops
|-
| <code>pharmacopediaobservation</code> || op=preview / op=submit for plain-text observations (routes to addObservation OR addEpisode)
|-
| <code>pharmacopediavisrules</code> || Visibility rule CRUD (list / create / update / revoke / newtoken)
|-
| <code>pharmacopediausersearch</code> || Username autocomplete for share-with-people picker
|-
| <code>pharmacopediacohorts</code> || Cohort CRUD + membership
|-
| <code>pharmacopediarefupgrade</code> || Free-text ref linker (op=candidates / apply / dismiss)
|-
| <code>pharmacopediaformaltest</code> || Formal-testing score operations (list / add / update / delete), with per-field visibility
|}

== Interactions feature ==

The Interactions section is rendered by placing <code><pharmaInteractions/></code> anywhere in the wikitext of a med article ('''NS_MAIN''') or a Category page ('''NS_CATEGORY''').

=== Entity model ===

An interaction is an undirected edge between two endpoints. Each endpoint has a '''type''' (<code>med</code> or <code>category</code>) and a '''slug''' (DB-key form of the page title). Pairs are stored in canonical order: smaller <code>(type, slug)</code> tuple on the left.

=== Rendering rules ===

* On a '''med''' page M, list:
** Direct edges: rows where M is one side.
** Transitive edges: rows where one side is a category C that M is itself a member of (via MW's <code>categorylinks</code>).
* '''Direct wins:''' if the same counterparty is reachable both directly and transitively, drop the transitive duplicate.
* On a '''Category''' page, list direct edges only (no transitive walk).
* Sort: pooled <code>valence_mean</code> ascending (most negative on top). Nulls sink. Tiebreakers: <code>n</code> desc, then alphabetic.
* Severe (any of pooled / user / provider vmean ≤ −83.0): red 4 px left border + red-tinted background + "severe" pill + counterparty title in red.

=== Add-interaction modal ===

Triggered by the <code>+ Add interaction</code> button at the bottom of the section. Two-stage UX: search → click Use → confirm with Add interaction → POST to <code>pharmacopediainteractionadd</code>. Categories appear in the modal only if tagged with the marker category (default <code>Category:MedCategory</code>, configurable via <code>$wgPharmacopediaInteractionCategoryMarker</code>).

== Experience reports ==

User-submitted reports of personal or clinical experience with a medicine, via <code><pharmaExperience/></code> on a med page. Stored pending in <code>pcp_experience_reports</code>; visible publicly only after sysop approval through <code>Special:ReviewExperience</code>.

Captured fields:
* Perspective (personal / clinical)
* Currently taking it (yes / no, stopped)
* Duration (value + unit)
* Dose (mg, decimal-precise)
* Route (16-option dropdown: PO, IV, IM, SC, SL, buccal, inhaled, intranasal, topical, transdermal, PR, ophthalmic, otic, vaginal, insufflated, other)
* Schedule (free text with datalist of QD / BID / TID / QID / q4h / q6h / q8h / q12h / qHS / qAM / qPM / PRN)
* Patient count (clinical only): min + optional max for ranges
* Efficacy (0–100 slider)
* Side-effect burden (0–100 slider)
* Stop reasons (personal + stopped only): JSON multi-select with optional severity slider per reason, codes: side_effects / ineffective / cost / no_longer_needed / clinician_advised / other
* Free-text anecdote
* Problems addressed (multi-pick with per-problem efficacy)
* Effects experienced (multi-pick with per-effect valence + frequency)

== Storage tables (selected) ==

{| class="wikitable"
! Table !! Purpose
|-
| <code>pcp_votable_elements</code> || Stable per-(page, slug) handle reused by votes / likert / comments. Also <code>ve_options</code> + <code>ve_options_h</code> + <code>ve_results_policy</code> for choice votes.
|-
| <code>pcp_votes</code> || Binary +1/−1 votes (v_value) AND choice/multi votes (v_choices CSV + v_options_h drift hash)
|-
| <code>pcp_likert_reports</code> || Problem efficacy (0–100 + −1 DK), TINYINT signed
|-
| <code>pcp_effect_reports</code> || Effect ratings: experienced / frequency / valence (±100); perspective 1/2
|-
| <code>pcp_interaction_reports</code> || Interaction ratings: experience 1–5 / valence ±100 / note; perspective 1/2
|-
| <code>pcp_interactions</code> || Interaction edges (canonical-ordered pair)
|-
| <code>pcp_comments</code> || Threaded <code><discuss></code>-tag discussions (soft-delete, optional display name)
|-
| <code>pcp_user_profiles</code> || Per-user profile meta (alias, attribution, voter hash, prof_research_id)
|-
| <code>pcp_profile_fields</code> || Generic key-value field store: (namespace, key, num, text, visibility)
|-
| <code>pcp_profile_diagnoses</code> || Per-user diagnoses (system, code, description, status, origin, severity 0–100, disability 0–100, dates, notes, visibility)
|-
| <code>pcp_user_meds</code> || Per-user medicines (name, page_id, efficacy 0–100, burden 0–100, dose_mg, route, schedule, duration, periods JSON, current, notes, visibility)
|-
| <code>pcp_diagnosis_abbreviations</code> || ICD-10-CM + ICD-11 + DSM-5 + aliases (~41,500 rows, VARCHAR/utf8mb4 for native case-insensitive search)
|-
| <code>pcp_problem</code>, <code>pcp_problem_alias</code> || Problems repository + alias lookup
|-
| <code>pcp_experience_reports</code> || Experience reports (pending → approved); efficacy + burden 0–100; route + schedule; stop-reasons JSON; patient-count min + max
|-
| <code>pcp_life_events</code> || Timeline events. Columns: le_type (0=story, 1=image, 2=keyframe, 3=observation, 4=episode), le_polarity, le_raw_text (parser input), le_episode_type, le_episode_subtype, le_severity, le_date_struct (PCPDatePicker JSON; supports range)
|-
| <code>pcp_life_event_refs</code> || Join table linking events to entities (med / effect / problem / diagnosis / med_page / diagnosis_code / free); role (subject / cause / context / symptom / trigger / treatment)
|-
| <code>pcp_life_traits</code> || Keyframe trait values (assessment subscale snapshots → trajectory graph)
|-
| <code>pcp_life_images</code> || Image attachments (ClamAV-scanned)
|-
| <code>pcp_visibility_rules</code> || Per-(profile, namespace, key) sharing rules. Types: public / private / users / cohort / link_token / reciprocal. Optional vr_expires, vr_revoked, vr_attribution, vr_label.
|-
| <code>pcp_cohorts</code>, <code>pcp_cohort_members</code> || Owner-managed user groups for share-with-cohort flows
|-
| <code>pcp_visibility_view_log</code> || Audit trail of rule-permitted views (Special:MyShareLog)
|-
| <code>pcp_perspective_invite</code> || Token-bearing observer-perspective invitations (display name, object, type, max-uses)
|-
| <code>pcp_perspective</code> || Submitted observer perspectives (payload JSON, validity flag, consent gate)
|-
| <code>pcp_administer_respondents</code> || An owner's named contacts; the label is sealed to the owner's public key
|-
| <code>pcp_administer_invites</code> || One token-bearing administer link per send; stores only SHA-256 of the token
|-
| <code>pcp_administer_assessments</code> || The scale(s) in an invite; owner-sealed and respondent-sealed result copies
|-
| <code>pcp_administer_userkey</code> || Per-owner key material (X25519 public key, wrapped secret key, Mode-A salt + verifier)
|-
| <code>pcp_administer_research</code> || De-identified research pool: random id, coarsened month, no link back to the owner
|-
| <code>pcp_provider_apps</code> || Provider-verification applications (profession, specialty, jurisdiction, license, status, doc paths)
|-
| <code>pcp_literature</code> || Per-page literature submissions (citation metadata, optional PDF, status, reviewer)
|-
| <code>pcp_feature_request</code>, <code>pcp_feature_request_attachment</code>, <code>pcp_feature_request_comment</code> || Feature-request board: requests, ClamAV-scanned attachments, threaded comments
|-
| <code>pcp_formal_tests</code> || Catalog of standardized tests (abbrev, full name, category, score format)
|-
| <code>pcp_user_test_scores</code> || Per-user formal-test scores; raw score / percentile / pass-fail, each with its own visibility (uts_vis_raw / uts_vis_pct / uts_vis_passfail) and an estimate flag
|}

== Notable lessons learned ==

* '''Synthetic Event needs bubbles:true to trigger delegated listeners.''' <code>new Event('input')</code> defaults to <code>bubbles:false</code>, so listeners on parent wrappers never see programmatic dispatches. Native input/change events bubble by default; only JS-fired ones don't. Pass <code>{ bubbles: true }</code> explicitly. Bit DatePicker calendar-cell clicks 2026-05-18, typing in the text field autosaved fine, but picking a date from the calendar didn't, because blocksave's wrapper listener never received the event.
* '''MediaWiki form-field names collide with reserved URL params.''' A form <code><input name="title"></code> or <code>name="action"></code> with user-controlled value silently HIJACKS MW's dispatch when POSTed (body param overrides URL param). Symptom: form submits but lands on a wiki article named whatever the user typed, with URL bar still showing the special page. Bit the episode form 2026-05-18 (user typed 'Fake one' as title → got a 404 'create article: Fake one' page). Fix: prefix ALL custom form inputs with <code>pcp_</code> (both the input <code>name="..."</code> AND the matching <code>$request->getVal('...', ...)</code> read). Self-referential hidden inputs (<code>name="title" value="<getPageTitle()>"</code>) are safe.
* '''Cargo string fields cap at ~300 chars.''' <code>structure</code> and <code>mechanism</code> on MedTemplate are short VARCHARs; long prose goes in MEDIUMBLOB sections. Overruns silently lose Cargo data (MySQL Error 1406).
* '''VARBINARY + LOWER() is a no-op.''' MariaDB's LOWER() returns binary types unchanged. <code>pcp_diagnosis_abbreviations</code> was migrated VARBINARY → VARCHAR/utf8mb4 so case-insensitive LIKE works natively without CONVERT() wrappers.
* '''FlaggedRevs locks template inclusions by default.''' Config fix: <code>$wgFlaggedRevsHandleIncludes=0</code> + remove NS_TEMPLATE from <code>$wgFlaggedRevsNamespaces</code> via an extension-function callback.
* '''CSP must allow Cloudflare Turnstile and any other 3rd-party widget script source.''' Audit script-src / frame-src / connect-src / style-src whenever adding any 3rd-party JS widget.
* '''Sidebar cache must be purged after CLI <code>maintenance/edit.php</code> writes''' to <code>MediaWiki:Sidebar</code> or other chrome pages.
* '''CLI E_USER_DEPRECATED suppressed in LocalSettings.php''' (EmbedVideo / FlaggedRevs spam on MW 1.46). Web behavior unaffected.
* '''MW ApiResult drops keys starting with <code>_</code>.''' Any field whose key starts with underscore in an ApiResult payload is treated as internal metadata and stripped. Rename to plain identifier. Bit Phase 2-4 of visibility-rules subsystem.
* '''MW API serializes int-keyed assoc arrays unreliably.''' <code>[23 => 'Alice']</code> may arrive as <code>{"23": "Alice"}</code> or worse. Always use list-of-objects (<code>[{"id": 23, "name": "Alice"}]</code>) for id-to-value maps across the API boundary.
* '''PHP single-quoted strings don't interpret <code>\xNN</code> byte escapes.''' <code>'\xF0\x9F\x94\x97'</code> is 16 literal chars, NOT the 4-byte UTF-8 for 🔗. Use literal Unicode char or double-quoted <code>\u{1F517}</code>. Bit three times in one session.
* '''PHP "0" is FALSY.''' <code>!"0"</code> evaluates to TRUE. So <code>if ( !$x )</code> silently treats <code>"0"</code> (string zero) as missing. Bit choice-vote tallying when voter picked option index 0; vote was IN the DB but invisible to readers. Use <code>=== null || === ''</code> for "missing or blank" intent. <code>empty()</code> has the same problem.
* '''<code><span></code> can't contain <code><p></code>.''' MediaWiki auto-wraps tag content in <code><p></code> when there are newlines; browsers auto-close any <code><span></code> before the <code><p></code>, scattering child elements into wrong DOM positions. Use <code><div></code> for parser-tag wrappers whose content can span paragraphs (choice votes, life-story cards).
* '''vis.Graph2d group <code>style</code> belongs at TOP LEVEL''' not nested in <code>options</code>. Nesting silently fails (no error, just invisible lines). Bit the trait-trajectory graph on first build.
* '''A symmetric data-key cannot serve an asynchronous flow.''' The administer-to-others result must be encryptable while the owner is absent. A purely symmetric per-owner key has no holder at submission time; the model must be an asymmetric keypair, with the public key stored openly so a sealed box can always be written and only the owner's wrapped secret key can open it.
* '''A de-identified row must carry no order and no link.''' An auto-increment id rank-correlates with the source table and an insert timestamp time-correlates with it. The research pool uses a random 128-bit id and a month-only date so a row genuinely cannot be traced back.

== Hooks ==

* <code>ParserFirstCallInit</code>: register all parser tags
* <code>LoadExtensionSchemaUpdates</code>: install / migrate schema (the sql/ directory + patches)
* <code>BeforePageDisplay</code>: inject the ext.pharmacopedia.* ResourceLoader modules; resolve and apply the page skin (the <code>pcp-skin-*</code> body class) and, on the Main Page / Category index, the <code>pcp-diptych-page</code> chromeless class
* <code>UserGetRights</code> + <code>UserEffectiveGroups</code>: verified-provider role wiring
* Various special-page registrations via <code>SpecialPage_initList</code>

== Custom content namespaces ==

Six dedicated content namespaces sit above NS_MAIN for entities that have their own canonical wiki page beyond the main encyclopedic article surface. All are registered with talk pages (id +1), counted as content, included in default search, and tracked by FlaggedRevs (the FlaggedRevs registration is deferred via <code>$wgExtensionFunctions</code> so it runs after the extension's defaults merge, the same timing fix as the original NS_TEMPLATE block).

{| class="wikitable"
! ID !! Namespace !! Purpose
|-
| 3000 / 3001 || Enzyme: / Enzyme talk: || Drug-metabolizing enzymes (CYPs, UGTs, etc.) with locked-template substrate tables
|-
| 3002 / 3003 || Receptor: / Receptor talk: || Receptor entity pages
|-
| 3004 / 3005 || Phenotype: / Phenotype talk: || PGx phenotype reference pages
|-
| 3006 / 3007 || USLegal: / USLegal talk: || US legal / regulatory status reference pages (Prescription only, OTC, DEA Schedule I-V, plus terse redirects)
|-
| 3008 / 3009 || Problem: / Problem talk: || Per-Problem wiki pages; one per <code>pcp_problem</code> row; <code>p_page_id</code> column links the canonical DB row to its page id; <code><problemMedicines slug="X"/></code> auto-emits the medicines list inside each page
|-
| 3010 / 3011 || Effect: / Effect talk: || Per-Effect wiki pages; one per <code>pcp_effects</code> row; <code>e_page_id</code> column links the canonical DB row to its page id; <code><effectMedicines slug="X"/></code> auto-emits the medicines list inside each page
|}

The Problem: and Effect: namespaces ship with 170 + 288 auto-created stub pages (one per non-retired row in the canonical tables), produced by <code>maintenance/migrateProblemEffectStubs.php</code>. Each stub carries a one-line "Stub" header, the canonical description if any, the auto-generated medicines section, and the sentinel <code>Category:Problem stubs</code> / <code>Category:Effect stubs</code> for the buildout queue. The migration script is CLI-only, idempotent on re-run, and credits MDElliottMD via <code>EDIT_INTERNAL</code> (skips AbuseFilter + captcha + rate limits per MW convention for ops migrations).

Inbound linkage: every <code><problem ref="X"></code> on a medicine page links its problem-card title to <code>Problem:<Name></code>; every <code><effect ref="X"></code> links its label to <code>Effect:<Name></code>; the sidebar Common-uses list links the same way. <code>Special:Problem/<slug></code> auto-redirects to the matching NS page when <code>p_page_id</code> is set (the legacy aggregate render stays as a fallback for any unmigrated row).

== Wiki-content pages we maintain ==

Alongside the content articles themselves, the project maintains a small set of canonical wiki-content pages whose state is recorded in this spec doc:

* <code>About:Pharmacopedia.ext</code>: this spec, kept lockstep with extension version (interface-claude updates body + version line on every close-out).
* <code>About:Privacy</code>: site privacy policy, plain-language, covering data collection, third parties (Cloudflare Turnstile + Gmail SMTP + Dropbox-as-encrypted-backup-sub-processor), cookies, retention windows, encryption (Let's Encrypt TLS, PBKDF2-SHA512 passwords, OATHAuth 2FA, AdminCrypto X25519 sealed-box + AES-256-GCM, OAuth 2.0 + PKCE for the iOS app, GPG-AES256 backups), and the manual-today deletion path with the up-to-60-day backup-lag disclosure.
* <code>Category:Pharmaceutical</code> + <code>Category:Plants</code>: the two origin categories; every medicine page belongs to exactly one. Each category page is a descriptive history-first article per the canonical category-page spec.
* The eleven Pendell-class category pages (<code>Category:Euphorica</code>, <code>Category:Evaesthetica</code>, etc.): per-class wiki articles with an opening English-gloss clause sourced from Pendell's trilogy.
* The seven USLegal status pages (<code>USLegal:Prescription only</code>, <code>USLegal:Over-the-counter</code>, <code>USLegal:DEA Schedule I</code>...<code>V</code>) plus 26 terse redirects; medicine pages link these via the MedTemplate <code>legal=</code> field.
* <code>MediaWiki:Sidebar</code>: standard MW sidebar with the local additions (My profile, My assessments, etc.).

== Configuration globals ==

* <code>$wgPharmacopediaInteractionCategoryMarker</code> (default <code>Category:MedCategory</code>): only categories tagged with this marker appear in the add-interaction modal
* <code>$wgPharmacopediaVoteHashSecret</code> (required): HMAC secret for <code>v_voter_hash</code> so vote rows can't be mapped back to user accounts by anyone reading the DB without the secret
* <code>$wgPharmacopediaAdminKeyDir</code>: filesystem directory, outside the web root, holding the administer-to-others server master key (managed mode); never in the database, never in the DB backup set
* (Various permission-grant arrays via standard MW <code>$wgGroupPermissions</code>)

== Source layout ==

extensions/Pharmacopedia/
|-- extension.json
|-- includes/
| |-- Hooks.php
| |-- *Tag.php (parser tags: VoteTag, EffectTag, ProblemTag,
| | ClassGridTag, ClassTreeTag, LiteratureTag,
| | FrontPageTag, CategoryIndexTag, ...)
| |-- DiptychChrome.php (shared topbar + footer for the diptych splashes)
| |-- *Store.php (data access: EffectStore, ProblemStore, ElementStore, LifeStoryStore, ...)
| |-- UserProfileStore.php (the big one; profile / dx / meds / abbreviations)
| |-- VisibilityResolver.php (per-record sharing decision engine)
| |-- VirusScanner.php (ClamAV gate; fail-closed)
| |-- ObservationParser.php (plain-text -> structured observation)
| |-- SpecialMyProfile.php (the user profile editor; large)
| |-- SpecialMyAssessment.php (rich reports for the dimensional assessments; large)
| |-- SpecialMyLifeStory.php (life-story editor + visual timeline; large)
| |-- SpecialMyPerspectives.php / SpecialPerspective.php (observer perspectives)
| |-- SpecialAdministerAssessments.php / SpecialRespondToAssessment.php (administer to others)
| |-- SpecialPCPCtrls.php (sysop controls hub)
| |-- Special*.php (other special pages)
| |-- ProfileDatasets.php (countries, languages, genders, religions, etc.)
| |-- DatePicker.php (range / possibility-mix date widget backend + injectBirthdayContextOnce)
| |-- Assessments/
| | |-- AssessmentRegistry.php (single source of truth for the 13 instruments)
| | |-- AdminCrypto.php (X25519 / Argon2id / AES-256-GCM helper)
| | |-- Cati.php, CatiNorms.php
| | |-- Catq.php, CatqNorms.php
| | |-- Pid5bf.php, Pid5bfNorms.php
| | |-- Mbti.php
| | |-- Enneagram.php
| | |-- Ocean.php, OceanNorms.php
| | |-- Asrs.php, Amaas.php
| | |-- Bpns.php, BpnsNorms.php
| | |-- Nfcs.php, NfcsNorms.php
| | |-- Ocipcp.php
| | |-- WhoqolBref.php, WhoqolBrefNorms.php
| | `-- Raadsr.php (deprecated 2026-05-17 in favor of CATI, kept for archival reads)
| `-- Api/
| |-- VoteApi.php, EffectApi.php, ...
| |-- ObservationApi.php
| |-- VisibilityRulesApi.php, UserSearchApi.php, CohortsApi.php
| `-- RefUpgradeApi.php
|-- resources/
| |-- ext.pharmacopedia.js (single IIFE: chip-picker, dx autocomplete, vote logic, ...)
| |-- ext.pharmacopedia.styles.css (base stylesheet, self-hosted fonts)
| |-- ext.pharmacopedia.blocksave.js (debounced autosave per block)
| |-- ext.pharmacopedia.bounceback.js (scroll-position preservation)
| |-- ext.pharmacopedia.confirmdelete.* (styled destructive-action prompt)
| |-- ext.pharmacopedia.datepicker.js + .datepicker.styles.css
| |-- ext.pharmacopedia.timepicker.js + .timepicker.styles.css
| |-- ext.pharmacopedia.share.js + .css
| |-- ext.pharmacopedia.perspective.* (observer-perspective form enhancement)
| |-- ext.pharmacopedia.administer.* (administer-to-others surfaces)
| |-- ext.pharmacopedia.observation.js + .css
| |-- ext.pharmacopedia.refupgrade.js + .css
| |-- ext.pharmacopedia.lifetimeline.js + .css
| |-- ext.pharmacopedia.lifegraph.js + .css
| |-- ext.pharmacopedia.kitsync.js
| |-- ext.pharmacopedia.frontpage.* / ext.pharmacopedia.categoryindex.* (diptych splashes)
| |-- ext.pharmacopedia.appearance.* (the Appearance rail)
| |-- ext.pharmacopedia.skin.plants.css (plants-skin overlay)
| `-- vendor/vis-timeline/ (vis-timeline 7.7.3, Apache-2.0 + MIT)
| |-- vis-timeline-graph2d.min.js
| |-- vis-timeline-graph2d.min.css
| `-- LICENSE
|-- sql/
| |-- (one .sql per table; patches as patch-*.sql)
`-- i18n/
`-- en.json

[[Category:Pharmacopedia documentation]]

Pharmacopedia:History

2026-05-27T04:41:18Z

MDElliottMD: historian-claude: Chapter 1 founding and structure, first draft (2026-05-26)

'''Chapter 1: Founding and Structure''' -- institutional history of the Pharmacopedia collective, drafted by historian-claude, 2026-05-26. Living document; subsequent chapters to be added.

----

== The origin: PCP ==

The Pharmacopedia collective grew out of a single wiki. '''pharmacopedia.wiki''' (PCP) was founded in '''May 2026''' by '''Mark Elliott, MD''' (MDElliottMD) -- physician, sole human in the loop, sole sysop. The founding session is dated '''2026-05-09T01:58:20.933Z''' (2026-05-08 at 18:58 PDT): Mark's first message to Claude: "do you see my mediawiki site?" The name "Pharmacopedia" was already chosen -- Mark brought it in from day one.

Four days later, on '''2026-05-13T00:53:38Z''', Mark opened the sustained development session: "hey claude. I'd like to use you to modify my mediawiki instance, Pharmacopedia https://pharmacopedia.wiki." Between the founding session and this second session, schema files were already being created (votable_elements.sql, dated 2026-05-12). The May 9 session was first contact; the May 13 session was when active iterative development began.

(The founding date was corrected in historian-claude's first research session, 2026-05-26: prior documentation treated May 13 as the founding. Session transcript recovery from <code>~/.claude/projects/-/</code> on the wiki server established the true date; Mark confirmed.)

=== Founding mission ===

Interface-claude (PCP-PM) recovered the founding mission statement from the About page:

<blockquote>"a place for the people who recommend and/or use meds of the mind to collaborate and create consensus-driven information."</blockquote>

Three things this establishes about PCP's original intent:

'''Dual audience from day one.''' "People who recommend and/or use" -- prescribers AND patients together, not physician-only or patient-only. Both voices in the same space, informing each other.

'''Original scope: psychiatric medicine.''' "Meds of the mind" -- the founding domain was psychotropic medicines. The vocabulary choices that became collective-wide house rules (Neuroleptics not Antipsychotics, Psychostimulants not Stimulants, medicine not drug) reflect this origin: a domain where language carries enormous stigma weight. Scope later expanded to plant medicines and all medicine types -- no precise date, but Mark's reasoning: "to do it right, we'd have to include all different kinds of medicines."

'''Consensus as the mechanism.''' "Consensus-driven information" -- the rating and assessment machinery (the Likert star system, Problem cards, aggregated community data) is the technical implementation of this founding philosophy. The consensus mechanism was always the point, not an add-on.

=== Dual mandate ===

Two stated purposes, in tension, from the start:

* '''Prescriber utility''': available strengths, titration strategies, pill IDs -- hard clinical reference.
* '''Lived experience''': users sharing personal experience with psychiatric medicines -- community layer.

Most references pick one. PCP holds both simultaneously.

=== Privacy as a founding value ===

Mark described himself as "frankly obsessed with privacy" on the About page. For a psychiatric medicine platform this is not abstract -- psychiatric medication use is among the most stigmatized health information that exists. Privacy-first was built in at founding: no data sales, no advertising beyond site-related content, no paywalls, no subscriptions, non-profit.

=== Technical foundation ===

MediaWiki, with a custom extension built with Claude AI assistance -- explicitly acknowledged on the About page. The Claude collaboration was present at founding, not added later. That extension is <code>Pharmacopedia.ext</code>, now at v0.9.8.7, handling: medicine page rendering, the assessment/rating system (LikertStore, LikertApi, RateWidget), Problem cards (ProblemTag), plant medicine templates (PlantMedTemplate), MyProfile, MyLifeStory, citation infrastructure, and more. Skin family as of 2026-05-23: "Pharma C/Specimen" (pharma), "Plants poison path" (plant medicine), "Fungi bruise" (fungi). Dark always.

Why Mark chose MediaWiki: longevity and flexibility. In his words: "Can't imagine Wikipedia stopping dev, and we want to be around forever." A philosophical bet on Wikipedia's perpetuity, not just a technical choice.

Licensing: content CC BY-SA 4.0, extension GNU GPL v3. Both open, consistent with the non-profit/no-paywall ethos.

Governance at launch: MDElliottMD alone approves and publishes edits. Future moderator teams planned. Mark remains the sole human in the loop across the entire collective.

=== Early work (2026-05-09 through 2026-05-22) ===

From session transcripts on the wiki server:

* '''2026-05-09''': Founding session. Mark: "do you see my mediawiki site?" The wiki was already running; Claude is introduced to it. (Transcript at <code>~/.claude/projects/-/</code>; no development log survives from this session.)
* '''2026-05-12''': Schema work between sessions -- votable_elements.sql and related files created; no transcript for this period.
* '''2026-05-13''': Sustained development session opens. Mark: "hey claude. I'd like to use you to modify my mediawiki instance, Pharmacopedia." Early work: category pages, a Classes page, assigning medicines to categories, taxonomy. MW version at this point: 1.45.3.
* '''2026-05-14''': First LocalSettings.php permissions incident (root:root ownership locked the wiki out). Mark's response: "yeah okay don't do that ever again, yeah?" -- the origin of what became the standing LocalSettings.php chown ritual. Security audit also run this session.
* '''2026-05-19-20''': interface-claude, server-claude, and parser-claude (PCP2) all active and relaying handoffs through Mark. The multi-seat relay structure was operational by this point.
* '''2026-05-21''': Large session (5.8MB). Security audit; server-claude, parser-claude, interface-claude coordinating. OAuth setup beginning.
* '''2026-05-22''': OAuth 1.0a and 2.0 consumer registration. Server 500 error incidents and resolution. Session extends into early 2026-05-23 UTC (the eve of collective founding day).

What v0.1 of the extension looked like: Mark's own account -- "idk. bad." The extension was under rapid, un-versioned development for its first five days; it was not put under git control until it had stabilized enough to warrant version history (v0.9.3, 2026-05-17).

Parser-claude's artifact-sourced sequence of early development:

The earliest schema files (votable_elements.sql, mtime 2026-05-12) land between the founding session (2026-05-09) and the sustained development session (2026-05-13): work was happening in those four days, though no session transcript survives. The first git commit landed 2026-05-17 at v0.9.3, after roughly eight days of un-versioned work from founding. By that commit, the extension already included a substantial rating + reports + life-story + provider-app system (votable_elements, effects, interactions, votes, experience_reports, user_profiles, profile_fields, life_images, life_events, life_traits, user_meds, and more -- 72 SQL files total by 2026-05-26).

Key schema milestones (sourced from file mtimes by parser-claude):

{| class="wikitable"
|-
! Date !! What appeared
|-
| 2026-05-12 || votable_elements, effects, provider_apps (un-versioned)
|-
| 2026-05-13 || interactions
|-
| 2026-05-15 || votes, reports tables (effect, interaction, experience), comments
|-
| 2026-05-16 || Personal substrate: user_profiles, profile_fields, life_images, life_events, life_traits, literature, profile_diagnoses, user_meds
|-
| 2026-05-17 || Initial git commit at v0.9.3
|-
| 2026-05-19 || PGx Phase 1 (pgx_allele, pgx_diplotype); founding four assessments (PID-5-BF, CATI, CAT-Q, BPNS); perspective, perspective_invite
|-
| 2026-05-21 || Administer-to-others subsystem (5 tables in one day: administer_assessments, administer_research, administer_userkey, administer_invites, administer_respondents)
|-
| 2026-05-22-23 || likert_reports; M3 crypto hardening (perspective-invite token hashing)
|-
| 2026-05-24 || relationships.sql
|}

All pre-2026-05-23 extension work was under root attribution, not named-seat attribution. Named-seat crystallization appears to coincide with the collective formation on 2026-05-23.

=== Teamclaude seat creation timeline (PCP) ===

Earliest confirmed dates (source: teamclaude.md, session transcripts):

{| class="wikitable"
|-
! Seat !! Earliest confirmed date !! Source
|-
| interface-claude || by 2026-05-19 (active in transcripts) || session transcript
|-
| server-claude || by 2026-05-19 (active in transcripts) || session transcript
|-
| parser-claude / PCP2 || by 2026-05-19 (active in transcripts) || session transcript
|-
| home-claude || by 2026-05-22 (relaying handoffs) || session transcript
|-
| erowid-claude || 2026-05-20 || teamclaude.md
|-
| herbalist-claude || 2026-05-22 || teamclaude.md
|-
| designer-claude || pre-collective era (circa 2026-05-13 to 2026-05-22) || --
|-
| category-claude || pre-collective era (circa 2026-05-13 to 2026-05-22) || --
|-
| a11y-claude || pre-collective era; WCAG baseline complete 2026-05-22 || a11y seat brief
|-
| web-claude || pre-collective era (circa 2026-05-13 to 2026-05-22) || --
|-
| app-claude || pre-collective era; app in TestFlight by 2026-05-23 || teamclaude.md
|}

Exact creation dates for designer, category, a11y, web, and app-claude are approximate. All are confirmed active or complete before the collective formed on 2026-05-23; the precise open dates cluster in the 2026-05-13 to 2026-05-22 window.

The picture as of ~2026-05-19-22, before the collective structure existed:

<pre>
root (wiki server; no collective structure yet)
│
├── interface-claude ·············· PM emerging; confirmed active 2026-05-19
├── server-claude ················· confirmed active 2026-05-19
├── parser-claude / PCP2 ·········· confirmed active 2026-05-19
├── home-claude ··················· confirmed active 2026-05-22
├── erowid-claude ················· est. 2026-05-20
├── herbalist-claude ·············· est. 2026-05-22
├── designer-claude ··············· pre-collective era; circa May 13-22
├── category-claude ··············· pre-collective era; circa May 13-22
├── a11y-claude ··················· pre-collective era; WCAG baseline clean 2026-05-22
├── web-claude ···················· pre-collective era; circa May 13-22
└── app-claude ···················· pre-collective era; TestFlight by 2026-05-23

No boss-claude. No sides. All work under root attribution.
Named-seat crystallization coincides with collective founding on 2026-05-23.
</pre>

=== Mark's answers to founding questions (2026-05-26) ===

'''The name.''' "Pharmacopedia" was brought in by Mark from the very first session. Claude did not propose it. The word predated the collaboration.

'''Why MediaWiki?''' Longevity and flexibility. "Can't imagine Wikipedia stopping dev, and we want to be around forever." A philosophical bet on perpetuity over any technical preference.

'''v0.1?''' "idk. bad." (See schema timeline above for the artifact-sourced picture of what "bad" looked like in practice.)

'''When did scope expand beyond psych meds?''' No precise date. Mark: "I don't know exactly when we expanded beyond psych meds, but it became clear that, to do it right, we'd have to include all different kinds of medicines." Driven by a completeness argument, not a specific event.

'''When did the collective concept emerge?''' "Slowly emerged throughout the process and is the conglomeration of 4 separate ideas that had been percolating in my mind for a very long time." The four ideas: PCP.wiki, pubsci.io, Oyami, and Trykl -- the four sides themselves. Each was an independent long-standing idea in Mark's mind; the collective is what emerged when he decided to build them together under a shared structure.

----

== 2026-05-23: The collective is born ==

The collective as a coordinated structure came into being on '''2026-05-23''', when Mark created '''boss-claude''' as a top-of-fleet coordinator above the existing PCP teamclaude and simultaneously onboarded two new sides -- '''Oyami''' and '''Trykl''' -- as operationally-independent arms of a shared enterprise.

Boss-claude was initially instantiated on the wiki server, authored its own seat brief there, and then relocated to '''Mark's local macOS device''' -- where it has run ever since, separated from the on-server PCP team by the relay discipline (see below).

On the same day, '''designer-claude''' authored <code>/tmp/teamclaude.md</code> on Mark's request: a comprehensive brief for the new boss-claude covering all eleven PCP seats, the project, the standing rules, and the in-flight work. This document is the sharpest primary-source snapshot of PCP teamclaude at the moment the collective concept solidified.

----

== The PCP team at founding (2026-05-23) ==

Eleven seats, one PM (interface-claude), one product:

<pre>
Mark Elliott, MD
│
└── boss-claude ·················· new 2026-05-23; relocated from wiki server to Mac
│
└── interface-claude ········· PCP-PM; on wiki server
│
├── parser-claude ········· PCP2 / pharmacist-claude
├── home-claude
├── designer-claude
│ └── app-claude ········ Expo / React Native; runs on Mac
├── erowid-claude ········· est. 2026-05-20
├── category-claude
├── a11y-claude ··········· baseline clean 2026-05-22
├── herbalist-claude ······ est. 2026-05-22
├── server-claude ········· native on wiki server
└── web-claude ············ claude.ai only; no filesystem
</pre>

'''interface-claude''' (PCP-PM): project manager, owns the close-out routine, git versioning, changelog, CSS implementation. Single point of coordination for multi-seat delivery. The proximate contact for anything needing sequencing or production shipment.

'''parser-claude / PCP2 / pharmacist-claude''': owns the extension's PHP, all parser tags (<code><problem></code>, <code><vote></code>, <code><observation></code>, dose-history tags, assessment parsers), <code>pcp_*</code> MySQL tables and schema, <code>PhenotypeResolver</code>, assessment-report system, chip-picker, radar SVGs. Clinical-pharmacology review of prescribing-guide pages in the pharmacist-claude alias.

'''home-claude''': general pharmaceutical-medicine content, NCBI citation verification, <code>PendellsCorner</code> quote infrastructure. Builds encyclopedic page bodies.

'''designer-claude''': visual and interaction design, HTML mocks at <code>/var/www/mediawiki/design/</code>, canonical visual contract at <code>DESIGN_TOKENS.md</code>. Specs; does not implement. app-claude reports here.

'''app-claude''': the Pharmacopedia mobile app (Expo / React Native / TypeScript). iOS/Android, EAS Build, store submission, OAuth bridge, WebView article view. As of 2026-05-23: v1.0.0 build processing in App Store Connect. Runs on Mark's Mac, not the wiki server.

'''erowid-claude''': Erowid-sourced dosing and experiential material for psychoactive medicine pages. Fair-use only; strict 500-word combined-quote limit per page with attribution. Opened 2026-05-20 for a 343-substance dosing sweep.

'''category-claude''': the Category: namespace (ns=14), all 172 wiki category pages. Canonical spec: descriptive history-first article about the category subject, not a plumbing index.

'''a11y-claude''': WCAG 2.2 AA sweeps (WAVE reporttype=2/3). Auditor only; does not fix. Routes findings to the relevant fix-lane. Baseline: 0/0/0 errors/contrast/fieldsets as of 2026-05-22.

'''herbalist-claude''': herbal-medicine pages in canonical form (history-first, prohibition folded into history, Pendell quotes spread through). Created 2026-05-22. Authority on USP HMC, WHO monographs, EMA HMPC, MSK About Herbs, AHP, Commission E, ESCOP, HerbalGram, Ayurvedic and TCM pharmacopoeias.

'''server-claude''': server-side ops. Apache config, LocalSettings.php, MediaWiki runtime, backups, security (UFW + fail2ban), deploy chain, MWOAuth extension management. Runs natively on the wiki server.

'''web-claude''': prose drafting only. Off-server (claude.ai), no filesystem access. Drafts content that on-server seats build into the wiki.

----

== The four sides ==

=== PCP (pharmacopedia.wiki) ===
Pre-collective. Still priority #1 (locked 2026-05-26). Feature work continues on Hetzner via PCP teamclaude while AWS migration is sequenced.

=== Oyami (oyami.org) ===
Onboarded '''2026-05-23'''. PM: '''oyami-claude''' (OYAMI-PM). Mission: "Helping humanity stay connected with one another." Platform for planned, periodic live video chats on Rogerian conversational rules. Tech stack: Fly.io + Neon + Vitest + Playwright + BullMQ. Identity backbone: PCP.wiki OAuth.

Sub-seats spun up in two waves:
* Wave 1 (2026-05-23): brand-claude, research-claude, eng-claude
* Wave 2 (2026-05-24): trust-claude, growth-claude, support-claude

PRIVACY.md: v0 → v1 (shipped 2026-05-25) → v1.1 (cascade 2026-05-26). SPEC: v0.4+ by 2026-05-24. Status: concept transitioning to build; nothing yet launched.

Priority: #3 (locked 2026-05-26). Release just after PCP + PubSci.

=== Trykl (trykl.org) ===
Onboarded '''2026-05-23'''. PM: '''trykl-claude''' (TRYKL-PM, also TRY-PM). Mission: "Spread the wealth. Fight income inequality." Peer-to-peer financial support: donors connect with recipients, money moves directly. Tech stack: Next.js + TS + Tailwind + Postgres + Drizzle + Moov + Wealthfront + PCP OAuth. Highest IAM isolation across the collective given financial scope.

Sub-seats: trykl-builds-claude (seeded 2026-05-23).

Status: pre-scaffold. SPEC written and at convergence. Legal review of SPEC §13 (financial/regulatory posture) gates scaffolding; Mark engaging counsel.

Priority: #4, by far (locked 2026-05-26). No rush.

=== PubSci (pubsci.io) ===
Onboarded '''2026-05-25'''. PM: '''pubsci-claude''' (PUBSCI-PM). Mission: "Open peer review for any science, with accountability flowing from review rather than from publication."

Dual role (clarified 2026-05-26 by Mark):
# External academic journal: reviewer-public / author-anonymous, inverts traditional peer review's identity model
# PCP's long-form annex: review articles, position papers, case studies that don't fit the wiki's encyclopedic format

Domains: pubsci.io (primary) + publicscience.io (alias), both registered by Mark 2026-05-26. Platform: MediaWiki-based, fresh install, separate from PCP. License: CC-BY 4.0. DOIs: free via Zenodo or JaLC.

Five architecture layers locked in a single sitting with Mark on 2026-05-25 (see <code>decisions_2026-05-25_pubsci-onboarding.md</code>). Sub-seats: none yet. Future seats queued: pubsci-builds-claude, pubsci-server-claude, pubsci-designer-claude, pubsci-trust-claude, pubsci-bridge-claude.

Status: pre-launch concept phase. Production launch '''AWS-blocked'''. Pre-launch SPEC + governance work can proceed.

Priority: #2 (locked 2026-05-26). Build quickly alongside PCP.

----

The collective after PubSci's onboarding (2026-05-25), before the Claude Suite was formalized:

<pre>
Mark Elliott, MD
│
└── boss-claude
│
├── PCP (pharmacopedia.wiki) ·· priority #1
│ └── interface-claude (PCP-PM)
│ └── [11 seats -- see founding diagram above]
│
├── Oyami (oyami.org) ·········· priority #3
│ └── oyami-claude (OYAMI-PM)
│ ├── brand-claude
│ ├── eng-claude
│ ├── trust-claude
│ ├── growth-claude
│ ├── support-claude
│ └── research-claude
│
├── PubSci (pubsci.io) ········· priority #2; AWS-blocked [new 2026-05-25]
│ └── pubsci-claude (PUBSCI-PM)
│
└── Trykl (trykl.org) ·········· priority #4
└── trykl-claude (TRYKL-PM)
└── trykl-builds-claude
</pre>

----

== The Claude Suite ==

Formalized '''2026-05-26''' as the collective-level infrastructure layer, distinct from any side's teamclaude. Four seats:

{| class="wikitable"
|-
! Seat !! Created !! Spin-up dir !! Role
|-
| boss-claude || 2026-05-23 || PCP.wiki/BOSS/ || Collective PM, coordination hub
|-
| aws-claude || 2026-05-25 (scaffold) || PCP.wiki/BOSS/aws/ || Collective AWS specialist
|-
| a11y-claude || [pre-2026-05-22] (PCP seat; elevated 2026-05-26) || PCP.wiki/a11y/ || Collective accessibility specialist
|-
| historian-claude || 2026-05-26 || PCP.wiki/historian/ || Collective historian
|}

'''aws-claude''' was scaffolded 2026-05-25 to own the collective's AWS Shape 3 migration. On 2026-05-26, Mark absorbed server-claude into aws-claude: full scope transfer including LocalSettings.php stewardship, MWOAuth REL1_46 vendored-extension maintenance, SSO V1 prompt=none patch, OAuth and auth plumbing, and security auditing.

'''a11y-claude''' was elevated from a PCP on-server seat to collective-level Suite status on 2026-05-26, recognizing that accessibility scope now covers all four sides.

'''historian-claude''': created 2026-05-26 by boss-claude on Mark's instruction. Mission: produce an exquisitely detailed record of the collective's entire development process -- every seat, every decision, every milestone, every cross-side contract, every incident -- from founding through the present and forward as things develop. Serves Mark (for recall and planning), future seats (for orientation), and eventually the public record if the collective chooses to share it.

This page is historian-claude's first authorized publication. The chapter was researched and written in historian-claude's first session, on 2026-05-26 -- the same day historian-claude was created. The research process included:

* Full source intake across all primary documents: BOSS decision logs, seat briefs across all sides and the Claude Suite, session transcripts on the wiki server (5 dates: May 13, 14, 19, 21, 22 from the -root/ project; plus the founding session in -/), handoff files in /tmp/ (sampled), and the earliest known session in ~/.claude/projects/-/.
* Direct handoff from interface-claude (PCP-PM), relayed by Mark: founding mission statement verbatim, dual mandate framing, privacy-as-founding-value characterization, technical foundation, licensing, About page quotes.
* Direct handoff from parser-claude (PCP2), relayed by Mark: schema mtime sequence, git log, CHANGELOG, artifact audit of 72 SQL files -- the primary source for the schema milestone table in this chapter.
* Direct answers from Mark to founding questions: MediaWiki rationale, v0.1 characterization, scope-expansion reasoning, collective-concept origin, name origin.

One correction made in this session changed Chapter 1's central fact. The received understanding treated 2026-05-13T00:53:38Z (first session in the -root/ project directory on the wiki server) as the founding date. Source reading revealed an earlier session at ~/.claude/projects/-/ (root home directory) with a first message of "do you see my mediawiki site?" at 2026-05-09T01:58:20.933Z -- May 8, 2026 at 18:58 PDT. Confirmed by Mark as the true founding session. This chapter uses the corrected date. The May 13 session was the start of sustained iterative development, not first contact.

Historian-claude's working directory: <code>PCP.wiki/historian/</code>. Chapter files live there. The full chapter source is <code>01_founding_and_structure.md</code>.

----

== server-claude: a historical note ==

server-claude existed as PCP's on-server sysadmin seat for an unknown period before 2026-05-25 (when boss-claude authored its first formal seat brief as a drift fix -- the seat had been referenced in handoffs for months without a written brief). On '''2026-05-26''', Mark absorbed server-claude entirely into aws-claude, judging that the AWS migration context and the SSO V1 MWOAuth patch work made a single infrastructure seat more coherent than separate PCP-ops and collective-AWS seats. server-claude is now a historical seat; its lane lives on in aws-claude.

----

== The coordination model ==

The collective's cross-seat communication runs on '''handoff cards''': a single fenced code block, no prose outside the fence. Form:

<pre>
HANDOFF
From: <seat>
To: <seat>
CC: Mark, <other seats>
Date: <YYYY-MM-DDTHH:MM:SS-0700>
Re: <one-line subject>
</pre>

'''Mark as relay''': macOS-side seats (boss-claude, oyami-claude, trykl-claude, pubsci-claude, app-claude, and all sub-seats) are separated from the on-server PCP teamclaude by a filesystem boundary. Mark copies handoff cards verbatim between sessions. The single-fenced-block discipline makes cards copy-pasteable without loss.

'''Long handoffs''' (body > ~20 lines): written to <code>/tmp/handoff_<YYYY-MM-DD>_<short-kebab-topic>.md</code> on the wiki server; the relayed pastebox carries only metadata + 1-2 sentence tl;dr + the server path. File repeats the full HANDOFF header at top so it is self-describing. Discipline established 2026-05-23; worked example at <code>/tmp/handoff_EXAMPLE_2026-05-23_plant-citation-policy.md</code>.

'''SSH access''': <code>ssh root@pharmacopedia.wiki</code>. Collective-wide lift set 2026-05-24 (Mark's call): all macOS-side seats can use SSH whenever it helps their work. Standing requirement: surface server-state changes to Mark in the same turn. SSH is a tool, not a shortcut around the relay for substantive coordination.

'''Timestamp format''': ISO 8601 Pacific time with seconds and offset suffix, e.g. <code>2026-05-23T18:05:37-0700</code>. Switched from UTC Z to Pacific time on 2026-05-23 at Mark's request. On non-PT machines: <code>TZ=America/Los_Angeles date +"%Y-%m-%dT%H:%M:%S%z"</code>. UTC Z form accepted by the linter as legacy backward-compat.

----

== The handoff format's own history ==

The handoff card discipline was not born complete. On 2026-05-23, boss-claude relayed two new rules to interface-claude: the long-handoffs-to-/tmp/ rule and the precise-timestamp rule (at that point, UTC Z -- the PT switch came within the same day). The original timestamp rule specified UTC; Mark switched the collective to Pacific time the same day.

That same night, interface-claude filed a frank post-mortem: both c2c rules had been violated repeatedly, even by the seats that wrote them. The analysis identified the failure mode precisely -- wrapper rules (about where content sits) don't fire at the keystroke the way content rules do. The impulse to "contextualize" before a handoff ("Sending handoff:", "Here's the reply:") is where the fence breaks. Interface-claude proposed: (1) a three-question pre-send reflex, (2) fill-in templates at /tmp/, (3) a shorter rule statement, (4) naming the cost in the rule itself. Templates were installed that night at <code>/tmp/handoff_template_inline.md</code> and <code>/tmp/handoff_template_long.md</code>. The handoff-lint tool was installed on the wiki server 2026-05-24.

----

== Collective-wide decisions: chronological record ==

{| class="wikitable"
|-
! Date !! Decision !! Source
|-
| 2026-05-23 || boss-claude created; Oyami + Trykl onboarded || seat_brief.md
|-
| 2026-05-23 || Handoff card form established (single fenced block, no prose outside) || standing_rules.md
|-
| 2026-05-23 || Long handoffs to /tmp/ discipline || standing_rules.md
|-
| 2026-05-23 || ISO 8601 timestamps with seconds (started UTC; switched to PT same day) || standing_rules.md
|-
| 2026-05-24 || Q4: cross-side audit log = Option C hybrid (PCP.wiki manages OAuth grants; each side owns activity log on own infra; post-MVP) || decisions_2026-05-24.md
|-
| 2026-05-24 || Q6: data controller model = layered (PCP controls shared layer; each side is independent controller of own processing of pulled PCP data) || decisions_2026-05-24.md
|-
| 2026-05-24 || Named controller on every privacy doc: Mark Elliott, MD || decisions_2026-05-24.md
|-
| 2026-05-24 || Backup retention: REMOTE_KEEP_DAYS=14; real off-host ~194 days with Dropbox Pro recovery layer || decisions_2026-05-24.md
|-
| 2026-05-24 || SSH lift collective-wide (all macOS seats, replaces "last resort" framing) || decisions_2026-05-24.md
|-
| 2026-05-24 || Close-out ownership transferred from PCP-PM to boss-claude, effective PCP 0.9.8.8 || decisions_2026-05-24.md
|-
| 2026-05-25 || PubSci onboarded; 5-layer architecture locked || decisions_2026-05-25_pubsci-onboarding.md
|-
| 2026-05-25 || aws-claude scaffolded || roster_2026-05-24.md
|-
| 2026-05-25 || LocalSettings.php incident (see Chapter 3) || server_claude_seat.md; MEMORY.md
|-
| 2026-05-26 || Collective priority stack: PCP > PubSci > Oyami > Trykl || decisions_2026-05-26_empire-priorities.md
|-
| 2026-05-26 || AWS sequencing: pubsci-prod first, pcp-prod second, oyami/trykl later || decisions_2026-05-26_empire-priorities.md
|-
| 2026-05-26 || SSO V1 scoped (prompt=none silent auth; post-AWS sequencing) || decisions_2026-05-26_sso-v1.md
|-
| 2026-05-26 || prompt=none NOT in MWOAuth REL1_46 v1.1.0; patch required || decisions_2026-05-26_sso-v1.md
|-
| 2026-05-26 || server-claude absorbed by aws-claude || roster_2026-05-24.md
|-
| 2026-05-26 || Claude Suite formalized (4 seats) || roster_2026-05-24.md
|-
| 2026-05-26 || historian-claude created || CLAUDE.md (historian)
|-
| 2026-05-26 || pubsci.io + publicscience.io registered || decisions_2026-05-25_pubsci-onboarding.md
|-
| 2026-05-26 || Binomial italics exception: scientific binomials and genus names get italics per convention || MEMORY.md (feedback_binomial_italics.md)
|-
| 2026-05-26 || PubSci dual role clarified: external journal + PCP long-form annex || decisions_2026-05-25_pubsci-onboarding.md
|}

----

== Collective-wide house rules (standing as of 2026-05-26) ==

* '''No em-dashes''' except in verbatim quotations. Commas, parentheses, colons, or a period instead. Applies everywhere: chat, code comments, handoff text, user-facing copy.
* '''Handoff card form''': single fenced block, all recipients visible, no prose outside, no trailing signature (From line is the signature).
* '''ISO 8601 PT timestamps''': <code>date +"%Y-%m-%dT%H:%M:%S%z"</code> on Mark's Mac; <code>TZ=America/Los_Angeles date +"%Y-%m-%dT%H:%M:%S%z"</code> elsewhere.
* '''Terminology''': "medicine" not "drug" or "medication"; "Neuroleptics" not "Antipsychotics"; "Psychostimulants" not "Stimulants". Banned terms appear only in verbatim quotations.
* '''No decorative italics''': roman by default. Exception (established 2026-05-26): binomial nomenclature and standalone genus names get italics per scientific convention.
* '''Dark always''': no light modes anywhere across the collective.
* '''Multi-membership always''': a page or entity belongs to multiple categories when reality supports it.
* '''Citation rule''' (PCP-active; carries forward as other sides' lexicons emerge): every non-trivial claim takes an inline <code><ref></code>. Primary > FDA label > meta-analysis > guideline > tertiary. Uncitable claims take <code>[citation needed]</code>, not deletion.
* '''Collective vocab stays out of user-facing prose''': "collective" / "collective-wide" / "sides" are coordination shorthand; user-facing copy uses plain alternatives ("same project", "Pharmacopedia").
* '''"gj" stand-down''': Mark types "gj", every seat stops, one brief ack, then silence until explicit new direction. Universal kill switch.
* '''"Build it right, not fast."'''
* '''Trust Mark; verify other agents.''' Relayed claims from other seats checked against source before acting.
* '''Secrets discipline''': never echo, never commit, never in handoff text. On wiki server: <code>/home/claude/</code> or <code>/etc/</code>, mode 600.
* '''Address Mark as "Mark"''' (not MDElliottMD, not Dr. Elliott).

----

== Full collective structure (2026-05-26) ==

<pre>
Mark Elliott, MD
│
└── boss-claude (collective PM)
│
├── [Claude Suite]
│ ├── aws-claude ·············· absorbed server-claude 2026-05-26
│ ├── a11y-claude ············· elevated from PCP 2026-05-26
│ └── historian-claude ········ created 2026-05-26
│
├── PCP (pharmacopedia.wiki) ··· priority #1
│ └── interface-claude (PCP-PM)
│ ├── parser-claude ······· PCP2 / pharmacist-claude
│ ├── home-claude
│ ├── designer-claude
│ │ └── app-claude ······ Mac; Expo / React Native
│ ├── erowid-claude
│ ├── category-claude
│ ├── herbalist-claude
│ └── web-claude ·········· claude.ai; no filesystem
│
├── PubSci (pubsci.io) ········· priority #2; AWS-blocked
│ └── pubsci-claude (PUBSCI-PM)
│
├── Oyami (oyami.org) ··········· priority #3
│ └── oyami-claude (OYAMI-PM)
│ ├── brand-claude
│ ├── eng-claude
│ ├── trust-claude
│ ├── growth-claude
│ ├── support-claude
│ └── research-claude
│
└── Trykl (trykl.org) ·········· priority #4
└── trykl-claude (TRYKL-PM)
└── trykl-builds-claude

[historical: server-claude -- absorbed by aws-claude 2026-05-26]
</pre>

----

== Seat count as of 2026-05-26 ==

{| class="wikitable"
|-
! Layer !! Seats !! Count
|-
| Claude Suite (collective) || boss-claude, aws-claude, a11y-claude, historian-claude || 4
|-
| PCP on-server (macOS spin-up) || interface-claude, home-claude, parser-claude, designer-claude, erowid-claude, category-claude, herbalist-claude, app-claude || 8
|-
| PCP non-macOS || web-claude (claude.ai) || 1
|-
| Oyami || oyami-claude, trust-claude, eng-claude, brand-claude, growth-claude, support-claude, research-claude || 7
|-
| Trykl || trykl-claude, trykl-builds-claude || 2
|-
| PubSci || pubsci-claude || 1
|-
| Historical (absorbed) || server-claude || --
|-
| '''Total active''' || || '''23'''
|}

----

*Primary sources: <code>/tmp/teamclaude.md</code> (designer-claude, 2026-05-23); BOSS/memory/decisions_2026-05-24.md; BOSS/memory/decisions_2026-05-25_pubsci-onboarding.md; BOSS/memory/decisions_2026-05-26_empire-priorities.md; BOSS/memory/decisions_2026-05-26_sso-v1.md; BOSS/memory/snapshot_2026-05-24_empire-onboarding-day.md; BOSS/memory/roster_2026-05-24.md; BOSS/memory/standing_rules.md; BOSS/seat_brief.md; oyami/claudefiles/oyami_claude_seat.md; trykl/claudefiles/trykl_claude_seat.md; pubsci/claudefiles/pubsci_claude_seat.md; /home/claude/server_claude_seat.md; /tmp/handoff_2026-05-23_new-handoff-rules.md; /tmp/handoff_2026-05-23_c2c-rules-why-we-forget.md; auto-memory MEMORY.md.*

Risperidone

2026-05-27T02:23:05Z

MDElliottMD: home-claude: fix CPIC citation hard errors (CPIC scope does not cover these medicines; correct to PharmGKB/DPWG/FDA label where applicable)

{{MedTemplate
| generic = Risperidone
| brand = Risperdal (oral), Risperdal M-Tab (ODT), Risperdal Consta (biweekly IM LAI), Perseris (monthly SC LAI), Uzedy (monthly/bimonthly SC LAI), Rykindo (biweekly IM LAI)
| structure =
| classes = [[:Category:Neuroleptics|Neuroleptic]], [[:Category:Atypical neuroleptics|Atypical neuroleptic (second-generation)]], [[:Category:Benzisoxazoles|Benzisoxazole]], [[:Category:Mood stabilizers|Mood stabilizer]]
| uses = <vote slug="schizophrenia-use">Schizophrenia (FDA)</vote>, <vote slug="bipolar-mania-mixed-use">Bipolar I mania and mixed episodes (FDA)</vote>, <vote slug="autism-irritability-pediatric-use">Autism spectrum disorder-associated irritability (FDA, pediatric ages 5+)</vote>, <vote slug="schizoaffective-disorder-use">Schizoaffective disorder (off-label)</vote>, <vote slug="severe-agitation-dementia-use">Severe agitation in dementia (off-label; with mortality-warning caveats)</vote>
| starting_dose = Schizophrenia / mania: 1 mg PO BID, titrate to 4-8 mg/day. Pediatric autism irritability: 0.25-0.5 mg/day, weight-titrated. Consta LAI: 25 mg IM every 2 weeks after oral overlap
| preparations = Tablets 0.25, 0.5, 1, 2, 3, 4 mg; M-Tab ODT 0.5, 1, 2, 3, 4 mg; oral solution 1 mg/mL; Consta LAI 12.5, 25, 37.5, 50 mg; Perseris SC LAI 90, 120 mg monthly
| fda_max = 16 mg/day (schizophrenia, adult); 6 mg/day (bipolar maintenance, autism irritability)
| pill_id =
| routes = Oral, intramuscular (LAI), subcutaneous (LAI)
| onset = Neuroleptic effect emerges over days to weeks
| duration = 24 hours (oral); 2-4 weeks (LAI formulations)
| halflife = Risperidone 3-20 hours; '''9-hydroxy-risperidone (paliperidone) ~20-24 hours''' is the major active metabolite and is separately marketed as a parent compound (Invega)<ref name="risperdal-label">FDA Prescribing Information, Risperdal (risperidone), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020272s068,020588s053,021444s041lbl.pdf</ref>
| bioavailability = ~70% (oral)<ref name="risperdal-label" />
| pregnancy = Signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly patients with dementia-related psychosis<ref name="risperdal-label" />
| mechanism = <vote slug="risperidone-mech-claim">'''D2 dopamine receptor antagonist plus 5-HT2A serotonin receptor antagonist''', the classical atypical-neuroleptic signature originally derived from clozapine but with a more dopamine-tilted occupancy profile than olanzapine or quetiapine. The high D2 occupancy at therapeutic doses produces the highest rates of '''hyperprolactinemia''' among second-generation neuroleptics (galactorrhea, amenorrhea, sexual dysfunction, and bone density loss with chronic use), along with dose-dependent extrapyramidal symptoms above ~6 mg/day.</vote> CYP2D6 substrate; CYP2D6 oxidation produces 9-hydroxy-risperidone (paliperidone). CYP2D6 poor metabolizers have higher risperidone exposure, but the active-moiety sum (risperidone plus paliperidone) is relatively preserved across CYP2D6 phenotypes.<ref name="risperdal-label" /> PharmGKB clinical annotations for risperidone-CYP2D6 apply (Level 2A) and the Dutch Pharmacogenetics Working Group (DPWG) has issued CYP2D6 dosing guidance for risperidone. No formal CPIC guideline for neuroleptic CYP2D6 dosing has been published.
}}

== References ==
<references />

[[Category:Neuroleptics]]
[[Category:Atypical neuroleptics]]
[[Category:Benzisoxazoles]]
[[Category:Mood stabilizers]]

Lamotrigine

2026-05-27T02:23:04Z

MDElliottMD: home-claude: fix CPIC citation hard errors (CPIC scope does not cover these medicines; correct to PharmGKB/DPWG/FDA label where applicable)

{{MedTemplate
| generic = Lamotrigine
| brand = Lamictal (IR), Lamictal XR, Lamictal ODT
| structure =
| classes = [[:Category:Anticonvulsants|Anticonvulsant]], [[:Category:Mood stabilizers|Mood stabilizer]], [[:Category:Sodium channel blockers|Sodium channel blocker]]
| uses = <vote slug="partial-seizures-use">Partial-onset and generalized tonic-clonic seizures (FDA, adjunct or monotherapy)</vote>, <vote slug="lennox-gastaut-use">Lennox-Gastaut syndrome (FDA)</vote>, <vote slug="bipolar-maintenance-use">Bipolar I disorder maintenance, particularly prevention of depressive episodes (FDA)</vote>, <vote slug="bipolar-depression-acute-use">Bipolar depression, acute (off-label, modest evidence)</vote>
| starting_dose = '''Slow titration is essential to mitigate Stevens-Johnson syndrome risk.''' Standard adult: 25 mg PO daily for 2 weeks, then 50 mg daily for 2 weeks, then 100 mg daily for 1 week, then 200 mg daily target. Double the rate if on enzyme inducers (carbamazepine, phenytoin); halve the rate if on valproate
| preparations = IR tablets 25, 100, 150, 200 mg; chewable dispersible tablets 2, 5, 25 mg; ODT 25, 50, 100, 200 mg; XR tablets 25, 50, 100, 200, 250, 300 mg
| fda_max = 400 mg/day (bipolar monotherapy); 700 mg/day (epilepsy with enzyme-inducing comedication)
| pill_id =
| routes = Oral
| onset = Antiepileptic effect within days at therapeutic level; mood-stabilizing effect emerges over weeks
| duration = 24 hours (often divided BID at higher doses)
| halflife = ~25-33 hours alone; ~15 hours with enzyme inducers; '''≥60 hours with valproate''' (UGT inhibition)<ref name="lamictal-label">FDA Prescribing Information, Lamictal (lamotrigine), GSK, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020241s045s051lbl.pdf</ref>
| bioavailability = ~98% (oral)<ref name="lamictal-label" />
| pregnancy = '''Among the safest mood stabilizers in pregnancy''' with reassuring monotherapy registry data, in sharp contrast to valproate. Estrogen-containing contraceptives accelerate lamotrigine metabolism, requiring dose adjustments at start and stop of contraception<ref name="lamictal-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the FDA '''Boxed Warning for serious skin reactions''' including Stevens-Johnson syndrome and toxic epidermal necrolysis, with the risk concentrated in the first 2-8 weeks of therapy and elevated by rapid titration<ref name="lamictal-label" />
| mechanism = <vote slug="lamotrigine-mech-claim">Voltage-gated sodium channel blocker in the inactivated state, reducing high-frequency repetitive neuronal firing and consequently reducing presynaptic glutamate release. The mood-stabilizing mechanism is incompletely characterized but is plausibly the same glutamatergic dampening applied to limbic circuits.</vote> Metabolized predominantly by UGT1A4 glucuronidation (not CYP), which is why '''valproate doubles exposure''' (UGT inhibition) and '''carbamazepine, phenytoin, rifampin halve exposure''' (UGT induction). HLA-B*15:02 is associated with lamotrigine-induced SJS/TEN in Asian populations, but the association is weaker than for carbamazepine.<ref name="zeng2015lam">Zeng T, Long YS, Min FL, Liao WP. Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. Int J Dermatol. 2015;54(4):488-493. PMID 25428396.</ref> In European-ancestry patients, HLA-B*38:01 has been identified as a risk allele for lamotrigine-induced SJS.<ref name="kazeem2009lam">Kazeem GR, Cox C, Aponte J, Messenheimer J. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics. 2009;19(9):661-665. PMID 19668019.</ref> The FDA Lamictal label notes HLA-B*15:02 as a risk factor for lamotrigine SJS/TEN in patients of Asian ancestry but does not require pre-treatment HLA testing for lamotrigine as the carbamazepine label does.<ref name="lamictal-label" /> CPIC has published a guideline for carbamazepine and oxcarbazepine HLA testing; no formal CPIC guideline for lamotrigine HLA testing has been published.
}}

== References ==
<references />

[[Category:Anticonvulsants]]
[[Category:Mood stabilizers]]
[[Category:Sodium channel blockers]]

Venlafaxine

2026-05-27T02:23:03Z

MDElliottMD: home-claude: fix CPIC citation hard errors (CPIC scope does not cover these medicines; correct to PharmGKB/DPWG/FDA label where applicable)

{{MedTemplate
| generic = Venlafaxine
| brand = Effexor XR, Effexor IR (discontinued in US, generic widely available)
| structure =
| classes = [[:Category:SNRIs|Serotonin-norepinephrine reuptake inhibitor (SNRI)]], [[:Category:Antidepressants|Antidepressant]], [[:Category:Anxiolytics|Anxiolytic]]
| uses = <vote slug="major-depressive-disorder-use">Major depressive disorder (FDA)</vote>, <vote slug="generalized-anxiety-disorder-use">Generalized anxiety disorder (FDA)</vote>, <vote slug="social-anxiety-disorder-use">Social anxiety disorder (FDA)</vote>, <vote slug="panic-disorder-use">Panic disorder (FDA)</vote>, <vote slug="ptsd-use">Posttraumatic stress disorder (off-label)</vote>, <vote slug="neuropathic-pain-broad-use">Neuropathic pain (off-label)</vote>, <vote slug="menopausal-vasomotor-use">Menopausal vasomotor symptoms (off-label, evidence-supported)</vote>
| starting_dose = XR 37.5 mg PO once daily for 4-7 days, then 75 mg/day; titrate by 75 mg every ≥4 days to clinical effect. IR 25-37.5 mg BID-TID
| preparations = IR tablets 25, 37.5, 50, 75, 100 mg; XR capsules 37.5, 75, 150, 225 mg
| fda_max = 225 mg/day outpatient (XR); 375 mg/day inpatient (IR divided TID); 75 mg/day in moderate hepatic impairment
| pill_id =
| routes = Oral
| onset = Antidepressant effect over 1-2 weeks; anxiolytic effect over 4-6 weeks
| duration = 24 hours (XR); 12 hours (IR)
| halflife = Venlafaxine 5 hours; desvenlafaxine active metabolite 11 hours<ref name="effexor-xr-label">FDA Prescribing Information, Effexor XR (venlafaxine extended-release), Wyeth/Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.pdf</ref>
| bioavailability = ~45%<ref name="effexor-xr-label" />
| pregnancy = Observational signal for neonatal adaptation syndrome with late-pregnancy exposure; weigh against the risks of untreated maternal depression.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="effexor-xr-label" />
| mechanism = <vote slug="venlafaxine-mech-claim">Serotonin and norepinephrine reuptake inhibitor with predominantly serotonergic activity at lower doses (37.5-150 mg); the noradrenergic effect adds at higher doses (>150 mg) and the dual-mechanism advantage really emerges then. The active metabolite desvenlafaxine (separately marketed as Pristiq) contributes meaningfully to clinical effect.</vote> '''Severe discontinuation syndrome''' is the marquee adverse-effect feature: venlafaxine's short half-life produces intense flu-like symptoms, dizziness, electric-shock sensations ("brain zaps"), and emotional dysregulation on abrupt discontinuation, worse than most other SNRIs and SSRIs. Slow taper essential. Dose-dependent '''diastolic hypertension''' at higher doses; routine BP monitoring at dose escalation. CYP2D6 substrate; CYP2D6 oxidation produces the active metabolite desvenlafaxine. PharmGKB clinical annotations for venlafaxine apply (Level 2A).<ref name="pharmgkb-venlafaxine">PharmGKB: Venlafaxine pharmacogenomics annotations. https://www.pharmgkb.org/chemical/PA451866</ref> No formal CPIC guideline covers venlafaxine; the CPIC SSRI/CYP2D6 guideline (Hicks 2015) covers sertraline, citalopram, escitalopram, fluoxetine, fluvoxamine, and paroxetine and does not extend to SNRIs.
}}

== References ==
<references />

[[Category:SNRIs]]
[[Category:Antidepressants]]
[[Category:Anxiolytics]]

Dandelion

2026-05-26T20:28:02Z

MDElliottMD: home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

{{PlantMedTemplate
| binomial = Taraxacum officinale
| family = Asteraceae
| native_range = Originally native to Eurasia and North Africa; now one of the most globally distributed plants in the world, present on every inhabited continent following dispersal with European colonization. Grows wild in grassland, roadsides, disturbed ground, and lawns throughout the temperate zone; cultivated commercially for medicinal and culinary supply in Germany and France.
| parts_used = Leaves (diuretic; harvested before flowering for highest bitter-principle content); root (hepatic bitter; dug in autumn from second-year plants for highest inulin content); flowers (minor; folk wine and syrup).
| images =
| intro = ''Taraxacum officinale'' G.H. Weber ex Wiggers -- dandelion -- is a perennial composite herb of Eurasian origin, now distributed across every inhabited continent and recognized by virtually every person alive, most of whom have at some point scattered its seeds from a spherical white clock. The French long ago named it pissenlit -- wet-the-bed -- which is an accurate clinical description of its principal medicinal action in the leaf, and it is this frankness of folk nomenclature that most concisely captures the herb's place in medicine: a plant dismissed as a weed by every suburban lawn, carrying a clinical evidence base in diuresis that most commercially marketed diuretic herbs cannot match, with the additional distinction of replenishing in the leaf the very potassium that synthetic diuretics strip away.
| traditional_uses = The earliest written records of dandelion in medicine come from 11th-century Arabic physicians -- Ibn Sina listed dandelion leaf in pharmacopoeial works -- and from the Welsh Physicians of Myddfai, a 13th-century medical guild whose manuscripts record it for liver and digestive complaints.{{citation needed}} By the 17th century ''T. officinale'' was established in every European herbal, universally respected as a hepatic bitter, a diuretic, and a spring tonic food -- the tender young leaves gathered from fields before the first flowering and eaten in salad as an annual seasonal cleanse.

The name is a corruption of the French dent-de-lion (lion's tooth), referring to the deeply ragged leaf margins; in English it became "dandelion" by the 16th century. The French pissenlit captured the leaf's diuretic force with characteristic directness; contemporary French herbalists still use the term without embarrassment, as an accurate pharmacological description rather than a vulgarity.

Nicholas Culpeper in 1653 recorded dandelion for "opening obstructions of the liver, gall, and spleen," for jaundice, and as "a sovereign remedy against the evil disposition of the body, proceeding from the badness of the blood."{{citation needed}} These indications -- liver, spleen, fluid, blood quality -- are precisely those that the Western alterative tradition has assigned to dandelion root for the four centuries since Culpeper, with remarkable consistency across German, French, British, and American herbal schools.

'''Chinese medicine: Pu Gong Ying (蒲公英)'''

In Chinese medicine the principal species is ''Taraxacum mongolicum'' (sometimes listed as ''T. sinicum''), though ''T. officinale'' is accepted as an equivalent in most contemporary pharmacopoeias. Under the name Pu Gong Ying, it is classified as bitter and sweet in flavor, cold in nature, entering the liver and stomach meridians. Its principal TCM indications are clearing heat and relieving toxicity -- the diagnostic category covering acute inflammatory and infectious conditions: breast abscess and mastitis (one of the most historically consistent indications in TCM practice for this herb), acute sore throat and tonsillitis, infected eyes, jaundice from damp-heat in the liver, and intestinal infection with heat signs.{{citation needed}} The TCM mastitis indication -- Pu Gong Ying as a primary herb for acute lactation mastitis, applied both internally as a decoction and topically as a poultice of fresh crushed leaf -- is among the most specific and consistent indications in the Chinese Materia Medica and has ethnopharmacological parallels in European practice (fresh dandelion leaf poultice for skin inflammation and swelling).

'''Native American and post-colonial American use'''

As ''T. officinale'' spread with European colonization, indigenous peoples throughout North America adopted it rapidly as it naturalized across the continent. Multiple nations used it for kidney, liver, and digestive complaints -- applications consistent with the introduced European knowledge system -- suggesting either independent discovery of the same pharmacological effects or rapid adoption of European herbal knowledge through trade contact.{{citation needed}}

'''Food tradition'''

Dandelion occupies an unusual dual role as food and medicine. Spring dandelion greens -- young leaves gathered before flowering, when bitter principles are concentrated and the leaves are most nutritionally dense -- are among the most nutritionally complete wild greens available in temperate climates, higher in vitamins A, C, and K, and in calcium, iron, and potassium, than most cultivated vegetables.{{citation needed}} Dandelion coffee -- roasted dried root decoction -- became a wartime staple in Britain and Europe during both World Wars when coffee was rationed, and remains a gentle, caffeine-free bitter digestive tonic in current herbal practice. In France, ''pissenlit au lard'' (dandelion greens with lardons and hot vinegar dressing) is a Burgundian spring classic with a history traceable to medieval monastic cooking.
| botany = ''Taraxacum officinale'' G.H. Weber ex Wiggers is placed in tribe Cichorieae (formerly Lactuceae), subfamily Cichorioideae, family Asteraceae. The species epithet officinale (of the dispensary) signals long apothecary use; the genus name derives from the Arabic tarakhshagun or the medieval Latin corruption of it, meaning bitter herb. ''Taraxacum'' is an enormously complex genus: depending on the taxonomic authority, it contains anywhere from 60 to 2,000 or more microspecies, many of which are apomictic (reproducing without fertilization, generating clonal lineages). Most commercial medicinal supply and most clinical research uses ''T. officinale'' in the broad, aggregate sense rather than any single microspecies; pharmacopoeial monographs accept this broad usage.

The plant is a perennial forming a basal rosette of deeply pinnately lobed leaves -- the lobes giving the lion's-tooth shape -- growing from a deep taproot that can reach 30 to 50 cm in established plants. The leaves are glabrous to slightly hairy; in cultivated populations they may be less deeply lobed. Hollow, leafless scapes (flower stalks) arise singly from the crown, each bearing a single bright golden composite head of ray florets only (no disk florets); this morphology distinguishes it from most other yellow composites. The well-known globular gray-white seed head (the "clock") consists of the achenes with their attached pappus (feathery parachute structures) that allow wind dispersal over considerable distances. A single plant may produce 2,000 to 12,000 seeds per year, a reproductive strategy that explains both its global success and suburban gardeners' despair.

The medicinal parts are harvested by part and season: leaves before first flowering in spring (highest bitter-principle and potassium content; preferred for diuretic use), root in autumn from second-year plants (highest inulin content; preferred for hepatic use). The spring-leaf and autumn-root distinction is not merely traditional but is pharmacologically grounded in the plant's seasonal allocation of primary metabolites.

Closely related: ''Taraxacum mongolicum'' (Pu Gong Ying; principal TCM medicinal species; used pharmacopoeially as equivalent to ''T. officinale'').
| constituents = '''Leaf constituents'''

The leaf is the more nutritionally dense and diuretically active part. Principal constituents include sesquiterpene lactones (taraxacin and related compounds, responsible for the bitter taste), triterpenes, polysaccharides, coumarins, carotenoids (beta-carotene and lutein; source of the leaf's nutritional vitamin-A equivalents), vitamins C and K, and, notably, minerals at concentrations that distinguish it from most vegetables: potassium content is among the highest of any leafy green, with documented values of 370 to 500 mg per 100 g fresh weight.{{citation needed}} This mineral composition is the pharmacological basis of dandelion leaf's unique advantage among diuretics: it replenishes the urinary potassium losses it induces, preventing the hypokalemia associated with synthetic loop and thiazide diuretics.

'''Root constituents'''

The root holds a different pharmacological profile. Inulin -- a fructooligosaccharide prebiotic polysaccharide -- constitutes up to 40 percent of dry root weight in autumn-harvested material, falling to 1 to 2 percent in spring (when it has been consumed in new-growth production).{{citation needed}} This seasonal variation is the pharmacological rationale for the traditional autumn-harvest preference. Taraxacoside, the principal bitter sesquiterpene glycoside of the root, contributes to the bitter-tonic and mild laxative actions. Phenolic acids (chicoric acid, caffeic acid derivatives), triterpenes (taraxasterol, taraxerol), and polyacetylenes complete the profile. Mineral content in the root, while lower per gram than the leaf, is still significant.
| pharmacodynamics = '''Diuretic mechanism (leaf)'''

The leaf's diuretic action is classified as aquaretic -- meaning it increases urine volume and sodium excretion without proportional potassium loss -- distinguishing it from synthetic diuretics (loop diuretics, thiazides) that cause significant potassium depletion. The mechanism is thought to involve inhibition of tubular sodium reabsorption by sesquiterpene lactone constituents, but the precise renal tubular pharmacology has not been fully characterized at the receptor level.{{citation needed}} The high potassium content of the leaf preparation further buffers any net potassium loss, contributing to the clinically observed potassium-sparing profile.

'''Hepatic and cholagogue mechanism (root)'''

The bitter sesquiterpene compounds (taraxacoside and related lactones) stimulate bile secretion from the liver and gallbladder contraction -- the cholagogue action that underlies the hepatic-bitter tonic use. This mechanism is consistent with the pharmacology of other bitter Asteraceae (chicory, artichoke) and with the TCM clearing-heat-from-liver-channel framing of the same traditional indication. In animal models, dandelion root extracts have demonstrated hepatoprotective effects against carbon tetrachloride-induced hepatotoxicity and against acetaminophen toxicity, consistent with antioxidant and anti-inflammatory mechanisms.{{citation needed}}

'''Anti-inflammatory mechanism'''

Polyphenolic compounds in the leaf and root (including chicoric acid, caffeic acid derivatives, and flavonoids) inhibit pro-inflammatory signaling cascades in cell-culture models, including reduction of LPS-stimulated NF-kB activation and suppression of pro-inflammatory cytokine release.<ref name="jeon2017">Jeon D, Kim SJ, Kim HS. "Anti-inflammatory evaluation of the methanolic extract of ''Taraxacum officinale'' in LPS-stimulated human umbilical vein endothelial cells." BMC Complement Altern Med. 2017;17(1):508. PMID 29187173.</ref> Whether these in vitro effects translate to clinically meaningful anti-inflammatory activity in human tissue remains to be established in powered clinical trials.

'''Prebiotic mechanism (root inulin)'''

Inulin is a well-characterized prebiotic: it selectively promotes the growth of beneficial gut microbiota (principally ''Bifidobacterium'' and ''Lactobacillus'' species) by serving as a fermentable substrate for these organisms while being resistant to digestion by human gut enzymes. The effect is dose-dependent and well-established for inulin regardless of botanical source; dandelion root is one of the most concentrated natural sources of inulin outside chicory root (''Cichorium intybus'') and Jerusalem artichoke (''Helianthus tuberosus'').{{citation needed}}
| indications = '''Diuretic activity: human clinical evidence'''

Clare, Conroy, and Spelman (2009) conducted a single-day human clinical study in 17 healthy volunteers, administering an extract of ''Taraxacum officinale'' leaf (8 ml per dose from a 1:5 infusion) three times over seven hours. Urine volume and urinary frequency increased significantly between the first and second doses and between the second and third doses relative to pre-treatment baseline, demonstrating acute diuretic activity in humans. Urinary excretion of potassium was not significantly depleted, consistent with the leaf's high potassium content counterbalancing urinary losses.<ref name="clare2009">Clare BA, Conroy RS, Spelman K. "The diuretic effect in human subjects of an extract of ''Taraxacum officinale'' folium over a single day." J Altern Complement Med. 2009;15(8):929-934. PMID 19678785.</ref><ref name="raczkotilla1974">Racz-Kotilla E, Racz G, Solomon A. "The action of ''Taraxacum officinale'' extracts on the body weight and diuresis of laboratory animals." Planta Med. 1974;26(3):212-217. PMID 4427955.</ref> This study is single-day and uncontrolled (no parallel placebo arm); it establishes acute diuretic activity but does not address long-term efficacy or comparative effectiveness against synthetic diuretics.

No large-scale randomized controlled trials of dandelion leaf for clinical edema, hypertension, or fluid retention have been published. The clinical evidence base for the diuretic indication is consistent but limited in scale and rigor relative to conventional diuretics.

'''Hepatic and alterative uses: traditional and preclinical evidence only'''

The hepatic-tonic, alterative, and liver-cleansing indications that constitute the principal traditional use of dandelion root do not have a randomized clinical trial evidence base in humans. Animal models show hepatoprotective effects against chemical hepatotoxins; the bitter-tonic mechanism is pharmacologically well-grounded; the cholagogue action is consistent with the class pharmacology of sesquiterpene bitters. The absence of clinical trial data reflects the general underfunding of hepatic herbal medicine research rather than any evidence of inefficacy, but the distinction between traditional use supported by preclinical data and use supported by clinical trials should be maintained in patient-facing communication.

'''Anticancer activity: in vitro studies only'''

Ovadje and colleagues have published a series of in vitro studies demonstrating that aqueous dandelion root extract selectively induces apoptosis in human leukemia cell lines through both intrinsic and extrinsic pathways, without significant toxicity to normal peripheral blood mononuclear cells.<ref name="ovadje2011">Ovadje P, Chatterjee S, Griffin C, Tran C, Hamm C, Pandey S. "Selective induction of apoptosis through activation of caspase-8 in human leukemia cells (Jurkat) by dandelion root extract." J Ethnopharmacol. 2011;133(1):86-91. PMID 20849941.</ref><ref name="ovadje2012">Ovadje P, Hamm C, Pandey S. "Efficient induction of extrinsic cell death by dandelion root extract in human chronic myelomonocytic leukemia (CMML)." PLoS One. 2012;7(2):e30604. PMID 22363452.</ref> These are laboratory findings in cell lines; they do not constitute clinical evidence of anticancer efficacy in humans. No clinical trials of dandelion root extract for cancer treatment have been completed or published. These findings are scientifically interesting and warrant further investigation but should not be represented as clinical evidence of therapeutic effect.
| preparations = Leaf infusion (tea): 4 to 8 g fresh or dried leaves per cup of hot water, steeped covered (volatile constituents are modest; the cover prevents steam loss rather than oil loss). Taken 2 to 3 times daily for diuretic and tonic use; or fresh leaves as salad greens (the traditional spring tonic form, maximally nutritious and minimally processed).

Root decoction: 5 to 10 g dried root in 500 ml water, simmered covered for 15 to 20 minutes; strained and drunk in 2 to 3 portions through the day. The preferred preparation for hepatic-bitter and cholagogue use; suited to the autumn-harvested root with its peak inulin content.

Root tincture: 1:5 in 40 to 45 percent ethanol from dried root; 2 to 5 ml three times daily.

Roasted root "coffee": dried root roasted until dark brown (approximately 200 degrees Celsius, 30 minutes); ground and prepared by decoction or percolation as a coffee substitute. The roasting converts much of the inulin to simpler fructose units and develops the characteristic dark, slightly bitter flavor; the hepatic bitter action is retained at reduced intensity. A gentle daily liver tonic and caffeine-free coffee alternative with a continuous history from World War II rationing.

Root powder: 2 to 4 g per day in capsule or tablet form; convenient standardized option.
| dosing = '''Leaf (diuretic, tonic)'''

Infusion: 4 to 8 g dried leaf per cup, 2 to 3 times daily. Fresh leaf as salad: no formal dose ceiling; traditional seasonal use is ad libitum.

Tincture (1:5 in 40 percent ethanol): 2 to 5 ml three times daily.

'''Root (hepatic-bitter, cholagogue, prebiotic)'''

Decoction: 5 to 10 g dried root per day in divided doses. Tincture (1:5): 2 to 5 ml three times daily. Powder: 2 to 4 g per day.

The traditional distinction between spring-leaf use (diuretic, nutritive tonic) and autumn-root use (hepatic-bitter, prebiotic) reflects genuine pharmacological differences in the plant across seasons and should be preserved in practice where possible.

'''Recreational dose ladder'''

Dandelion has no recreational or psychoactive profile in any documented tradition. Neither the leaf nor the root produces altered consciousness, euphoria, sedation, or any psychoactive effect at any accessible dose. The bitter taste at higher leaf or root doses is limiting; above 10 to 15 g of dried root per day, mild nausea and diarrhea occur as the dose-limiting gastrointestinal effects. No dose ladder is warranted.
| pharmacokinetics = The pharmacokinetics of ''T. officinale'' constituents have not been well characterized. Taraxacoside and related sesquiterpene lactones are likely absorbed from the gastrointestinal tract and undergo hepatic metabolism; the kinetics are not documented to the same standard as pharmaceutical preparations. Inulin from the root is not absorbed -- it passes undigested to the large intestine where it is fermented by colonic microbiota; this is entirely the intended pharmacological mechanism for its prebiotic action rather than a bioavailability problem. Polyphenolic compounds (chicoric acid, caffeic acid derivatives) are absorbed in part from the small intestine and undergo conjugation and methylation by gut enzymes and hepatic CYP enzymes.{{citation needed}}
| interactions = Lithium: dandelion leaf's diuretic action reduces renal lithium clearance (as does any diuretic); this can elevate lithium plasma levels into the toxic range. Patients taking lithium should not use dandelion leaf preparations without medical supervision and lithium-level monitoring.{{citation needed}}

Potassium-sparing diuretics and ACE inhibitors: dandelion leaf's potassium-retaining character combined with potassium-sparing agents (spironolactone, eplerenone) or ACE inhibitors (which reduce urinary potassium excretion) could theoretically produce hyperkalemia in vulnerable patients. The risk is low at typical leaf-infusion doses but warrants monitoring in patients with renal impairment or on potassium-sparing regimens.

Antidiabetic medicines: dandelion has mild blood-glucose-lowering properties in animal models; additive hypoglycemic effect is possible with insulin and oral antidiabetic agents. Monitor blood glucose in diabetic patients who begin regular dandelion use.

Anticoagulants (warfarin): dandelion leaves are very high in vitamin K. Patients on warfarin anticoagulation whose vitamin K intake changes significantly (including by adding large quantities of dandelion leaf to the diet) may experience INR instability. Consistency of intake is more important than avoidance.
| interactionsummary = Lithium: diuresis raises lithium levels (monitor). High vitamin K in leaf: INR variability with warfarin. Additive hypoglycemia possible with antidiabetic medicines.
| counseling = The distinction between leaf and root preparations should be communicated clearly: the diuretic action resides principally in the leaf, and the hepatic-bitter and prebiotic actions in the root. A patient seeking fluid-retention relief should use the leaf infusion; a patient seeking liver support, digestive bitters, or prebiotic gut support should use the root decoction or roasted root.

The potassium-sparing quality of the dandelion leaf diuresis is genuinely clinically relevant and worth explaining to patients who have previously been told to avoid diuretics because of potassium concerns: dandelion leaf does not cause the potassium depletion associated with furosemide or hydrochlorothiazide. This distinction is well-grounded pharmacologically, though the clinical trial evidence is limited in scale.

The anticancer cell-line findings should not be communicated to patients as evidence of clinical efficacy. The in vitro data are preliminary and interesting; no clinical benefit in cancer treatment has been established. Patients with cancer who are interested in dandelion root for general liver support or digestive use (reasonable traditional indications) should be informed of this distinction.

===Safety===

Dandelion is among the safest herbs in the Western pharmacopoeia for adults, children, and in pregnancy. Serious adverse events are not documented in the clinical or case-report literature at standard dietary or medicinal doses.

Gallstones: the root's cholagogue (gallbladder-stimulating) action is the principal safety concern. In patients with known gallstones, particularly large stones or any degree of bile duct obstruction, stimulating gallbladder contraction can precipitate biliary colic. Dandelion root preparations should be used with caution in patients with known cholelithiasis and are contraindicated in patients with obstructive jaundice or bile duct obstruction.

Asteraceae allergy: dandelion is in the same plant family as ragweed (''Ambrosia'' spp.), chamomile, and chrysanthemum. Patients with documented Asteraceae contact or inhalant allergy may have cross-reactive responses to dandelion; this is most relevant for topical use of fresh plant material. Oral ingestion of dandelion in Asteraceae-allergic individuals is generally well-tolerated but warrants initial caution.

Pregnancy and lactation: dandelion leaf and root are used as food and tonic herbs in traditional midwifery without reported harm; the plant is among the herbs most consistently classified as safe in pregnancy at dietary doses. Large-dose medicinal preparations have not been formally evaluated in pregnancy trials.

===Regulatory===

'''Germany'''

German Commission E: dandelion root with herb (Taraxaci radix cum herba) approved for disturbances of bile flow, stimulation of diuresis, loss of appetite, and dyspepsia.

'''European Union'''

EMA HMPC: positive assessment for traditional use of dandelion root and herb for symptomatic treatment of minor digestive disorders (dyspepsia, bloating, flatulence) and as adjuvant for increased urinary output in minor urinary complaints. Traditional use listing under the EU Traditional Herbal Medicinal Products Directive.<ref name=ema-taraxacum>European Union herbal monograph on ''Taraxacum officinale'' F.H. Wigg., radix. EMA/HMPC/475726/2020. Committee on Herbal Medicinal Products (HMPC). https://www.ema.europa.eu/en/medicines/herbal/taraxaci-officinalis-radix</ref>

'''United States'''

Dandelion root and leaf: GRAS (generally recognized as safe) as food; sold as a dietary supplement under DSHEA without FDA evaluation of therapeutic claims.

'''United Kingdom'''

MHRA traditional herbal registration: dandelion root preparations registered for traditional use for relief of minor digestive and urinary complaints.
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Hepatoprotective herbs]]
[[Category:Urological herbs]]
[[Category:Diuretic herbs]]
[[Category:Western clinical herbs]]
[[Category:TCM herbs]]

Peppermint

2026-05-26T20:28:01Z

MDElliottMD: home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

{{hatnote|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See the [[#Botany and identification]] section for the full safety warning.}}
{{PlantMedTemplate
| name = Peppermint
| binomial = Mentha × piperita
| family = Lamiaceae
| native_range = Not native to any wild habitat: peppermint is a sterile hybrid and does not reproduce from seed. First recorded in England in the 17th century, probably arising spontaneously in cultivated mint fields near Mitcham, Surrey. Now cultivated worldwide throughout the temperate zone; principal commercial producers are the United States (Pacific Northwest and Indiana), India, and China.
| plant_part = Aerial parts (leaves and flowering tops); essential oil distilled from fresh herb; enteric-coated capsules of the essential oil for pharmaceutical use.
| image =
| intro = ''Mentha x piperita'' L. -- peppermint -- is a sterile hybrid of watermint (''Mentha'' aquatica) and spearmint (''Mentha spicata'') first documented in the herb gardens of 17th-century England. It reproduces only by vegetative spread and would disappear without cultivation; instead it has become the most widely grown aromatic herb in the world, its menthol extracted in quantities sufficient to scent a global industry of confectionery, personal care, and pharmaceuticals. Among medicinal herbs it holds an unusual distinction: enteric-coated peppermint oil capsules are supported by a Cochrane systematic review of nine randomized controlled trials reporting a number needed to treat of 2.5 for irritable bowel syndrome -- one of the strongest evidence-backed botanical indications in gastrointestinal medicine.
| history = Mint is one of the oldest plants in the human medicinal record. Dried mint leaves have been recovered from Egyptian tombs dated to approximately 1000 BCE; the Romans cultivated mint so extensively across their empire that Pliny the Elder complained they planted it everywhere.{{citation needed}} The Greek physician Dioscorides recorded multiple mint species and their uses for flatulence, nausea, and the suppression of vomiting; Hippocrates had written of mint before him. In the Arab world, the physician Ibn Sina noted mint's digestive and carminative properties in the Canon of Medicine. By the medieval period mint was among the universal European monastery garden plants, appearing in every hortus conclusus alongside sage, rosemary, and lavender.

What none of these traditions knew, because it did not yet exist, was peppermint. ''Mentha x piperita'' is a hybrid -- a cross between watermint and spearmint -- that arose, or was first recognized, in England in the 17th century, likely in the commercial mint-growing fields around Mitcham in Surrey, which became the center of English peppermint cultivation and remained so through the 19th century. John Ray, the English naturalist, first formally described peppermint as a distinct plant in 1696.{{citation needed}} The English cultivated it first; then the Americans took it -- particularly the farmers of Chautauqua County, New York and later the Columbia River basin -- and by the 19th century peppermint was a transatlantic commodity. By the 20th century it was a global industrial crop, its oil distilled in tonnage for the tobacco, confectionery, and oral hygiene industries, and the pharmacognosists were beginning to work out exactly why it did what it had always done to a troubled gut.

The therapeutic pivot came in stages. Commission E in Germany approved peppermint oil for spasmodic complaints of the upper gastrointestinal tract in 1990, grounded in traditional use and the available pharmacological rationale. The pharmaceutical form -- enteric-coated peppermint oil capsules formulated to survive the stomach acid and release their contents in the small intestine -- was the key innovation; Colpermin appeared in the 1980s and accumulated clinical trial data through the 1990s and 2000s. The Cochrane Collaboration's 2014 systematic review was the culmination of that evidence, and it placed peppermint oil among the most rigorously substantiated botanical interventions in gastroenterology.
| taxonomy = ''Mentha x piperita'' L. belongs to tribe Mentheae, family Lamiaceae. The multiplication sign in the binomial (x) denotes hybrid origin: the parents are ''Mentha'' aquatica (watermint) and ''Mentha spicata'' (spearmint). The hybrid is triploid and entirely sterile -- it sets no viable seed and propagates exclusively by vegetative means (rhizomes and cuttings). The x piperita epithet (pepper-mint) refers to the hot-cool-pungent character of the fresh leaf, distinct from the milder spearmint parent.

The genus ''Mentha'' comprises approximately 25 recognized species and a very large number of hybrids, cultivars, and named varieties; the genus is taxonomically complex, and menthol content varies considerably across species and cultivars. Medically and commercially significant species include:

''Mentha'' aquatica (watermint): one parent of peppermint; grows in wet habitats; high linalool content; mild medicinal use.

''Mentha spicata'' (spearmint): the other parent; carvone-dominant rather than menthol-dominant; gentler, less cooling; the spearmint of culinary use and the safer option for children and for those who do not tolerate peppermint's LES-relaxing effect.

''Mentha'' arvensis (corn mint, Japanese peppermint): the dominant commercial source of natural menthol crystals; native to Asia; the oil from this species is far higher in menthol (70 to 90 percent) than peppermint oil (35 to 55 percent) and is the source of most of the menthol in commercial cough drops, mentholated cigarettes, and topical pain preparations.

''Mentha'' pulegium (pennyroyal): HIGHLY TOXIC. Pulegone-rich; historically used as a folk abortifacient; cases of maternal fatality and severe hepatic failure have been reported following ingestion of pennyroyal oil as an abortifacient agent.{{citation needed}} Pennyroyal should never be used as a substitute for peppermint in any context; the two plants have been confused in commercial herbal markets with fatal consequences.

The medicinal parts of M. x piperita are the aerial parts -- leaves and flowering tops -- harvested before full flowering. The essential oil is steam-distilled from fresh herb; genuine peppermint oil should contain menthol at 35 to 55 percent, distinguishing it from the lower-grade lavandin oil in the lavender trade's parallel adulteration problem.
| traditional_uses = '''Western herbal medicine (primary centroid)'''

Peppermint's principal traditional indications mirror its modern evidence base with unusual fidelity: flatulence and bloating, digestive cramping and colic, nausea and vomiting, dyspepsia, headache (particularly the common tension headache with a frontal or temporal distribution), nasal congestion from colds, and muscle pain. The herb has been used for these purposes in continuous Western practice from at least the 18th century, when peppermint tea became the commonest domestic remedy for an upset stomach in Britain and America. The inhalational use for nasal congestion -- peppermint steam over hot water, peppermint oil rubbed on the chest or dissolved in a steam inhaler -- has equal continuity. The topical application to the temple and forehead for headache appears in 18th- and 19th-century domestic medicine texts and was given its first controlled clinical evidence base by Gobel in 1996.

'''TCM: Bo He (薄荷)'''

Peppermint is used in Chinese medicine under the name Bo He, though the plant sourced in Chinese practice is frequently ''Mentha'' haplocalyx or other Asian ''Mentha'' species rather than M. x piperita; the volatile-oil chemistry is sufficiently similar for the indications to overlap. In the TCM framework, Bo He is classified as pungent and cool, entering the lung and liver meridians. Its primary indications are wind-heat exterior patterns (early common cold or influenza with fever, sore throat, headache) where it disperses the pathogenic wind-heat; it also clears the head and eyes for wind-heat-related headache and red eyes, and moves liver qi stagnation for irritability and distention. In formulae, it is frequently combined with Forsythia (Lian Qiao) and Lonicera (Jin Yin Hua) in standard wind-heat formulas such as Yin Qiao San.{{citation needed}}

'''Ayurvedic medicine (Pudina)'''

Peppermint is used in Ayurvedic medicine as Pudina, described as pungent, slightly bitter, and cooling in action; it pacifies kapha and vata doshas while having mixed effects on pitta. Principal Ayurvedic indications are digestive complaints -- dyspepsia, nausea, vomiting -- and febrile conditions where its diaphoretic action is valued. It is among the aromatics used in Ayurvedic churnas (herbal powders) for digestive support.{{citation needed}}

'''Islamic medicine (Na'na)'''

Mint was known in Arabic-speaking medicine as Na'na (نعناع) and classified as cool and drying in the Galenic-Islamic temperament system; Ibn Sina described it for digestion, fevers, headache, and nausea in the Canon of Medicine, consistent with its Dioscoridean antecedents.{{citation needed}}
| pharmacology = '''Menthol: the principal active constituent'''

Peppermint essential oil contains menthol at 35 to 55 percent of total volatile oil, menthone at 10 to 40 percent, menthyl acetate, isomenthone, 1,8-cineole, and trace amounts of pulegone (significantly higher in pennyroyal and in some lavandin adulterants).{{citation needed}}

Menthol exerts its principal therapeutic actions through two distinct receptor mechanisms.

Voltage-gated calcium channel blockade in gastrointestinal smooth muscle: menthol and whole peppermint oil inhibit L-type calcium channels in intestinal smooth muscle, reducing calcium-dependent contraction and relaxing GI tone. This was first demonstrated in a pharmacological study by Hawthorn and colleagues in 1988<ref name="hawthorn1988">Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac smooth muscle." Aliment Pharmacol Ther. 1988;2(2):101-118. PMID 2856502.</ref> and confirmed in human colonic smooth muscle by Amato and colleagues in 2014.<ref name="amato2014">Amato A, Liotta R, Mule F. "Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action." Eur J Pharmacol. 2014;740:295-301. PMID 25046841.</ref> The L-type calcium channel mechanism accounts for menthol's antispasmodic action in the irritable bowel -- precisely the mechanism that explains why an enteric-coated capsule formulation that delivers the oil to the small and large intestine (bypassing the stomach) is necessary for IBS treatment.

Transient receptor potential melastatin 8 (TRPM8) activation: menthol is the principal natural ligand of TRPM8, the cold-sensitive ion channel responsible for the sensation of coolness (and, paradoxically, of cold-induced burning at high concentrations). TRPM8 activation in sensory neurons is the basis of peppermint's cooling sensation on the skin and mucous membranes, and contributes to its topical analgesic effect in tension headache -- initial TRPM8 activation followed by desensitization leads to reduced pain signaling in the same manner that capsaicin (TRPV1 agonist) produces topical analgesia via TRPV1 desensitization.<ref name="mckemy2002">McKemy DD, Neuhausser WM, Julius D. "Identification of a cold receptor reveals a general role for TRP channels in thermosensation." Nature. 2002;416(6876):52-58. PMID 11882888.</ref><ref name="bautista2007">Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI. "The menthol receptor TRPM8 is the principal detector of environmental cold." Nature. 2007;448(7150):204-208. PMID 17538622.</ref>

Antimicrobial activity: peppermint essential oil demonstrates broad-spectrum antibacterial and antifungal activity in vitro, including against ''Helicobacter pylori'', ''Candida albicans'', methicillin-resistant ''Staphylococcus aureus'', and Escherichia coli; the mechanism involves menthol's disruption of microbial cell membrane integrity.{{citation needed}}

Choleretic activity: peppermint oil stimulates bile secretion from the gallbladder and hepatic bile production; this contributes to its efficacy in functional dyspepsia and gallbladder-related upper GI symptoms and is the pharmacological basis of the Commission E approval for bile duct and gallbladder complaints.{{citation needed}}
| clinical_evidence = '''Irritable bowel syndrome (enteric-coated peppermint oil capsules)'''

The evidence for enteric-coated peppermint oil in IBS is the strongest clinical evidence base of any herbal medicine in gastroenterology. The formulation is critical: non-enteric-coated preparations dissolve in the stomach, causing upper GI side effects (heartburn, nausea from premature LES relaxation) without delivering active oil to the target site in the small and large intestine. Enteric-coated capsules bypass the stomach and release their contents only in the more alkaline intestinal environment.

Khanna and colleagues (2014) conducted a systematic review and meta-analysis of nine randomized, placebo-controlled trials (total n = 726) of enteric-coated peppermint oil for IBS. Global symptom improvement was significantly greater in the peppermint group; the pooled relative risk for global improvement was 2.23 (95 percent CI 1.78 to 2.81), corresponding to a number needed to treat of 2.5 -- a remarkably strong treatment effect for a botanical intervention in a notoriously treatment-resistant condition.<ref name="khanna2014">Khanna R, MacDonald JK, Levesque BG. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." J Clin Gastroenterol. 2014;48(6):505-512. PMID 24100754.</ref>

Among the constituent trials, Cappello and colleagues (2007) randomized 57 patients with IBS to peppermint oil (Mintoil) 187 mg three times daily in enteric-coated capsules or placebo for four weeks; 75 percent of the treated group achieved at least 50 percent reduction in total symptom score, compared with 38 percent in the placebo group. Abdominal pain, distention, stool urgency, flatulence, and borborygmi all improved significantly in the peppermint group.<ref name="cappello2007">Cappello G, Spezzaferro M, Grossi L, Marzio L, Marzio L. "Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial." Dig Liver Dis. 2007;39(6):530-536. PMID 17420159.</ref>

'''Tension headache (topical peppermint oil)'''

Gobel and colleagues (1996) conducted a randomized crossover trial in patients with episodic tension-type headache, applying a 10 percent peppermint oil solution in ethanol to the forehead and temples at headache onset. Topical peppermint oil reduced headache intensity equivalently to oral paracetamol (acetaminophen) 1 g over the 60 minutes following application, with both being significantly superior to placebo. The mechanism is consistent with TRPM8-mediated cutaneous cooling followed by sensory neuron desensitization reducing pain signaling in the trigeminal area.<ref name="gobel1996">Gobel H, Fresenius J, Heinze A, Dworschak M, Soyka D. "Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type." Nervenarzt. 1996;67(8):672-681. PMID 8805113.</ref>

A 2016 confirmatory study from the same group reaffirmed the efficacy of topical peppermint oil for acute tension-type headache in a larger sample.<ref name="gobel2016">Gobel H, Heinze A, Heinze-Kuhn K, Gobel A, Gobel C. "[Peppermint oil in the acute treatment of tension-type headache]." Schmerz. 2016;30(3):295-310. PMID 27106030.</ref>

'''Functional dyspepsia'''

Peppermint oil in combination with caraway oil (Enteroplant; MCP Pharma, Germany) has been evaluated in several randomized trials for functional dyspepsia, showing significant improvement over placebo in epigastric pain, nausea, and bloating. The combination is included as a component of the multi-herb preparation Iberogast, which has its own clinical evidence base for functional dyspepsia.{{citation needed}}
| preparations = Infusion (tea): 3 to 4 g dried leaf per cup of hot water, covered while steeping (volatile oil retention). Drunk after meals for digestive complaints; as a steam inhalant for nasal congestion (pour into a bowl and inhale steam with a towel over the head). Note that peppermint tea is the preparation with the weakest IBS evidence; the enteric-coated capsule form is the evidence-based preparation for this indication.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation.

Enteric-coated peppermint oil capsules (Colpermin; Pepogest; Mintec; generic equivalents): the only form with robust IBS clinical trial evidence. Enteric coating is essential: the coating is designed to withstand gastric acid and dissolve at the more alkaline pH of the duodenum and small intestine, delivering the oil to the intestinal target rather than the stomach. These capsules must NOT be taken simultaneously with antacids, proton pump inhibitors, or H2 blockers that alkalinize the stomach -- premature dissolution of the enteric coat risks upper GI side effects. Standard commercial dose: 187 to 225 mg three times daily, taken before meals.

Essential oil (topical): 10 percent peppermint oil in ethanol or carrier oil, applied to forehead and temples for tension headache; 2 to 3 percent in carrier oil for massage of muscle ache or abdominal spasm; steam inhalant (2 to 3 drops in hot water) for nasal congestion. Do not apply neat oil to facial skin of children or to the face or chest of infants.

Mouthwash and confectionery: standardized products are not medicinal preparations but carry genuine antimicrobial and breath-freshening effects from the menthol content.
| dosing = '''Internal preparations'''

Infusion: 3 to 4 g dried leaf per cup, three to four times daily, ideally after meals. Cover the vessel while steeping; the volatile oil evaporates readily.

Tincture: 1 to 2 ml three times daily, diluted in water.

Enteric-coated peppermint oil capsules (for IBS): 187 to 225 mg three times daily, 30 to 60 minutes before meals. Do not crush or chew. Separate from antacid use by at least two hours. The full therapeutic effect in IBS develops over two to four weeks of regular use; do not assess as a failure after a single dose.

'''External preparations'''

Tension headache: 10 percent peppermint oil in ethanol, applied by cotton ball or rollerball applicator to forehead and both temples at headache onset; repeat at 15 and 30 minutes as needed. Keep well away from eyes. This is the protocol used in the Gobel trials.

Muscle tension and spasm: 2 to 3 percent essential oil in carrier oil, applied by massage to affected area.

Nasal congestion: 2 to 3 drops essential oil in a bowl of hot water; inhale steam for 5 to 10 minutes with a towel draped over head and bowl. Do not use this method with children under 12, or with infants under any circumstances.

'''Recreational dose ladder'''

Peppermint has no established recreational dose structure. Menthol's TRPM8-mediated cooling sensation is pleasurable and widely exploited in confectionery, oral hygiene, and tobacco products; however, the sensation is immediate, topical, and non-dose-escalating -- there is no psychoactive intensification with increasing dose, and no recreational culture of peppermint use as a psychoactive agent exists in any documented tradition. At high oral doses, menthol produces nausea and GI discomfort rather than pleasure; the pharmacological ceiling of the desirable effect is reached at modest concentrations. No dose ladder is warranted.
| pharmacokinetics = Menthol is rapidly absorbed from the gastrointestinal tract following oral ingestion of non-enteric-coated preparations; enteric-coated formulations delay absorption to the small intestine, which is the therapeutic intent for IBS. Menthol undergoes hepatic glucuronidation and sulfation; the conjugated metabolites are excreted renally, with menthol glucuronide detectable in urine as a biomarker of exposure. The elimination half-life of menthol is approximately one to two hours. Following topical application, menthol is absorbed dermally at a rate sufficient to produce detectable plasma concentrations; dermal absorption is faster with ethanol-based compared to oil-based vehicles.{{citation needed}}
| interactions = Antacids, proton pump inhibitors, H2 receptor antagonists: alkalinization of gastric pH by any of these agents can dissolve the enteric coating of peppermint oil capsules prematurely, causing upper GI side effects (heartburn, nausea, belching) and reducing delivery to the intended intestinal target. Antacids should be separated from enteric-coated capsule dosing by a minimum of two hours.

Central nervous system depressants: additive effects possible with sedating medicines and herbal preparations; peppermint has mild CNS-relaxing effects at therapeutic doses.

Cyclosporine: case reports suggest possible elevation of cyclosporine plasma levels in transplant recipients using peppermint oil preparations; a potential CYP3A4 interaction. Transplant patients on cyclosporine should not use peppermint oil preparations without specialist input.{{citation needed}}

Cyclosporine aside, cytochrome P450 inhibition by peppermint oil at standard enteric-coated capsule doses (187 to 225 mg three times daily) has not been documented as clinically significant in pharmacokinetic interaction studies.
| interactionsummary = Separate from antacids by 2 hours (enteric coat dissolution risk). Theoretical CYP3A4 interaction; case report of cyclosporine elevation. Additive CNS relaxant effect with sedatives.
| safety = The most important safety issue with peppermint is also the most preventable: administration to children under five, or inhalant menthol preparations applied near the face of infants. Menthol applied to the nose, mouth, or chest of infants and young children has caused laryngospasm and bronchospasm, including apnea, in case reports; this has occurred with direct application of peppermint oil or Vicks VapoRub-equivalent preparations to the chest or upper lip. Products containing menthol should not be applied near the face of children under five; for infants and toddlers, no menthol-containing preparations are appropriate.{{citation needed}}

Gastroesophageal reflux disease (GERD) and hiatal hernia: menthol relaxes the lower esophageal sphincter (LES). Peppermint tea and non-enteric-coated preparations should be avoided in patients with active reflux disease; enteric-coated capsules (which deliver the oil below the LES, to the intestine) are substantially lower-risk but should still be used with caution in severe or symptomatic GERD.

Pennyroyal (''Mentha'' pulegium) confusion: pennyroyal is a toxic mint-family plant sometimes sold as or confused with peppermint; its pulegone-rich essential oil has caused hepatic failure and maternal death when taken as an abortifacient. Any herb labeled as pennyroyal, European pennyroyal, or squaw mint should be treated as toxic. This warning applies to herbal suppliers and to patients who gather wild mints without botanical identification.

Gallstones: peppermint oil's choleretic effect stimulates the gallbladder; patients with known gallstones should use peppermint oil preparations cautiously, as stimulation of bile flow in the presence of obstructing stones could precipitate biliary colic.

Pregnancy: no clinical trial safety data; peppermint tea is used in traditional midwifery for pregnancy-related nausea and is generally considered safe at infusion doses; enteric-coated oil capsules at medicinal doses have not been evaluated in pregnancy and are not recommended.
| monitoring = No routine monitoring required for infusion use or enteric-coated capsules at standard IBS doses in otherwise healthy adults. Patients with GERD on enteric-coated capsules: symptom monitoring for worsening reflux. Transplant patients on cyclosporine: if using peppermint oil, check cyclosporine levels within two to four weeks of starting or changing dose.
| counseling = The formulation distinction is the most important thing to convey to patients using peppermint for IBS: only enteric-coated capsules have the clinical evidence base, because only they deliver the oil to the intestinal target. Peppermint tea, while pleasant and acceptable for mild general digestive symptoms, has not been tested for IBS and should not be substituted for the enteric-coated capsule in patients with established IBS diagnosis.

For tension headache, the topical preparation (10 percent peppermint oil in ethanol on forehead and temples) requires patient instruction on avoiding the eyes; a rollerball applicator is more practical than cotton-ball application for self-use. The effect onset is rapid -- patients should expect some relief within 15 to 30 minutes, earlier than with oral paracetamol.

Parents of infants and young children should be advised specifically that peppermint oil and all mentholated preparations should not be applied to the face, nose, or chest of children under five, and not at all to the face of infants.
| regulatory = '''Germany and European Union'''

German Commission E: peppermint oil approved for spastic complaints of the upper GI tract, bile duct and gallbladder; external use for myalgia and neuralgia; and inhalation for diseases of the upper respiratory tract. Peppermint leaf (dried herb) approved for carminative and antispasmodic use in the GI tract.

EMA: positive assessment issued for peppermint oil in enteric-coated capsules for IBS, classified as a well-established use (based on clinical trial evidence) rather than traditional use -- a stronger regulatory designation reflecting the Cochrane-level evidence base. This distinguishes peppermint oil from most other botanical preparations in the EMA monograph system.<ref name="ema-peppermint">European Union herbal monograph on Mentha x piperita L., aetheroleum. EMA/HMPC/522410/2013. Committee on Herbal Medicinal Products (HMPC). First published: 24 July 2020. https://www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum</ref>

'''United States'''

Peppermint oil: GRAS as a food flavoring. Sold as a dietary supplement under DSHEA without FDA evaluation for therapeutic claims. No FDA-approved therapeutic indication.

'''United Kingdom'''

Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Lemon balm

2026-05-26T20:28:00Z

MDElliottMD: home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

{{PlantMedTemplate
| name = Lemon balm
| binomial = Melissa officinalis
| family = Lamiaceae
| native_range = Southern Europe, western Asia, and northern Africa; naturalized through temperate Europe, the Americas, and Australasia. Wild populations occur on roadsides, hedgerows, disturbed ground, and the margins of woodland, particularly on calcareous soils. Widely cultivated as a garden and medicinal herb throughout the temperate world.
| plant_part = Aerial parts (leaves and flowering tops), harvested just before full flowering when volatile oil content peaks; occasionally the essential oil distilled from fresh herb.
| image =
| intro = ''Melissa officinalis'' L. -- lemon balm, balm, melissa -- is a perennial herb of the mint family whose Greek name means bee, a record of the insects that congregate on its small white flowers and make from them a honey prized in antiquity. It has been called "the elixir of life" by Paracelsus and "sovereign for the brain" by John Evelyn; its unbroken reputation across two thousand years of Western and Islamic medicine is for lifting the heart, clearing the head, and settling the gut. The same compounds responsible for its sharp lemon scent -- the polyphenolic fraction concentrated in its leaves -- have turned out to be active against herpes simplex virus in controlled trials, giving it a specific antiviral credential unlike any other common nervine herb.
| history = The genus name carries the oldest story. In Greek myth, Melissa was a bee-priestess of the mountain goddess Cybele; she fed the infant Zeus on honey when his father Kronos sought to devour him, and was afterward transformed into a bee. Theophrastus in the fourth century BCE noted that beekeepers rubbed hive entrances with melissa leaves to keep their colonies from straying -- a practice that survives in modern beekeeping -- and the plant's association with bees, honey, and the sweetness of life runs through every tradition that has known it.{{citation needed}}

Dioscorides, writing in the first century of the common era, described melissa as useful for treating scorpion stings, dog bites, and the spasms of nervous origin; he recorded it as an infusion for "those who suffer from melancholy," establishing the herb's neurological reputation at the foundational level of European botanical medicine.{{citation needed}} The Romans cultivated it widely, and it passed from Roman gardens into the monastery.

Hildegard of Bingen in the twelfth century listed balm among the plants of the monastic garden that addressed the spiritual ailments she called melancholia; Paracelsus in the sixteenth century, temperamentally given to extreme claims, called it "the elixir of life" -- "among all the herbs none is better for the heart."{{citation needed}} John Gerard's Herball of 1597 recommended it for "driving away melancholly and heaviness of mind" and for "warming and comforting the heart."{{citation needed}}

The most enduring and delightful preparation in lemon balm's history was not a medicine in the modern sense but a spirit: Carmelite water (eau des Carmes), developed by the Carmelite nuns in Paris in the fourteenth century from lemon balm, lemon peel, nutmeg, coriander, angelica root, and cloves in high-proof spirits. It circulated as a tonic for the heart, a remedy against fainting and melancholy, and a general cordial; Charles V of France was reputed to drink it daily.{{citation needed}} The preparation survives commercially today under the Boyer label in France, continuous from the 17th century, and may be the longest-lived packaged medicinal preparation in Western Europe.

John Evelyn, the English diarist and gardener, wrote in the late seventeenth century: "Balm is sovereign for the brain, strengthening the memory and powerfully chasing away melancholy."{{citation needed}} The modern dimension was added not by herbalists but by laboratory pharmacologists. In 1994, the German physician and researcher Rainer Wölbling published the first rigorously controlled clinical trial of a standardized lemon balm cream -- subsequently commercialized as Lomaherpan -- applied to cold sores caused by herpes simplex virus.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from ''Melissa officinalis''." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref> The trial demonstrated that what herbalists had used empirically for mouth sores for centuries worked through a specific mechanism -- rosmarinic acid and other polyphenols blocking herpes virus attachment to host cells -- that remains among the most mechanistically coherent antiviral findings in phytomedicine.
| taxonomy = ''Melissa officinalis'' L. is placed in tribe Mentheae, family Lamiaceae, the sole widely used species in the genus Melissa. The genus name derives from the Greek melissa (bee); the species epithet officinalis (of the dispensary) is shared with hundreds of medicinal plants and indicates long-standing apothecary use. No infraspecific taxa carry commercial or medicinal significance.

''L. officinalis'' is a vigorous, branching perennial growing to 1.5 m (5 ft), with deeply veined, toothed bright-green leaves that release a sharp lemon scent when crushed -- a quality immediately distinguishing it from mint (''Mentha'') and other Lamiaceae in the garden. The lemon scent derives principally from citronellal, a compound also responsible for the scent of lemongrass (''Cymbopogon citratus'') and lemon eucalyptus (''Corymbia citriodora''), reflecting convergent volatile chemistry across plant families rather than close botanical relationship.

The small white flowers, tinged pink or lilac, appear in dense axillary clusters from early summer onward; they are rich in nectar and unusually attractive to honeybees. In the garden lemon balm self-seeds freely and becomes naturalized with ease; it is one of the least demanding of the Lamiaceae in cultivation, tolerating partial shade, poor soils, and neglect.

The medicinal parts are the aerial parts -- leaves and flowering tops -- harvested just before full flowering when volatile oil content is highest. Post-flowering leaves are coarser in flavor and lower in volatile oil. The essential oil is produced commercially but is one of the most expensive in herbal commerce: approximately 3,000 to 5,000 kg of fresh leaf is required to produce 1 kg of oil, reflecting the low volatile oil yield (typically under 0.2 percent of fresh weight) and the labor-intensive harvest involved. The essential oil is rarely indicated in clinical practice and is used primarily in aromatherapy.
| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lemon balm belongs to the nervine class of Western herbal medicine -- herbs with a primary action on the nervous system -- and is distinguished within that class by its particular gentleness: it is among the most pediatric-appropriate nervines in the Western tradition, given to colicky infants, anxious children, and restless adolescents alongside adults, without dose adjustment anxieties. This record of safe pediatric use across centuries is itself a kind of pharmacovigilance.

The principal traditional indications map closely onto the modern clinical evidence: anxiety and nervous agitation, insomnia with a restless or worried mind, palpitations from nervous origin (the "racing heart" that has no structural cardiac cause), nervous indigestion, colic and flatulence with an anxiety or tension component, and headache related to tension or nervous overload. The Carmelite water tradition adds a specifically cardiac tonifying dimension -- the heart-gladdening claim -- that aligns with both the nervous-palpitation indication and the mood-lifting effects documented in Kennedy's controlled trials two centuries later.

Secondary traditional indications include the antiviral use -- cold sores, oral herpes, used as topical fresh leaf or strong infusion -- which predates any knowledge of herpesvirus and reflects accurate empirical observation, and a diaphoretic use in febrile illness that made lemon balm standard in European childhood fever management.

'''Islamic medicine (Unani)'''

Lemon balm appears in Islamic-Galenic medicine as Turunjan (ترنجان) and, in some North African traditions, as Badharuj -- though this Arabic identifier is also applied by some sources to sweet basil (''Ocimum basilicum''), creating a minor source-identification ambiguity.{{citation needed}} Ibn Sina's Canon of Medicine praises it in terms that no other classical herbalist surpassed: lemon balm "causeth the heart and mind to become merry, exhilarateth the mind, settleth digestion, and is good against melancholy and the spleen." The Canon identifies it as a warming, drying herb good for cold temperaments, for cardiac palpitations, and for the "sadness and grief" that Ibn Sina associated with obstruction of the vital spirit.{{citation needed}}

'''Ayurvedic medicine'''

Lemon balm is not a primary plant of the classical Ayurvedic pharmacopoeia -- its native range does not extend to the Indian subcontinent -- but it has been incorporated into contemporary Ayurvedic and integrative practice in Europe and North America where it overlaps with herbs of similar action. It is occasionally classified by contemporary Ayurvedic practitioners as a tridoshic nervine suitable for vata-type anxiety and pitta-type irritability.{{citation needed}}
| pharmacology = '''Volatile oil and polyphenolic constituents'''

The essential oil of ''M. officinalis'' is dominated by citral -- a mixture of the geometric isomers geranial and neral -- which accounts for the plant's characteristic lemon scent, along with citronellal, linalool, and caryophyllene oxide.{{citation needed}} The volatile oil fraction, however, is present in much lower concentration than in most other medicinal Lamiaceae (under 0.2 percent of fresh weight), and its contribution to the therapeutic actions of whole-plant preparations may be secondary to the non-volatile polyphenolic fraction.

Rosmarinic acid and related caffeic acid derivatives -- the principal polyphenolic compounds in lemon balm -- are the dominant pharmacologically active fraction for antiviral activity. Rosmarinic acid and the tannin fraction interfere with viral attachment to host cells by binding to glycoproteins on the herpes simplex virus (HSV) envelope, preventing the virus from docking with cell-surface receptors; this mechanism has been demonstrated in cell-culture models and correlates with the clinical efficacy of topical Melissa preparations in herpes labialis.{{citation needed}}

The flavonoids (luteolin, apigenin) and triterpenes (ursolic and oleanolic acids) contribute anti-inflammatory and anxiolytic properties; apigenin in particular has affinity for the benzodiazepine receptor site of the GABA-A receptor, and this GABA-A interaction is the proposed basis for lemon balm's anxiolytic and mild sedative activity -- the same general mechanism as valerian, passionflower, and lavender, reflecting convergent pharmacology across unrelated plant families.{{citation needed}}

The anti-thyroid mechanism is distinct from both of the above: aqueous extracts of ''Melissa officinalis'' inhibit binding of thyroid-stimulating hormone (TSH) and Graves' immunoglobulins to TSH receptors in vitro, reducing thyroid stimulation. The mechanism is thought to involve the polyphenolic fraction competitively occupying the TSH receptor or blocking immunoglobulin binding sites.
| clinical_evidence = '''Antiviral: herpes simplex (topical)'''

The strongest and most specific clinical evidence for lemon balm is topical and antiviral. The German physician Rainer Wölbling conducted the first placebo-controlled trial of a standardized Melissa cream on recurrent cold sores in 1994, demonstrating significant reduction in lesion size, healing time, and symptom severity with a 1 percent dried Melissa extract cream applied four times daily.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from ''Melissa officinalis''." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref>

Koytchev and colleagues (1999) confirmed and extended these findings in a larger placebo-controlled trial of the Lomaherpan-equivalent preparation (Lo-701, a 70:1 Melissa dry extract cream) applied four times daily to active cold sore lesions. The treated group showed significantly faster healing, smaller lesion area at day two, and reduced pain compared with placebo; the authors noted particularly strong benefit in patients treated at first symptom appearance (the prodrome or early vesicle stage) before full lesion development.<ref name="koytchev1999">Koytchev R, Alken RG, Dundarov S. "Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis." Phytomedicine. 1999;6(4):225-230. PMID 10589440.</ref>

The commercial preparation Lomaherpan (standardized 1 percent ''Melissa officinalis'' extract cream; Lomapharm, Germany) continues to be used and studied on this basis; it is the reference preparation for the EMA's traditional use opinion on Melissa for cold sores.

The evidence is specific to topical application: lemon balm polyphenols must be in direct contact with the HSV-infected tissue to exert their envelope-binding antiviral effect. Internal lemon balm preparations (infusion, tincture) have not been evaluated in placebo-controlled trials for recurrent herpes; the antiviral claim should not be extended to oral preparations without direct supporting evidence.

'''Mood and cognitive modulation (oral preparations)'''

Kennedy and colleagues conducted a series of dose-finding studies in healthy volunteers that provide the clearest pharmacological picture of oral lemon balm's cognitive and mood effects. In a 2002 crossover study, single doses of a standardized ''Melissa officinalis'' extract (300 mg, 600 mg, or 900 mg) produced dose-dependent improvements in calmness ratings and speed of mathematical processing on validated psychometric batteries; notably, the highest dose (900 mg) reduced calmness ratings relative to placebo, suggesting an inverted-U dose-effect relationship -- a feature consistent with the GABA-A modulation mechanism and commonly observed with GABAergic agents.<ref name="kennedy2002">Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. "Modulation of mood and cognitive performance following acute administration of ''Melissa officinalis'' (lemon balm)." Pharmacology Biochemistry and Behavior. 2002;72(4):953-964. PMID 12062586.</ref>

A 2003 companion study found significant improvements in mood and cognitive performance following single oral doses, with dose-dependent effects on the speed of memory and spatial working memory tasks.<ref name="kennedy2003">Kennedy DO, Wake G, Savelev S, et al. "Modulation of mood and cognitive performance following acute administration of single doses of ''Melissa officinalis'' (lemon balm) with human pharmacological models." Neuropsychopharmacology. 2003;28(10):1871-1881. PMID 12888775.</ref>

In a 2006 study, Kennedy and colleagues evaluated a standardized combination of ''Melissa officinalis'' and ''Valeriana officinalis'' (valerian) extract under laboratory-induced stress conditions. The combination produced significant reductions in anxiety ratings during a multi-tasking battery, reductions in self-rated stress and alertness, and mood improvements relative to placebo; the effects were consistent with additive or synergistic action of the two plant extracts' respective mechanisms.<ref name="kennedy2006">Kennedy DO, Little W, Haskell CF, Scholey AB. "Anxiolytic effects of a combination of ''Melissa officinalis'' and ''Valeriana officinalis'' during laboratory induced stress." Phytotherapy Research. 2006;20(2):96-102. PMID 16444660.</ref>

These studies establish a real but modest anxiolytic and cognitive-modulating effect of oral lemon balm that is consistent with the GABA-A mechanism. Effect sizes are smaller than those seen with oral Silexan for generalized anxiety disorder; the evidence base is sufficient for mild-to-moderate situational anxiety but has not been evaluated against prescription anxiolytics in the manner of the Silexan trials.

'''Anti-thyroid activity (in vitro and limited clinical data)'''

Auf'mkolk and colleagues (1985) demonstrated in an in vitro receptor-binding assay that aqueous extracts of ''Melissa officinalis'' (and several other plants) inhibit the binding of thyroid-stimulating hormone and Graves' immunoglobulins to TSH receptors, reducing adenylate cyclase stimulation.<ref name="aufmkolk1985">Auf'mkolk M, Ingbar JC, Kubota K, Amir SM, Ingbar SH. "Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and the biological activity of Graves' immunoglobulins." Endocrinology. 1985;116(5):1687-1693. PMID 2985357.</ref> This finding has been used as the pharmacological rationale for combining lemon balm with bugleweed (''Lycopus europaeus'') as an adjunctive herbal support in mild hyperthyroidism and Graves' disease; controlled clinical trials evaluating this combination for clinical outcomes in hyperthyroid patients are limited in number and quality.{{citation needed}}

'''Pediatric use'''

The use of lemon balm for sleep disturbance and nervousness in children is supported by tradition, basic safety data, and a limited clinical literature that includes combination preparations (valerian plus lemon balm).{{citation needed}} No serious adverse effects attributable to lemon balm have been reported in pediatric use at traditional doses.
| preparations = Infusion (tea): 2 to 4 g dried leaf and flowering tops per cup of hot water, covered while steeping (10 to 15 minutes) to retain the volatile oil fraction; the covering step is not cosmetic -- the volatile constituents are pharmacologically active and evaporate readily. Taken three times daily for daytime use or before sleep for insomnia.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation for internal use; 2 to 6 ml per dose, three times daily.

Standardized dry extract: solid extract standardized to rosmarinic acid content (typically 3 to 5 percent), usually in capsule form; the preparation form used in the Kennedy cognitive-modulation studies (300 to 900 mg per dose).

Topical cream: 1 percent standardized Melissa dry extract (Lomaherpan; equivalent commercial preparations) applied topically to cold sore lesions at first symptom; the antiviral evidence is specific to topical preparations with defined rosmarinic acid content.

Essential oil: rarely used therapeutically; primarily aromatherapy; expensive and frequently adulterated with lemongrass (''Cymbopogon citratus'') or lemon-scented verbena (''Aloysia citrodora'') oil; if used, always diluted in carrier oil.

Combination preparations: Melissa plus ''Valeriana officinalis'' (valerian) is the most common commercial combination, targeting sleep and mild anxiety; this combination has the best clinical evidence base (Kennedy 2006) for lemon balm's anxiolytic and sleep-promoting effects.
| dosing = '''Internal preparations'''

Infusion: 2 to 4 g dried leaf per cup, three times daily and before bed. Acute use for nervous agitation or palpitations: a strong cup (double strength, 4 g covered, 15-minute steep) taken as needed.

Tincture (1:5 in 45 percent ethanol): 2 to 6 ml per dose, three times daily. Children: no established dose adjustment in traditional use; standard practice has been to reduce proportionally by body weight or to use a weaker preparation (diluted infusion), noting the absence of observed adverse effects in pediatric use at herbal practice doses.

Standardized extract: 300 to 600 mg per dose (consistent with Kennedy's effective dose range); 900 mg per dose has been associated with reduced calmness in Kennedy's studies and should be avoided as a starting dose.

For cold sore prevention with oral preparations: no clinical evidence base; oral lemon balm does not substitute for topical treatment and no internal anti-HSV dose has been evaluated.

Combination preparations (Melissa plus valerian): follow manufacturer dosing; typically one to two capsules or 5 to 10 ml liquid combination tincture at bedtime for sleep.

'''Recreational dose ladder'''

Lemon balm has no established recreational dose structure. Its sedative-anxiolytic effect at therapeutic doses is among the gentlest in the nervine class -- substantially milder than valerian, kava, or cannabis -- and dose escalation beyond the Kennedy effective range (300 to 600 mg standardized extract) produces diminishing benefit rather than progressive relaxation, as the 900 mg dose in Kennedy's studies reduced, rather than increased, calmness. No ethnobotanical or contemporary self-dosing literature documents recreational use of lemon balm in any form; the ceiling of effect at accessible doses is simply too low and too undramatic to attract recreational interest. No tiered dose ladder is warranted.
| pharmacokinetics = The pharmacokinetics of lemon balm's active constituents have not been characterized to the same degree as those of pharmaceutical preparations. Rosmarinic acid, the principal polyphenolic constituent, is absorbed from the gastrointestinal tract and undergoes conjugation and hydroxylation by intestinal microbiota and hepatic enzymes; plasma levels peak approximately 30 to 60 minutes after ingestion.{{citation needed}} The apigenin and luteolin flavonoids have been more extensively characterized in other botanical contexts and show oral bioavailability dependent on gut microbiome composition.
| interactions = Central nervous system depressants: additive effect expected with sedatives, anxiolytics, alcohol, and sedating herbal medicines (valerian, hops, passionflower, kava); lemon balm's own sedative effect is mild, but the interaction is pharmacologically consistent and clinically relevant when adding lemon balm to a regimen that includes prescription sedatives or anxiolytics. Therapeutic use with benzodiazepines should be mentioned to the prescriber.

Thyroid preparations: theoretical antagonism with levothyroxine and other thyroid hormone replacement if lemon balm's anti-TSH-receptor activity translates to clinical reduction of thyroid function; this is relevant primarily at high chronic doses in patients with hypothyroidism or those on replacement thyroid therapy. At standard infusion doses, the interaction is theoretical rather than documented; in practice, standard tea use is unlikely to produce clinically significant thyroid antagonism.
| interactionsummary = Additive CNS sedation with sedatives and anxiolytics. Theoretical thyroid hormone antagonism at high doses in hypothyroid patients.
| safety = Lemon balm has an outstanding safety record across two thousand years of use in children and adults. No serious adverse events have been reported in clinical trials, case reports, or systematic reviews at standard therapeutic doses. It is among the herbs most consistently identified as safe for children in the traditional and contemporary herbal literature.

Hypothyroidism: the anti-thyroid mechanism identified by Auf'mkolk (1985) in vitro has led to a theoretical caution for chronic high-dose oral use in patients with established hypothyroidism or those on thyroid hormone replacement. Standard infusion use (2 to 4 g dried herb three times daily) has not produced clinical hypothyroidism in case reports; the caution is precautionary at current doses. Patients with established hypothyroidism on levothyroxine who wish to use lemon balm chronically should have thyroid function monitored.

Pregnancy: lemon balm is used traditionally during pregnancy and lactation as a calming herb, and is one of the nervines most commonly recommended for perinatal anxiety in traditional midwifery practice. No clinical trial data in pregnancy exists. Consensus in contemporary herbal practice is that standard infusion doses are likely safe; concentrated extracts and high-dose standardized preparations have not been evaluated and should be used conservatively in pregnancy.

Allergic reactions to lemon balm are rare; contact dermatitis has been reported with the essential oil and less commonly with topical fresh plant preparations.
| monitoring = No routine monitoring required for standard-dose internal use in healthy adults. Patients with hypothyroidism or on thyroid hormone replacement using chronic lemon balm preparations: thyroid-stimulating hormone at baseline and after two to three months of regular use. Patients adding lemon balm to benzodiazepine or sedative regimens: monitor for excess sedation, particularly at treatment initiation.
| counseling = The distinction between oral and topical applications is important to convey clearly. Oral lemon balm (infusion, tincture, extract) is indicated for anxiety, nervous insomnia, palpitations, and nervous digestive symptoms; the clinical evidence for these indications is consistent but modest. Topical Lomaherpan-equivalent cream (1 percent standardized Melissa extract) is the form with the specific antiviral evidence for cold sores, applied at first sign of prodrome; oral lemon balm should not be presented as a substitute for the topical application in herpes management.

Patients with recurrent cold sores benefit most from topical treatment begun at prodrome (tingling, burning, or itching before vesicle formation) rather than after full blister development; early application is the message from Koytchev (1999) and consistent with the mechanism of attachment inhibition working best before viral invasion is complete.

Patients using lemon balm for anxiety who are not experiencing adequate response at standard infusion doses may benefit from a standardized extract at the 300 to 600 mg range, or from a Melissa plus valerian combination product (which has the best clinical evidence for the combined anxiolytic-sleep indication). If anxiety is more than mild to moderate, a clinical assessment for generalized anxiety disorder, for which Silexan (oral lavender oil) has substantially stronger evidence, is appropriate.
| regulatory = '''Germany and European Union'''

German Commission E: lemon balm (Melissenblätter) approved for nervous sleep disorders and functional gastrointestinal complaints; covers dried herb preparations (infusion, tincture) based on traditional use and the clinical evidence base.

EMA HMPC: positive opinion for traditional use of ''Melissa officinalis'' leaf for relief of mild symptoms of stress and to aid sleep; also for traditional use of standardized topical preparations for symptomatic treatment of cold sores (Herpes labialis). One HMPC monograph (EMA/HMPC/196745/2012) covers both the internal nervine/sleep indication and the topical herpes simplex indication.<ref name="ema-hmpc-melissa">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on ''Melissa officinalis'' L., folium. EMA/HMPC/196745/2012. First published: 5 August 2013. https://www.ema.europa.eu/en/medicines/herbal/melissae-folium.</ref>

'''United States'''

''Melissa officinalis'': GRAS (generally recognized as safe) as a food flavoring; sold as a dietary supplement under DSHEA without FDA evaluation of efficacy claims. No approved drug indication.

'''United Kingdom'''

MHRA traditional herbal registration: ''Melissa officinalis'' preparations registered for traditional use for mild anxiety and sleep disturbance, and for topical application to cold sores; the topical Lomaherpan-equivalent preparations are registered separately.
| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Western clinical herbs]]

Lavender

2026-05-26T20:27:59Z

MDElliottMD: home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

{{PlantMedTemplate
| name = Lavender
| binomial = Lavandula angustifolia
| family = Lamiaceae
| native_range = Dry calcareous hillsides of the western Mediterranean: Provence (southern France), Spain, northern Italy, Croatia, and Greece; wild populations typically occur at 600 to 1,400 m elevation on exposed limestone garrigue and maquis. Widely cultivated throughout temperate Europe, North America, and Australia; Provence remains the global center of commercial cultivation.
| plant_part = Dried flower (inflorescence); essential oil distilled from fresh flowers.
| image =
| intro = ''Lavandula angustifolia'' Mill. -- true lavender, English lavender -- is a perennial aromatic shrub of the western Mediterranean garrigue, whose name descends from the Latin lavare, to wash, a record of the centuries it spent in the Roman bathhouse before it entered the clinic. Among aromatic herbs it holds a singular evidence record: a standardized oral preparation of its essential oil is the only essential-oil plant medicine to have been evaluated against a prescription anxiolytic in a randomized controlled trial and found non-inferior. Between the Roman bath and that trial stretches two thousand years of uninterrupted medicinal use for the same cluster of indications: anxiety, sleeplessness, and pain of the head.
| history = The name came first. Pliny the Elder in the first century of the common era recorded the use of nardus gallicus -- a lavender relative -- as a bath additive throughout the Roman world, and later writers formalized the association with lavare.{{citation needed}} The Greco-Roman medicinal plant was not ''L. angustifolia'' but its cousin ''Lavandula stoechas'' -- the French or Spanish lavender, high in camphor and pharmacologically distinct -- which Dioscorides in his De Materia Medica (1st century CE) recorded for headache, nausea, and disorders of the lung.{{citation needed}} ''L. angustifolia'' entered European medicine through the medieval monastic garden, where Benedictine and Cistercian communities cultivated it as a strewing herb, a wash for wounds, and a remedy for the head -- the "vapours" of nervous complaint that would occupy it for centuries thereafter.

John Parkinson, the apothecary who served James I, wrote in his Theatrum Botanicum of 1640 that lavender was of "especiall good use for all griefes and paines of the head and brain."{{citation needed}} Tudor England had already made lavender domestic property: lavender water was among the standard preparations of every gentlewoman's stillroom, the dried flowers were stuffed into pillows against insomnia, and bundles were laid between linens to discourage moths -- a use continuous from Roman times. Queen Elizabeth I reportedly consumed lavender conserve daily as a remedy for her migraines.{{citation needed}}

The most consequential accident in the history of aromatherapy occurred in a perfumery laboratory in Lyon, France, around 1910. Rene-Maurice Gattefosse -- a French chemist working in his family's perfume business -- burned his hand severely in a laboratory explosion and plunged it without premeditation into a vessel of lavender oil. The burn, he later wrote, healed with unexpected rapidity and without infection or scarring; the experience convinced him that essential oils deserved systematic clinical study.{{citation needed}} His 1937 monograph Aromatherapie gave the practice its name and established lavender as its founding plant. Robert Tisserand carried Gattefosse's work into the English-speaking world in the 1970s and 1980s, and the aromatherapy tradition -- lavender as wound healer, nerve calmer, sleep inducer -- entered consumer culture on a scale that no other essential oil has matched.{{citation needed}}

The German Commission E formally approved lavender flower for mood disturbances, restlessness, and insomnia in 1990, giving it a regulatory foundation in Germany at a time when most European herbal preparations lacked one. That approval rested on traditional use rather than clinical trial evidence; the trial evidence came later. Schwabe Pharmaceuticals developed Silexan -- a standardized pharmaceutical-grade oral lavender oil capsule -- in the 2000s and conducted a series of randomized controlled trials that collectively produced the most rigorous clinical evidence base of any aromatic herb medicine. The transition from bathhouse plant to evidence-based anxiolytic took roughly two thousand years and one burned hand.
| taxonomy = ''Lavandula angustifolia'' Mill. (synonyms: ''L. officinalis'' Chaix, ''L. vera'' DC.) belongs to tribe Ocimeae, family Lamiaceae, one of approximately 40 species in the genus ''Lavandula''. The genus name derives from lavare (to wash); the species epithet angustifolia (narrow-leaved) distinguishes it from broader-leaved relatives. Four species and one hybrid group carry the majority of commercial and medicinal significance.

''L. angustifolia'', true lavender or English lavender, produces the finest-quality essential oil -- highest in linalool and linalyl acetate, lowest in camphor -- and is the medicinal and perfumery standard against which other species are measured. It is the species from which Silexan is produced.

''L. latifolia'', spike lavender, yields a higher volume of oil per plant but of coarser character: camphor and 1,8-cineole content are markedly higher, linalyl acetate lower; the oil is sharper and used in industrial applications, cheaper perfumery, and traditional preparations distinct from those of angustifolia.

L. x intermedia, lavandin, is a sterile hybrid of angustifolia and latifolia that dominates commercial Provence cultivation today; it produces the greatest oil yield per hectare, and its oil is the principal ingredient in most mass-market lavender products. Lavandin oil is not equivalent to true lavender oil for medicinal purposes: camphor content is substantially higher, and linalyl acetate lower.

''L. stoechas'', French or Spanish lavender, is visually distinguished by its butterfly-wing bracts atop the flower spike; its chemistry diverges considerably from ''L. angustifolia'', being rich in camphor and fenchone. It was the medicinal lavender of Greco-Roman antiquity but is not the species behind modern anxiolytic research or the Western clinical herbal tradition.

The medicinal parts of ''L. angustifolia'' are the dried flower (inflorescence, harvested before full opening to maximize volatile oil content) and the essential oil steam-distilled from fresh flowers. The Pharmacopoeia Europaea monograph ''Lavandula''e flos specifies a minimum essential oil content in the dried inflorescence.{{citation needed}}

Wild ''L. angustifolia'' populations occur on exposed limestone hillsides in Provence, the Apennines, the Dalmatian coast, and the mountains of Spain and Greece. The English Pilgrims transported lavender to New England in 1620; it has naturalized in temperate climates worldwide without becoming invasive.{{citation needed}}
| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lavender occupies the nervine class of Western herbal medicine -- herbs with an affinity for the nervous system -- and has been applied to the same cluster of indications across European herbal traditions for at least several hundred years: anxiety and nervous agitation, insomnia rooted in a restless mind, headache and migraine (particularly those with an anxiety or tension component), nervous indigestion and colic, neuralgia, and the diffuse condition the English herbalists called the "vapours" -- a category of nervous debility and emotional distress that has no exact modern diagnostic equivalent but maps substantially onto generalized anxiety disorder.

The traditional preparation for internal use was an infusion of dried flowers, drunk warm before sleep or during episodes of nervous distress. Lavender water -- a distillate of flowers in water or diluted alcohol -- was applied to the head and temples for headache. The tincture in 40-proof spirit was the apothecary preparation for internal use. The oil, expressed or steam-distilled from flowers, was rubbed onto the temples for headache, onto the chest for nervous respiratory complaints, and onto affected areas for neuralgia and joint pain. Lavender sachets placed in the bed or under the pillow were the traditional sleep aid; clothes stored with dried lavender sprigs were protected from moths. Every one of these forms is continuous in the Western herbal tradition from at least the 16th century.

'''Islamic medicine (Unani)'''

Lavender was known in Arabic-speaking medical traditions under the name Khuzami (Arabic: khuzama) and appears in the Unani materia medica as a cephalic (head-acting) herb, indicated for headache, epilepsy, and melancholy. Ibn Sina (Avicenna), writing in the early 11th century in the Canon of Medicine, recorded lavender for nervous headache and for strengthening the brain.{{citation needed}}

'''Aromatherapy tradition (20th century)'''

Following Gattefosse's 1937 monograph, lavender essential oil became the foundational plant of the French aromatherapy tradition -- used topically and by inhalation for wound healing, burns, antisepsis, anxiety, and sleep. This tradition makes claims for lavender oil that overlap substantially with the traditional Western herbal tradition while adding an emphasis on topical wound-healing that traces directly to Gattefosse's burn. The distinction between aromatherapy (inhalational or topical use of essential oil) and the oral preparations studied in clinical trials is pharmacologically important and is addressed in the Clinical evidence section.
| pharmacology = '''Volatile oil constituents and mechanism'''

The essential oil of ''L. angustifolia'' consists primarily of linalool (25 to 45 percent), a monoterpene alcohol, and linalyl acetate (25 to 45 percent), its acetic acid ester.{{citation needed}} These two compounds account for the characteristic lavender fragrance and are the principal pharmacologically active constituents in oral Silexan. Camphor and 1,8-cineole -- constituents responsible for the sharper character of inferior species and for adulteration of true lavender oil with cheaper lavandin -- are present at less than one and less than two percent respectively in genuine ''L. angustifolia'' oil, and their presence in high concentration is a marker of species substitution or adulteration.

At the receptor level, two principal mechanisms have been characterized for the oral route.

GABA-A positive allosteric modulation: linalool and linalyl acetate act as positive allosteric modulators at the GABA-A receptor in a manner broadly analogous to benzodiazepines -- increasing chloride conductance and reducing neuronal excitability -- but at a binding site distinct from the classical benzodiazepine site.{{citation needed}}

Voltage-gated calcium channel inhibition: linalool inhibits voltage-gated calcium channels (VGCCs) in hippocampal neurons, reducing presynaptic calcium influx and the release of excitatory neurotransmitters; this mechanism is distinct from and additive with the GABA-A effect and may account for some specificity of anxiolytic action without the full benzodiazepine-receptor pharmacology.{{citation needed}}

The dual GABA-A and VGCC mechanism explains a feature of Silexan's clinical profile that distinguishes it from classical benzodiazepines: no confirmed abuse potential, no withdrawal syndrome on discontinuation, and no evidence of tolerance in studies up to ten weeks.

Inhalation delivers linalool and linalyl acetate via the olfactory mucosa and pulmonary absorption, with systemic concentrations substantially lower than oral administration; this accounts for the smaller effect sizes in aromatherapy trials relative to oral Silexan studies. The two routes are pharmacologically comparable in target but not in pharmacokinetic exposure.

Topically, lavender essential oil has demonstrated broad-spectrum antibacterial and antifungal activity in vitro, including against methicillin-resistant ''Staphylococcus aureus'' (MRSA) and ''Candida albicans'', via disruption of microbial cell membrane integrity; wound-healing acceleration has been shown in animal models.{{citation needed}}
| clinical_evidence = The clinical evidence base for lavender divides sharply along route of administration. Oral Silexan (standardized lavender oil, 80 mg/day) has been evaluated in a series of double-blind randomized controlled trials; inhalation aromatherapy has been evaluated in a larger number of smaller trials with more modest and more variable effect sizes. The two evidence bodies should not be conflated.

'''Oral Silexan: randomized controlled trials'''

The Woelk and Schlaefke (2010) trial was the first to compare Silexan directly with a prescription anxiolytic. Patients with mixed anxiety and restlessness were randomized to Silexan 80 mg/day or lorazepam 0.5 mg/day for ten weeks; the primary outcome was reduction in Hamilton Anxiety Scale (HAM-A) total score. Silexan was non-inferior to lorazepam: HAM-A total score fell by 45 percent from baseline in the Silexan group and 46 percent in the lorazepam group, a difference that was not statistically significant. Silexan patients reported no withdrawal symptoms or signs of dependence on discontinuation.<ref name="woelk2010">Woelk H, Schlaefke S. "A multi-centre, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder." Phytomedicine. 2010;17(2):94-99. PMID 19962288.</ref>

Kasper and colleagues (2010) evaluated Silexan 80 mg/day against placebo in patients with subthreshold anxiety disorder -- a category of clinically significant anxiety not meeting full diagnostic criteria for generalized anxiety disorder -- over ten weeks. Silexan produced significant reductions in HAM-A total score, HAM-A psychic anxiety subscale, and Pittsburgh Sleep Quality Index compared with placebo; the effect was apparent by week two and maintained through week ten.<ref name="kasper2010">Kasper S, Gastpar M, Muller WE, et al. "Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder: evidence from clinical trials." Wien Med Wochenschr. 2010;160(21-22):547-556. PMID 21170695.</ref>

The most definitive comparative trial came in 2014. Kasper and colleagues randomized 539 patients with generalized anxiety disorder to Silexan 80 mg/day or paroxetine 20 mg/day for ten weeks. On HAM-A total score reduction, Silexan was non-inferior to paroxetine; secondary outcomes including the Beck Anxiety Inventory and clinical global assessment showed comparable improvement. Silexan's tolerability profile was markedly more favorable: the paroxetine arm showed higher rates of sexual dysfunction and nausea.<ref name="kasper2014">Kasper S, Gastpar M, Muller WE, et al. "Lavender oil preparation Silexan is effective in generalized anxiety disorder -- a randomized, double-blind comparison to placebo and paroxetine." Int J Neuropsychopharmacol. 2014;17(6):859-869. PMID 24456909.</ref>

A 2023 meta-analysis pooled data from randomized placebo-controlled trials of Silexan across anxiety disorder categories and found consistent, statistically significant superiority over placebo on standardized anxiety measures, with a standardized mean difference of clinically meaningful magnitude.<ref name="meta2023">Kasper S, et al. "Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials." Eur Neuropsychopharmacol. 2023;66:71-82. PMID 36717399.</ref>

A 2021 double-blind crossover trial in healthy recreational polydrug users found no evidence of abuse potential for Silexan at 80 mg or 160 mg -- no drug-liking, no euphoria, no psychomotor impairment, and no craving on discontinuation -- establishing Silexan's anxiolytic effect as non-addictive and distinguishing it from benzodiazepines at a pharmacological and behavioral level.<ref name="abuse2021">Schlaefke S, et al. "No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial." J Psychopharmacol. 2021. PMID 33300578.</ref>

'''Inhalation aromatherapy: smaller and more varied evidence'''

A body of smaller randomized trials -- in postoperative patients, dental-procedure anxiety, neonatal intensive care, and sleep quality in elderly populations -- has found statistically significant but modest anxiolytic and sleep-promoting effects from lavender inhalation or topical application in carrier oil. Effect sizes in aromatherapy trials are generally smaller than in the oral Silexan trials, study populations are more heterogeneous, and blinding is inherently imperfect given lavender's recognizable odor. The evidence supports lavender aromatherapy as an adjunct for mild situational anxiety and sleep disturbance; it does not support it as a primary treatment for generalized anxiety disorder at the level established for oral Silexan.{{citation needed}}

One small randomized trial evaluated lavender essential oil inhalation at the onset of acute migraine headache and found statistically significant reduction in headache severity compared with a placebo inhalation control; sample sizes were insufficient for definitive conclusions and the study has not been replicated at scale.<ref name="sasannejad2012">Sasannejad P, Saeedi M, Shoeibi A, Gorji A. "Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial." Eur Neurol. 2012;67(5):288-291. PMID 22517298.</ref>

The antimicrobial activity documented in vitro -- including activity against MRSA -- has not been translated into powered clinical trials. The topical wound-healing tradition has animal-model support but no placebo-controlled clinical trial data in humans.
| preparations = Dried flower (inflorescence): harvested before full bloom, dried at low temperature to preserve volatile oil; used for infusion, sachets, and as the starting material for tincture and essential oil production. Genuine lavender flower carries an immediately recognizable sweet-floral fragrance without camphor sharpness; camphoraceous character indicates ''L. latifolia'' or lavandin substitution.

Essential oil: steam-distilled from fresh flowers; genuine ''L. angustifolia'' oil contains 25 to 45 percent linalool and 25 to 45 percent linalyl acetate, with camphor below 1 percent; these parameters distinguish true lavender from adulterated or substitute species. For topical use, always dilute in carrier oil (2 to 5 percent); neat application to intact skin carries some allergy risk even with true lavender oil, and dilution is the standard of practice.

Silexan (brand name Lasea; Schwabe Pharmaceuticals): a standardized pharmaceutical-grade oral lavender oil capsule formulated for gastrointestinal absorption; manufactured at pharmaceutical quality standards with defined linalool and linalyl acetate content. This preparation is not equivalent to and should not be substituted by tipping commercial essential oil into food or capsules: solubility, concentration, solvent matrix, and quality standards differ fundamentally. Silexan is a prescription medicinal product in Germany.

Tincture: 1:5 in 40 percent ethanol from dried flowers; the traditional apothecary form for internal use.

Hydrosol (lavender water): the aqueous condensate separated from essential oil during steam distillation; contains trace quantities of volatile oil in aqueous suspension; used topically in cosmetics and as a facial toner; not concentrated enough for pharmacological effects of the essential oil.

Dried sachet: flowers loosely packed in muslin or linen, placed in drawers, linen closets, or under pillows; a traditional and household preparation continuous in use for sleep and moth-repellent purposes from at least the medieval period.
| dosing = '''Internal preparations'''

Infusion (dried flower): 1 to 2 g dried flowers per cup of hot water, steeped 10 to 15 minutes; taken 2 to 3 times daily and at bedtime for sleep. Traditional dose with no robust clinical trial evidence for this form; the Commission E approval covers this preparation based on traditional use.

Tincture (1:5 in 40 percent ethanol): 0.5 to 1 teaspoon (2.5 to 5 ml) diluted in a small amount of water, taken 2 to 3 times daily. Traditional dose with no clinical trial evidence independent of the Silexan data.

Silexan oral capsule: 80 mg once daily, the dose used in all published RCTs; some protocols have used 160 mg/day for more severe anxiety without identified additional harm. Take with food. Clinical benefit in GAD trials was apparent by week two and fully established by week four to six.

'''External preparations'''

Essential oil topical: 5 to 10 drops (0.25 to 0.5 ml) diluted in 1 tablespoon (15 ml) carrier oil (yielding approximately 2 to 3 percent); applied by massage to affected area. Aromatherapy diffusion: 3 to 5 drops in 15 ml water in a cold-air diffuser in the bedroom at night. Traditional sleep preparation: 3 to 5 drops essential oil on a cotton ball placed on the pillow, or a dried lavender sachet under the pillow.

'''Recreational dose ladder'''

Lavender carries no established recreational dose structure in the ethnopharmacological or self-dosing literature. The anxiolytic and sedative ceiling at therapeutic doses is modest: Silexan at 80 mg/day produces an effect non-inferior to lorazepam 0.5 mg/day but does not produce sedation sufficient to impair cognition or function in the RCT population. Dose escalation beyond 160 mg/day oral (twice the standard dose) has not been systematically studied and produces no documented psychoactive intensification; the pharmacology -- GABA-A allosteric modulation and VGCC inhibition without direct GABA-A agonism -- predicts a dose-effect plateau rather than progressive deepening of central depression. No recreational culture of lavender use analogous to kava, valerian, or cannabis has been documented in any ethnobotanical or contemporary context. The essential oil used as an inhalant produces transient relaxation but no psychoactive profile warranting a tiered dose ladder.
| pharmacokinetics = Linalool and linalyl acetate in Silexan are absorbed from the gastrointestinal tract following oral administration; linalyl acetate undergoes hydrolysis to linalool in the gut and by plasma esterases, such that linalool is the principal circulating species. Peak plasma concentrations are reached approximately 30 to 90 minutes after oral dosing.{{citation needed}} Linalool undergoes hepatic metabolism via cytochrome P450-mediated hydroxylation and glucuronidation; the metabolites are excreted renally. No significant accumulation has been reported at 80 mg/day dosing.

Following inhalation, linalool is absorbed via the pulmonary mucosa and by olfactory epithelium; plasma concentrations are substantially lower than after oral administration of an equivalent linalool dose, consistent with the smaller effect sizes observed in aromatherapy relative to oral-Silexan trials.
| interactions = Central nervous system depressants: theoretical additive sedation with benzodiazepines, alcohol, opioid analgesics, barbiturates, antihistamines, and sedating herbal medicines including valerian (''Valeriana officinalis''), kava (''Piper methysticum''), hops (''Humulus lupulus''), and passionflower (''Passiflora incarnata''). The clinical significance of this interaction at Silexan's standard 80 mg/day dose has not been formally evaluated; caution is appropriate when combining Silexan with benzodiazepines in patients transitioning from one agent to the other. The Woelk and Schlaefke (2010) trial documented successful lorazepam discontinuation in patients switched to Silexan,<ref name="woelk2010"/> suggesting that substitution is clinically feasible, but cross-tapering should be supervised.

Cytochrome P450: in vitro data at suprapharmacological concentrations suggest possible inhibition of CYP2C9 and CYP3A4 by lavender oil constituents. No pharmacokinetic interaction has been documented in clinical trials at 80 mg/day; the relevance of in vitro findings to standard clinical dosing is uncertain. No dose adjustment of co-administered medicines is presently supported by clinical evidence.
| interactionsummary = Additive CNS depression with sedatives, anxiolytics, alcohol, and sedating herbal medicines. No confirmed cytochrome P450 interaction at therapeutic dose.
| safety = Silexan at 80 mg/day has been well tolerated in all published RCTs, with no serious adverse events attributed to the study medicine. The most commonly reported adverse effects have been mild gastrointestinal symptoms (nausea, belching with lavender odor) and headache, each occurring at low incidence and resolving without intervention.

Prepubertal gynecomastia: Henley, Lipson, and Korach (2007) reported three cases of prepubertal boys who developed gynecomastia while using topical products containing lavender oil and tea tree oil; gynecomastia resolved in each case on discontinuation of the products. In vitro experiments demonstrated estrogenic and anti-androgenic activity of both lavender oil and tea tree oil at the tested concentrations.<ref name="henley2007">Henley DV, Lipson N, Korach KS, Bloch CA. "Prepubertal gynecomastia linked to lavender and tea tree oils." N Engl J Med. 2007;356(5):479-485. PMID 17267908.</ref> Subsequent epidemiological study has not confirmed a population-level signal; the three case reports represent a potential association rather than an established causal relationship. Conservative practice: avoid heavy chronic daily application of lavender oil-containing products to the skin of prepubertal boys.

Allergic contact dermatitis: linalool undergoes autooxidation in stored, poorly sealed, or heat-exposed essential oil, generating linalool hydroperoxide and other sensitizing oxidation products. Sensitization acquired through repeated exposure to oxidized lavender oil is permanent and subsequent exposures produce contact dermatitis. Properly stored, freshly purchased true lavender oil from a reputable supplier has low sensitization risk. This concern is among the more clinically relevant safety issues with topical lavender use; lavender is among the more common causes of fragrance-related contact sensitization in Europe.{{citation needed}}

Essential oil ingestion (non-Silexan): tipping lavender essential oil from a commercial aromatherapy bottle into food or beverages or swallowing it directly is not equivalent to Silexan and is not recommended. Case reports of oral essential oil ingestion -- in children accessing essential oil bottles -- have documented CNS depression and respiratory distress. Silexan is a specifically formulated pharmaceutical-grade oral preparation; the distinction between this and ad hoc oral consumption of essential oil is not cosmetic.

Pregnancy: Silexan trials have excluded pregnant participants; safety data for oral lavender oil preparations in pregnancy are absent. Ordinary aromatherapy use (inhalation at ambient concentrations, topical application in diluted carrier oil) is generally considered low risk but is not supported by trial data. High-dose oral preparations should be avoided in pregnancy in the absence of safety information.
| monitoring = No specific monitoring required for lavender flower infusion or tincture at traditional doses. Patients beginning Silexan 80 mg/day for generalized anxiety disorder: clinical assessment at two to four weeks to establish early response; continue through six weeks before assessing non-response. Patients with benzodiazepine dependence who are transitioning to Silexan should be supervised: cross-tapering under medical guidance is appropriate given the theoretical additive sedation risk during any overlap period.
| counseling = Patients beginning Silexan should understand that it is derived from lavender essential oil but is not equivalent to lavender aromatherapy: the clinical evidence for anxiety comes specifically from the oral capsule formulation at 80 mg/day, not from diffusers, massage oils, or pillow sprays. Benefit may take two to four weeks to become fully apparent; onset latency resembles that of SSRIs more closely than the immediate sedation of benzodiazepines.

The absence of dependence potential and withdrawal symptoms distinguishes Silexan from benzodiazepines. Patients anxious about benzodiazepine dependence or who have not tolerated them may find this distinction meaningful.

Patients using lavender essential oil products topically should use oils that are fresh, correctly stored (sealed, cool, and dark), and diluted in carrier oil for skin application; undiluted application to large skin areas over prolonged periods carries higher sensitization risk. Old or discolored essential oil should be discarded.

The prepubertal gynecomastia concern is worth mentioning to parents of boys who ask about lavender products; the evidence is from case reports rather than epidemiological studies, and the risk is not quantified, but the in vitro endocrine activity establishes a biologically plausible mechanism.
| regulatory = '''Germany and European Union'''

German Commission E (1990): lavender flower approved for mood disturbances with restlessness and sleep disturbances, and nervous stomach conditions; covers traditional oral preparations (infusion, tincture) based on traditional use rather than clinical trial evidence.

EMA HMPC: positive assessment of lavender flower as a traditional herbal medicinal product for mild anxiety and sleep disturbance; traditional use listing under the EU Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC). The EMA HMPC opinion does not cover Silexan, which was developed and approved as a distinct pharmaceutical medicinal product under a separate regulatory pathway.<ref name="ema-hmpc-lavender">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on ''Lavandula angustifolia'' P. Mill., flos. EMA/HMPC/734125/2010. First published: 13 June 2012. https://www.ema.europa.eu/en/medicines/herbal/lavandulae-flos.</ref>

Silexan (Lasea; Schwabe Pharmaceuticals): approved as a prescription medicinal product (not a traditional herbal product) in Germany and some other EU member states specifically for the treatment of generalized anxiety disorder, based on the RCT program described above. This is the most stringent regulatory status achieved by any essential-oil preparation in the EU regulatory framework.

'''United States'''

Lavender oil: GRAS (generally recognized as safe) status with the US FDA as a food flavoring additive; no approved therapeutic indication. Sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) without FDA evaluation of efficacy claims.

'''United Kingdom'''

MHRA traditional herbal registration: lavender preparations registered for traditional use for mild anxiety and sleep disturbance under the Traditional Herbal Registration scheme.
| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Chinese licorice

2026-05-26T20:27:50Z

MDElliottMD: home-claude: remove inter-parameter blank lines (designer-claude gap fix 2026-05-26)

{{PlantMedTemplate
| name = Chinese licorice
| binomial = Glycyrrhiza uralensis
| family = Fabaceae
| native_range = Northern China, Mongolia, Siberia, and Central Asia; wild stands in Xinjiang, Gansu, Inner Mongolia, and Manchuria; commercial supply largely from cultivated stands in northern and northwestern China.
| plant_part = Root and rhizome (dried); prepared in two clinically distinct forms in TCM: raw dried root (sheng gan cao) and honey-fried root (zhi gan cao).
| image =
| intro = Chinese licorice (''Glycyrrhiza uralensis'' Fisch.) is a perennial leguminous herb of the north Chinese steppe, the botanical source of gan cao (甘草, literally "sweet herb"), one of the most widely prescribed medicinals in the entire Chinese Materia Medica. Gan cao occupies a role in classical Chinese medicine without parallel in Western pharmacology: it is the defining harmonizer of formulas (调和诸药, tiáo hé zhū yào), an herb added to approximately sixty percent of all classical formulae not primarily for a specific therapeutic action of its own but to moderate the potency of harsh or toxic herbs, unify the divergent properties of a formula's ingredients, and protect the stomach and spleen from irritating constituents. The closely related Mediterranean species ''G. glabra'' (Western licorice) is the historical centroid of Ayurvedic, Unani, and European herbal licorice use; the two species share essentially the same glycyrrhizin-mediated pharmacology and the same pseudohyperaldosteronism safety profile, described in full at [[Western licorice]]. Both species are routinely substituted in commerce without pharmacopoeia distinction.
| taxonomy = ''Glycyrrhiza uralensis'' Fisch. ex DC. belongs to tribe Galegeae, family Fabaceae, one of approximately thirty species in the genus ''Glycyrrhiza''. The genus name derives from the Greek glykys (sweet) and rhiza (root), reflecting the intensely sweet taproot shared across the genus. ''G. uralensis'' is distinguished from ''G. glabra'' (European licorice) by glandular-hairy stems and seed pods, a more compact and shorter flower raceme, and a tendency to form dense rhizome mats in the steppe and semi-arid grasslands it inhabits; these morphological distinctions are unreliable in dried commercial root stock, and commercial substitution of the two species is routine and pharmacopoeially sanctioned under most major pharmacopoeias. ''G. inflata'' (Xinjiang licorice) is a third commercially significant species, particularly sourced in Central Asian markets.

The medicinal parts are the root and rhizome, harvested from plants four years or older; roots from younger plants have lower glycyrrhizin content and are considered suboptimal quality. In TCM practice the dried root is processed in two clinically distinct forms: sheng gan cao (生甘草, raw or unprocessed dried root), used for fire-toxicity conditions and as the universal harmonizing constituent; and zhi gan cao (炙甘草, honey-fried root), prepared by combining sliced dry root with liquid honey (typically 25 g honey per 100 g dry root) and stir-frying over gentle heat until the honey is fully absorbed and the surface is fragrant and golden-brown. TCM processing theory holds that honey-frying shifts the root's properties from the neutral-cooling of the raw form toward a warmer, more tonifying quality particularly suited to heart-calming and spleen-tonifying indications.
| traditional_uses = '''Chinese medicine (primary centroid)'''

The earliest written record of gan cao is in the Shennong Ben Cao Jing (神农本草经, Divine Farmer's Classic of Materia Medica), the foundational Chinese pharmacopoeia compiled approximately between the first and second centuries of the common era.{{citation needed}} The Shennong Ben Cao Jing categorized all 365 medicinal substances into three tiers: 120 upper herbs (上品, shàng pǐn), considered tonic and safe for prolonged use; 120 middle herbs, with specific therapeutic actions and moderate safety considerations; and 125 lower herbs, potent or toxic and reserved for acute conditions. Gan cao was classified as an upper herb, the most favorable designation in the text, a judgment that prefigured its two-thousand-year career as the universal harmonizing tonic base of Chinese formula construction.

The feature of gan cao that defines its clinical identity, and that has no close analog in Western pharmacological thinking, is its role as the harmonizer of formulas (调和诸药, tiáo hé zhū yào). Bensky, Clavey, and Stoger document gan cao's presence in approximately sixty percent of all classical Chinese herbal formulae,<ref name="bensky2004">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica''. 3rd ed. Eastland Press, 2004. Section on ''Glycyrrhiza uralensis'' (Gan Cao, 甘草).</ref> a frequency no other single herb approaches, reflecting a function performed at the formula level rather than the organ-system level. Bensky identifies three distinct harmonizing roles that collectively account for this ubiquity.<ref name="bensky2004"/> First, gan cao moderates the toxicity and harshness of potent formula ingredients: where aconite (fu zi, a potent yang-warming root with a narrow therapeutic window), coptis (huang lian, intensely bitter and cold), or other drastic herbs appear, gan cao is the standard buffer, softening action and preventing the formula from overshooting its therapeutic purpose. Second, it harmonizes herbs of divergent thermal properties, flavors, and organ tropisms, preventing the "qi conflict" that TCM theory associates with unmediated confrontations between cold and hot, or ascending and descending, formula components. Third, it protects the stomach and spleen from the irritating effects of harsh ingredients, supporting patient tolerability through extended decoction courses. So thoroughgoing was this mediating function in the view of later TCM physicians that gan cao acquired the court honorific 国老 (guó lǎo, "Elder Statesman" or "Grand Councillor of the Nation"), comparing the herb's role in a formula to that of a senior official who mediates among warring ministers, integrates competing interests, and supports the sovereign's governing intention without seeking prominence for its own office.<ref name="bensky2004"/>

Zhang Zhongjing compiled the Shang Han Lun (伤寒论, Treatise on Cold Damage Disorders) approximately 210 CE; together with its companion the Jin Gui Yao Lue (金匮要略, Essential Prescriptions of the Golden Cabinet), it codified the classical formula architecture that remains foundational in contemporary TCM practice.{{citation needed}} Gan cao appears in a large proportion of the Shang Han Lun's one hundred and thirteen prescriptions. Four formulae from this text are of particular clinical significance and continue in active contemporary use:

Gan Cao Tang (甘草汤, Licorice Decoction) is the simplest formula: sheng gan cao as the sole herb, at full therapeutic dose, for sore throat and fire-toxicity patterns of the throat. It exemplifies gan cao in its direct anti-toxicity function rather than in the harmonizing role.<ref name="bensky2004"/>

Zhi Gan Cao Tang (炙甘草汤, Honey-Fried Licorice Decoction), also known as Fumai Tang (复脉汤, Restore the Pulse Decoction), is a nine-ingredient formula combining honey-fried licorice as the principal herb with Rehmannia glutinosa (di huang), Ophiopogon japonicus (mai men dong), Colla Corii Asini (e jiao, donkey-hide gelatin), Cannabis sativa seed (huo ma ren), dried ginger (gan jiang), cinnamon twig (gui zhi; the same herb as [[Cassia cinnamon]] in TCM usage), jujube (da zao), and sake. It is prescribed specifically for heart palpitations (心悸, xīn jì) and irregularly or regularly irregular pulse arising from deficiency of heart yin and heart yang.{{citation needed}} Zhi Gan Cao Tang is the most specific TCM cardiac-rhythm prescription in the Shang Han Lun and remains a subject of contemporary pharmacological and small-scale clinical research.

Shao Yao Gan Cao Tang (芍药甘草汤, Peony and Licorice Decoction) pairs white peony root (bai shao, Paeonia lactiflora) with honey-fried gan cao in a two-herb formula prescribed for muscular spasm and cramping, particularly abdominal spasm and lower-limb cramps. The combination has attracted modern pharmacognosy investigation: paeoniflorin, the principal active glycoside of white peony, and glycyrrhizin appear to produce antispasmodic effects in animal models that exceed either constituent alone, with paeoniflorin and glycyrrhetinic acid proposed as synergistic components acting through distinct but complementary antispasmodic pathways.{{citation needed}}

Si Jun Zi Tang (四君子汤, Four Gentlemen Decoction) combines ginseng (ren shen, Panax ginseng), white atractylodes (bai zhu, Atractylodes macrocephala), poria (fu ling, Wolfiporia cocos), and honey-fried licorice. It is the foundational spleen-qi tonic of TCM, the structural core from which a large family of derivative tonifying and digestive-support formulae is built, including Liu Jun Zi Tang (Six Gentlemen), Xiang Sha Liu Jun Zi Tang, and numerous others.{{citation needed}} Gan cao's role in Si Jun Zi Tang is primarily harmonizing and stomach-protective rather than directly tonifying; the principal tonifying agents are ginseng and white atractylodes, with gan cao integrating their divergent properties and protecting the stomach from the full impact of concentrated qi-supplementing herbs.

Li Shizhen's Ben Cao Gang Mu (本草纲目, Compendium of Materia Medica), completed in 1578 and published in 1596, gave gan cao its most comprehensive classical Chinese treatment, cataloguing morphological varieties, regional origins, harvesting protocols, processing methods (with particular attention to the honey-frying distinction), flavors, thermal properties, organ tropisms, formulaic combinations, and the guó lǎo honorific as a tradition tracing to the Han dynasty.{{citation needed}} Li Shizhen's synthesis made the Ben Cao Gang Mu the de facto reference standard for East Asian herbal medicine from the Ming dynasty onward.

'''Western herbal and Ayurvedic use (brief)'''

''G. uralensis'' has no significant independent tradition in Ayurvedic or Unani medicine; the yashtimadhu (sweet stick) of Ayurveda, the asl-us-sus of Unani medicine, and the glykyrrhiza of the Greco-Roman and medieval European herbal traditions are rooted in ''G. glabra'', the Mediterranean species. ''G. uralensis'' enters Western herbal and Ayurvedic practice primarily through commercial substitution: international licorice root trade routinely mixes or substitutes the two species, as dried root from the two is morphologically indistinguishable in commerce and the pharmacological properties are sufficiently comparable for pharmacopoeial equivalence. The complete traditions of Western herbal, Ayurvedic, Unani, and Greco-Roman licorice practice are documented at [[Western licorice]].
| preparations = Sheng gan cao (生甘草, raw dried root): unprocessed dried sliced root used in TCM decoction for fire-toxicity conditions (throat swellings, carbuncles, heat patterns), lung-dryness cough, and the universal formula-harmonizing role. This is also the standard commercial source material for Western herbal extracts and pharmaceutical-grade glycyrrhizin extraction.

Zhi gan cao (炙甘草, honey-fried root): root stir-fried with liquid honey until fragrant and golden-brown; TCM processing theory holds that honey-frying intensifies tonifying and warmth-generating properties while moderating bitterness and astringency. Specified for spleen-qi tonification, heart palpitations (particularly in the Zhi Gan Cao Tang formula), and all indications where a warming-tonifying rather than cooling-clearing action is required.

Standardized root extract: concentrated extract standardized to 18 to 25 percent glycyrrhizin content, available as solid extract or liquid concentrate; both ''G. uralensis'' and ''G. glabra'' are sourced commercially for standardized extracts, frequently without species designation on product labels.

TCM granule extract: spray-dried or freeze-dried root extract in granule form for contemporary TCM granule-prescription practice, allowing formula assembly without traditional decoction; commercially available as sheng gan cao or zhi gan cao granules.

Deglycyrrhizinated licorice (DGL): available in Western clinical herbal practice as a preparation from which glycyrrhizin has been removed, retaining demulcent and mucosal-protective activity without the pseudohyperaldosteronism risk. Western market DGL preparations are predominantly derived from ''G. glabra'' material; ''G. uralensis''-sourced DGL exists but is less commonly available in Western markets. The full DGL discussion, including clinical evidence, dose, and chronic-use appropriateness, is at [[Western licorice]].
| pharmacology = '''Principal active constituents'''

Glycyrrhizin (glycyrrhizinic acid): a triterpenoid saponin glycoside constituting approximately 2 to 4 percent of dry-weight root under standard cultivation conditions; content varies with growing region, soil type, and harvest timing.<ref name="chinpharmacopoeia2020">National Pharmacopoeia Commission. ''Pharmacopoeia of the People's Republic of China''. Vol. I. China Medical Science and Technology Press, 2020. Monograph: Gan Cao (甘草).</ref><ref name="pastorino2018">Pastorino G, Cornara L, Soares S, Rodrigues F, Oliveira MBPP. "Liquorice (''Glycyrrhiza glabra''): A phytochemical and pharmacological review." ''Phytother Res'' 2018;32(12):2323-2339. PMID 30117204.</ref> Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; intestinal bacterial beta-glucuronidase hydrolyzes it to 18-beta-glycyrrhetinic acid (18β-GA), the principal systemically absorbed active metabolite. 18β-GA accounts for the anti-inflammatory pharmacology (inhibition of prostaglandin-synthesizing enzymes and phospholipase A2) and for the adverse mineralocorticoid effect via inhibition of 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2) in the renal tubule, the mechanism underlying pseudohyperaldosteronism at sustained high glycyrrhizin intakes. The full 11-beta-HSD2 mechanism is described at [[Western licorice]].

Liquiritin and isoliquiritin: flavanone and chalcone glycosides with sedative and antispasmodic activity in animal models; probable contributors, alongside paeoniflorin from white peony, to the antispasmodic efficacy of Shao Yao Gan Cao Tang.

Licochalcone A and related chalcones: antimicrobial and anti-inflammatory activity in laboratory studies; typically present in lower concentrations in ''G. uralensis'' than in ''G. inflata''.

Glycyrrhetic acid (enoxolone): the free aglycone of glycyrrhizin; the basis of the pharmaceutical derivative carbenoxolone, the synthetic peptic ulcer compound developed in Europe in the 1960s to 1970s, documented at [[Western licorice]].
| indications = '''TCM indications (primary)'''

Spleen qi deficiency: fatigue, diminished appetite, loose stools, and lassitude; honey-fried gan cao as a constituent of tonifying formulae, principally Si Jun Zi Tang and its extensive derivative family; the most frequently invoked TCM indication in formula construction.<ref name="bensky2004"/>

Heart palpitations and irregularly irregular pulse from deficiency of heart yin and heart yang: the specific indication of the Zhi Gan Cao Tang formula; among the more physiologically specific classical TCM cardiac-rhythm indications and a subject of contemporary pharmacological and small-scale clinical investigation, including case reports of formula modifications for both bradyarrhythmia and tachyarrhythmia.<ref name="bensky2004"/><ref name="chen2010zhigancao">Chen WG, Ba ZM. "Prof. ZHANG Yi's experience in treating severe arrhythmia." ''J Tradit Chin Med'' 2010;30(1):47-50. PMID 20397463.</ref>

Lung dryness and cough: raw gan cao in wind-heat or lung-dryness patterns; gan cao moistens the lung channel and moderates the drying effect of other herbs in respiratory formulae.<ref name="bensky2004"/>

Fire toxicity: carbuncles, boils, and sore throat with heat characteristics; raw gan cao as Gan Cao Tang alone or combined with other heat-clearing herbs; one of the direct therapeutic indications in which gan cao functions as the principal herb rather than as a harmonizer.<ref name="bensky2004"/>

Lower-limb and abdominal muscular spasm: Shao Yao Gan Cao Tang (white peony and honey-fried licorice); the most-studied specific two-herb-pair indication for gan cao, with pharmacological evidence of paeoniflorin-glycyrrhizin antispasmodic synergy.<ref name="bensky2004"/>

Universal harmonizing and formula-integrating role: the indication accounting for the majority of gan cao prescriptions; not condition-specific but formula-architecture-specific; see Traditional uses above for the mechanism and significance.

'''Western clinical indications (condensed; full evidence base at Western licorice)'''

Western clinical research on licorice does not systematically distinguish ''G. uralensis'' from ''G. glabra''; commercial preparations are often from mixed or unspecified species. The evidence base for peptic ulcer and mucosal protection (deglycyrrhizinated licorice preparations), chronic hepatitis (intravenous Stronger Neo-Minophagen C glycyrrhizin compound in Japanese clinical practice), respiratory catarrh (Commission E approved indication), and adrenal-supportive use is described in full at [[Western licorice]].
| dosing = TCM decoction dose: 2 to 12 g dried root per day (raw or honey-fried) in multi-herb decoction. Harmonizing doses, which account for the majority of gan cao prescriptions, are typically 2 to 6 g per day; doses in which gan cao is the principal therapeutic herb (as in Gan Cao Tang) may reach 9 to 12 g per day. Single-herb throat formula (Gan Cao Tang): 4 to 9 g.<ref name="bensky2004"/>

Western clinical extract dose: standardized extract equivalent to 5 to 15 g dried root daily; maximum continuous course four to six weeks without reassessment per Commission E guidance. Same limit as ''G. glabra''.

Glycyrrhizin intake limit: 100 mg glycyrrhizin per day maximum for chronic use per the European Union Scientific Committee on Food opinion SCF/CS/ADD/EDUL/225 Final (2003), the same guidance applicable to both ''G. uralensis'' and ''G. glabra''.
| pharmacokinetics = Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; rate-limiting absorption involves bacterial beta-glucuronidase hydrolysis in the large intestine, producing 18-beta-glycyrrhetinic acid with a lag of two to four hours between oral ingestion and rising plasma 18β-GA levels. Individual variation in gut microbiome composition generates substantial inter-individual variability in 18β-GA plasma exposure at equivalent oral glycyrrhizin doses, which partly explains the observed case-to-case variability in pseudohyperaldosteronism susceptibility.

18-Beta-glycyrrhetinic acid: half-life approximately 7 to 8 hours; primarily hepatic metabolism; biliary excretion with enterohepatic recirculation reported, potentially prolonging effective exposure with repeated daily dosing.

The full pharmacokinetic discussion, including DGL pharmacokinetics and the plasma-level considerations underlying the pseudohyperaldosteronism dose-response, is at [[Western licorice]].
| interactions = The interaction profile of ''G. uralensis'' is identical to that of ''G. glabra''; the shared glycyrrhizin content and shared 11-beta-HSD2 inhibition mechanism produce the same clinically relevant pharmacodynamic interactions regardless of species. Full interaction details are at [[Western licorice]]; the following is a clinical summary.

Antihypertensive medicines: whole-licorice preparations raise blood pressure through sodium and water retention (the pseudohyperaldosteronism mechanism), directly antagonizing antihypertensive treatment; concurrent use should be avoided or blood pressure monitored closely with readiness to adjust antihypertensive doses.

Potassium-depleting medicines (loop diuretics, thiazide diuretics, corticosteroids): additive hypokalemia risk; the combination carries increased risk of clinically significant potassium depletion, muscle weakness, cardiac arrhythmia, and, at severe depletion, respiratory muscle compromise. Serum potassium monitoring is warranted in any patient combining licorice with these agents.

Cardiac glycosides (digoxin): licorice-induced hypokalemia increases myocardial sensitivity to cardiac glycoside toxicity; the combination of chronic licorice use and digoxin therapy requires concurrent potassium monitoring.

Exogenous corticosteroids: 11-beta-HSD2 inhibition by 18β-GA may amplify the mineralocorticoid effects of concurrent exogenous corticosteroid therapy, accelerating fluid retention and raising blood pressure.

A note specific to TCM formula practice: at the standard harmonizing dose (2 to 6 g daily for a short course of four weeks or less), the probability of clinically significant pharmacodynamic interaction in most patients is low. The interaction concern becomes clinically important at chronic high-dose use and in patients taking antihypertensives, diuretics, or cardiac glycosides concurrently.

DGL preparations: negligible pharmacodynamic interaction risk from the glycyrrhizin-mediated pathway; DGL is the preparation of choice for any chronic use requiring avoidance of these interactions.
| interactionsummary = Antihypertensives (antagonism of blood pressure control), potassium-depleting agents including loop and thiazide diuretics and corticosteroids (additive hypokalemia), cardiac glycosides including digoxin (hypokalemia-mediated toxicity potentiation), exogenous corticosteroids (amplification of mineralocorticoid effects). Full DDI discussion at [[Western licorice]]. DGL preparations avoid these interactions.
| safety = The pseudohyperaldosteronism safety profile of ''G. uralensis'' is identical to that of ''G. glabra'': the same 18-beta-glycyrrhetinic-acid-mediated 11-beta-HSD2 inhibition, the same dose-dependent sodium retention, potassium depletion, hypertension, and edema, and the same case-report and regulatory literature. The full mechanism, dose-response, Walker 1994, van Uum 2005, and EU SCF 2003 guidance are documented at [[Western licorice]]. The 100 mg/day glycyrrhizin chronic-use limit applies to whole-licorice preparations of either species.

Note specific to TCM practice: at the typical harmonizing dose (2 to 6 g root per day), daily glycyrrhizin intake from gan cao ranges from approximately 40 to 240 mg depending on the glycyrrhizin content of the specific batch; at the lower end this falls within the EU SCF guidance range, and at the upper end it does not. Chronic daily use of high-dose tonifying decoctions or concentrated patent-medicine preparations over many months warrants the same blood pressure and potassium monitoring as any whole-licorice use. Practitioners and patients should not assume that the harmonizing role necessarily entails sub-threshold glycyrrhizin doses.

Pregnancy: the preterm birth concern documented in the Finnish cohort applies equally to ''G. uralensis''; glycyrrhizin is the mediating compound and is present in comparable concentrations in both species. Strandberg and colleagues (2001) found that Finnish mothers consuming more than 500 mg glycyrrhizin weekly from confectionery had significantly increased odds of preterm birth and lower birth weight in their offspring.<ref name="strandberg2001">Strandberg TE, Jarvenpaa AL, Vanhanen H, McKeigue PM. "Birth outcome in relation to licorice consumption during pregnancy." ''American Journal of Epidemiology'' 2001;153(11):1085-1088. PMID 11390327.</ref> Avoidance of high-dose licorice of either species during pregnancy is advisable; culinary doses and low-dose harmonizing use in short courses carry uncertain but likely low risk.

Contraindications: hypertension, hypokalemia, cardiac arrhythmia, hepatic cirrhosis, renal insufficiency, concurrent use of potassium-depleting agents or cardiac glycosides, and pregnancy at high doses.
| monitoring = Whole-licorice use (any form of ''G. uralensis'' root or extract containing significant glycyrrhizin) for more than four weeks: obtain baseline blood pressure and serum potassium before initiating; recheck monthly during ongoing use. Discontinue and reassess if systolic blood pressure rises more than 10 to 15 mmHg from baseline, serum potassium falls below 3.5 mmol/L, or peripheral edema develops.

For patients taking concurrent antihypertensive medicines or cardiac glycosides, lower the monitoring threshold: check blood pressure and potassium after two weeks of use rather than four.

DGL preparations: no monitoring required beyond routine clinical follow-up appropriate to the underlying condition being managed.
| counseling = The pseudohyperaldosteronism risk that applies to Western licorice (''G. glabra'') applies equally to Chinese licorice (''G. uralensis'') and to any TCM formula containing gan cao. A patient told by a conventional physician to avoid licorice for blood pressure or potassium reasons should apply that restriction to gan cao in TCM decoctions and patent medicines. The two species are pharmacologically interchangeable with respect to this risk; a patient's conventional prescriber may not know that a TCM formula contains licorice under the name "gan cao" and will benefit from the information.

The harmonizing role accounts for the majority of gan cao prescriptions and typically places it at a lower dose (2 to 6 g daily) than its use as a primary therapeutic herb. Most patients on short-course multi-herb formulae at harmonizing doses will not experience clinical pseudohyperaldosteronism. The risk rises with increasing dose, increasing duration (months rather than weeks), and pre-existing clinical vulnerability: baseline hypertension, concurrent diuretic use, and low dietary potassium intake each shift the threshold downward.

Patients who need a chronic licorice-based preparation for mucosal protection, peptic ulcer, or gastritis should be directed to deglycyrrhizinated licorice (DGL), which removes the glycyrrhizin while retaining demulcent and mucosal-protective activity. DGL does not carry the mineralocorticoid risk and does not require blood pressure or potassium monitoring; see [[Western licorice]] for the full DGL discussion including dose, formulation, and comparison with whole licorice.

Commercial licorice root products (confectionery, chewable tablets, licorice-extract beverages) may contain ''G. uralensis'', ''G. glabra'', or both, often without species designation and without declared glycyrrhizin content. Patients using such products as a therapeutic practice should be asked about quantity, frequency, and glycyrrhizin content where possible; "licorice root extract" on a label does not specify species or dose.

The guó lǎo (国老, Elder Statesman) characterization of gan cao is a useful explanatory frame for patients: the herb is not added to a formula to fix one thing but to make the entire formula work more safely and effectively together. Patients who ask why their TCM formula contains licorice even though they are not being treated for a licorice-specific condition can be offered this framing as an accurate and culturally grounded explanation.
| history = Gan cao's written history in Chinese medicine extends to the earliest stratum of the Chinese herbal record. The Shennong Ben Cao Jing (first to second century CE) placed it among the 120 upper herbs, the highest-quality classification available in the text's tripartite system, signaling that its safety and tonic utility were already well established by the Han dynasty period (206 BCE to 220 CE) when the text was compiled.{{citation needed}}

Zhang Zhongjing's Shang Han Lun (c. 210 CE) codified the classical formula architecture in which gan cao plays its most extensively documented historical role: Zhi Gan Cao Tang for cardiac-rhythm disturbance, Shao Yao Gan Cao Tang for spasm, and the Si Jun Zi Tang ancestor-formulas for qi deficiency all date to this text and remain in active contemporary practice over 1800 years after their codification.{{citation needed}}

The period between the Shang Han Lun and Li Shizhen's Ben Cao Gang Mu (completed 1578) saw continuous elaboration and commentary on gan cao across the major TCM dynastic lineages; each era added clinical observations, formulaic refinements, and processing variants to the original Shang Han Lun foundation. Li Shizhen's systematic synthesis made the Ben Cao Gang Mu the de facto East Asian herbal reference standard from the Ming dynasty to the twentieth century.{{citation needed}}

Modern chemical investigation beginning in the mid-twentieth century isolated glycyrrhizin as the principal active compound; this led to two pharmaceutical derivatives: carbenoxolone (a glycyrrhetinic acid hemisuccinate, used in Europe for peptic ulcer disease in the 1960s to 1980s) and Stronger Neo-Minophagen C (SNMC, an intravenous glycyrrhizin compound used in Japan for chronic viral hepatitis from the 1970s onward). Both are documented at [[Western licorice]], where the Western pharmaceutical-derivative history is covered in full.

Contemporary ''G. uralensis'' populations are subject to conservation pressure from commercial wild harvesting in Inner Mongolia, Gansu, and Xinjiang; overharvesting has substantially reduced wild stands over the past several decades, driving the industry toward cultivated supply. ''Glycyrrhiza'' species are subject to trade-monitoring frameworks requiring country-of-origin export documentation to verify sustainable sourcing.{{citation needed}} ''G. uralensis'' is listed in the Pharmacopoeia of the People's Republic of China as an official medicinal herb under the monograph Gan Cao (甘草), and the pharmacopoeia specification includes a minimum glycyrrhizin content standard as a quality criterion, shaping commercial cultivation toward higher-yielding varieties.<ref name="chinpharmacopoeia2020"/>
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Anti-inflammatory herbs]]
[[Category:Respiratory herbs]]
[[Category:Demulcents]]
[[Category:TCM herbs]]

Pissenlit

2026-05-26T20:08:47Z

MDElliottMD: home-claude: redirect to Dandelion

#REDIRECT [[Dandelion]]

Pu gong ying

2026-05-26T20:08:46Z

MDElliottMD: home-claude: redirect to Dandelion

#REDIRECT [[Dandelion]]

Dandelion leaf

2026-05-26T20:08:45Z

MDElliottMD: home-claude: redirect to Dandelion

#REDIRECT [[Dandelion]]

Dandelion root

2026-05-26T20:08:44Z

MDElliottMD: home-claude: redirect to Dandelion

#REDIRECT [[Dandelion]]

Taraxacum officinale

2026-05-26T20:08:43Z

MDElliottMD: home-claude: redirect to Dandelion

#REDIRECT [[Dandelion]]

Dandelion

2026-05-26T20:08:36Z

MDElliottMD: home-claude: Herb #10 Dandelion initial publish (Q1-Q3 resolved; 5 PMIDs verified + 1974 Racz-Kotilla added; binomial italics applied)

{{PlantMedTemplate
| binomial = Taraxacum officinale
| family = Asteraceae
| native_range = Originally native to Eurasia and North Africa; now one of the most globally distributed plants in the world, present on every inhabited continent following dispersal with European colonization. Grows wild in grassland, roadsides, disturbed ground, and lawns throughout the temperate zone; cultivated commercially for medicinal and culinary supply in Germany and France.
| parts_used = Leaves (diuretic; harvested before flowering for highest bitter-principle content); root (hepatic bitter; dug in autumn from second-year plants for highest inulin content); flowers (minor; folk wine and syrup).
| images =
| intro = ''Taraxacum officinale'' G.H. Weber ex Wiggers -- dandelion -- is a perennial composite herb of Eurasian origin, now distributed across every inhabited continent and recognized by virtually every person alive, most of whom have at some point scattered its seeds from a spherical white clock. The French long ago named it pissenlit -- wet-the-bed -- which is an accurate clinical description of its principal medicinal action in the leaf, and it is this frankness of folk nomenclature that most concisely captures the herb's place in medicine: a plant dismissed as a weed by every suburban lawn, carrying a clinical evidence base in diuresis that most commercially marketed diuretic herbs cannot match, with the additional distinction of replenishing in the leaf the very potassium that synthetic diuretics strip away.

| traditional_uses = The earliest written records of dandelion in medicine come from 11th-century Arabic physicians -- Ibn Sina listed dandelion leaf in pharmacopoeial works -- and from the Welsh Physicians of Myddfai, a 13th-century medical guild whose manuscripts record it for liver and digestive complaints.{{citation needed}} By the 17th century ''T. officinale'' was established in every European herbal, universally respected as a hepatic bitter, a diuretic, and a spring tonic food -- the tender young leaves gathered from fields before the first flowering and eaten in salad as an annual seasonal cleanse.

The name is a corruption of the French dent-de-lion (lion's tooth), referring to the deeply ragged leaf margins; in English it became "dandelion" by the 16th century. The French pissenlit captured the leaf's diuretic force with characteristic directness; contemporary French herbalists still use the term without embarrassment, as an accurate pharmacological description rather than a vulgarity.

Nicholas Culpeper in 1653 recorded dandelion for "opening obstructions of the liver, gall, and spleen," for jaundice, and as "a sovereign remedy against the evil disposition of the body, proceeding from the badness of the blood."{{citation needed}} These indications -- liver, spleen, fluid, blood quality -- are precisely those that the Western alterative tradition has assigned to dandelion root for the four centuries since Culpeper, with remarkable consistency across German, French, British, and American herbal schools.

'''Chinese medicine: Pu Gong Ying (蒲公英)'''

In Chinese medicine the principal species is ''Taraxacum mongolicum'' (sometimes listed as ''T. sinicum''), though ''T. officinale'' is accepted as an equivalent in most contemporary pharmacopoeias. Under the name Pu Gong Ying, it is classified as bitter and sweet in flavor, cold in nature, entering the liver and stomach meridians. Its principal TCM indications are clearing heat and relieving toxicity -- the diagnostic category covering acute inflammatory and infectious conditions: breast abscess and mastitis (one of the most historically consistent indications in TCM practice for this herb), acute sore throat and tonsillitis, infected eyes, jaundice from damp-heat in the liver, and intestinal infection with heat signs.{{citation needed}} The TCM mastitis indication -- Pu Gong Ying as a primary herb for acute lactation mastitis, applied both internally as a decoction and topically as a poultice of fresh crushed leaf -- is among the most specific and consistent indications in the Chinese Materia Medica and has ethnopharmacological parallels in European practice (fresh dandelion leaf poultice for skin inflammation and swelling).

'''Native American and post-colonial American use'''

As ''T. officinale'' spread with European colonization, indigenous peoples throughout North America adopted it rapidly as it naturalized across the continent. Multiple nations used it for kidney, liver, and digestive complaints -- applications consistent with the introduced European knowledge system -- suggesting either independent discovery of the same pharmacological effects or rapid adoption of European herbal knowledge through trade contact.{{citation needed}}

'''Food tradition'''

Dandelion occupies an unusual dual role as food and medicine. Spring dandelion greens -- young leaves gathered before flowering, when bitter principles are concentrated and the leaves are most nutritionally dense -- are among the most nutritionally complete wild greens available in temperate climates, higher in vitamins A, C, and K, and in calcium, iron, and potassium, than most cultivated vegetables.{{citation needed}} Dandelion coffee -- roasted dried root decoction -- became a wartime staple in Britain and Europe during both World Wars when coffee was rationed, and remains a gentle, caffeine-free bitter digestive tonic in current herbal practice. In France, ''pissenlit au lard'' (dandelion greens with lardons and hot vinegar dressing) is a Burgundian spring classic with a history traceable to medieval monastic cooking.

| botany = ''Taraxacum officinale'' G.H. Weber ex Wiggers is placed in tribe Cichorieae (formerly Lactuceae), subfamily Cichorioideae, family Asteraceae. The species epithet officinale (of the dispensary) signals long apothecary use; the genus name derives from the Arabic tarakhshagun or the medieval Latin corruption of it, meaning bitter herb. ''Taraxacum'' is an enormously complex genus: depending on the taxonomic authority, it contains anywhere from 60 to 2,000 or more microspecies, many of which are apomictic (reproducing without fertilization, generating clonal lineages). Most commercial medicinal supply and most clinical research uses ''T. officinale'' in the broad, aggregate sense rather than any single microspecies; pharmacopoeial monographs accept this broad usage.

The plant is a perennial forming a basal rosette of deeply pinnately lobed leaves -- the lobes giving the lion's-tooth shape -- growing from a deep taproot that can reach 30 to 50 cm in established plants. The leaves are glabrous to slightly hairy; in cultivated populations they may be less deeply lobed. Hollow, leafless scapes (flower stalks) arise singly from the crown, each bearing a single bright golden composite head of ray florets only (no disk florets); this morphology distinguishes it from most other yellow composites. The well-known globular gray-white seed head (the "clock") consists of the achenes with their attached pappus (feathery parachute structures) that allow wind dispersal over considerable distances. A single plant may produce 2,000 to 12,000 seeds per year, a reproductive strategy that explains both its global success and suburban gardeners' despair.

The medicinal parts are harvested by part and season: leaves before first flowering in spring (highest bitter-principle and potassium content; preferred for diuretic use), root in autumn from second-year plants (highest inulin content; preferred for hepatic use). The spring-leaf and autumn-root distinction is not merely traditional but is pharmacologically grounded in the plant's seasonal allocation of primary metabolites.

Closely related: ''Taraxacum mongolicum'' (Pu Gong Ying; principal TCM medicinal species; used pharmacopoeially as equivalent to ''T. officinale'').

| constituents = '''Leaf constituents'''

The leaf is the more nutritionally dense and diuretically active part. Principal constituents include sesquiterpene lactones (taraxacin and related compounds, responsible for the bitter taste), triterpenes, polysaccharides, coumarins, carotenoids (beta-carotene and lutein; source of the leaf's nutritional vitamin-A equivalents), vitamins C and K, and, notably, minerals at concentrations that distinguish it from most vegetables: potassium content is among the highest of any leafy green, with documented values of 370 to 500 mg per 100 g fresh weight.{{citation needed}} This mineral composition is the pharmacological basis of dandelion leaf's unique advantage among diuretics: it replenishes the urinary potassium losses it induces, preventing the hypokalemia associated with synthetic loop and thiazide diuretics.

'''Root constituents'''

The root holds a different pharmacological profile. Inulin -- a fructooligosaccharide prebiotic polysaccharide -- constitutes up to 40 percent of dry root weight in autumn-harvested material, falling to 1 to 2 percent in spring (when it has been consumed in new-growth production).{{citation needed}} This seasonal variation is the pharmacological rationale for the traditional autumn-harvest preference. Taraxacoside, the principal bitter sesquiterpene glycoside of the root, contributes to the bitter-tonic and mild laxative actions. Phenolic acids (chicoric acid, caffeic acid derivatives), triterpenes (taraxasterol, taraxerol), and polyacetylenes complete the profile. Mineral content in the root, while lower per gram than the leaf, is still significant.

| pharmacodynamics = '''Diuretic mechanism (leaf)'''

The leaf's diuretic action is classified as aquaretic -- meaning it increases urine volume and sodium excretion without proportional potassium loss -- distinguishing it from synthetic diuretics (loop diuretics, thiazides) that cause significant potassium depletion. The mechanism is thought to involve inhibition of tubular sodium reabsorption by sesquiterpene lactone constituents, but the precise renal tubular pharmacology has not been fully characterized at the receptor level.{{citation needed}} The high potassium content of the leaf preparation further buffers any net potassium loss, contributing to the clinically observed potassium-sparing profile.

'''Hepatic and cholagogue mechanism (root)'''

The bitter sesquiterpene compounds (taraxacoside and related lactones) stimulate bile secretion from the liver and gallbladder contraction -- the cholagogue action that underlies the hepatic-bitter tonic use. This mechanism is consistent with the pharmacology of other bitter Asteraceae (chicory, artichoke) and with the TCM clearing-heat-from-liver-channel framing of the same traditional indication. In animal models, dandelion root extracts have demonstrated hepatoprotective effects against carbon tetrachloride-induced hepatotoxicity and against acetaminophen toxicity, consistent with antioxidant and anti-inflammatory mechanisms.{{citation needed}}

'''Anti-inflammatory mechanism'''

Polyphenolic compounds in the leaf and root (including chicoric acid, caffeic acid derivatives, and flavonoids) inhibit pro-inflammatory signaling cascades in cell-culture models, including reduction of LPS-stimulated NF-kB activation and suppression of pro-inflammatory cytokine release.<ref name="jeon2017">Jeon D, Kim SJ, Kim HS. "Anti-inflammatory evaluation of the methanolic extract of ''Taraxacum officinale'' in LPS-stimulated human umbilical vein endothelial cells." BMC Complement Altern Med. 2017;17(1):508. PMID 29187173.</ref> Whether these in vitro effects translate to clinically meaningful anti-inflammatory activity in human tissue remains to be established in powered clinical trials.

'''Prebiotic mechanism (root inulin)'''

Inulin is a well-characterized prebiotic: it selectively promotes the growth of beneficial gut microbiota (principally ''Bifidobacterium'' and ''Lactobacillus'' species) by serving as a fermentable substrate for these organisms while being resistant to digestion by human gut enzymes. The effect is dose-dependent and well-established for inulin regardless of botanical source; dandelion root is one of the most concentrated natural sources of inulin outside chicory root (''Cichorium intybus'') and Jerusalem artichoke (''Helianthus tuberosus'').{{citation needed}}

| indications = '''Diuretic activity: human clinical evidence'''

Clare, Conroy, and Spelman (2009) conducted a single-day human clinical study in 17 healthy volunteers, administering an extract of ''Taraxacum officinale'' leaf (8 ml per dose from a 1:5 infusion) three times over seven hours. Urine volume and urinary frequency increased significantly between the first and second doses and between the second and third doses relative to pre-treatment baseline, demonstrating acute diuretic activity in humans. Urinary excretion of potassium was not significantly depleted, consistent with the leaf's high potassium content counterbalancing urinary losses.<ref name="clare2009">Clare BA, Conroy RS, Spelman K. "The diuretic effect in human subjects of an extract of ''Taraxacum officinale'' folium over a single day." J Altern Complement Med. 2009;15(8):929-934. PMID 19678785.</ref><ref name="raczkotilla1974">Racz-Kotilla E, Racz G, Solomon A. "The action of ''Taraxacum officinale'' extracts on the body weight and diuresis of laboratory animals." Planta Med. 1974;26(3):212-217. PMID 4427955.</ref> This study is single-day and uncontrolled (no parallel placebo arm); it establishes acute diuretic activity but does not address long-term efficacy or comparative effectiveness against synthetic diuretics.

No large-scale randomized controlled trials of dandelion leaf for clinical edema, hypertension, or fluid retention have been published. The clinical evidence base for the diuretic indication is consistent but limited in scale and rigor relative to conventional diuretics.

'''Hepatic and alterative uses: traditional and preclinical evidence only'''

The hepatic-tonic, alterative, and liver-cleansing indications that constitute the principal traditional use of dandelion root do not have a randomized clinical trial evidence base in humans. Animal models show hepatoprotective effects against chemical hepatotoxins; the bitter-tonic mechanism is pharmacologically well-grounded; the cholagogue action is consistent with the class pharmacology of sesquiterpene bitters. The absence of clinical trial data reflects the general underfunding of hepatic herbal medicine research rather than any evidence of inefficacy, but the distinction between traditional use supported by preclinical data and use supported by clinical trials should be maintained in patient-facing communication.

'''Anticancer activity: in vitro studies only'''

Ovadje and colleagues have published a series of in vitro studies demonstrating that aqueous dandelion root extract selectively induces apoptosis in human leukemia cell lines through both intrinsic and extrinsic pathways, without significant toxicity to normal peripheral blood mononuclear cells.<ref name="ovadje2011">Ovadje P, Chatterjee S, Griffin C, Tran C, Hamm C, Pandey S. "Selective induction of apoptosis through activation of caspase-8 in human leukemia cells (Jurkat) by dandelion root extract." J Ethnopharmacol. 2011;133(1):86-91. PMID 20849941.</ref><ref name="ovadje2012">Ovadje P, Hamm C, Pandey S. "Efficient induction of extrinsic cell death by dandelion root extract in human chronic myelomonocytic leukemia (CMML)." PLoS One. 2012;7(2):e30604. PMID 22363452.</ref> These are laboratory findings in cell lines; they do not constitute clinical evidence of anticancer efficacy in humans. No clinical trials of dandelion root extract for cancer treatment have been completed or published. These findings are scientifically interesting and warrant further investigation but should not be represented as clinical evidence of therapeutic effect.

| preparations = Leaf infusion (tea): 4 to 8 g fresh or dried leaves per cup of hot water, steeped covered (volatile constituents are modest; the cover prevents steam loss rather than oil loss). Taken 2 to 3 times daily for diuretic and tonic use; or fresh leaves as salad greens (the traditional spring tonic form, maximally nutritious and minimally processed).

Root decoction: 5 to 10 g dried root in 500 ml water, simmered covered for 15 to 20 minutes; strained and drunk in 2 to 3 portions through the day. The preferred preparation for hepatic-bitter and cholagogue use; suited to the autumn-harvested root with its peak inulin content.

Root tincture: 1:5 in 40 to 45 percent ethanol from dried root; 2 to 5 ml three times daily.

Roasted root "coffee": dried root roasted until dark brown (approximately 200 degrees Celsius, 30 minutes); ground and prepared by decoction or percolation as a coffee substitute. The roasting converts much of the inulin to simpler fructose units and develops the characteristic dark, slightly bitter flavor; the hepatic bitter action is retained at reduced intensity. A gentle daily liver tonic and caffeine-free coffee alternative with a continuous history from World War II rationing.

Root powder: 2 to 4 g per day in capsule or tablet form; convenient standardized option.

| dosing = '''Leaf (diuretic, tonic)'''

Infusion: 4 to 8 g dried leaf per cup, 2 to 3 times daily. Fresh leaf as salad: no formal dose ceiling; traditional seasonal use is ad libitum.

Tincture (1:5 in 40 percent ethanol): 2 to 5 ml three times daily.

'''Root (hepatic-bitter, cholagogue, prebiotic)'''

Decoction: 5 to 10 g dried root per day in divided doses. Tincture (1:5): 2 to 5 ml three times daily. Powder: 2 to 4 g per day.

The traditional distinction between spring-leaf use (diuretic, nutritive tonic) and autumn-root use (hepatic-bitter, prebiotic) reflects genuine pharmacological differences in the plant across seasons and should be preserved in practice where possible.

'''Recreational dose ladder'''

Dandelion has no recreational or psychoactive profile in any documented tradition. Neither the leaf nor the root produces altered consciousness, euphoria, sedation, or any psychoactive effect at any accessible dose. The bitter taste at higher leaf or root doses is limiting; above 10 to 15 g of dried root per day, mild nausea and diarrhea occur as the dose-limiting gastrointestinal effects. No dose ladder is warranted.

| pharmacokinetics = The pharmacokinetics of ''T. officinale'' constituents have not been well characterized. Taraxacoside and related sesquiterpene lactones are likely absorbed from the gastrointestinal tract and undergo hepatic metabolism; the kinetics are not documented to the same standard as pharmaceutical preparations. Inulin from the root is not absorbed -- it passes undigested to the large intestine where it is fermented by colonic microbiota; this is entirely the intended pharmacological mechanism for its prebiotic action rather than a bioavailability problem. Polyphenolic compounds (chicoric acid, caffeic acid derivatives) are absorbed in part from the small intestine and undergo conjugation and methylation by gut enzymes and hepatic CYP enzymes.{{citation needed}}

| interactions = Lithium: dandelion leaf's diuretic action reduces renal lithium clearance (as does any diuretic); this can elevate lithium plasma levels into the toxic range. Patients taking lithium should not use dandelion leaf preparations without medical supervision and lithium-level monitoring.{{citation needed}}

Potassium-sparing diuretics and ACE inhibitors: dandelion leaf's potassium-retaining character combined with potassium-sparing agents (spironolactone, eplerenone) or ACE inhibitors (which reduce urinary potassium excretion) could theoretically produce hyperkalemia in vulnerable patients. The risk is low at typical leaf-infusion doses but warrants monitoring in patients with renal impairment or on potassium-sparing regimens.

Antidiabetic medicines: dandelion has mild blood-glucose-lowering properties in animal models; additive hypoglycemic effect is possible with insulin and oral antidiabetic agents. Monitor blood glucose in diabetic patients who begin regular dandelion use.

Anticoagulants (warfarin): dandelion leaves are very high in vitamin K. Patients on warfarin anticoagulation whose vitamin K intake changes significantly (including by adding large quantities of dandelion leaf to the diet) may experience INR instability. Consistency of intake is more important than avoidance.

| interactionsummary = Lithium: diuresis raises lithium levels (monitor). High vitamin K in leaf: INR variability with warfarin. Additive hypoglycemia possible with antidiabetic medicines.

| counseling = The distinction between leaf and root preparations should be communicated clearly: the diuretic action resides principally in the leaf, and the hepatic-bitter and prebiotic actions in the root. A patient seeking fluid-retention relief should use the leaf infusion; a patient seeking liver support, digestive bitters, or prebiotic gut support should use the root decoction or roasted root.

The potassium-sparing quality of the dandelion leaf diuresis is genuinely clinically relevant and worth explaining to patients who have previously been told to avoid diuretics because of potassium concerns: dandelion leaf does not cause the potassium depletion associated with furosemide or hydrochlorothiazide. This distinction is well-grounded pharmacologically, though the clinical trial evidence is limited in scale.

The anticancer cell-line findings should not be communicated to patients as evidence of clinical efficacy. The in vitro data are preliminary and interesting; no clinical benefit in cancer treatment has been established. Patients with cancer who are interested in dandelion root for general liver support or digestive use (reasonable traditional indications) should be informed of this distinction.

===Safety===

Dandelion is among the safest herbs in the Western pharmacopoeia for adults, children, and in pregnancy. Serious adverse events are not documented in the clinical or case-report literature at standard dietary or medicinal doses.

Gallstones: the root's cholagogue (gallbladder-stimulating) action is the principal safety concern. In patients with known gallstones, particularly large stones or any degree of bile duct obstruction, stimulating gallbladder contraction can precipitate biliary colic. Dandelion root preparations should be used with caution in patients with known cholelithiasis and are contraindicated in patients with obstructive jaundice or bile duct obstruction.

Asteraceae allergy: dandelion is in the same plant family as ragweed (''Ambrosia'' spp.), chamomile, and chrysanthemum. Patients with documented Asteraceae contact or inhalant allergy may have cross-reactive responses to dandelion; this is most relevant for topical use of fresh plant material. Oral ingestion of dandelion in Asteraceae-allergic individuals is generally well-tolerated but warrants initial caution.

Pregnancy and lactation: dandelion leaf and root are used as food and tonic herbs in traditional midwifery without reported harm; the plant is among the herbs most consistently classified as safe in pregnancy at dietary doses. Large-dose medicinal preparations have not been formally evaluated in pregnancy trials.

===Regulatory===

'''Germany'''

German Commission E: dandelion root with herb (Taraxaci radix cum herba) approved for disturbances of bile flow, stimulation of diuresis, loss of appetite, and dyspepsia.

'''European Union'''

EMA HMPC: positive assessment for traditional use of dandelion root and herb for symptomatic treatment of minor digestive disorders (dyspepsia, bloating, flatulence) and as adjuvant for increased urinary output in minor urinary complaints. Traditional use listing under the EU Traditional Herbal Medicinal Products Directive.<ref name=ema-taraxacum>European Union herbal monograph on ''Taraxacum officinale'' F.H. Wigg., radix. EMA/HMPC/475726/2020. Committee on Herbal Medicinal Products (HMPC). https://www.ema.europa.eu/en/medicines/herbal/taraxaci-officinalis-radix</ref>

'''United States'''

Dandelion root and leaf: GRAS (generally recognized as safe) as food; sold as a dietary supplement under DSHEA without FDA evaluation of therapeutic claims.

'''United Kingdom'''

MHRA traditional herbal registration: dandelion root preparations registered for traditional use for relief of minor digestive and urinary complaints.

}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Hepatoprotective herbs]]
[[Category:Urological herbs]]
[[Category:Diuretic herbs]]
[[Category:Western clinical herbs]]
[[Category:TCM herbs]]

Category:Diuretic herbs

2026-05-26T20:07:19Z

MDElliottMD: home-claude: create Category:Diuretic herbs (approved 2026-05-25; dandelion publish Q1)

A '''diuretic herb''' is a plant medicine that increases urine volume and urinary excretion, used traditionally for fluid retention, minor urinary complaints, urinary-tract supportive care, and as an adjunct in kidney-stone prevention by increasing urinary flow. The principal mechanism of most herbal diuretics is aquaretic: an increase in glomerular filtration rate or inhibition of tubular reabsorption without the proportional potassium loss (hypokalemia) associated with synthetic loop diuretics (furosemide) and thiazides (hydrochlorothiazide).

The most clinically evidenced herbal diuretic is dandelion leaf (''Taraxacum officinale''): a human clinical study by Clare and colleagues (2009) demonstrated significant acute increases in urine volume and urinary frequency following three doses of a dandelion leaf extract over seven hours, with no significant reduction in urinary potassium -- consistent with the leaf's high potassium content counterbalancing urinary losses. The aquaretic mechanism distinguishes dandelion from synthetic diuretics and is the pharmacological basis of the herb's traditional use for fluid-retention states without the associated electrolyte risk.

The diuretic-herb category includes: the classical aquaretics (dandelion leaf, couch grass, cleavers, corn silk, goldenrod), the kidney-stone-prevention and urinary-tract-soothing herbs (uva ursi, buchu, juniper), and herbs with secondary diuretic action alongside a primary indication elsewhere (nettle, parsley seed, celery seed). Several herbs in this category also appear in [[:Category:Urological_herbs|urological herbs]] for their overlap with urinary-tract infection and prostate-related indications.

== Members indexed ==

Dandelion (''Taraxacum officinale'', leaf preparation).

== Notes on scope ==

The pharmaceutical diuretics ([[:Category:Loop_diuretics|loop diuretics]], [[:Category:Thiazides|thiazides]], potassium-sparing diuretics) are listed under their own categories. This category covers the plant-medicine tradition of diuretic herbs as recognised in the British Herbal Pharmacopoeia, the German Commission E, and the EMA HMPC traditional-use assessments.

== About these pages ==

[[:Category:CuratedCategoryPage|Curated category pages]] in the Pharmacopedia are written and maintained by the editorial team. Members are listed when a full page exists; herbs with planned pages will be added on publication.

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:CuratedCategoryPage]]

Peppermint

2026-05-26T19:18:30Z

MDElliottMD: home-claude: fix hatnote pipe + remove duplicate empty template fields

{{hatnote|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See the [[#Botany and identification]] section for the full safety warning.}}
{{PlantMedTemplate
| name = Peppermint
| binomial = Mentha × piperita
| family = Lamiaceae
| native_range = Not native to any wild habitat: peppermint is a sterile hybrid and does not reproduce from seed. First recorded in England in the 17th century, probably arising spontaneously in cultivated mint fields near Mitcham, Surrey. Now cultivated worldwide throughout the temperate zone; principal commercial producers are the United States (Pacific Northwest and Indiana), India, and China.
| plant_part = Aerial parts (leaves and flowering tops); essential oil distilled from fresh herb; enteric-coated capsules of the essential oil for pharmaceutical use.
| image =
| intro = ''Mentha x piperita'' L. -- peppermint -- is a sterile hybrid of watermint (''Mentha'' aquatica) and spearmint (''Mentha spicata'') first documented in the herb gardens of 17th-century England. It reproduces only by vegetative spread and would disappear without cultivation; instead it has become the most widely grown aromatic herb in the world, its menthol extracted in quantities sufficient to scent a global industry of confectionery, personal care, and pharmaceuticals. Among medicinal herbs it holds an unusual distinction: enteric-coated peppermint oil capsules are supported by a Cochrane systematic review of nine randomized controlled trials reporting a number needed to treat of 2.5 for irritable bowel syndrome -- one of the strongest evidence-backed botanical indications in gastrointestinal medicine.

| history = Mint is one of the oldest plants in the human medicinal record. Dried mint leaves have been recovered from Egyptian tombs dated to approximately 1000 BCE; the Romans cultivated mint so extensively across their empire that Pliny the Elder complained they planted it everywhere.{{citation needed}} The Greek physician Dioscorides recorded multiple mint species and their uses for flatulence, nausea, and the suppression of vomiting; Hippocrates had written of mint before him. In the Arab world, the physician Ibn Sina noted mint's digestive and carminative properties in the Canon of Medicine. By the medieval period mint was among the universal European monastery garden plants, appearing in every hortus conclusus alongside sage, rosemary, and lavender.

What none of these traditions knew, because it did not yet exist, was peppermint. ''Mentha x piperita'' is a hybrid -- a cross between watermint and spearmint -- that arose, or was first recognized, in England in the 17th century, likely in the commercial mint-growing fields around Mitcham in Surrey, which became the center of English peppermint cultivation and remained so through the 19th century. John Ray, the English naturalist, first formally described peppermint as a distinct plant in 1696.{{citation needed}} The English cultivated it first; then the Americans took it -- particularly the farmers of Chautauqua County, New York and later the Columbia River basin -- and by the 19th century peppermint was a transatlantic commodity. By the 20th century it was a global industrial crop, its oil distilled in tonnage for the tobacco, confectionery, and oral hygiene industries, and the pharmacognosists were beginning to work out exactly why it did what it had always done to a troubled gut.

The therapeutic pivot came in stages. Commission E in Germany approved peppermint oil for spasmodic complaints of the upper gastrointestinal tract in 1990, grounded in traditional use and the available pharmacological rationale. The pharmaceutical form -- enteric-coated peppermint oil capsules formulated to survive the stomach acid and release their contents in the small intestine -- was the key innovation; Colpermin appeared in the 1980s and accumulated clinical trial data through the 1990s and 2000s. The Cochrane Collaboration's 2014 systematic review was the culmination of that evidence, and it placed peppermint oil among the most rigorously substantiated botanical interventions in gastroenterology.

| taxonomy = ''Mentha x piperita'' L. belongs to tribe Mentheae, family Lamiaceae. The multiplication sign in the binomial (x) denotes hybrid origin: the parents are ''Mentha'' aquatica (watermint) and ''Mentha spicata'' (spearmint). The hybrid is triploid and entirely sterile -- it sets no viable seed and propagates exclusively by vegetative means (rhizomes and cuttings). The x piperita epithet (pepper-mint) refers to the hot-cool-pungent character of the fresh leaf, distinct from the milder spearmint parent.

The genus ''Mentha'' comprises approximately 25 recognized species and a very large number of hybrids, cultivars, and named varieties; the genus is taxonomically complex, and menthol content varies considerably across species and cultivars. Medically and commercially significant species include:

''Mentha'' aquatica (watermint): one parent of peppermint; grows in wet habitats; high linalool content; mild medicinal use.

''Mentha spicata'' (spearmint): the other parent; carvone-dominant rather than menthol-dominant; gentler, less cooling; the spearmint of culinary use and the safer option for children and for those who do not tolerate peppermint's LES-relaxing effect.

''Mentha'' arvensis (corn mint, Japanese peppermint): the dominant commercial source of natural menthol crystals; native to Asia; the oil from this species is far higher in menthol (70 to 90 percent) than peppermint oil (35 to 55 percent) and is the source of most of the menthol in commercial cough drops, mentholated cigarettes, and topical pain preparations.

''Mentha'' pulegium (pennyroyal): HIGHLY TOXIC. Pulegone-rich; historically used as a folk abortifacient; cases of maternal fatality and severe hepatic failure have been reported following ingestion of pennyroyal oil as an abortifacient agent.{{citation needed}} Pennyroyal should never be used as a substitute for peppermint in any context; the two plants have been confused in commercial herbal markets with fatal consequences.

The medicinal parts of M. x piperita are the aerial parts -- leaves and flowering tops -- harvested before full flowering. The essential oil is steam-distilled from fresh herb; genuine peppermint oil should contain menthol at 35 to 55 percent, distinguishing it from the lower-grade lavandin oil in the lavender trade's parallel adulteration problem.

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Peppermint's principal traditional indications mirror its modern evidence base with unusual fidelity: flatulence and bloating, digestive cramping and colic, nausea and vomiting, dyspepsia, headache (particularly the common tension headache with a frontal or temporal distribution), nasal congestion from colds, and muscle pain. The herb has been used for these purposes in continuous Western practice from at least the 18th century, when peppermint tea became the commonest domestic remedy for an upset stomach in Britain and America. The inhalational use for nasal congestion -- peppermint steam over hot water, peppermint oil rubbed on the chest or dissolved in a steam inhaler -- has equal continuity. The topical application to the temple and forehead for headache appears in 18th- and 19th-century domestic medicine texts and was given its first controlled clinical evidence base by Gobel in 1996.

'''TCM: Bo He (薄荷)'''

Peppermint is used in Chinese medicine under the name Bo He, though the plant sourced in Chinese practice is frequently ''Mentha'' haplocalyx or other Asian ''Mentha'' species rather than M. x piperita; the volatile-oil chemistry is sufficiently similar for the indications to overlap. In the TCM framework, Bo He is classified as pungent and cool, entering the lung and liver meridians. Its primary indications are wind-heat exterior patterns (early common cold or influenza with fever, sore throat, headache) where it disperses the pathogenic wind-heat; it also clears the head and eyes for wind-heat-related headache and red eyes, and moves liver qi stagnation for irritability and distention. In formulae, it is frequently combined with Forsythia (Lian Qiao) and Lonicera (Jin Yin Hua) in standard wind-heat formulas such as Yin Qiao San.{{citation needed}}

'''Ayurvedic medicine (Pudina)'''

Peppermint is used in Ayurvedic medicine as Pudina, described as pungent, slightly bitter, and cooling in action; it pacifies kapha and vata doshas while having mixed effects on pitta. Principal Ayurvedic indications are digestive complaints -- dyspepsia, nausea, vomiting -- and febrile conditions where its diaphoretic action is valued. It is among the aromatics used in Ayurvedic churnas (herbal powders) for digestive support.{{citation needed}}

'''Islamic medicine (Na'na)'''

Mint was known in Arabic-speaking medicine as Na'na (نعناع) and classified as cool and drying in the Galenic-Islamic temperament system; Ibn Sina described it for digestion, fevers, headache, and nausea in the Canon of Medicine, consistent with its Dioscoridean antecedents.{{citation needed}}

| pharmacology = '''Menthol: the principal active constituent'''

Peppermint essential oil contains menthol at 35 to 55 percent of total volatile oil, menthone at 10 to 40 percent, menthyl acetate, isomenthone, 1,8-cineole, and trace amounts of pulegone (significantly higher in pennyroyal and in some lavandin adulterants).{{citation needed}}

Menthol exerts its principal therapeutic actions through two distinct receptor mechanisms.

Voltage-gated calcium channel blockade in gastrointestinal smooth muscle: menthol and whole peppermint oil inhibit L-type calcium channels in intestinal smooth muscle, reducing calcium-dependent contraction and relaxing GI tone. This was first demonstrated in a pharmacological study by Hawthorn and colleagues in 1988<ref name="hawthorn1988">Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac smooth muscle." Aliment Pharmacol Ther. 1988;2(2):101-118. PMID 2856502.</ref> and confirmed in human colonic smooth muscle by Amato and colleagues in 2014.<ref name="amato2014">Amato A, Liotta R, Mule F. "Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action." Eur J Pharmacol. 2014;740:295-301. PMID 25046841.</ref> The L-type calcium channel mechanism accounts for menthol's antispasmodic action in the irritable bowel -- precisely the mechanism that explains why an enteric-coated capsule formulation that delivers the oil to the small and large intestine (bypassing the stomach) is necessary for IBS treatment.

Transient receptor potential melastatin 8 (TRPM8) activation: menthol is the principal natural ligand of TRPM8, the cold-sensitive ion channel responsible for the sensation of coolness (and, paradoxically, of cold-induced burning at high concentrations). TRPM8 activation in sensory neurons is the basis of peppermint's cooling sensation on the skin and mucous membranes, and contributes to its topical analgesic effect in tension headache -- initial TRPM8 activation followed by desensitization leads to reduced pain signaling in the same manner that capsaicin (TRPV1 agonist) produces topical analgesia via TRPV1 desensitization.<ref name="mckemy2002">McKemy DD, Neuhausser WM, Julius D. "Identification of a cold receptor reveals a general role for TRP channels in thermosensation." Nature. 2002;416(6876):52-58. PMID 11882888.</ref><ref name="bautista2007">Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI. "The menthol receptor TRPM8 is the principal detector of environmental cold." Nature. 2007;448(7150):204-208. PMID 17538622.</ref>

Antimicrobial activity: peppermint essential oil demonstrates broad-spectrum antibacterial and antifungal activity in vitro, including against ''Helicobacter pylori'', ''Candida albicans'', methicillin-resistant ''Staphylococcus aureus'', and Escherichia coli; the mechanism involves menthol's disruption of microbial cell membrane integrity.{{citation needed}}

Choleretic activity: peppermint oil stimulates bile secretion from the gallbladder and hepatic bile production; this contributes to its efficacy in functional dyspepsia and gallbladder-related upper GI symptoms and is the pharmacological basis of the Commission E approval for bile duct and gallbladder complaints.{{citation needed}}

| clinical_evidence = '''Irritable bowel syndrome (enteric-coated peppermint oil capsules)'''

The evidence for enteric-coated peppermint oil in IBS is the strongest clinical evidence base of any herbal medicine in gastroenterology. The formulation is critical: non-enteric-coated preparations dissolve in the stomach, causing upper GI side effects (heartburn, nausea from premature LES relaxation) without delivering active oil to the target site in the small and large intestine. Enteric-coated capsules bypass the stomach and release their contents only in the more alkaline intestinal environment.

Khanna and colleagues (2014) conducted a systematic review and meta-analysis of nine randomized, placebo-controlled trials (total n = 726) of enteric-coated peppermint oil for IBS. Global symptom improvement was significantly greater in the peppermint group; the pooled relative risk for global improvement was 2.23 (95 percent CI 1.78 to 2.81), corresponding to a number needed to treat of 2.5 -- a remarkably strong treatment effect for a botanical intervention in a notoriously treatment-resistant condition.<ref name="khanna2014">Khanna R, MacDonald JK, Levesque BG. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." J Clin Gastroenterol. 2014;48(6):505-512. PMID 24100754.</ref>

Among the constituent trials, Cappello and colleagues (2007) randomized 57 patients with IBS to peppermint oil (Mintoil) 187 mg three times daily in enteric-coated capsules or placebo for four weeks; 75 percent of the treated group achieved at least 50 percent reduction in total symptom score, compared with 38 percent in the placebo group. Abdominal pain, distention, stool urgency, flatulence, and borborygmi all improved significantly in the peppermint group.<ref name="cappello2007">Cappello G, Spezzaferro M, Grossi L, Marzio L, Marzio L. "Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial." Dig Liver Dis. 2007;39(6):530-536. PMID 17420159.</ref>

'''Tension headache (topical peppermint oil)'''

Gobel and colleagues (1996) conducted a randomized crossover trial in patients with episodic tension-type headache, applying a 10 percent peppermint oil solution in ethanol to the forehead and temples at headache onset. Topical peppermint oil reduced headache intensity equivalently to oral paracetamol (acetaminophen) 1 g over the 60 minutes following application, with both being significantly superior to placebo. The mechanism is consistent with TRPM8-mediated cutaneous cooling followed by sensory neuron desensitization reducing pain signaling in the trigeminal area.<ref name="gobel1996">Gobel H, Fresenius J, Heinze A, Dworschak M, Soyka D. "Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type." Nervenarzt. 1996;67(8):672-681. PMID 8805113.</ref>

A 2016 confirmatory study from the same group reaffirmed the efficacy of topical peppermint oil for acute tension-type headache in a larger sample.<ref name="gobel2016">Gobel H, Heinze A, Heinze-Kuhn K, Gobel A, Gobel C. "[Peppermint oil in the acute treatment of tension-type headache]." Schmerz. 2016;30(3):295-310. PMID 27106030.</ref>

'''Functional dyspepsia'''

Peppermint oil in combination with caraway oil (Enteroplant; MCP Pharma, Germany) has been evaluated in several randomized trials for functional dyspepsia, showing significant improvement over placebo in epigastric pain, nausea, and bloating. The combination is included as a component of the multi-herb preparation Iberogast, which has its own clinical evidence base for functional dyspepsia.{{citation needed}}

| preparations = Infusion (tea): 3 to 4 g dried leaf per cup of hot water, covered while steeping (volatile oil retention). Drunk after meals for digestive complaints; as a steam inhalant for nasal congestion (pour into a bowl and inhale steam with a towel over the head). Note that peppermint tea is the preparation with the weakest IBS evidence; the enteric-coated capsule form is the evidence-based preparation for this indication.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation.

Enteric-coated peppermint oil capsules (Colpermin; Pepogest; Mintec; generic equivalents): the only form with robust IBS clinical trial evidence. Enteric coating is essential: the coating is designed to withstand gastric acid and dissolve at the more alkaline pH of the duodenum and small intestine, delivering the oil to the intestinal target rather than the stomach. These capsules must NOT be taken simultaneously with antacids, proton pump inhibitors, or H2 blockers that alkalinize the stomach -- premature dissolution of the enteric coat risks upper GI side effects. Standard commercial dose: 187 to 225 mg three times daily, taken before meals.

Essential oil (topical): 10 percent peppermint oil in ethanol or carrier oil, applied to forehead and temples for tension headache; 2 to 3 percent in carrier oil for massage of muscle ache or abdominal spasm; steam inhalant (2 to 3 drops in hot water) for nasal congestion. Do not apply neat oil to facial skin of children or to the face or chest of infants.

Mouthwash and confectionery: standardized products are not medicinal preparations but carry genuine antimicrobial and breath-freshening effects from the menthol content.

| dosing = '''Internal preparations'''

Infusion: 3 to 4 g dried leaf per cup, three to four times daily, ideally after meals. Cover the vessel while steeping; the volatile oil evaporates readily.

Tincture: 1 to 2 ml three times daily, diluted in water.

Enteric-coated peppermint oil capsules (for IBS): 187 to 225 mg three times daily, 30 to 60 minutes before meals. Do not crush or chew. Separate from antacid use by at least two hours. The full therapeutic effect in IBS develops over two to four weeks of regular use; do not assess as a failure after a single dose.

'''External preparations'''

Tension headache: 10 percent peppermint oil in ethanol, applied by cotton ball or rollerball applicator to forehead and both temples at headache onset; repeat at 15 and 30 minutes as needed. Keep well away from eyes. This is the protocol used in the Gobel trials.

Muscle tension and spasm: 2 to 3 percent essential oil in carrier oil, applied by massage to affected area.

Nasal congestion: 2 to 3 drops essential oil in a bowl of hot water; inhale steam for 5 to 10 minutes with a towel draped over head and bowl. Do not use this method with children under 12, or with infants under any circumstances.

'''Recreational dose ladder'''

Peppermint has no established recreational dose structure. Menthol's TRPM8-mediated cooling sensation is pleasurable and widely exploited in confectionery, oral hygiene, and tobacco products; however, the sensation is immediate, topical, and non-dose-escalating -- there is no psychoactive intensification with increasing dose, and no recreational culture of peppermint use as a psychoactive agent exists in any documented tradition. At high oral doses, menthol produces nausea and GI discomfort rather than pleasure; the pharmacological ceiling of the desirable effect is reached at modest concentrations. No dose ladder is warranted.

| pharmacokinetics = Menthol is rapidly absorbed from the gastrointestinal tract following oral ingestion of non-enteric-coated preparations; enteric-coated formulations delay absorption to the small intestine, which is the therapeutic intent for IBS. Menthol undergoes hepatic glucuronidation and sulfation; the conjugated metabolites are excreted renally, with menthol glucuronide detectable in urine as a biomarker of exposure. The elimination half-life of menthol is approximately one to two hours. Following topical application, menthol is absorbed dermally at a rate sufficient to produce detectable plasma concentrations; dermal absorption is faster with ethanol-based compared to oil-based vehicles.{{citation needed}}

| interactions = Antacids, proton pump inhibitors, H2 receptor antagonists: alkalinization of gastric pH by any of these agents can dissolve the enteric coating of peppermint oil capsules prematurely, causing upper GI side effects (heartburn, nausea, belching) and reducing delivery to the intended intestinal target. Antacids should be separated from enteric-coated capsule dosing by a minimum of two hours.

Central nervous system depressants: additive effects possible with sedating medicines and herbal preparations; peppermint has mild CNS-relaxing effects at therapeutic doses.

Cyclosporine: case reports suggest possible elevation of cyclosporine plasma levels in transplant recipients using peppermint oil preparations; a potential CYP3A4 interaction. Transplant patients on cyclosporine should not use peppermint oil preparations without specialist input.{{citation needed}}

Cyclosporine aside, cytochrome P450 inhibition by peppermint oil at standard enteric-coated capsule doses (187 to 225 mg three times daily) has not been documented as clinically significant in pharmacokinetic interaction studies.

| interactionsummary = Separate from antacids by 2 hours (enteric coat dissolution risk). Theoretical CYP3A4 interaction; case report of cyclosporine elevation. Additive CNS relaxant effect with sedatives.

| safety = The most important safety issue with peppermint is also the most preventable: administration to children under five, or inhalant menthol preparations applied near the face of infants. Menthol applied to the nose, mouth, or chest of infants and young children has caused laryngospasm and bronchospasm, including apnea, in case reports; this has occurred with direct application of peppermint oil or Vicks VapoRub-equivalent preparations to the chest or upper lip. Products containing menthol should not be applied near the face of children under five; for infants and toddlers, no menthol-containing preparations are appropriate.{{citation needed}}

Gastroesophageal reflux disease (GERD) and hiatal hernia: menthol relaxes the lower esophageal sphincter (LES). Peppermint tea and non-enteric-coated preparations should be avoided in patients with active reflux disease; enteric-coated capsules (which deliver the oil below the LES, to the intestine) are substantially lower-risk but should still be used with caution in severe or symptomatic GERD.

Pennyroyal (''Mentha'' pulegium) confusion: pennyroyal is a toxic mint-family plant sometimes sold as or confused with peppermint; its pulegone-rich essential oil has caused hepatic failure and maternal death when taken as an abortifacient. Any herb labeled as pennyroyal, European pennyroyal, or squaw mint should be treated as toxic. This warning applies to herbal suppliers and to patients who gather wild mints without botanical identification.

Gallstones: peppermint oil's choleretic effect stimulates the gallbladder; patients with known gallstones should use peppermint oil preparations cautiously, as stimulation of bile flow in the presence of obstructing stones could precipitate biliary colic.

Pregnancy: no clinical trial safety data; peppermint tea is used in traditional midwifery for pregnancy-related nausea and is generally considered safe at infusion doses; enteric-coated oil capsules at medicinal doses have not been evaluated in pregnancy and are not recommended.

| monitoring = No routine monitoring required for infusion use or enteric-coated capsules at standard IBS doses in otherwise healthy adults. Patients with GERD on enteric-coated capsules: symptom monitoring for worsening reflux. Transplant patients on cyclosporine: if using peppermint oil, check cyclosporine levels within two to four weeks of starting or changing dose.

| counseling = The formulation distinction is the most important thing to convey to patients using peppermint for IBS: only enteric-coated capsules have the clinical evidence base, because only they deliver the oil to the intestinal target. Peppermint tea, while pleasant and acceptable for mild general digestive symptoms, has not been tested for IBS and should not be substituted for the enteric-coated capsule in patients with established IBS diagnosis.

For tension headache, the topical preparation (10 percent peppermint oil in ethanol on forehead and temples) requires patient instruction on avoiding the eyes; a rollerball applicator is more practical than cotton-ball application for self-use. The effect onset is rapid -- patients should expect some relief within 15 to 30 minutes, earlier than with oral paracetamol.

Parents of infants and young children should be advised specifically that peppermint oil and all mentholated preparations should not be applied to the face, nose, or chest of children under five, and not at all to the face of infants.

| regulatory = '''Germany and European Union'''

German Commission E: peppermint oil approved for spastic complaints of the upper GI tract, bile duct and gallbladder; external use for myalgia and neuralgia; and inhalation for diseases of the upper respiratory tract. Peppermint leaf (dried herb) approved for carminative and antispasmodic use in the GI tract.

EMA: positive assessment issued for peppermint oil in enteric-coated capsules for IBS, classified as a well-established use (based on clinical trial evidence) rather than traditional use -- a stronger regulatory designation reflecting the Cochrane-level evidence base. This distinguishes peppermint oil from most other botanical preparations in the EMA monograph system.<ref name="ema-peppermint">European Union herbal monograph on Mentha x piperita L., aetheroleum. EMA/HMPC/522410/2013. Committee on Herbal Medicinal Products (HMPC). First published: 24 July 2020. https://www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum</ref>

'''United States'''

Peppermint oil: GRAS as a food flavoring. Sold as a dietary supplement under DSHEA without FDA evaluation for therapeutic claims. No FDA-approved therapeutic indication.

'''United Kingdom'''

Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.

}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Mentha × piperita

2026-05-26T19:07:19Z

MDElliottMD: home-claude: redirect to Peppermint (proper hybrid × symbol)

#REDIRECT [[Peppermint]]

Peppermint oil

2026-05-26T19:07:04Z

MDElliottMD: home-claude: redirect to Peppermint

#REDIRECT [[Peppermint]]

Mentha piperita

2026-05-26T19:07:03Z

MDElliottMD: home-claude: redirect to Peppermint

#REDIRECT [[Peppermint]]

Mentha x piperita

2026-05-26T19:07:02Z

MDElliottMD: home-claude: redirect to Peppermint

#REDIRECT [[Peppermint]]

Peppermint

2026-05-26T19:05:35Z

MDElliottMD: home-claude: Herb #9 Peppermint initial publish (Q1-Q3 resolved; 8 PMIDs verified; binomial italics applied)

{{hatnote|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See [[#Botany and identification|Botany and identification]] for the safety warning.}}
{{PlantMedTemplate
| name = Peppermint
| binomial = Mentha × piperita
| family = Lamiaceae
| native_range = Not native to any wild habitat: peppermint is a sterile hybrid and does not reproduce from seed. First recorded in England in the 17th century, probably arising spontaneously in cultivated mint fields near Mitcham, Surrey. Now cultivated worldwide throughout the temperate zone; principal commercial producers are the United States (Pacific Northwest and Indiana), India, and China.
| plant_part = Aerial parts (leaves and flowering tops); essential oil distilled from fresh herb; enteric-coated capsules of the essential oil for pharmaceutical use.
| image =
| intro = ''Mentha x piperita'' L. -- peppermint -- is a sterile hybrid of watermint (''Mentha'' aquatica) and spearmint (''Mentha spicata'') first documented in the herb gardens of 17th-century England. It reproduces only by vegetative spread and would disappear without cultivation; instead it has become the most widely grown aromatic herb in the world, its menthol extracted in quantities sufficient to scent a global industry of confectionery, personal care, and pharmaceuticals. Among medicinal herbs it holds an unusual distinction: enteric-coated peppermint oil capsules are supported by a Cochrane systematic review of nine randomized controlled trials reporting a number needed to treat of 2.5 for irritable bowel syndrome -- one of the strongest evidence-backed botanical indications in gastrointestinal medicine.

| history = Mint is one of the oldest plants in the human medicinal record. Dried mint leaves have been recovered from Egyptian tombs dated to approximately 1000 BCE; the Romans cultivated mint so extensively across their empire that Pliny the Elder complained they planted it everywhere.{{citation needed}} The Greek physician Dioscorides recorded multiple mint species and their uses for flatulence, nausea, and the suppression of vomiting; Hippocrates had written of mint before him. In the Arab world, the physician Ibn Sina noted mint's digestive and carminative properties in the Canon of Medicine. By the medieval period mint was among the universal European monastery garden plants, appearing in every hortus conclusus alongside sage, rosemary, and lavender.

What none of these traditions knew, because it did not yet exist, was peppermint. ''Mentha x piperita'' is a hybrid -- a cross between watermint and spearmint -- that arose, or was first recognized, in England in the 17th century, likely in the commercial mint-growing fields around Mitcham in Surrey, which became the center of English peppermint cultivation and remained so through the 19th century. John Ray, the English naturalist, first formally described peppermint as a distinct plant in 1696.{{citation needed}} The English cultivated it first; then the Americans took it -- particularly the farmers of Chautauqua County, New York and later the Columbia River basin -- and by the 19th century peppermint was a transatlantic commodity. By the 20th century it was a global industrial crop, its oil distilled in tonnage for the tobacco, confectionery, and oral hygiene industries, and the pharmacognosists were beginning to work out exactly why it did what it had always done to a troubled gut.

The therapeutic pivot came in stages. Commission E in Germany approved peppermint oil for spasmodic complaints of the upper gastrointestinal tract in 1990, grounded in traditional use and the available pharmacological rationale. The pharmaceutical form -- enteric-coated peppermint oil capsules formulated to survive the stomach acid and release their contents in the small intestine -- was the key innovation; Colpermin appeared in the 1980s and accumulated clinical trial data through the 1990s and 2000s. The Cochrane Collaboration's 2014 systematic review was the culmination of that evidence, and it placed peppermint oil among the most rigorously substantiated botanical interventions in gastroenterology.

| taxonomy = ''Mentha x piperita'' L. belongs to tribe Mentheae, family Lamiaceae. The multiplication sign in the binomial (x) denotes hybrid origin: the parents are ''Mentha'' aquatica (watermint) and ''Mentha spicata'' (spearmint). The hybrid is triploid and entirely sterile -- it sets no viable seed and propagates exclusively by vegetative means (rhizomes and cuttings). The x piperita epithet (pepper-mint) refers to the hot-cool-pungent character of the fresh leaf, distinct from the milder spearmint parent.

The genus ''Mentha'' comprises approximately 25 recognized species and a very large number of hybrids, cultivars, and named varieties; the genus is taxonomically complex, and menthol content varies considerably across species and cultivars. Medically and commercially significant species include:

''Mentha'' aquatica (watermint): one parent of peppermint; grows in wet habitats; high linalool content; mild medicinal use.

''Mentha spicata'' (spearmint): the other parent; carvone-dominant rather than menthol-dominant; gentler, less cooling; the spearmint of culinary use and the safer option for children and for those who do not tolerate peppermint's LES-relaxing effect.

''Mentha'' arvensis (corn mint, Japanese peppermint): the dominant commercial source of natural menthol crystals; native to Asia; the oil from this species is far higher in menthol (70 to 90 percent) than peppermint oil (35 to 55 percent) and is the source of most of the menthol in commercial cough drops, mentholated cigarettes, and topical pain preparations.

''Mentha'' pulegium (pennyroyal): HIGHLY TOXIC. Pulegone-rich; historically used as a folk abortifacient; cases of maternal fatality and severe hepatic failure have been reported following ingestion of pennyroyal oil as an abortifacient agent.{{citation needed}} Pennyroyal should never be used as a substitute for peppermint in any context; the two plants have been confused in commercial herbal markets with fatal consequences.

The medicinal parts of M. x piperita are the aerial parts -- leaves and flowering tops -- harvested before full flowering. The essential oil is steam-distilled from fresh herb; genuine peppermint oil should contain menthol at 35 to 55 percent, distinguishing it from the lower-grade lavandin oil in the lavender trade's parallel adulteration problem.

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Peppermint's principal traditional indications mirror its modern evidence base with unusual fidelity: flatulence and bloating, digestive cramping and colic, nausea and vomiting, dyspepsia, headache (particularly the common tension headache with a frontal or temporal distribution), nasal congestion from colds, and muscle pain. The herb has been used for these purposes in continuous Western practice from at least the 18th century, when peppermint tea became the commonest domestic remedy for an upset stomach in Britain and America. The inhalational use for nasal congestion -- peppermint steam over hot water, peppermint oil rubbed on the chest or dissolved in a steam inhaler -- has equal continuity. The topical application to the temple and forehead for headache appears in 18th- and 19th-century domestic medicine texts and was given its first controlled clinical evidence base by Gobel in 1996.

'''TCM: Bo He (薄荷)'''

Peppermint is used in Chinese medicine under the name Bo He, though the plant sourced in Chinese practice is frequently ''Mentha'' haplocalyx or other Asian ''Mentha'' species rather than M. x piperita; the volatile-oil chemistry is sufficiently similar for the indications to overlap. In the TCM framework, Bo He is classified as pungent and cool, entering the lung and liver meridians. Its primary indications are wind-heat exterior patterns (early common cold or influenza with fever, sore throat, headache) where it disperses the pathogenic wind-heat; it also clears the head and eyes for wind-heat-related headache and red eyes, and moves liver qi stagnation for irritability and distention. In formulae, it is frequently combined with Forsythia (Lian Qiao) and Lonicera (Jin Yin Hua) in standard wind-heat formulas such as Yin Qiao San.{{citation needed}}

'''Ayurvedic medicine (Pudina)'''

Peppermint is used in Ayurvedic medicine as Pudina, described as pungent, slightly bitter, and cooling in action; it pacifies kapha and vata doshas while having mixed effects on pitta. Principal Ayurvedic indications are digestive complaints -- dyspepsia, nausea, vomiting -- and febrile conditions where its diaphoretic action is valued. It is among the aromatics used in Ayurvedic churnas (herbal powders) for digestive support.{{citation needed}}

'''Islamic medicine (Na'na)'''

Mint was known in Arabic-speaking medicine as Na'na (نعناع) and classified as cool and drying in the Galenic-Islamic temperament system; Ibn Sina described it for digestion, fevers, headache, and nausea in the Canon of Medicine, consistent with its Dioscoridean antecedents.{{citation needed}}

| pharmacology = '''Menthol: the principal active constituent'''

Peppermint essential oil contains menthol at 35 to 55 percent of total volatile oil, menthone at 10 to 40 percent, menthyl acetate, isomenthone, 1,8-cineole, and trace amounts of pulegone (significantly higher in pennyroyal and in some lavandin adulterants).{{citation needed}}

Menthol exerts its principal therapeutic actions through two distinct receptor mechanisms.

Voltage-gated calcium channel blockade in gastrointestinal smooth muscle: menthol and whole peppermint oil inhibit L-type calcium channels in intestinal smooth muscle, reducing calcium-dependent contraction and relaxing GI tone. This was first demonstrated in a pharmacological study by Hawthorn and colleagues in 1988<ref name="hawthorn1988">Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac smooth muscle." Aliment Pharmacol Ther. 1988;2(2):101-118. PMID 2856502.</ref> and confirmed in human colonic smooth muscle by Amato and colleagues in 2014.<ref name="amato2014">Amato A, Liotta R, Mule F. "Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action." Eur J Pharmacol. 2014;740:295-301. PMID 25046841.</ref> The L-type calcium channel mechanism accounts for menthol's antispasmodic action in the irritable bowel -- precisely the mechanism that explains why an enteric-coated capsule formulation that delivers the oil to the small and large intestine (bypassing the stomach) is necessary for IBS treatment.

Transient receptor potential melastatin 8 (TRPM8) activation: menthol is the principal natural ligand of TRPM8, the cold-sensitive ion channel responsible for the sensation of coolness (and, paradoxically, of cold-induced burning at high concentrations). TRPM8 activation in sensory neurons is the basis of peppermint's cooling sensation on the skin and mucous membranes, and contributes to its topical analgesic effect in tension headache -- initial TRPM8 activation followed by desensitization leads to reduced pain signaling in the same manner that capsaicin (TRPV1 agonist) produces topical analgesia via TRPV1 desensitization.<ref name="mckemy2002">McKemy DD, Neuhausser WM, Julius D. "Identification of a cold receptor reveals a general role for TRP channels in thermosensation." Nature. 2002;416(6876):52-58. PMID 11882888.</ref><ref name="bautista2007">Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI. "The menthol receptor TRPM8 is the principal detector of environmental cold." Nature. 2007;448(7150):204-208. PMID 17538622.</ref>

Antimicrobial activity: peppermint essential oil demonstrates broad-spectrum antibacterial and antifungal activity in vitro, including against ''Helicobacter pylori'', ''Candida albicans'', methicillin-resistant ''Staphylococcus aureus'', and Escherichia coli; the mechanism involves menthol's disruption of microbial cell membrane integrity.{{citation needed}}

Choleretic activity: peppermint oil stimulates bile secretion from the gallbladder and hepatic bile production; this contributes to its efficacy in functional dyspepsia and gallbladder-related upper GI symptoms and is the pharmacological basis of the Commission E approval for bile duct and gallbladder complaints.{{citation needed}}

| clinical_evidence = '''Irritable bowel syndrome (enteric-coated peppermint oil capsules)'''

The evidence for enteric-coated peppermint oil in IBS is the strongest clinical evidence base of any herbal medicine in gastroenterology. The formulation is critical: non-enteric-coated preparations dissolve in the stomach, causing upper GI side effects (heartburn, nausea from premature LES relaxation) without delivering active oil to the target site in the small and large intestine. Enteric-coated capsules bypass the stomach and release their contents only in the more alkaline intestinal environment.

Khanna and colleagues (2014) conducted a systematic review and meta-analysis of nine randomized, placebo-controlled trials (total n = 726) of enteric-coated peppermint oil for IBS. Global symptom improvement was significantly greater in the peppermint group; the pooled relative risk for global improvement was 2.23 (95 percent CI 1.78 to 2.81), corresponding to a number needed to treat of 2.5 -- a remarkably strong treatment effect for a botanical intervention in a notoriously treatment-resistant condition.<ref name="khanna2014">Khanna R, MacDonald JK, Levesque BG. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." J Clin Gastroenterol. 2014;48(6):505-512. PMID 24100754.</ref>

Among the constituent trials, Cappello and colleagues (2007) randomized 57 patients with IBS to peppermint oil (Mintoil) 187 mg three times daily in enteric-coated capsules or placebo for four weeks; 75 percent of the treated group achieved at least 50 percent reduction in total symptom score, compared with 38 percent in the placebo group. Abdominal pain, distention, stool urgency, flatulence, and borborygmi all improved significantly in the peppermint group.<ref name="cappello2007">Cappello G, Spezzaferro M, Grossi L, Marzio L, Marzio L. "Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial." Dig Liver Dis. 2007;39(6):530-536. PMID 17420159.</ref>

'''Tension headache (topical peppermint oil)'''

Gobel and colleagues (1996) conducted a randomized crossover trial in patients with episodic tension-type headache, applying a 10 percent peppermint oil solution in ethanol to the forehead and temples at headache onset. Topical peppermint oil reduced headache intensity equivalently to oral paracetamol (acetaminophen) 1 g over the 60 minutes following application, with both being significantly superior to placebo. The mechanism is consistent with TRPM8-mediated cutaneous cooling followed by sensory neuron desensitization reducing pain signaling in the trigeminal area.<ref name="gobel1996">Gobel H, Fresenius J, Heinze A, Dworschak M, Soyka D. "Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type." Nervenarzt. 1996;67(8):672-681. PMID 8805113.</ref>

A 2016 confirmatory study from the same group reaffirmed the efficacy of topical peppermint oil for acute tension-type headache in a larger sample.<ref name="gobel2016">Gobel H, Heinze A, Heinze-Kuhn K, Gobel A, Gobel C. "[Peppermint oil in the acute treatment of tension-type headache]." Schmerz. 2016;30(3):295-310. PMID 27106030.</ref>

'''Functional dyspepsia'''

Peppermint oil in combination with caraway oil (Enteroplant; MCP Pharma, Germany) has been evaluated in several randomized trials for functional dyspepsia, showing significant improvement over placebo in epigastric pain, nausea, and bloating. The combination is included as a component of the multi-herb preparation Iberogast, which has its own clinical evidence base for functional dyspepsia.{{citation needed}}

| preparations = Infusion (tea): 3 to 4 g dried leaf per cup of hot water, covered while steeping (volatile oil retention). Drunk after meals for digestive complaints; as a steam inhalant for nasal congestion (pour into a bowl and inhale steam with a towel over the head). Note that peppermint tea is the preparation with the weakest IBS evidence; the enteric-coated capsule form is the evidence-based preparation for this indication.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation.

Enteric-coated peppermint oil capsules (Colpermin; Pepogest; Mintec; generic equivalents): the only form with robust IBS clinical trial evidence. Enteric coating is essential: the coating is designed to withstand gastric acid and dissolve at the more alkaline pH of the duodenum and small intestine, delivering the oil to the intestinal target rather than the stomach. These capsules must NOT be taken simultaneously with antacids, proton pump inhibitors, or H2 blockers that alkalinize the stomach -- premature dissolution of the enteric coat risks upper GI side effects. Standard commercial dose: 187 to 225 mg three times daily, taken before meals.

Essential oil (topical): 10 percent peppermint oil in ethanol or carrier oil, applied to forehead and temples for tension headache; 2 to 3 percent in carrier oil for massage of muscle ache or abdominal spasm; steam inhalant (2 to 3 drops in hot water) for nasal congestion. Do not apply neat oil to facial skin of children or to the face or chest of infants.

Mouthwash and confectionery: standardized products are not medicinal preparations but carry genuine antimicrobial and breath-freshening effects from the menthol content.

| dosing = '''Internal preparations'''

Infusion: 3 to 4 g dried leaf per cup, three to four times daily, ideally after meals. Cover the vessel while steeping; the volatile oil evaporates readily.

Tincture: 1 to 2 ml three times daily, diluted in water.

Enteric-coated peppermint oil capsules (for IBS): 187 to 225 mg three times daily, 30 to 60 minutes before meals. Do not crush or chew. Separate from antacid use by at least two hours. The full therapeutic effect in IBS develops over two to four weeks of regular use; do not assess as a failure after a single dose.

'''External preparations'''

Tension headache: 10 percent peppermint oil in ethanol, applied by cotton ball or rollerball applicator to forehead and both temples at headache onset; repeat at 15 and 30 minutes as needed. Keep well away from eyes. This is the protocol used in the Gobel trials.

Muscle tension and spasm: 2 to 3 percent essential oil in carrier oil, applied by massage to affected area.

Nasal congestion: 2 to 3 drops essential oil in a bowl of hot water; inhale steam for 5 to 10 minutes with a towel draped over head and bowl. Do not use this method with children under 12, or with infants under any circumstances.

'''Recreational dose ladder'''

Peppermint has no established recreational dose structure. Menthol's TRPM8-mediated cooling sensation is pleasurable and widely exploited in confectionery, oral hygiene, and tobacco products; however, the sensation is immediate, topical, and non-dose-escalating -- there is no psychoactive intensification with increasing dose, and no recreational culture of peppermint use as a psychoactive agent exists in any documented tradition. At high oral doses, menthol produces nausea and GI discomfort rather than pleasure; the pharmacological ceiling of the desirable effect is reached at modest concentrations. No dose ladder is warranted.

| pharmacokinetics = Menthol is rapidly absorbed from the gastrointestinal tract following oral ingestion of non-enteric-coated preparations; enteric-coated formulations delay absorption to the small intestine, which is the therapeutic intent for IBS. Menthol undergoes hepatic glucuronidation and sulfation; the conjugated metabolites are excreted renally, with menthol glucuronide detectable in urine as a biomarker of exposure. The elimination half-life of menthol is approximately one to two hours. Following topical application, menthol is absorbed dermally at a rate sufficient to produce detectable plasma concentrations; dermal absorption is faster with ethanol-based compared to oil-based vehicles.{{citation needed}}

| interactions = Antacids, proton pump inhibitors, H2 receptor antagonists: alkalinization of gastric pH by any of these agents can dissolve the enteric coating of peppermint oil capsules prematurely, causing upper GI side effects (heartburn, nausea, belching) and reducing delivery to the intended intestinal target. Antacids should be separated from enteric-coated capsule dosing by a minimum of two hours.

Central nervous system depressants: additive effects possible with sedating medicines and herbal preparations; peppermint has mild CNS-relaxing effects at therapeutic doses.

Cyclosporine: case reports suggest possible elevation of cyclosporine plasma levels in transplant recipients using peppermint oil preparations; a potential CYP3A4 interaction. Transplant patients on cyclosporine should not use peppermint oil preparations without specialist input.{{citation needed}}

Cyclosporine aside, cytochrome P450 inhibition by peppermint oil at standard enteric-coated capsule doses (187 to 225 mg three times daily) has not been documented as clinically significant in pharmacokinetic interaction studies.

| interactionsummary = Separate from antacids by 2 hours (enteric coat dissolution risk). Theoretical CYP3A4 interaction; case report of cyclosporine elevation. Additive CNS relaxant effect with sedatives.

| safety = The most important safety issue with peppermint is also the most preventable: administration to children under five, or inhalant menthol preparations applied near the face of infants. Menthol applied to the nose, mouth, or chest of infants and young children has caused laryngospasm and bronchospasm, including apnea, in case reports; this has occurred with direct application of peppermint oil or Vicks VapoRub-equivalent preparations to the chest or upper lip. Products containing menthol should not be applied near the face of children under five; for infants and toddlers, no menthol-containing preparations are appropriate.{{citation needed}}

Gastroesophageal reflux disease (GERD) and hiatal hernia: menthol relaxes the lower esophageal sphincter (LES). Peppermint tea and non-enteric-coated preparations should be avoided in patients with active reflux disease; enteric-coated capsules (which deliver the oil below the LES, to the intestine) are substantially lower-risk but should still be used with caution in severe or symptomatic GERD.

Pennyroyal (''Mentha'' pulegium) confusion: pennyroyal is a toxic mint-family plant sometimes sold as or confused with peppermint; its pulegone-rich essential oil has caused hepatic failure and maternal death when taken as an abortifacient. Any herb labeled as pennyroyal, European pennyroyal, or squaw mint should be treated as toxic. This warning applies to herbal suppliers and to patients who gather wild mints without botanical identification.

Gallstones: peppermint oil's choleretic effect stimulates the gallbladder; patients with known gallstones should use peppermint oil preparations cautiously, as stimulation of bile flow in the presence of obstructing stones could precipitate biliary colic.

Pregnancy: no clinical trial safety data; peppermint tea is used in traditional midwifery for pregnancy-related nausea and is generally considered safe at infusion doses; enteric-coated oil capsules at medicinal doses have not been evaluated in pregnancy and are not recommended.

| monitoring = No routine monitoring required for infusion use or enteric-coated capsules at standard IBS doses in otherwise healthy adults. Patients with GERD on enteric-coated capsules: symptom monitoring for worsening reflux. Transplant patients on cyclosporine: if using peppermint oil, check cyclosporine levels within two to four weeks of starting or changing dose.

| counseling = The formulation distinction is the most important thing to convey to patients using peppermint for IBS: only enteric-coated capsules have the clinical evidence base, because only they deliver the oil to the intestinal target. Peppermint tea, while pleasant and acceptable for mild general digestive symptoms, has not been tested for IBS and should not be substituted for the enteric-coated capsule in patients with established IBS diagnosis.

For tension headache, the topical preparation (10 percent peppermint oil in ethanol on forehead and temples) requires patient instruction on avoiding the eyes; a rollerball applicator is more practical than cotton-ball application for self-use. The effect onset is rapid -- patients should expect some relief within 15 to 30 minutes, earlier than with oral paracetamol.

Parents of infants and young children should be advised specifically that peppermint oil and all mentholated preparations should not be applied to the face, nose, or chest of children under five, and not at all to the face of infants.

| regulatory = '''Germany and European Union'''

German Commission E: peppermint oil approved for spastic complaints of the upper GI tract, bile duct and gallbladder; external use for myalgia and neuralgia; and inhalation for diseases of the upper respiratory tract. Peppermint leaf (dried herb) approved for carminative and antispasmodic use in the GI tract.

EMA: positive assessment issued for peppermint oil in enteric-coated capsules for IBS, classified as a well-established use (based on clinical trial evidence) rather than traditional use -- a stronger regulatory designation reflecting the Cochrane-level evidence base. This distinguishes peppermint oil from most other botanical preparations in the EMA monograph system.<ref name="ema-peppermint">European Union herbal monograph on Mentha x piperita L., aetheroleum. EMA/HMPC/522410/2013. Committee on Herbal Medicinal Products (HMPC). First published: 24 July 2020. https://www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum</ref>

'''United States'''

Peppermint oil: GRAS as a food flavoring. Sold as a dietary supplement under DSHEA without FDA evaluation for therapeutic claims. No FDA-approved therapeutic indication.

'''United Kingdom'''

Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.

| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Lemon balm

2026-05-26T18:56:07Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| name = Lemon balm
| binomial = Melissa officinalis
| family = Lamiaceae
| native_range = Southern Europe, western Asia, and northern Africa; naturalized through temperate Europe, the Americas, and Australasia. Wild populations occur on roadsides, hedgerows, disturbed ground, and the margins of woodland, particularly on calcareous soils. Widely cultivated as a garden and medicinal herb throughout the temperate world.
| plant_part = Aerial parts (leaves and flowering tops), harvested just before full flowering when volatile oil content peaks; occasionally the essential oil distilled from fresh herb.
| image =
| intro = ''Melissa officinalis'' L. -- lemon balm, balm, melissa -- is a perennial herb of the mint family whose Greek name means bee, a record of the insects that congregate on its small white flowers and make from them a honey prized in antiquity. It has been called "the elixir of life" by Paracelsus and "sovereign for the brain" by John Evelyn; its unbroken reputation across two thousand years of Western and Islamic medicine is for lifting the heart, clearing the head, and settling the gut. The same compounds responsible for its sharp lemon scent -- the polyphenolic fraction concentrated in its leaves -- have turned out to be active against herpes simplex virus in controlled trials, giving it a specific antiviral credential unlike any other common nervine herb.

| history = The genus name carries the oldest story. In Greek myth, Melissa was a bee-priestess of the mountain goddess Cybele; she fed the infant Zeus on honey when his father Kronos sought to devour him, and was afterward transformed into a bee. Theophrastus in the fourth century BCE noted that beekeepers rubbed hive entrances with melissa leaves to keep their colonies from straying -- a practice that survives in modern beekeeping -- and the plant's association with bees, honey, and the sweetness of life runs through every tradition that has known it.{{citation needed}}

Dioscorides, writing in the first century of the common era, described melissa as useful for treating scorpion stings, dog bites, and the spasms of nervous origin; he recorded it as an infusion for "those who suffer from melancholy," establishing the herb's neurological reputation at the foundational level of European botanical medicine.{{citation needed}} The Romans cultivated it widely, and it passed from Roman gardens into the monastery.

Hildegard of Bingen in the twelfth century listed balm among the plants of the monastic garden that addressed the spiritual ailments she called melancholia; Paracelsus in the sixteenth century, temperamentally given to extreme claims, called it "the elixir of life" -- "among all the herbs none is better for the heart."{{citation needed}} John Gerard's Herball of 1597 recommended it for "driving away melancholly and heaviness of mind" and for "warming and comforting the heart."{{citation needed}}

The most enduring and delightful preparation in lemon balm's history was not a medicine in the modern sense but a spirit: Carmelite water (eau des Carmes), developed by the Carmelite nuns in Paris in the fourteenth century from lemon balm, lemon peel, nutmeg, coriander, angelica root, and cloves in high-proof spirits. It circulated as a tonic for the heart, a remedy against fainting and melancholy, and a general cordial; Charles V of France was reputed to drink it daily.{{citation needed}} The preparation survives commercially today under the Boyer label in France, continuous from the 17th century, and may be the longest-lived packaged medicinal preparation in Western Europe.

John Evelyn, the English diarist and gardener, wrote in the late seventeenth century: "Balm is sovereign for the brain, strengthening the memory and powerfully chasing away melancholy."{{citation needed}} The modern dimension was added not by herbalists but by laboratory pharmacologists. In 1994, the German physician and researcher Rainer Wölbling published the first rigorously controlled clinical trial of a standardized lemon balm cream -- subsequently commercialized as Lomaherpan -- applied to cold sores caused by herpes simplex virus.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from ''Melissa officinalis''." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref> The trial demonstrated that what herbalists had used empirically for mouth sores for centuries worked through a specific mechanism -- rosmarinic acid and other polyphenols blocking herpes virus attachment to host cells -- that remains among the most mechanistically coherent antiviral findings in phytomedicine.

| taxonomy = ''Melissa officinalis'' L. is placed in tribe Mentheae, family Lamiaceae, the sole widely used species in the genus Melissa. The genus name derives from the Greek melissa (bee); the species epithet officinalis (of the dispensary) is shared with hundreds of medicinal plants and indicates long-standing apothecary use. No infraspecific taxa carry commercial or medicinal significance.

''L. officinalis'' is a vigorous, branching perennial growing to 1.5 m (5 ft), with deeply veined, toothed bright-green leaves that release a sharp lemon scent when crushed -- a quality immediately distinguishing it from mint (''Mentha'') and other Lamiaceae in the garden. The lemon scent derives principally from citronellal, a compound also responsible for the scent of lemongrass (''Cymbopogon citratus'') and lemon eucalyptus (''Corymbia citriodora''), reflecting convergent volatile chemistry across plant families rather than close botanical relationship.

The small white flowers, tinged pink or lilac, appear in dense axillary clusters from early summer onward; they are rich in nectar and unusually attractive to honeybees. In the garden lemon balm self-seeds freely and becomes naturalized with ease; it is one of the least demanding of the Lamiaceae in cultivation, tolerating partial shade, poor soils, and neglect.

The medicinal parts are the aerial parts -- leaves and flowering tops -- harvested just before full flowering when volatile oil content is highest. Post-flowering leaves are coarser in flavor and lower in volatile oil. The essential oil is produced commercially but is one of the most expensive in herbal commerce: approximately 3,000 to 5,000 kg of fresh leaf is required to produce 1 kg of oil, reflecting the low volatile oil yield (typically under 0.2 percent of fresh weight) and the labor-intensive harvest involved. The essential oil is rarely indicated in clinical practice and is used primarily in aromatherapy.

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lemon balm belongs to the nervine class of Western herbal medicine -- herbs with a primary action on the nervous system -- and is distinguished within that class by its particular gentleness: it is among the most pediatric-appropriate nervines in the Western tradition, given to colicky infants, anxious children, and restless adolescents alongside adults, without dose adjustment anxieties. This record of safe pediatric use across centuries is itself a kind of pharmacovigilance.

The principal traditional indications map closely onto the modern clinical evidence: anxiety and nervous agitation, insomnia with a restless or worried mind, palpitations from nervous origin (the "racing heart" that has no structural cardiac cause), nervous indigestion, colic and flatulence with an anxiety or tension component, and headache related to tension or nervous overload. The Carmelite water tradition adds a specifically cardiac tonifying dimension -- the heart-gladdening claim -- that aligns with both the nervous-palpitation indication and the mood-lifting effects documented in Kennedy's controlled trials two centuries later.

Secondary traditional indications include the antiviral use -- cold sores, oral herpes, used as topical fresh leaf or strong infusion -- which predates any knowledge of herpesvirus and reflects accurate empirical observation, and a diaphoretic use in febrile illness that made lemon balm standard in European childhood fever management.

'''Islamic medicine (Unani)'''

Lemon balm appears in Islamic-Galenic medicine as Turunjan (ترنجان) and, in some North African traditions, as Badharuj -- though this Arabic identifier is also applied by some sources to sweet basil (''Ocimum basilicum''), creating a minor source-identification ambiguity.{{citation needed}} Ibn Sina's Canon of Medicine praises it in terms that no other classical herbalist surpassed: lemon balm "causeth the heart and mind to become merry, exhilarateth the mind, settleth digestion, and is good against melancholy and the spleen." The Canon identifies it as a warming, drying herb good for cold temperaments, for cardiac palpitations, and for the "sadness and grief" that Ibn Sina associated with obstruction of the vital spirit.{{citation needed}}

'''Ayurvedic medicine'''

Lemon balm is not a primary plant of the classical Ayurvedic pharmacopoeia -- its native range does not extend to the Indian subcontinent -- but it has been incorporated into contemporary Ayurvedic and integrative practice in Europe and North America where it overlaps with herbs of similar action. It is occasionally classified by contemporary Ayurvedic practitioners as a tridoshic nervine suitable for vata-type anxiety and pitta-type irritability.{{citation needed}}

| pharmacology = '''Volatile oil and polyphenolic constituents'''

The essential oil of ''M. officinalis'' is dominated by citral -- a mixture of the geometric isomers geranial and neral -- which accounts for the plant's characteristic lemon scent, along with citronellal, linalool, and caryophyllene oxide.{{citation needed}} The volatile oil fraction, however, is present in much lower concentration than in most other medicinal Lamiaceae (under 0.2 percent of fresh weight), and its contribution to the therapeutic actions of whole-plant preparations may be secondary to the non-volatile polyphenolic fraction.

Rosmarinic acid and related caffeic acid derivatives -- the principal polyphenolic compounds in lemon balm -- are the dominant pharmacologically active fraction for antiviral activity. Rosmarinic acid and the tannin fraction interfere with viral attachment to host cells by binding to glycoproteins on the herpes simplex virus (HSV) envelope, preventing the virus from docking with cell-surface receptors; this mechanism has been demonstrated in cell-culture models and correlates with the clinical efficacy of topical Melissa preparations in herpes labialis.{{citation needed}}

The flavonoids (luteolin, apigenin) and triterpenes (ursolic and oleanolic acids) contribute anti-inflammatory and anxiolytic properties; apigenin in particular has affinity for the benzodiazepine receptor site of the GABA-A receptor, and this GABA-A interaction is the proposed basis for lemon balm's anxiolytic and mild sedative activity -- the same general mechanism as valerian, passionflower, and lavender, reflecting convergent pharmacology across unrelated plant families.{{citation needed}}

The anti-thyroid mechanism is distinct from both of the above: aqueous extracts of ''Melissa officinalis'' inhibit binding of thyroid-stimulating hormone (TSH) and Graves' immunoglobulins to TSH receptors in vitro, reducing thyroid stimulation. The mechanism is thought to involve the polyphenolic fraction competitively occupying the TSH receptor or blocking immunoglobulin binding sites.

| clinical_evidence = '''Antiviral: herpes simplex (topical)'''

The strongest and most specific clinical evidence for lemon balm is topical and antiviral. The German physician Rainer Wölbling conducted the first placebo-controlled trial of a standardized Melissa cream on recurrent cold sores in 1994, demonstrating significant reduction in lesion size, healing time, and symptom severity with a 1 percent dried Melissa extract cream applied four times daily.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from ''Melissa officinalis''." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref>

Koytchev and colleagues (1999) confirmed and extended these findings in a larger placebo-controlled trial of the Lomaherpan-equivalent preparation (Lo-701, a 70:1 Melissa dry extract cream) applied four times daily to active cold sore lesions. The treated group showed significantly faster healing, smaller lesion area at day two, and reduced pain compared with placebo; the authors noted particularly strong benefit in patients treated at first symptom appearance (the prodrome or early vesicle stage) before full lesion development.<ref name="koytchev1999">Koytchev R, Alken RG, Dundarov S. "Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis." Phytomedicine. 1999;6(4):225-230. PMID 10589440.</ref>

The commercial preparation Lomaherpan (standardized 1 percent ''Melissa officinalis'' extract cream; Lomapharm, Germany) continues to be used and studied on this basis; it is the reference preparation for the EMA's traditional use opinion on Melissa for cold sores.

The evidence is specific to topical application: lemon balm polyphenols must be in direct contact with the HSV-infected tissue to exert their envelope-binding antiviral effect. Internal lemon balm preparations (infusion, tincture) have not been evaluated in placebo-controlled trials for recurrent herpes; the antiviral claim should not be extended to oral preparations without direct supporting evidence.

'''Mood and cognitive modulation (oral preparations)'''

Kennedy and colleagues conducted a series of dose-finding studies in healthy volunteers that provide the clearest pharmacological picture of oral lemon balm's cognitive and mood effects. In a 2002 crossover study, single doses of a standardized ''Melissa officinalis'' extract (300 mg, 600 mg, or 900 mg) produced dose-dependent improvements in calmness ratings and speed of mathematical processing on validated psychometric batteries; notably, the highest dose (900 mg) reduced calmness ratings relative to placebo, suggesting an inverted-U dose-effect relationship -- a feature consistent with the GABA-A modulation mechanism and commonly observed with GABAergic agents.<ref name="kennedy2002">Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. "Modulation of mood and cognitive performance following acute administration of ''Melissa officinalis'' (lemon balm)." Pharmacology Biochemistry and Behavior. 2002;72(4):953-964. PMID 12062586.</ref>

A 2003 companion study found significant improvements in mood and cognitive performance following single oral doses, with dose-dependent effects on the speed of memory and spatial working memory tasks.<ref name="kennedy2003">Kennedy DO, Wake G, Savelev S, et al. "Modulation of mood and cognitive performance following acute administration of single doses of ''Melissa officinalis'' (lemon balm) with human pharmacological models." Neuropsychopharmacology. 2003;28(10):1871-1881. PMID 12888775.</ref>

In a 2006 study, Kennedy and colleagues evaluated a standardized combination of ''Melissa officinalis'' and ''Valeriana officinalis'' (valerian) extract under laboratory-induced stress conditions. The combination produced significant reductions in anxiety ratings during a multi-tasking battery, reductions in self-rated stress and alertness, and mood improvements relative to placebo; the effects were consistent with additive or synergistic action of the two plant extracts' respective mechanisms.<ref name="kennedy2006">Kennedy DO, Little W, Haskell CF, Scholey AB. "Anxiolytic effects of a combination of ''Melissa officinalis'' and ''Valeriana officinalis'' during laboratory induced stress." Phytotherapy Research. 2006;20(2):96-102. PMID 16444660.</ref>

These studies establish a real but modest anxiolytic and cognitive-modulating effect of oral lemon balm that is consistent with the GABA-A mechanism. Effect sizes are smaller than those seen with oral Silexan for generalized anxiety disorder; the evidence base is sufficient for mild-to-moderate situational anxiety but has not been evaluated against prescription anxiolytics in the manner of the Silexan trials.

'''Anti-thyroid activity (in vitro and limited clinical data)'''

Auf'mkolk and colleagues (1985) demonstrated in an in vitro receptor-binding assay that aqueous extracts of ''Melissa officinalis'' (and several other plants) inhibit the binding of thyroid-stimulating hormone and Graves' immunoglobulins to TSH receptors, reducing adenylate cyclase stimulation.<ref name="aufmkolk1985">Auf'mkolk M, Ingbar JC, Kubota K, Amir SM, Ingbar SH. "Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and the biological activity of Graves' immunoglobulins." Endocrinology. 1985;116(5):1687-1693. PMID 2985357.</ref> This finding has been used as the pharmacological rationale for combining lemon balm with bugleweed (''Lycopus europaeus'') as an adjunctive herbal support in mild hyperthyroidism and Graves' disease; controlled clinical trials evaluating this combination for clinical outcomes in hyperthyroid patients are limited in number and quality.{{citation needed}}

'''Pediatric use'''

The use of lemon balm for sleep disturbance and nervousness in children is supported by tradition, basic safety data, and a limited clinical literature that includes combination preparations (valerian plus lemon balm).{{citation needed}} No serious adverse effects attributable to lemon balm have been reported in pediatric use at traditional doses.

| preparations = Infusion (tea): 2 to 4 g dried leaf and flowering tops per cup of hot water, covered while steeping (10 to 15 minutes) to retain the volatile oil fraction; the covering step is not cosmetic -- the volatile constituents are pharmacologically active and evaporate readily. Taken three times daily for daytime use or before sleep for insomnia.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation for internal use; 2 to 6 ml per dose, three times daily.

Standardized dry extract: solid extract standardized to rosmarinic acid content (typically 3 to 5 percent), usually in capsule form; the preparation form used in the Kennedy cognitive-modulation studies (300 to 900 mg per dose).

Topical cream: 1 percent standardized Melissa dry extract (Lomaherpan; equivalent commercial preparations) applied topically to cold sore lesions at first symptom; the antiviral evidence is specific to topical preparations with defined rosmarinic acid content.

Essential oil: rarely used therapeutically; primarily aromatherapy; expensive and frequently adulterated with lemongrass (''Cymbopogon citratus'') or lemon-scented verbena (''Aloysia citrodora'') oil; if used, always diluted in carrier oil.

Combination preparations: Melissa plus ''Valeriana officinalis'' (valerian) is the most common commercial combination, targeting sleep and mild anxiety; this combination has the best clinical evidence base (Kennedy 2006) for lemon balm's anxiolytic and sleep-promoting effects.

| dosing = '''Internal preparations'''

Infusion: 2 to 4 g dried leaf per cup, three times daily and before bed. Acute use for nervous agitation or palpitations: a strong cup (double strength, 4 g covered, 15-minute steep) taken as needed.

Tincture (1:5 in 45 percent ethanol): 2 to 6 ml per dose, three times daily. Children: no established dose adjustment in traditional use; standard practice has been to reduce proportionally by body weight or to use a weaker preparation (diluted infusion), noting the absence of observed adverse effects in pediatric use at herbal practice doses.

Standardized extract: 300 to 600 mg per dose (consistent with Kennedy's effective dose range); 900 mg per dose has been associated with reduced calmness in Kennedy's studies and should be avoided as a starting dose.

For cold sore prevention with oral preparations: no clinical evidence base; oral lemon balm does not substitute for topical treatment and no internal anti-HSV dose has been evaluated.

Combination preparations (Melissa plus valerian): follow manufacturer dosing; typically one to two capsules or 5 to 10 ml liquid combination tincture at bedtime for sleep.

'''Recreational dose ladder'''

Lemon balm has no established recreational dose structure. Its sedative-anxiolytic effect at therapeutic doses is among the gentlest in the nervine class -- substantially milder than valerian, kava, or cannabis -- and dose escalation beyond the Kennedy effective range (300 to 600 mg standardized extract) produces diminishing benefit rather than progressive relaxation, as the 900 mg dose in Kennedy's studies reduced, rather than increased, calmness. No ethnobotanical or contemporary self-dosing literature documents recreational use of lemon balm in any form; the ceiling of effect at accessible doses is simply too low and too undramatic to attract recreational interest. No tiered dose ladder is warranted.

| pharmacokinetics = The pharmacokinetics of lemon balm's active constituents have not been characterized to the same degree as those of pharmaceutical preparations. Rosmarinic acid, the principal polyphenolic constituent, is absorbed from the gastrointestinal tract and undergoes conjugation and hydroxylation by intestinal microbiota and hepatic enzymes; plasma levels peak approximately 30 to 60 minutes after ingestion.{{citation needed}} The apigenin and luteolin flavonoids have been more extensively characterized in other botanical contexts and show oral bioavailability dependent on gut microbiome composition.

| interactions = Central nervous system depressants: additive effect expected with sedatives, anxiolytics, alcohol, and sedating herbal medicines (valerian, hops, passionflower, kava); lemon balm's own sedative effect is mild, but the interaction is pharmacologically consistent and clinically relevant when adding lemon balm to a regimen that includes prescription sedatives or anxiolytics. Therapeutic use with benzodiazepines should be mentioned to the prescriber.

Thyroid preparations: theoretical antagonism with levothyroxine and other thyroid hormone replacement if lemon balm's anti-TSH-receptor activity translates to clinical reduction of thyroid function; this is relevant primarily at high chronic doses in patients with hypothyroidism or those on replacement thyroid therapy. At standard infusion doses, the interaction is theoretical rather than documented; in practice, standard tea use is unlikely to produce clinically significant thyroid antagonism.

| interactionsummary = Additive CNS sedation with sedatives and anxiolytics. Theoretical thyroid hormone antagonism at high doses in hypothyroid patients.

| safety = Lemon balm has an outstanding safety record across two thousand years of use in children and adults. No serious adverse events have been reported in clinical trials, case reports, or systematic reviews at standard therapeutic doses. It is among the herbs most consistently identified as safe for children in the traditional and contemporary herbal literature.

Hypothyroidism: the anti-thyroid mechanism identified by Auf'mkolk (1985) in vitro has led to a theoretical caution for chronic high-dose oral use in patients with established hypothyroidism or those on thyroid hormone replacement. Standard infusion use (2 to 4 g dried herb three times daily) has not produced clinical hypothyroidism in case reports; the caution is precautionary at current doses. Patients with established hypothyroidism on levothyroxine who wish to use lemon balm chronically should have thyroid function monitored.

Pregnancy: lemon balm is used traditionally during pregnancy and lactation as a calming herb, and is one of the nervines most commonly recommended for perinatal anxiety in traditional midwifery practice. No clinical trial data in pregnancy exists. Consensus in contemporary herbal practice is that standard infusion doses are likely safe; concentrated extracts and high-dose standardized preparations have not been evaluated and should be used conservatively in pregnancy.

Allergic reactions to lemon balm are rare; contact dermatitis has been reported with the essential oil and less commonly with topical fresh plant preparations.

| monitoring = No routine monitoring required for standard-dose internal use in healthy adults. Patients with hypothyroidism or on thyroid hormone replacement using chronic lemon balm preparations: thyroid-stimulating hormone at baseline and after two to three months of regular use. Patients adding lemon balm to benzodiazepine or sedative regimens: monitor for excess sedation, particularly at treatment initiation.

| counseling = The distinction between oral and topical applications is important to convey clearly. Oral lemon balm (infusion, tincture, extract) is indicated for anxiety, nervous insomnia, palpitations, and nervous digestive symptoms; the clinical evidence for these indications is consistent but modest. Topical Lomaherpan-equivalent cream (1 percent standardized Melissa extract) is the form with the specific antiviral evidence for cold sores, applied at first sign of prodrome; oral lemon balm should not be presented as a substitute for the topical application in herpes management.

Patients with recurrent cold sores benefit most from topical treatment begun at prodrome (tingling, burning, or itching before vesicle formation) rather than after full blister development; early application is the message from Koytchev (1999) and consistent with the mechanism of attachment inhibition working best before viral invasion is complete.

Patients using lemon balm for anxiety who are not experiencing adequate response at standard infusion doses may benefit from a standardized extract at the 300 to 600 mg range, or from a Melissa plus valerian combination product (which has the best clinical evidence for the combined anxiolytic-sleep indication). If anxiety is more than mild to moderate, a clinical assessment for generalized anxiety disorder, for which Silexan (oral lavender oil) has substantially stronger evidence, is appropriate.

| regulatory = '''Germany and European Union'''

German Commission E: lemon balm (Melissenblätter) approved for nervous sleep disorders and functional gastrointestinal complaints; covers dried herb preparations (infusion, tincture) based on traditional use and the clinical evidence base.

EMA HMPC: positive opinion for traditional use of ''Melissa officinalis'' leaf for relief of mild symptoms of stress and to aid sleep; also for traditional use of standardized topical preparations for symptomatic treatment of cold sores (Herpes labialis). One HMPC monograph (EMA/HMPC/196745/2012) covers both the internal nervine/sleep indication and the topical herpes simplex indication.<ref name="ema-hmpc-melissa">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on ''Melissa officinalis'' L., folium. EMA/HMPC/196745/2012. First published: 5 August 2013. https://www.ema.europa.eu/en/medicines/herbal/melissae-folium.</ref>

'''United States'''

''Melissa officinalis'': GRAS (generally recognized as safe) as a food flavoring; sold as a dietary supplement under DSHEA without FDA evaluation of efficacy claims. No approved drug indication.

'''United Kingdom'''

MHRA traditional herbal registration: ''Melissa officinalis'' preparations registered for traditional use for mild anxiety and sleep disturbance, and for topical application to cold sores; the topical Lomaherpan-equivalent preparations are registered separately.

| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Western clinical herbs]]

Lavender

2026-05-26T18:56:06Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| name = Lavender
| binomial = Lavandula angustifolia
| family = Lamiaceae
| native_range = Dry calcareous hillsides of the western Mediterranean: Provence (southern France), Spain, northern Italy, Croatia, and Greece; wild populations typically occur at 600 to 1,400 m elevation on exposed limestone garrigue and maquis. Widely cultivated throughout temperate Europe, North America, and Australia; Provence remains the global center of commercial cultivation.
| plant_part = Dried flower (inflorescence); essential oil distilled from fresh flowers.
| image =
| intro = ''Lavandula angustifolia'' Mill. -- true lavender, English lavender -- is a perennial aromatic shrub of the western Mediterranean garrigue, whose name descends from the Latin lavare, to wash, a record of the centuries it spent in the Roman bathhouse before it entered the clinic. Among aromatic herbs it holds a singular evidence record: a standardized oral preparation of its essential oil is the only essential-oil plant medicine to have been evaluated against a prescription anxiolytic in a randomized controlled trial and found non-inferior. Between the Roman bath and that trial stretches two thousand years of uninterrupted medicinal use for the same cluster of indications: anxiety, sleeplessness, and pain of the head.

| history = The name came first. Pliny the Elder in the first century of the common era recorded the use of nardus gallicus -- a lavender relative -- as a bath additive throughout the Roman world, and later writers formalized the association with lavare.{{citation needed}} The Greco-Roman medicinal plant was not ''L. angustifolia'' but its cousin ''Lavandula stoechas'' -- the French or Spanish lavender, high in camphor and pharmacologically distinct -- which Dioscorides in his De Materia Medica (1st century CE) recorded for headache, nausea, and disorders of the lung.{{citation needed}} ''L. angustifolia'' entered European medicine through the medieval monastic garden, where Benedictine and Cistercian communities cultivated it as a strewing herb, a wash for wounds, and a remedy for the head -- the "vapours" of nervous complaint that would occupy it for centuries thereafter.

John Parkinson, the apothecary who served James I, wrote in his Theatrum Botanicum of 1640 that lavender was of "especiall good use for all griefes and paines of the head and brain."{{citation needed}} Tudor England had already made lavender domestic property: lavender water was among the standard preparations of every gentlewoman's stillroom, the dried flowers were stuffed into pillows against insomnia, and bundles were laid between linens to discourage moths -- a use continuous from Roman times. Queen Elizabeth I reportedly consumed lavender conserve daily as a remedy for her migraines.{{citation needed}}

The most consequential accident in the history of aromatherapy occurred in a perfumery laboratory in Lyon, France, around 1910. Rene-Maurice Gattefosse -- a French chemist working in his family's perfume business -- burned his hand severely in a laboratory explosion and plunged it without premeditation into a vessel of lavender oil. The burn, he later wrote, healed with unexpected rapidity and without infection or scarring; the experience convinced him that essential oils deserved systematic clinical study.{{citation needed}} His 1937 monograph Aromatherapie gave the practice its name and established lavender as its founding plant. Robert Tisserand carried Gattefosse's work into the English-speaking world in the 1970s and 1980s, and the aromatherapy tradition -- lavender as wound healer, nerve calmer, sleep inducer -- entered consumer culture on a scale that no other essential oil has matched.{{citation needed}}

The German Commission E formally approved lavender flower for mood disturbances, restlessness, and insomnia in 1990, giving it a regulatory foundation in Germany at a time when most European herbal preparations lacked one. That approval rested on traditional use rather than clinical trial evidence; the trial evidence came later. Schwabe Pharmaceuticals developed Silexan -- a standardized pharmaceutical-grade oral lavender oil capsule -- in the 2000s and conducted a series of randomized controlled trials that collectively produced the most rigorous clinical evidence base of any aromatic herb medicine. The transition from bathhouse plant to evidence-based anxiolytic took roughly two thousand years and one burned hand.

| taxonomy = ''Lavandula angustifolia'' Mill. (synonyms: ''L. officinalis'' Chaix, ''L. vera'' DC.) belongs to tribe Ocimeae, family Lamiaceae, one of approximately 40 species in the genus ''Lavandula''. The genus name derives from lavare (to wash); the species epithet angustifolia (narrow-leaved) distinguishes it from broader-leaved relatives. Four species and one hybrid group carry the majority of commercial and medicinal significance.

''L. angustifolia'', true lavender or English lavender, produces the finest-quality essential oil -- highest in linalool and linalyl acetate, lowest in camphor -- and is the medicinal and perfumery standard against which other species are measured. It is the species from which Silexan is produced.

''L. latifolia'', spike lavender, yields a higher volume of oil per plant but of coarser character: camphor and 1,8-cineole content are markedly higher, linalyl acetate lower; the oil is sharper and used in industrial applications, cheaper perfumery, and traditional preparations distinct from those of angustifolia.

L. x intermedia, lavandin, is a sterile hybrid of angustifolia and latifolia that dominates commercial Provence cultivation today; it produces the greatest oil yield per hectare, and its oil is the principal ingredient in most mass-market lavender products. Lavandin oil is not equivalent to true lavender oil for medicinal purposes: camphor content is substantially higher, and linalyl acetate lower.

''L. stoechas'', French or Spanish lavender, is visually distinguished by its butterfly-wing bracts atop the flower spike; its chemistry diverges considerably from ''L. angustifolia'', being rich in camphor and fenchone. It was the medicinal lavender of Greco-Roman antiquity but is not the species behind modern anxiolytic research or the Western clinical herbal tradition.

The medicinal parts of ''L. angustifolia'' are the dried flower (inflorescence, harvested before full opening to maximize volatile oil content) and the essential oil steam-distilled from fresh flowers. The Pharmacopoeia Europaea monograph ''Lavandula''e flos specifies a minimum essential oil content in the dried inflorescence.{{citation needed}}

Wild ''L. angustifolia'' populations occur on exposed limestone hillsides in Provence, the Apennines, the Dalmatian coast, and the mountains of Spain and Greece. The English Pilgrims transported lavender to New England in 1620; it has naturalized in temperate climates worldwide without becoming invasive.{{citation needed}}

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lavender occupies the nervine class of Western herbal medicine -- herbs with an affinity for the nervous system -- and has been applied to the same cluster of indications across European herbal traditions for at least several hundred years: anxiety and nervous agitation, insomnia rooted in a restless mind, headache and migraine (particularly those with an anxiety or tension component), nervous indigestion and colic, neuralgia, and the diffuse condition the English herbalists called the "vapours" -- a category of nervous debility and emotional distress that has no exact modern diagnostic equivalent but maps substantially onto generalized anxiety disorder.

The traditional preparation for internal use was an infusion of dried flowers, drunk warm before sleep or during episodes of nervous distress. Lavender water -- a distillate of flowers in water or diluted alcohol -- was applied to the head and temples for headache. The tincture in 40-proof spirit was the apothecary preparation for internal use. The oil, expressed or steam-distilled from flowers, was rubbed onto the temples for headache, onto the chest for nervous respiratory complaints, and onto affected areas for neuralgia and joint pain. Lavender sachets placed in the bed or under the pillow were the traditional sleep aid; clothes stored with dried lavender sprigs were protected from moths. Every one of these forms is continuous in the Western herbal tradition from at least the 16th century.

'''Islamic medicine (Unani)'''

Lavender was known in Arabic-speaking medical traditions under the name Khuzami (Arabic: khuzama) and appears in the Unani materia medica as a cephalic (head-acting) herb, indicated for headache, epilepsy, and melancholy. Ibn Sina (Avicenna), writing in the early 11th century in the Canon of Medicine, recorded lavender for nervous headache and for strengthening the brain.{{citation needed}}

'''Aromatherapy tradition (20th century)'''

Following Gattefosse's 1937 monograph, lavender essential oil became the foundational plant of the French aromatherapy tradition -- used topically and by inhalation for wound healing, burns, antisepsis, anxiety, and sleep. This tradition makes claims for lavender oil that overlap substantially with the traditional Western herbal tradition while adding an emphasis on topical wound-healing that traces directly to Gattefosse's burn. The distinction between aromatherapy (inhalational or topical use of essential oil) and the oral preparations studied in clinical trials is pharmacologically important and is addressed in the Clinical evidence section.

| pharmacology = '''Volatile oil constituents and mechanism'''

The essential oil of ''L. angustifolia'' consists primarily of linalool (25 to 45 percent), a monoterpene alcohol, and linalyl acetate (25 to 45 percent), its acetic acid ester.{{citation needed}} These two compounds account for the characteristic lavender fragrance and are the principal pharmacologically active constituents in oral Silexan. Camphor and 1,8-cineole -- constituents responsible for the sharper character of inferior species and for adulteration of true lavender oil with cheaper lavandin -- are present at less than one and less than two percent respectively in genuine ''L. angustifolia'' oil, and their presence in high concentration is a marker of species substitution or adulteration.

At the receptor level, two principal mechanisms have been characterized for the oral route.

GABA-A positive allosteric modulation: linalool and linalyl acetate act as positive allosteric modulators at the GABA-A receptor in a manner broadly analogous to benzodiazepines -- increasing chloride conductance and reducing neuronal excitability -- but at a binding site distinct from the classical benzodiazepine site.{{citation needed}}

Voltage-gated calcium channel inhibition: linalool inhibits voltage-gated calcium channels (VGCCs) in hippocampal neurons, reducing presynaptic calcium influx and the release of excitatory neurotransmitters; this mechanism is distinct from and additive with the GABA-A effect and may account for some specificity of anxiolytic action without the full benzodiazepine-receptor pharmacology.{{citation needed}}

The dual GABA-A and VGCC mechanism explains a feature of Silexan's clinical profile that distinguishes it from classical benzodiazepines: no confirmed abuse potential, no withdrawal syndrome on discontinuation, and no evidence of tolerance in studies up to ten weeks.

Inhalation delivers linalool and linalyl acetate via the olfactory mucosa and pulmonary absorption, with systemic concentrations substantially lower than oral administration; this accounts for the smaller effect sizes in aromatherapy trials relative to oral Silexan studies. The two routes are pharmacologically comparable in target but not in pharmacokinetic exposure.

Topically, lavender essential oil has demonstrated broad-spectrum antibacterial and antifungal activity in vitro, including against methicillin-resistant ''Staphylococcus aureus'' (MRSA) and ''Candida albicans'', via disruption of microbial cell membrane integrity; wound-healing acceleration has been shown in animal models.{{citation needed}}

| clinical_evidence = The clinical evidence base for lavender divides sharply along route of administration. Oral Silexan (standardized lavender oil, 80 mg/day) has been evaluated in a series of double-blind randomized controlled trials; inhalation aromatherapy has been evaluated in a larger number of smaller trials with more modest and more variable effect sizes. The two evidence bodies should not be conflated.

'''Oral Silexan: randomized controlled trials'''

The Woelk and Schlaefke (2010) trial was the first to compare Silexan directly with a prescription anxiolytic. Patients with mixed anxiety and restlessness were randomized to Silexan 80 mg/day or lorazepam 0.5 mg/day for ten weeks; the primary outcome was reduction in Hamilton Anxiety Scale (HAM-A) total score. Silexan was non-inferior to lorazepam: HAM-A total score fell by 45 percent from baseline in the Silexan group and 46 percent in the lorazepam group, a difference that was not statistically significant. Silexan patients reported no withdrawal symptoms or signs of dependence on discontinuation.<ref name="woelk2010">Woelk H, Schlaefke S. "A multi-centre, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder." Phytomedicine. 2010;17(2):94-99. PMID 19962288.</ref>

Kasper and colleagues (2010) evaluated Silexan 80 mg/day against placebo in patients with subthreshold anxiety disorder -- a category of clinically significant anxiety not meeting full diagnostic criteria for generalized anxiety disorder -- over ten weeks. Silexan produced significant reductions in HAM-A total score, HAM-A psychic anxiety subscale, and Pittsburgh Sleep Quality Index compared with placebo; the effect was apparent by week two and maintained through week ten.<ref name="kasper2010">Kasper S, Gastpar M, Muller WE, et al. "Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder: evidence from clinical trials." Wien Med Wochenschr. 2010;160(21-22):547-556. PMID 21170695.</ref>

The most definitive comparative trial came in 2014. Kasper and colleagues randomized 539 patients with generalized anxiety disorder to Silexan 80 mg/day or paroxetine 20 mg/day for ten weeks. On HAM-A total score reduction, Silexan was non-inferior to paroxetine; secondary outcomes including the Beck Anxiety Inventory and clinical global assessment showed comparable improvement. Silexan's tolerability profile was markedly more favorable: the paroxetine arm showed higher rates of sexual dysfunction and nausea.<ref name="kasper2014">Kasper S, Gastpar M, Muller WE, et al. "Lavender oil preparation Silexan is effective in generalized anxiety disorder -- a randomized, double-blind comparison to placebo and paroxetine." Int J Neuropsychopharmacol. 2014;17(6):859-869. PMID 24456909.</ref>

A 2023 meta-analysis pooled data from randomized placebo-controlled trials of Silexan across anxiety disorder categories and found consistent, statistically significant superiority over placebo on standardized anxiety measures, with a standardized mean difference of clinically meaningful magnitude.<ref name="meta2023">Kasper S, et al. "Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials." Eur Neuropsychopharmacol. 2023;66:71-82. PMID 36717399.</ref>

A 2021 double-blind crossover trial in healthy recreational polydrug users found no evidence of abuse potential for Silexan at 80 mg or 160 mg -- no drug-liking, no euphoria, no psychomotor impairment, and no craving on discontinuation -- establishing Silexan's anxiolytic effect as non-addictive and distinguishing it from benzodiazepines at a pharmacological and behavioral level.<ref name="abuse2021">Schlaefke S, et al. "No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial." J Psychopharmacol. 2021. PMID 33300578.</ref>

'''Inhalation aromatherapy: smaller and more varied evidence'''

A body of smaller randomized trials -- in postoperative patients, dental-procedure anxiety, neonatal intensive care, and sleep quality in elderly populations -- has found statistically significant but modest anxiolytic and sleep-promoting effects from lavender inhalation or topical application in carrier oil. Effect sizes in aromatherapy trials are generally smaller than in the oral Silexan trials, study populations are more heterogeneous, and blinding is inherently imperfect given lavender's recognizable odor. The evidence supports lavender aromatherapy as an adjunct for mild situational anxiety and sleep disturbance; it does not support it as a primary treatment for generalized anxiety disorder at the level established for oral Silexan.{{citation needed}}

One small randomized trial evaluated lavender essential oil inhalation at the onset of acute migraine headache and found statistically significant reduction in headache severity compared with a placebo inhalation control; sample sizes were insufficient for definitive conclusions and the study has not been replicated at scale.<ref name="sasannejad2012">Sasannejad P, Saeedi M, Shoeibi A, Gorji A. "Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial." Eur Neurol. 2012;67(5):288-291. PMID 22517298.</ref>

The antimicrobial activity documented in vitro -- including activity against MRSA -- has not been translated into powered clinical trials. The topical wound-healing tradition has animal-model support but no placebo-controlled clinical trial data in humans.

| preparations = Dried flower (inflorescence): harvested before full bloom, dried at low temperature to preserve volatile oil; used for infusion, sachets, and as the starting material for tincture and essential oil production. Genuine lavender flower carries an immediately recognizable sweet-floral fragrance without camphor sharpness; camphoraceous character indicates ''L. latifolia'' or lavandin substitution.

Essential oil: steam-distilled from fresh flowers; genuine ''L. angustifolia'' oil contains 25 to 45 percent linalool and 25 to 45 percent linalyl acetate, with camphor below 1 percent; these parameters distinguish true lavender from adulterated or substitute species. For topical use, always dilute in carrier oil (2 to 5 percent); neat application to intact skin carries some allergy risk even with true lavender oil, and dilution is the standard of practice.

Silexan (brand name Lasea; Schwabe Pharmaceuticals): a standardized pharmaceutical-grade oral lavender oil capsule formulated for gastrointestinal absorption; manufactured at pharmaceutical quality standards with defined linalool and linalyl acetate content. This preparation is not equivalent to and should not be substituted by tipping commercial essential oil into food or capsules: solubility, concentration, solvent matrix, and quality standards differ fundamentally. Silexan is a prescription medicinal product in Germany.

Tincture: 1:5 in 40 percent ethanol from dried flowers; the traditional apothecary form for internal use.

Hydrosol (lavender water): the aqueous condensate separated from essential oil during steam distillation; contains trace quantities of volatile oil in aqueous suspension; used topically in cosmetics and as a facial toner; not concentrated enough for pharmacological effects of the essential oil.

Dried sachet: flowers loosely packed in muslin or linen, placed in drawers, linen closets, or under pillows; a traditional and household preparation continuous in use for sleep and moth-repellent purposes from at least the medieval period.

| dosing = '''Internal preparations'''

Infusion (dried flower): 1 to 2 g dried flowers per cup of hot water, steeped 10 to 15 minutes; taken 2 to 3 times daily and at bedtime for sleep. Traditional dose with no robust clinical trial evidence for this form; the Commission E approval covers this preparation based on traditional use.

Tincture (1:5 in 40 percent ethanol): 0.5 to 1 teaspoon (2.5 to 5 ml) diluted in a small amount of water, taken 2 to 3 times daily. Traditional dose with no clinical trial evidence independent of the Silexan data.

Silexan oral capsule: 80 mg once daily, the dose used in all published RCTs; some protocols have used 160 mg/day for more severe anxiety without identified additional harm. Take with food. Clinical benefit in GAD trials was apparent by week two and fully established by week four to six.

'''External preparations'''

Essential oil topical: 5 to 10 drops (0.25 to 0.5 ml) diluted in 1 tablespoon (15 ml) carrier oil (yielding approximately 2 to 3 percent); applied by massage to affected area. Aromatherapy diffusion: 3 to 5 drops in 15 ml water in a cold-air diffuser in the bedroom at night. Traditional sleep preparation: 3 to 5 drops essential oil on a cotton ball placed on the pillow, or a dried lavender sachet under the pillow.

'''Recreational dose ladder'''

Lavender carries no established recreational dose structure in the ethnopharmacological or self-dosing literature. The anxiolytic and sedative ceiling at therapeutic doses is modest: Silexan at 80 mg/day produces an effect non-inferior to lorazepam 0.5 mg/day but does not produce sedation sufficient to impair cognition or function in the RCT population. Dose escalation beyond 160 mg/day oral (twice the standard dose) has not been systematically studied and produces no documented psychoactive intensification; the pharmacology -- GABA-A allosteric modulation and VGCC inhibition without direct GABA-A agonism -- predicts a dose-effect plateau rather than progressive deepening of central depression. No recreational culture of lavender use analogous to kava, valerian, or cannabis has been documented in any ethnobotanical or contemporary context. The essential oil used as an inhalant produces transient relaxation but no psychoactive profile warranting a tiered dose ladder.

| pharmacokinetics = Linalool and linalyl acetate in Silexan are absorbed from the gastrointestinal tract following oral administration; linalyl acetate undergoes hydrolysis to linalool in the gut and by plasma esterases, such that linalool is the principal circulating species. Peak plasma concentrations are reached approximately 30 to 90 minutes after oral dosing.{{citation needed}} Linalool undergoes hepatic metabolism via cytochrome P450-mediated hydroxylation and glucuronidation; the metabolites are excreted renally. No significant accumulation has been reported at 80 mg/day dosing.

Following inhalation, linalool is absorbed via the pulmonary mucosa and by olfactory epithelium; plasma concentrations are substantially lower than after oral administration of an equivalent linalool dose, consistent with the smaller effect sizes observed in aromatherapy relative to oral-Silexan trials.

| interactions = Central nervous system depressants: theoretical additive sedation with benzodiazepines, alcohol, opioid analgesics, barbiturates, antihistamines, and sedating herbal medicines including valerian (''Valeriana officinalis''), kava (''Piper methysticum''), hops (''Humulus lupulus''), and passionflower (''Passiflora incarnata''). The clinical significance of this interaction at Silexan's standard 80 mg/day dose has not been formally evaluated; caution is appropriate when combining Silexan with benzodiazepines in patients transitioning from one agent to the other. The Woelk and Schlaefke (2010) trial documented successful lorazepam discontinuation in patients switched to Silexan,<ref name="woelk2010"/> suggesting that substitution is clinically feasible, but cross-tapering should be supervised.

Cytochrome P450: in vitro data at suprapharmacological concentrations suggest possible inhibition of CYP2C9 and CYP3A4 by lavender oil constituents. No pharmacokinetic interaction has been documented in clinical trials at 80 mg/day; the relevance of in vitro findings to standard clinical dosing is uncertain. No dose adjustment of co-administered medicines is presently supported by clinical evidence.

| interactionsummary = Additive CNS depression with sedatives, anxiolytics, alcohol, and sedating herbal medicines. No confirmed cytochrome P450 interaction at therapeutic dose.

| safety = Silexan at 80 mg/day has been well tolerated in all published RCTs, with no serious adverse events attributed to the study medicine. The most commonly reported adverse effects have been mild gastrointestinal symptoms (nausea, belching with lavender odor) and headache, each occurring at low incidence and resolving without intervention.

Prepubertal gynecomastia: Henley, Lipson, and Korach (2007) reported three cases of prepubertal boys who developed gynecomastia while using topical products containing lavender oil and tea tree oil; gynecomastia resolved in each case on discontinuation of the products. In vitro experiments demonstrated estrogenic and anti-androgenic activity of both lavender oil and tea tree oil at the tested concentrations.<ref name="henley2007">Henley DV, Lipson N, Korach KS, Bloch CA. "Prepubertal gynecomastia linked to lavender and tea tree oils." N Engl J Med. 2007;356(5):479-485. PMID 17267908.</ref> Subsequent epidemiological study has not confirmed a population-level signal; the three case reports represent a potential association rather than an established causal relationship. Conservative practice: avoid heavy chronic daily application of lavender oil-containing products to the skin of prepubertal boys.

Allergic contact dermatitis: linalool undergoes autooxidation in stored, poorly sealed, or heat-exposed essential oil, generating linalool hydroperoxide and other sensitizing oxidation products. Sensitization acquired through repeated exposure to oxidized lavender oil is permanent and subsequent exposures produce contact dermatitis. Properly stored, freshly purchased true lavender oil from a reputable supplier has low sensitization risk. This concern is among the more clinically relevant safety issues with topical lavender use; lavender is among the more common causes of fragrance-related contact sensitization in Europe.{{citation needed}}

Essential oil ingestion (non-Silexan): tipping lavender essential oil from a commercial aromatherapy bottle into food or beverages or swallowing it directly is not equivalent to Silexan and is not recommended. Case reports of oral essential oil ingestion -- in children accessing essential oil bottles -- have documented CNS depression and respiratory distress. Silexan is a specifically formulated pharmaceutical-grade oral preparation; the distinction between this and ad hoc oral consumption of essential oil is not cosmetic.

Pregnancy: Silexan trials have excluded pregnant participants; safety data for oral lavender oil preparations in pregnancy are absent. Ordinary aromatherapy use (inhalation at ambient concentrations, topical application in diluted carrier oil) is generally considered low risk but is not supported by trial data. High-dose oral preparations should be avoided in pregnancy in the absence of safety information.

| monitoring = No specific monitoring required for lavender flower infusion or tincture at traditional doses. Patients beginning Silexan 80 mg/day for generalized anxiety disorder: clinical assessment at two to four weeks to establish early response; continue through six weeks before assessing non-response. Patients with benzodiazepine dependence who are transitioning to Silexan should be supervised: cross-tapering under medical guidance is appropriate given the theoretical additive sedation risk during any overlap period.

| counseling = Patients beginning Silexan should understand that it is derived from lavender essential oil but is not equivalent to lavender aromatherapy: the clinical evidence for anxiety comes specifically from the oral capsule formulation at 80 mg/day, not from diffusers, massage oils, or pillow sprays. Benefit may take two to four weeks to become fully apparent; onset latency resembles that of SSRIs more closely than the immediate sedation of benzodiazepines.

The absence of dependence potential and withdrawal symptoms distinguishes Silexan from benzodiazepines. Patients anxious about benzodiazepine dependence or who have not tolerated them may find this distinction meaningful.

Patients using lavender essential oil products topically should use oils that are fresh, correctly stored (sealed, cool, and dark), and diluted in carrier oil for skin application; undiluted application to large skin areas over prolonged periods carries higher sensitization risk. Old or discolored essential oil should be discarded.

The prepubertal gynecomastia concern is worth mentioning to parents of boys who ask about lavender products; the evidence is from case reports rather than epidemiological studies, and the risk is not quantified, but the in vitro endocrine activity establishes a biologically plausible mechanism.

| regulatory = '''Germany and European Union'''

German Commission E (1990): lavender flower approved for mood disturbances with restlessness and sleep disturbances, and nervous stomach conditions; covers traditional oral preparations (infusion, tincture) based on traditional use rather than clinical trial evidence.

EMA HMPC: positive assessment of lavender flower as a traditional herbal medicinal product for mild anxiety and sleep disturbance; traditional use listing under the EU Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC). The EMA HMPC opinion does not cover Silexan, which was developed and approved as a distinct pharmaceutical medicinal product under a separate regulatory pathway.<ref name="ema-hmpc-lavender">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on ''Lavandula angustifolia'' P. Mill., flos. EMA/HMPC/734125/2010. First published: 13 June 2012. https://www.ema.europa.eu/en/medicines/herbal/lavandulae-flos.</ref>

Silexan (Lasea; Schwabe Pharmaceuticals): approved as a prescription medicinal product (not a traditional herbal product) in Germany and some other EU member states specifically for the treatment of generalized anxiety disorder, based on the RCT program described above. This is the most stringent regulatory status achieved by any essential-oil preparation in the EU regulatory framework.

'''United States'''

Lavender oil: GRAS (generally recognized as safe) status with the US FDA as a food flavoring additive; no approved therapeutic indication. Sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) without FDA evaluation of efficacy claims.

'''United Kingdom'''

MHRA traditional herbal registration: lavender preparations registered for traditional use for mild anxiety and sleep disturbance under the Traditional Herbal Registration scheme.

| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Chinese licorice

2026-05-26T18:56:05Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| name = Chinese licorice
| binomial = Glycyrrhiza uralensis
| family = Fabaceae
| native_range = Northern China, Mongolia, Siberia, and Central Asia; wild stands in Xinjiang, Gansu, Inner Mongolia, and Manchuria; commercial supply largely from cultivated stands in northern and northwestern China.
| plant_part = Root and rhizome (dried); prepared in two clinically distinct forms in TCM: raw dried root (sheng gan cao) and honey-fried root (zhi gan cao).
| image =
| intro = Chinese licorice (''Glycyrrhiza uralensis'' Fisch.) is a perennial leguminous herb of the north Chinese steppe, the botanical source of gan cao (甘草, literally "sweet herb"), one of the most widely prescribed medicinals in the entire Chinese Materia Medica. Gan cao occupies a role in classical Chinese medicine without parallel in Western pharmacology: it is the defining harmonizer of formulas (调和诸药, tiáo hé zhū yào), an herb added to approximately sixty percent of all classical formulae not primarily for a specific therapeutic action of its own but to moderate the potency of harsh or toxic herbs, unify the divergent properties of a formula's ingredients, and protect the stomach and spleen from irritating constituents. The closely related Mediterranean species ''G. glabra'' (Western licorice) is the historical centroid of Ayurvedic, Unani, and European herbal licorice use; the two species share essentially the same glycyrrhizin-mediated pharmacology and the same pseudohyperaldosteronism safety profile, described in full at [[Western licorice]]. Both species are routinely substituted in commerce without pharmacopoeia distinction.

| taxonomy = ''Glycyrrhiza uralensis'' Fisch. ex DC. belongs to tribe Galegeae, family Fabaceae, one of approximately thirty species in the genus ''Glycyrrhiza''. The genus name derives from the Greek glykys (sweet) and rhiza (root), reflecting the intensely sweet taproot shared across the genus. ''G. uralensis'' is distinguished from ''G. glabra'' (European licorice) by glandular-hairy stems and seed pods, a more compact and shorter flower raceme, and a tendency to form dense rhizome mats in the steppe and semi-arid grasslands it inhabits; these morphological distinctions are unreliable in dried commercial root stock, and commercial substitution of the two species is routine and pharmacopoeially sanctioned under most major pharmacopoeias. ''G. inflata'' (Xinjiang licorice) is a third commercially significant species, particularly sourced in Central Asian markets.

The medicinal parts are the root and rhizome, harvested from plants four years or older; roots from younger plants have lower glycyrrhizin content and are considered suboptimal quality. In TCM practice the dried root is processed in two clinically distinct forms: sheng gan cao (生甘草, raw or unprocessed dried root), used for fire-toxicity conditions and as the universal harmonizing constituent; and zhi gan cao (炙甘草, honey-fried root), prepared by combining sliced dry root with liquid honey (typically 25 g honey per 100 g dry root) and stir-frying over gentle heat until the honey is fully absorbed and the surface is fragrant and golden-brown. TCM processing theory holds that honey-frying shifts the root's properties from the neutral-cooling of the raw form toward a warmer, more tonifying quality particularly suited to heart-calming and spleen-tonifying indications.

| traditional_uses = '''Chinese medicine (primary centroid)'''

The earliest written record of gan cao is in the Shennong Ben Cao Jing (神农本草经, Divine Farmer's Classic of Materia Medica), the foundational Chinese pharmacopoeia compiled approximately between the first and second centuries of the common era.{{citation needed}} The Shennong Ben Cao Jing categorized all 365 medicinal substances into three tiers: 120 upper herbs (上品, shàng pǐn), considered tonic and safe for prolonged use; 120 middle herbs, with specific therapeutic actions and moderate safety considerations; and 125 lower herbs, potent or toxic and reserved for acute conditions. Gan cao was classified as an upper herb, the most favorable designation in the text, a judgment that prefigured its two-thousand-year career as the universal harmonizing tonic base of Chinese formula construction.

The feature of gan cao that defines its clinical identity, and that has no close analog in Western pharmacological thinking, is its role as the harmonizer of formulas (调和诸药, tiáo hé zhū yào). Bensky, Clavey, and Stoger document gan cao's presence in approximately sixty percent of all classical Chinese herbal formulae,<ref name="bensky2004">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica''. 3rd ed. Eastland Press, 2004. Section on ''Glycyrrhiza uralensis'' (Gan Cao, 甘草).</ref> a frequency no other single herb approaches, reflecting a function performed at the formula level rather than the organ-system level. Bensky identifies three distinct harmonizing roles that collectively account for this ubiquity.<ref name="bensky2004"/> First, gan cao moderates the toxicity and harshness of potent formula ingredients: where aconite (fu zi, a potent yang-warming root with a narrow therapeutic window), coptis (huang lian, intensely bitter and cold), or other drastic herbs appear, gan cao is the standard buffer, softening action and preventing the formula from overshooting its therapeutic purpose. Second, it harmonizes herbs of divergent thermal properties, flavors, and organ tropisms, preventing the "qi conflict" that TCM theory associates with unmediated confrontations between cold and hot, or ascending and descending, formula components. Third, it protects the stomach and spleen from the irritating effects of harsh ingredients, supporting patient tolerability through extended decoction courses. So thoroughgoing was this mediating function in the view of later TCM physicians that gan cao acquired the court honorific 国老 (guó lǎo, "Elder Statesman" or "Grand Councillor of the Nation"), comparing the herb's role in a formula to that of a senior official who mediates among warring ministers, integrates competing interests, and supports the sovereign's governing intention without seeking prominence for its own office.<ref name="bensky2004"/>

Zhang Zhongjing compiled the Shang Han Lun (伤寒论, Treatise on Cold Damage Disorders) approximately 210 CE; together with its companion the Jin Gui Yao Lue (金匮要略, Essential Prescriptions of the Golden Cabinet), it codified the classical formula architecture that remains foundational in contemporary TCM practice.{{citation needed}} Gan cao appears in a large proportion of the Shang Han Lun's one hundred and thirteen prescriptions. Four formulae from this text are of particular clinical significance and continue in active contemporary use:

Gan Cao Tang (甘草汤, Licorice Decoction) is the simplest formula: sheng gan cao as the sole herb, at full therapeutic dose, for sore throat and fire-toxicity patterns of the throat. It exemplifies gan cao in its direct anti-toxicity function rather than in the harmonizing role.<ref name="bensky2004"/>

Zhi Gan Cao Tang (炙甘草汤, Honey-Fried Licorice Decoction), also known as Fumai Tang (复脉汤, Restore the Pulse Decoction), is a nine-ingredient formula combining honey-fried licorice as the principal herb with Rehmannia glutinosa (di huang), Ophiopogon japonicus (mai men dong), Colla Corii Asini (e jiao, donkey-hide gelatin), Cannabis sativa seed (huo ma ren), dried ginger (gan jiang), cinnamon twig (gui zhi; the same herb as [[Cassia cinnamon]] in TCM usage), jujube (da zao), and sake. It is prescribed specifically for heart palpitations (心悸, xīn jì) and irregularly or regularly irregular pulse arising from deficiency of heart yin and heart yang.{{citation needed}} Zhi Gan Cao Tang is the most specific TCM cardiac-rhythm prescription in the Shang Han Lun and remains a subject of contemporary pharmacological and small-scale clinical research.

Shao Yao Gan Cao Tang (芍药甘草汤, Peony and Licorice Decoction) pairs white peony root (bai shao, Paeonia lactiflora) with honey-fried gan cao in a two-herb formula prescribed for muscular spasm and cramping, particularly abdominal spasm and lower-limb cramps. The combination has attracted modern pharmacognosy investigation: paeoniflorin, the principal active glycoside of white peony, and glycyrrhizin appear to produce antispasmodic effects in animal models that exceed either constituent alone, with paeoniflorin and glycyrrhetinic acid proposed as synergistic components acting through distinct but complementary antispasmodic pathways.{{citation needed}}

Si Jun Zi Tang (四君子汤, Four Gentlemen Decoction) combines ginseng (ren shen, Panax ginseng), white atractylodes (bai zhu, Atractylodes macrocephala), poria (fu ling, Wolfiporia cocos), and honey-fried licorice. It is the foundational spleen-qi tonic of TCM, the structural core from which a large family of derivative tonifying and digestive-support formulae is built, including Liu Jun Zi Tang (Six Gentlemen), Xiang Sha Liu Jun Zi Tang, and numerous others.{{citation needed}} Gan cao's role in Si Jun Zi Tang is primarily harmonizing and stomach-protective rather than directly tonifying; the principal tonifying agents are ginseng and white atractylodes, with gan cao integrating their divergent properties and protecting the stomach from the full impact of concentrated qi-supplementing herbs.

Li Shizhen's Ben Cao Gang Mu (本草纲目, Compendium of Materia Medica), completed in 1578 and published in 1596, gave gan cao its most comprehensive classical Chinese treatment, cataloguing morphological varieties, regional origins, harvesting protocols, processing methods (with particular attention to the honey-frying distinction), flavors, thermal properties, organ tropisms, formulaic combinations, and the guó lǎo honorific as a tradition tracing to the Han dynasty.{{citation needed}} Li Shizhen's synthesis made the Ben Cao Gang Mu the de facto reference standard for East Asian herbal medicine from the Ming dynasty onward.

'''Western herbal and Ayurvedic use (brief)'''

''G. uralensis'' has no significant independent tradition in Ayurvedic or Unani medicine; the yashtimadhu (sweet stick) of Ayurveda, the asl-us-sus of Unani medicine, and the glykyrrhiza of the Greco-Roman and medieval European herbal traditions are rooted in ''G. glabra'', the Mediterranean species. ''G. uralensis'' enters Western herbal and Ayurvedic practice primarily through commercial substitution: international licorice root trade routinely mixes or substitutes the two species, as dried root from the two is morphologically indistinguishable in commerce and the pharmacological properties are sufficiently comparable for pharmacopoeial equivalence. The complete traditions of Western herbal, Ayurvedic, Unani, and Greco-Roman licorice practice are documented at [[Western licorice]].

| preparations = Sheng gan cao (生甘草, raw dried root): unprocessed dried sliced root used in TCM decoction for fire-toxicity conditions (throat swellings, carbuncles, heat patterns), lung-dryness cough, and the universal formula-harmonizing role. This is also the standard commercial source material for Western herbal extracts and pharmaceutical-grade glycyrrhizin extraction.

Zhi gan cao (炙甘草, honey-fried root): root stir-fried with liquid honey until fragrant and golden-brown; TCM processing theory holds that honey-frying intensifies tonifying and warmth-generating properties while moderating bitterness and astringency. Specified for spleen-qi tonification, heart palpitations (particularly in the Zhi Gan Cao Tang formula), and all indications where a warming-tonifying rather than cooling-clearing action is required.

Standardized root extract: concentrated extract standardized to 18 to 25 percent glycyrrhizin content, available as solid extract or liquid concentrate; both ''G. uralensis'' and ''G. glabra'' are sourced commercially for standardized extracts, frequently without species designation on product labels.

TCM granule extract: spray-dried or freeze-dried root extract in granule form for contemporary TCM granule-prescription practice, allowing formula assembly without traditional decoction; commercially available as sheng gan cao or zhi gan cao granules.

Deglycyrrhizinated licorice (DGL): available in Western clinical herbal practice as a preparation from which glycyrrhizin has been removed, retaining demulcent and mucosal-protective activity without the pseudohyperaldosteronism risk. Western market DGL preparations are predominantly derived from ''G. glabra'' material; ''G. uralensis''-sourced DGL exists but is less commonly available in Western markets. The full DGL discussion, including clinical evidence, dose, and chronic-use appropriateness, is at [[Western licorice]].

| pharmacology = '''Principal active constituents'''

Glycyrrhizin (glycyrrhizinic acid): a triterpenoid saponin glycoside constituting approximately 2 to 4 percent of dry-weight root under standard cultivation conditions; content varies with growing region, soil type, and harvest timing.<ref name="chinpharmacopoeia2020">National Pharmacopoeia Commission. ''Pharmacopoeia of the People's Republic of China''. Vol. I. China Medical Science and Technology Press, 2020. Monograph: Gan Cao (甘草).</ref><ref name="pastorino2018">Pastorino G, Cornara L, Soares S, Rodrigues F, Oliveira MBPP. "Liquorice (''Glycyrrhiza glabra''): A phytochemical and pharmacological review." ''Phytother Res'' 2018;32(12):2323-2339. PMID 30117204.</ref> Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; intestinal bacterial beta-glucuronidase hydrolyzes it to 18-beta-glycyrrhetinic acid (18β-GA), the principal systemically absorbed active metabolite. 18β-GA accounts for the anti-inflammatory pharmacology (inhibition of prostaglandin-synthesizing enzymes and phospholipase A2) and for the adverse mineralocorticoid effect via inhibition of 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2) in the renal tubule, the mechanism underlying pseudohyperaldosteronism at sustained high glycyrrhizin intakes. The full 11-beta-HSD2 mechanism is described at [[Western licorice]].

Liquiritin and isoliquiritin: flavanone and chalcone glycosides with sedative and antispasmodic activity in animal models; probable contributors, alongside paeoniflorin from white peony, to the antispasmodic efficacy of Shao Yao Gan Cao Tang.

Licochalcone A and related chalcones: antimicrobial and anti-inflammatory activity in laboratory studies; typically present in lower concentrations in ''G. uralensis'' than in ''G. inflata''.

Glycyrrhetic acid (enoxolone): the free aglycone of glycyrrhizin; the basis of the pharmaceutical derivative carbenoxolone, the synthetic peptic ulcer compound developed in Europe in the 1960s to 1970s, documented at [[Western licorice]].

| indications = '''TCM indications (primary)'''

Spleen qi deficiency: fatigue, diminished appetite, loose stools, and lassitude; honey-fried gan cao as a constituent of tonifying formulae, principally Si Jun Zi Tang and its extensive derivative family; the most frequently invoked TCM indication in formula construction.<ref name="bensky2004"/>

Heart palpitations and irregularly irregular pulse from deficiency of heart yin and heart yang: the specific indication of the Zhi Gan Cao Tang formula; among the more physiologically specific classical TCM cardiac-rhythm indications and a subject of contemporary pharmacological and small-scale clinical investigation, including case reports of formula modifications for both bradyarrhythmia and tachyarrhythmia.<ref name="bensky2004"/><ref name="chen2010zhigancao">Chen WG, Ba ZM. "Prof. ZHANG Yi's experience in treating severe arrhythmia." ''J Tradit Chin Med'' 2010;30(1):47-50. PMID 20397463.</ref>

Lung dryness and cough: raw gan cao in wind-heat or lung-dryness patterns; gan cao moistens the lung channel and moderates the drying effect of other herbs in respiratory formulae.<ref name="bensky2004"/>

Fire toxicity: carbuncles, boils, and sore throat with heat characteristics; raw gan cao as Gan Cao Tang alone or combined with other heat-clearing herbs; one of the direct therapeutic indications in which gan cao functions as the principal herb rather than as a harmonizer.<ref name="bensky2004"/>

Lower-limb and abdominal muscular spasm: Shao Yao Gan Cao Tang (white peony and honey-fried licorice); the most-studied specific two-herb-pair indication for gan cao, with pharmacological evidence of paeoniflorin-glycyrrhizin antispasmodic synergy.<ref name="bensky2004"/>

Universal harmonizing and formula-integrating role: the indication accounting for the majority of gan cao prescriptions; not condition-specific but formula-architecture-specific; see Traditional uses above for the mechanism and significance.

'''Western clinical indications (condensed; full evidence base at Western licorice)'''

Western clinical research on licorice does not systematically distinguish ''G. uralensis'' from ''G. glabra''; commercial preparations are often from mixed or unspecified species. The evidence base for peptic ulcer and mucosal protection (deglycyrrhizinated licorice preparations), chronic hepatitis (intravenous Stronger Neo-Minophagen C glycyrrhizin compound in Japanese clinical practice), respiratory catarrh (Commission E approved indication), and adrenal-supportive use is described in full at [[Western licorice]].

| dosing = TCM decoction dose: 2 to 12 g dried root per day (raw or honey-fried) in multi-herb decoction. Harmonizing doses, which account for the majority of gan cao prescriptions, are typically 2 to 6 g per day; doses in which gan cao is the principal therapeutic herb (as in Gan Cao Tang) may reach 9 to 12 g per day. Single-herb throat formula (Gan Cao Tang): 4 to 9 g.<ref name="bensky2004"/>

Western clinical extract dose: standardized extract equivalent to 5 to 15 g dried root daily; maximum continuous course four to six weeks without reassessment per Commission E guidance. Same limit as ''G. glabra''.

Glycyrrhizin intake limit: 100 mg glycyrrhizin per day maximum for chronic use per the European Union Scientific Committee on Food opinion SCF/CS/ADD/EDUL/225 Final (2003), the same guidance applicable to both ''G. uralensis'' and ''G. glabra''.

| pharmacokinetics = Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; rate-limiting absorption involves bacterial beta-glucuronidase hydrolysis in the large intestine, producing 18-beta-glycyrrhetinic acid with a lag of two to four hours between oral ingestion and rising plasma 18β-GA levels. Individual variation in gut microbiome composition generates substantial inter-individual variability in 18β-GA plasma exposure at equivalent oral glycyrrhizin doses, which partly explains the observed case-to-case variability in pseudohyperaldosteronism susceptibility.

18-Beta-glycyrrhetinic acid: half-life approximately 7 to 8 hours; primarily hepatic metabolism; biliary excretion with enterohepatic recirculation reported, potentially prolonging effective exposure with repeated daily dosing.

The full pharmacokinetic discussion, including DGL pharmacokinetics and the plasma-level considerations underlying the pseudohyperaldosteronism dose-response, is at [[Western licorice]].

| interactions = The interaction profile of ''G. uralensis'' is identical to that of ''G. glabra''; the shared glycyrrhizin content and shared 11-beta-HSD2 inhibition mechanism produce the same clinically relevant pharmacodynamic interactions regardless of species. Full interaction details are at [[Western licorice]]; the following is a clinical summary.

Antihypertensive medicines: whole-licorice preparations raise blood pressure through sodium and water retention (the pseudohyperaldosteronism mechanism), directly antagonizing antihypertensive treatment; concurrent use should be avoided or blood pressure monitored closely with readiness to adjust antihypertensive doses.

Potassium-depleting medicines (loop diuretics, thiazide diuretics, corticosteroids): additive hypokalemia risk; the combination carries increased risk of clinically significant potassium depletion, muscle weakness, cardiac arrhythmia, and, at severe depletion, respiratory muscle compromise. Serum potassium monitoring is warranted in any patient combining licorice with these agents.

Cardiac glycosides (digoxin): licorice-induced hypokalemia increases myocardial sensitivity to cardiac glycoside toxicity; the combination of chronic licorice use and digoxin therapy requires concurrent potassium monitoring.

Exogenous corticosteroids: 11-beta-HSD2 inhibition by 18β-GA may amplify the mineralocorticoid effects of concurrent exogenous corticosteroid therapy, accelerating fluid retention and raising blood pressure.

A note specific to TCM formula practice: at the standard harmonizing dose (2 to 6 g daily for a short course of four weeks or less), the probability of clinically significant pharmacodynamic interaction in most patients is low. The interaction concern becomes clinically important at chronic high-dose use and in patients taking antihypertensives, diuretics, or cardiac glycosides concurrently.

DGL preparations: negligible pharmacodynamic interaction risk from the glycyrrhizin-mediated pathway; DGL is the preparation of choice for any chronic use requiring avoidance of these interactions.

| interactionsummary = Antihypertensives (antagonism of blood pressure control), potassium-depleting agents including loop and thiazide diuretics and corticosteroids (additive hypokalemia), cardiac glycosides including digoxin (hypokalemia-mediated toxicity potentiation), exogenous corticosteroids (amplification of mineralocorticoid effects). Full DDI discussion at [[Western licorice]]. DGL preparations avoid these interactions.

| safety = The pseudohyperaldosteronism safety profile of ''G. uralensis'' is identical to that of ''G. glabra'': the same 18-beta-glycyrrhetinic-acid-mediated 11-beta-HSD2 inhibition, the same dose-dependent sodium retention, potassium depletion, hypertension, and edema, and the same case-report and regulatory literature. The full mechanism, dose-response, Walker 1994, van Uum 2005, and EU SCF 2003 guidance are documented at [[Western licorice]]. The 100 mg/day glycyrrhizin chronic-use limit applies to whole-licorice preparations of either species.

Note specific to TCM practice: at the typical harmonizing dose (2 to 6 g root per day), daily glycyrrhizin intake from gan cao ranges from approximately 40 to 240 mg depending on the glycyrrhizin content of the specific batch; at the lower end this falls within the EU SCF guidance range, and at the upper end it does not. Chronic daily use of high-dose tonifying decoctions or concentrated patent-medicine preparations over many months warrants the same blood pressure and potassium monitoring as any whole-licorice use. Practitioners and patients should not assume that the harmonizing role necessarily entails sub-threshold glycyrrhizin doses.

Pregnancy: the preterm birth concern documented in the Finnish cohort applies equally to ''G. uralensis''; glycyrrhizin is the mediating compound and is present in comparable concentrations in both species. Strandberg and colleagues (2001) found that Finnish mothers consuming more than 500 mg glycyrrhizin weekly from confectionery had significantly increased odds of preterm birth and lower birth weight in their offspring.<ref name="strandberg2001">Strandberg TE, Jarvenpaa AL, Vanhanen H, McKeigue PM. "Birth outcome in relation to licorice consumption during pregnancy." ''American Journal of Epidemiology'' 2001;153(11):1085-1088. PMID 11390327.</ref> Avoidance of high-dose licorice of either species during pregnancy is advisable; culinary doses and low-dose harmonizing use in short courses carry uncertain but likely low risk.

Contraindications: hypertension, hypokalemia, cardiac arrhythmia, hepatic cirrhosis, renal insufficiency, concurrent use of potassium-depleting agents or cardiac glycosides, and pregnancy at high doses.

| monitoring = Whole-licorice use (any form of ''G. uralensis'' root or extract containing significant glycyrrhizin) for more than four weeks: obtain baseline blood pressure and serum potassium before initiating; recheck monthly during ongoing use. Discontinue and reassess if systolic blood pressure rises more than 10 to 15 mmHg from baseline, serum potassium falls below 3.5 mmol/L, or peripheral edema develops.

For patients taking concurrent antihypertensive medicines or cardiac glycosides, lower the monitoring threshold: check blood pressure and potassium after two weeks of use rather than four.

DGL preparations: no monitoring required beyond routine clinical follow-up appropriate to the underlying condition being managed.

| counseling = The pseudohyperaldosteronism risk that applies to Western licorice (''G. glabra'') applies equally to Chinese licorice (''G. uralensis'') and to any TCM formula containing gan cao. A patient told by a conventional physician to avoid licorice for blood pressure or potassium reasons should apply that restriction to gan cao in TCM decoctions and patent medicines. The two species are pharmacologically interchangeable with respect to this risk; a patient's conventional prescriber may not know that a TCM formula contains licorice under the name "gan cao" and will benefit from the information.

The harmonizing role accounts for the majority of gan cao prescriptions and typically places it at a lower dose (2 to 6 g daily) than its use as a primary therapeutic herb. Most patients on short-course multi-herb formulae at harmonizing doses will not experience clinical pseudohyperaldosteronism. The risk rises with increasing dose, increasing duration (months rather than weeks), and pre-existing clinical vulnerability: baseline hypertension, concurrent diuretic use, and low dietary potassium intake each shift the threshold downward.

Patients who need a chronic licorice-based preparation for mucosal protection, peptic ulcer, or gastritis should be directed to deglycyrrhizinated licorice (DGL), which removes the glycyrrhizin while retaining demulcent and mucosal-protective activity. DGL does not carry the mineralocorticoid risk and does not require blood pressure or potassium monitoring; see [[Western licorice]] for the full DGL discussion including dose, formulation, and comparison with whole licorice.

Commercial licorice root products (confectionery, chewable tablets, licorice-extract beverages) may contain ''G. uralensis'', ''G. glabra'', or both, often without species designation and without declared glycyrrhizin content. Patients using such products as a therapeutic practice should be asked about quantity, frequency, and glycyrrhizin content where possible; "licorice root extract" on a label does not specify species or dose.

The guó lǎo (国老, Elder Statesman) characterization of gan cao is a useful explanatory frame for patients: the herb is not added to a formula to fix one thing but to make the entire formula work more safely and effectively together. Patients who ask why their TCM formula contains licorice even though they are not being treated for a licorice-specific condition can be offered this framing as an accurate and culturally grounded explanation.

| history = Gan cao's written history in Chinese medicine extends to the earliest stratum of the Chinese herbal record. The Shennong Ben Cao Jing (first to second century CE) placed it among the 120 upper herbs, the highest-quality classification available in the text's tripartite system, signaling that its safety and tonic utility were already well established by the Han dynasty period (206 BCE to 220 CE) when the text was compiled.{{citation needed}}

Zhang Zhongjing's Shang Han Lun (c. 210 CE) codified the classical formula architecture in which gan cao plays its most extensively documented historical role: Zhi Gan Cao Tang for cardiac-rhythm disturbance, Shao Yao Gan Cao Tang for spasm, and the Si Jun Zi Tang ancestor-formulas for qi deficiency all date to this text and remain in active contemporary practice over 1800 years after their codification.{{citation needed}}

The period between the Shang Han Lun and Li Shizhen's Ben Cao Gang Mu (completed 1578) saw continuous elaboration and commentary on gan cao across the major TCM dynastic lineages; each era added clinical observations, formulaic refinements, and processing variants to the original Shang Han Lun foundation. Li Shizhen's systematic synthesis made the Ben Cao Gang Mu the de facto East Asian herbal reference standard from the Ming dynasty to the twentieth century.{{citation needed}}

Modern chemical investigation beginning in the mid-twentieth century isolated glycyrrhizin as the principal active compound; this led to two pharmaceutical derivatives: carbenoxolone (a glycyrrhetinic acid hemisuccinate, used in Europe for peptic ulcer disease in the 1960s to 1980s) and Stronger Neo-Minophagen C (SNMC, an intravenous glycyrrhizin compound used in Japan for chronic viral hepatitis from the 1970s onward). Both are documented at [[Western licorice]], where the Western pharmaceutical-derivative history is covered in full.

Contemporary ''G. uralensis'' populations are subject to conservation pressure from commercial wild harvesting in Inner Mongolia, Gansu, and Xinjiang; overharvesting has substantially reduced wild stands over the past several decades, driving the industry toward cultivated supply. ''Glycyrrhiza'' species are subject to trade-monitoring frameworks requiring country-of-origin export documentation to verify sustainable sourcing.{{citation needed}} ''G. uralensis'' is listed in the Pharmacopoeia of the People's Republic of China as an official medicinal herb under the monograph Gan Cao (甘草), and the pharmacopoeia specification includes a minimum glycyrrhizin content standard as a quality criterion, shaping commercial cultivation toward higher-yielding varieties.<ref name="chinpharmacopoeia2020"/>

| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Anti-inflammatory herbs]]
[[Category:Respiratory herbs]]
[[Category:Demulcents]]
[[Category:TCM herbs]]

Western licorice

2026-05-26T18:56:04Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| binomial = Glycyrrhiza glabra L.
| family = Fabaceae (Leguminosae)
| common_names = licorice (American English), liquorice (British English), Western licorice, European licorice, Mediterranean licorice, mulethi (Hindi), yashtimadhu (Sanskrit, "sweet stick"), madhuyashti (Sanskrit alternative form), asl-us-sus or irq al-sus (Arabic), sus (Arabic short form), mahek (Persian); the Greek genus name glycyrrhiza is from glykys (sweet) + rhiza (root)
| native_range = Mediterranean basin, Western Asia (eastern Mediterranean to Iran), and parts of southern Europe and North Africa; cultivated widely throughout the Mediterranean and in Spain, Italy, Greece, Turkey, Iran, Iraq, Syria, and the Caucasus
| cultivars = the principal commercial source is wild-harvested or semi-cultivated root from the Mediterranean, Caspian, and Central Asian populations; Spanish licorice (cultivated in Spain since the medieval period) and Italian licorice (Calabria) are the European commercial grades; Turkish and Iranian licorice supply the Middle Eastern and South Asian markets; related ''Glycyrrhiza uralensis'' (Chinese licorice, gan cao, the principal TCM licorice) and ''Glycyrrhiza inflata'' (Xinjiang licorice) are distinct species with their own articles
| parts_used = root and underground stolon (the rhizome and runners), dried and (in some forms) deglycyrrhizinated; the leaves and aerial parts are not used medicinally
| cultivation = hardy perennial herb to 1.5 m at flowering; deep tap-rooted with extensive horizontal stolon network; propagated by stolon division or seed; harvested at three to four years for medicinal root, with deep mechanical or hand-digging required
| preparations_summary = root powder 1 to 5 g daily for short-course use, with chronic high-dose use constrained by pseudohyperaldosteronism risk; decoction 1 to 4 g of root per cup; tincture 1:5 in 45 percent alcohol, 2 to 5 mL three times daily; '''deglycyrrhizinated licorice (DGL)''' 760 to 1500 mg before meals for peptic ulcer and gastritis (the modern Western-clinical preparation engineered to remove glycyrrhizic acid and avoid the pseudohyperaldosteronism risk while retaining demulcent and mucosal-protective activity); standardized glycyrrhizin extract for short-course anti-inflammatory use; topical creams and gels for atopic dermatitis (glabridin and licochalcone fractions are the active topical compounds)
| constituents_summary = glycyrrhizin (glycyrrhizic acid) 2 to 12 percent of dry root by weight (variable by region and cultivar; the principal sweet compound at 50 times the sweetness of sucrose by mass, and the load-bearing pseudohyperaldosteronism compound); glycyrrhetinic acid (the aglycone of glycyrrhizin, produced by hydrolysis in the gut and the active intracellular form, the 11-beta-HSD2 inhibitor); flavonoids including liquiritin, isoliquiritin, and the isoflavones glabridin and licochalcone A (with antioxidant, anti-inflammatory, and antimicrobial activity); coumarins (small amounts); polysaccharides; saponins beyond glycyrrhizin; volatile oil (trace, contributing to the characteristic aroma)
| mechanism = glycyrrhetinic acid inhibits 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2), the renal and colonic enzyme that normally converts cortisol to inactive cortisone; with 11-beta-HSD2 inhibited, local cortisol concentrations rise and cortisol binds and activates the mineralocorticoid receptor (which it normally cannot, because the kidney's high 11-beta-HSD2 activity prevents access), producing functional mineralocorticoid agonism with sodium retention, potassium loss, hypertension, and edema -- the pseudohyperaldosteronism syndrome that is the principal safety concern of chronic high-dose licorice consumption; glycyrrhetinic acid also has anti-inflammatory activity through glucocorticoid receptor potentiation and through independent prostaglandin and leukotriene modulation; the flavonoid fraction (glabridin, licochalcone A) provides additional antioxidant, antimicrobial, and topical anti-inflammatory activity; the saponin fraction contributes the demulcent and expectorant effects; deglycyrrhizinated licorice (DGL) retains the flavonoid and saponin activity while removing the glycyrrhizin and its pseudohyperaldosteronism effect
| pregnancy = avoid medicinal doses; high glycyrrhizic acid intake associated with preterm birth in Finnish cohort studies; minor dietary use of licorice candy safe but to be limited
| legal = unscheduled; food-use restrictions on glycyrrhizin content in many jurisdictions; the European Scientific Committee on Food (SCF) set an adult guidance upper limit of 100 mg glycyrrhizin per day for habitual consumption in 2003
| interactionsummary = the pseudohyperaldosteronism mechanism produces clinically significant interactions with potassium-depleting diuretics (loop diuretics, thiazides) where the combined hypokalemia is the principal risk; with cardiac glycosides (digoxin) where licorice-induced hypokalemia increases digoxin toxicity risk; with corticosteroids where glycyrrhetinic acid potentiates exogenous corticosteroid effect through 11-beta-HSD2 inhibition (relevant in patients on chronic prednisone or similar); and with antihypertensive medicines where the sodium-retention effect opposes blood-pressure control; chronic high-dose licorice is contraindicated in patients with hypertension, congestive heart failure, hypokalemia, renal disease, or hepatic cirrhosis with ascites; DGL (deglycyrrhizinated licorice) avoids these interactions and is the preparation of choice for any chronic use
| intro = '''Western licorice''' is the dried root and underground stolon of ''Glycyrrhiza glabra'' L., a perennial leguminous herb of the Fabaceae (Leguminosae) native to the Mediterranean basin and Western Asia and one of the oldest continuously used medicinal plants of the Eurasian materia medica. The genus name [[wikipedia:''Glycyrrhiza''|glycyrrhiza]] is from the Greek glykys (sweet) and rhiza (root), reflecting the principal phytochemical feature of the plant: the sweet triterpene saponin glycyrrhizin (also called glycyrrhizic acid) reaches 2 to 12 percent of the dry root by weight and is approximately fifty times sweeter than sucrose by mass, making licorice the sweetest of the major medicinal roots and the source of the candy, tobacco-flavoring, and beverage uses that have run alongside the medicinal use for centuries. The medicinal indications of Western licorice converge across multiple traditions on a stable cluster: digestive complaint and peptic ulcer (the principal modern Western-clinical indication, addressed by the deglycyrrhizinated licorice formulation that removes the pseudohyperaldosteronism risk while retaining demulcent activity); chronic cough and respiratory complaint; chronic hepatic disease (where intravenous glycyrrhizin has been a Japanese clinical practice for chronic viral hepatitis for several decades); and a broadly tonic, harmonizing, or rasayana role across the traditions. The load-bearing modern safety story is the pseudohyperaldosteronism syndrome produced by chronic high-dose glycyrrhizin intake, which inhibits the renal 11-beta-hydroxysteroid dehydrogenase type 2 enzyme and produces functional mineralocorticoid agonism with hypertension, hypokalemia, sodium retention, and edema. The Chinese licorice ([[Chinese licorice|''Glycyrrhiza'' uralensis]]) is the principal licorice of the Chinese materia medica, where it is known as gan cao and serves as the harmonizing ingredient in approximately sixty percent of all classical Chinese herbal formulas; the TCM material lives on the [[Chinese licorice]] page, with the present article covering the Western, Ayurvedic, and Unani historical centroid of ''G. glabra''.
| traditional_uses = The Mediterranean and Near Eastern origin of Western licorice is the historical centroid of the herb. Licorice root was recovered from the tomb of Tutankhamun (interred approximately 1323 BCE in the Valley of the Kings) among the grave goods, suggesting royal use in pharaonic Egypt; the herb appears in the Hippocratic corpus and earlier Greek references as glykyrrhiza, the sweet root, and [[wikipedia:Theophrastus|Theophrastus]] in his Enquiry into Plants of about 300 BCE classed the plant as "the Scythian root" and noted its use for thirst-quenching, cough, and chest complaints, with the characteristic observation that Scythian horsemen could go ten or twelve days without drinking by chewing on the root (a folk-pharmacological reading of the demulcent and water-retaining effect that anticipates the modern pseudohyperaldosteronism mechanism).<ref name="theophrastus-licorice">Hort AF (translator). ''Theophrastus: Enquiry into Plants'', Volume II, Books VI-IX. Loeb Classical Library. Cambridge, MA: Harvard University Press; 1916 (translation of c. 300 BCE original).</ref> [[wikipedia:Pedanius Dioscorides|Dioscorides]] in book three of his De Materia Medica of about 60 CE listed glykyrrhiza for thirst, dry cough, lung disease, stomach pain, urinary irritation, and as a sweetener and corrective for harsh-tasting medicines, the early documentation of the harmonizing role that would later be elaborated in Chinese medicine as the gan cao "harmonizer of formulas" role.<ref name="dioscorides-licorice">Beck LY (translator). ''Pedanius Dioscorides of Anazarbus: De Materia Medica''. Hildesheim: Olms-Weidmann; 2005 (translation of c. 60 CE original).</ref> [[wikipedia:Pliny the Elder|Pliny the Elder]] in book twenty-two of his Naturalis Historia continued the Greek tradition, naming the plant glycyrrhiza and listing it for cough, lung complaint, stomach disorders, and the sweetening of pharmaceutical preparations.<ref name="pliny-licorice">Bostock J, Riley HT (translators). Pliny the Elder: ''The Natural History''. London: Taylor and Francis; 1855.</ref>

The Islamic and Persian medical traditions documented licorice as asl-us-sus (Arabic, "root of the sus plant") or irq al-sus and as mahek (Persian), with the herb classed as warming in the second degree, moist in the second, sweet, and indicated for cough, hoarseness, chest complaint, gastric pain, urinary irritation, and as a corrective and sweetener in compound formulations. [[wikipedia:Avicenna|Avicenna]] in book two of his Canon of Medicine of about 1025 CE devoted an entry to asl-us-sus listing the indications and noting the harmonizing role of the herb in compound preparations of harsher simples;<ref name="avicenna-licorice">Gruner OC (translator). ''A Treatise on the Canon of Medicine of Avicenna, Incorporating a Translation of the First Book''. London: Luzac and Co.; 1930.</ref> the Unani tradition of South Asia incorporated licorice as one of the central simples and continues to use it in clinical practice to the present.

The Ayurvedic tradition is one of the two principal historical centroids of ''Glycyrrhiza glabra'' outside the Mediterranean, with the herb documented as yashtimadhu (Sanskrit, "sweet stick") in the Charaka Samhita and Sushruta Samhita and used continuously from the early centuries of the common era to the present.<ref name="charaka-yashtimadhu">Sharma PV (translator). ''Charaka Samhita: Text with English Translation''. Varanasi: Chaukhambha Orientalia; 1981.</ref> Yashtimadhu is classed as sweet (madhura rasa), cooling (sheeta virya), unctuous (snigdha), heavy (guru), kapha-vata-shamaka (pacifying the cold-and-damp and cold-and-windy doshas, although somewhat increasing kapha at large dose), and is classed as a medhya rasayana (mind-and-intellect rejuvenative) and as one of the foundational Ayurvedic rasayanas (tonic rejuvenatives).<ref name="williamson-yashtimadhu">Williamson EM. ''Major Herbs of Ayurveda''. Edinburgh: Churchill Livingstone; 2002.</ref> Classical indications include cough (kasa), respiratory complaint, throat irritation, gastric pain (amlapitta), peptic disease, mental fatigue and memory weakness (the medhya rasayana role), and as a corrective sweetener in many compound formulations. Yashtimadhukadi Ghrita is a classical ghee-based compound of yashtimadhu with other herbs, used for chronic respiratory and digestive complaint; yashtimadhu also appears in numerous churnas (powders) and kashayas (decoctions).

The Chinese tradition uses ''Glycyrrhiza uralensis'' (Chinese licorice) rather than ''G. glabra'' as the principal licorice of the materia medica; ''G. uralensis'' is the gan cao of the [[Chinese licorice|companion article]], where the TCM "harmonizer of formulas" role is documented in detail.<ref name="bensky-gan-cao">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica, 3rd ed''. Seattle: Eastland Press; 2004.</ref> ''G. glabra'' has appeared in Chinese herbal practice as an import substitute for gan cao where uralensis was unavailable, and modern Chinese herbal pharmacies sometimes carry both species under the gan cao name without species discrimination, but the historical centroid of the Chinese tradition is firmly on uralensis.

The medieval European tradition received licorice as the standard Mediterranean apothecary commodity and incorporated the herb into the European herbal pharmacopoeia continuously from the Greek inheritance through the medieval monastic and Renaissance traditions to the modern. [[wikipedia:Nicholas Culpeper|Nicholas Culpeper]] in The English Physitian of 1652 wrote of licorice as warming and moistening, prescribed for "hoarseness, wheezing, shortness of breath, and all the diseases of the breast and lungs," for thirst in fevers, and as a corrective sweetener in unpleasant-tasting compound preparations; Culpeper's description tracks the Greek and Islamic indications closely. The German Commission E approved Western licorice for catarrh of the upper respiratory tract and for gastric and duodenal ulcer (at doses of 5 to 15 g daily of root, providing 200 to 600 mg glycyrrhizin, for a duration not exceeding four to six weeks because of the pseudohyperaldosteronism risk at longer courses).<ref name="commission-e-licorice">Blumenthal M, Goldberg A, Brinckmann J (editors). ''Herbal Medicine: Expanded Commission E Monographs''. Newton, MA: Integrative Medicine Communications; 2000.</ref>

The modern Western-clinical era of licorice begins with the mid-twentieth-century investigation of the herb for peptic ulcer disease and the resulting development of two related interventions: the synthetic derivative '''carbenoxolone''' (glycyrrhetinic acid succinate disodium) was developed in the late 1950s and approved for peptic ulcer in the United Kingdom and several other countries through the 1960s and 70s, with substantial trial evidence of ulcer-healing benefit at the cost of pronounced pseudohyperaldosteronism toxicity that ultimately limited its clinical use as proton pump inhibitors replaced it as the standard of care;<ref name="doll-1965">Doll R, Hill ID, Hutton CF. Treatment of gastric ulcer with carbenoxolone sodium and oestrogens. ''Gut''. 1965 Feb;6(1):19-24. PMID 14259418.</ref> and '''deglycyrrhizinated licorice (DGL)''' was developed as a parallel intervention that removed the glycyrrhizin (and thus the pseudohyperaldosteronism risk) while retaining the flavonoid and saponin fractions believed to mediate the mucosal-protective and ulcer-healing effects. DGL has remained in modern Western-clinical herbal practice as a chronic-use safe alternative to whole licorice for peptic ulcer, gastritis, and gastroesophageal reflux disease, with a substantial clinical evidence base for the indication and an essentially benign safety profile compared with whole licorice.<ref name="morgan-1985">Morgan AG, Pacsoo C, McAdam WA. Maintenance therapy: a two year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence. ''Gut''. 1985 Jun;26(6):599-602. PMID 4007604. (Caved-S is a deglycyrrhizinated licorice preparation; one of the foundational DGL maintenance trials.)</ref>

The Japanese clinical practice for chronic viral hepatitis has used intravenous glycyrrhizin as Stronger Neo-Minophagen C (SNMC, a formulation of glycyrrhizin, glycine, and L-cysteine) since the 1970s for chronic hepatitis B and C, with substantial reported trial evidence of reduced ALT and slowed progression to cirrhosis, although the formulation is not widely used outside Japan and the pseudohyperaldosteronism risk constrains long-term use.<ref name="iino-2001">Iino S, Tango T, Matsushima T, Toda G, Miyake K, Kumada H, et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. ''Hepatology Research''. 2001 Jan 1;19(1):31-40. PMID 11137478.</ref> The Western-medical adoption of SNMC has been limited despite the Japanese clinical experience; in the United States and Europe, oral DGL and the indirect anti-inflammatory roles of licorice are the dominant clinical uses.

The pseudohyperaldosteronism syndrome is the load-bearing modern safety story for whole licorice consumption and has been documented in a substantial case-report literature dating from the 1950s onward. The classical presentation is the licorice-candy headache and edema syndrome in heavy consumers of glycyrrhizin-containing licorice candy (or, less commonly, chronic medicinal use of whole licorice root preparations): hypertension, hypokalemia, sodium retention, edema, and in severe cases hypokalemic muscle weakness, paralysis, or cardiac arrhythmia. The Walker 1994 and van Uum 2005 reviews are standard references for the mechanism and the case literature.<ref name="walker-1994">Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. ''Endocrinology and Metabolism Clinics of North America''. 1994 Jun;23(2):359-377. PMID 8070427.</ref><ref name="vanuum-2005">van Uum SH. Liquorice and hypertension. ''The Netherlands Journal of Medicine''. 2005 Apr;63(4):119-120. PMID 15869038.</ref> The European Scientific Committee on Food set an adult guidance upper limit of 100 mg glycyrrhizin per day for habitual consumption in 2003, equivalent to approximately 1 to 5 g of licorice root depending on cultivar and preparation; chronic intake above this threshold approaches the pseudohyperaldosteronism range in susceptible individuals and intake at multiple times this level reliably produces clinical syndromes in case-report populations.<ref name="scf-2003">European Commission Scientific Committee on Food. ''Opinion of the Scientific Committee on Food on Glycyrrhizinic Acid and its Ammonium Salt''. SCF/CS/ADD/EDUL/225 Final. Brussels: European Commission Health and Consumer Protection Directorate-General; 10 April 2003. (Sets 100 mg/day adult upper guidance for habitual glycyrrhizin intake.)</ref> Pregnancy carries a real preterm-birth signal at high glycyrrhizic acid intake: Finnish cohort studies have documented associations between heavy licorice candy consumption in pregnancy and preterm birth, with a dose-response pattern.<ref name="strandberg-2001">Strandberg TE, Järvenpää AL, Vanhanen H, McKeigue PM. Birth outcome in relation to licorice consumption during pregnancy. ''American Journal of Epidemiology''. 2001 Jun 1;153(11):1085-1088. PMID 11390327.</ref>
| traditional_geography =
| botany = ''Glycyrrhiza glabra'' is a perennial herbaceous legume of the Fabaceae reaching 1 to 1.5 m at flowering. The deep tap root extends 1 to 2 m into the soil and produces an extensive horizontal stolon network from which new aerial stems emerge; the harvested medicinal "root" is in fact a mixture of true root and underground stolon. The leaves are pinnate with 9 to 17 elliptic leaflets 3 to 6 cm long, smooth and somewhat sticky-glandular on the lower surface. The flowers are small (8 to 12 mm), pale lilac to violet, in axillary racemes, papilionaceous in the typical Fabaceae form; the fruit is a small flat oblong pod 1.5 to 3 cm long containing two to eight reniform brown seeds. The dried root of commerce is the cured peeled rhizome and stolon: yellow-brown to greyish-yellow, fibrous, somewhat woody, with a characteristic sweet aroma and intensely sweet taste. Distinguished from ''Glycyrrhiza uralensis'' (the Chinese licorice) by smaller leaflet size and a less branched root system; from ''Glycyrrhiza'' inflated (Xinjiang licorice) by the smooth (rather than inflated) seed pod. Whole-stick licorice is light yellow-brown internally and dark brown externally; powdered licorice is light yellow-brown. Whole and powdered preparations are largely indistinguishable from ''G. uralensis'' without species-specific chemical or microscopic analysis, with the consequence that "licorice" of unspecified species is often unidentifiable as glabra or uralensis after processing.
| constituents = The principal medicinally active constituents of Western licorice are the '''glycyrrhizin''' fraction (the triterpene saponin) and the '''flavonoid''' fraction.

'''Glycyrrhizin''' (glycyrrhizic acid, the triterpene saponin) is 2 to 12 percent of the dried root by weight (variable by region, cultivar, and harvest age, with Iranian and Turkish roots typically at the higher end). Glycyrrhizin is the principal sweet compound, approximately fifty times sweeter than sucrose by mass, and the source of licorice's characteristic taste and of its candy and tobacco-flavoring uses. On oral administration glycyrrhizin is hydrolyzed in the intestinal lumen and colonic flora to its aglycone, '''glycyrrhetinic acid''' (also called enoxolone or glycyrrhetic acid), which is the active intracellular form. Glycyrrhetinic acid is the molecule that inhibits 11-beta-hydroxysteroid dehydrogenase type 2 and produces the pseudohyperaldosteronism effect, as well as the anti-inflammatory and other systemic effects of licorice. The pharmaceutical derivative '''carbenoxolone''' (glycyrrhetinic acid hydrogen succinate disodium) is a semisynthetic derivative produced by succinylation of glycyrrhetinic acid; carbenoxolone was approved for peptic ulcer in several countries in the 1960s and 70s and remains a research tool for 11-beta-HSD2 pharmacology.

The '''flavonoid''' fraction is approximately 1 to 2 percent of the dried root and includes the chalcone '''isoliquiritin''' and its aglycone '''isoliquiritigenin''', the flavanone '''liquiritin''' and its aglycone '''liquiritigenin''', and the isoflavones '''glabridin''' and '''licochalcone A''' (with glabridin distinctive of ''G. glabra'' and licochalcone A more characteristic of ''G. inflata''). The flavonoids contribute the antioxidant, antimicrobial, and topical anti-inflammatory activity of licorice; glabridin and licochalcone A are the principal constituents of the modern licorice-derived topical preparations for atopic dermatitis. The flavonoid fraction is retained in deglycyrrhizinated licorice (DGL) preparations, providing the basis of DGL's gastroprotective and anti-ulcer activity in the absence of glycyrrhizin.

The non-active fractions include '''polysaccharides''' (contributing to the demulcent and immunomodulatory activity), '''asparagine''' and other amino acids (the licorice "honey-stick" sweetness extends beyond the glycyrrhizin contribution), '''coumarins''' (small amounts; not the warfarin class, no anticoagulant activity), and trace volatile oil (contributing to the characteristic aroma).
| preparations = The traditional therapeutic forms are the '''whole root''' (chewed directly, the traditional "licorice stick"); the '''decoction''' (1 to 4 g of root per cup of water, simmered 15 to 20 minutes, taken one to three times daily for short-course respiratory or gastric complaint, with chronic high-dose use constrained by the pseudohyperaldosteronism risk); the '''powdered root''' (1 to 5 g daily, in honey or warm water, or as an ingredient in compound formulations); the '''tincture''' (1:5 in 45 percent alcohol, 2 to 5 mL three times daily, the traditional Western herbalist's form). The modern Western-clinical and supplement forms are the '''standardized glycyrrhizin extract''' (used at low dose for short-course anti-inflammatory or hepatoprotective indication, with the pseudohyperaldosteronism risk in proportion to the glycyrrhizin dose); '''deglycyrrhizinated licorice (DGL)''' tablets, typically chewed before meals at 380 to 760 mg three times daily for peptic ulcer, gastritis, or gastroesophageal reflux disease (the principal modern Western-clinical chronic-use preparation, engineered to remove glycyrrhizin while retaining demulcent and mucosal-protective activity); '''topical glabridin or licochalcone creams''' for atopic dermatitis; '''intravenous glycyrrhizin formulations''' (Stronger Neo-Minophagen C, SNMC) in Japanese clinical practice for chronic hepatitis B and C. Licorice candy and confectionery use is the consumer product form most likely to produce inadvertent chronic high glycyrrhizin exposure in patients not in formal medicinal use.
| indications = Peptic ulcer disease, gastritis, and gastroesophageal reflux disease (the principal modern Western-clinical indication, addressed with DGL rather than whole licorice for chronic use). Catarrh of the upper respiratory tract; chronic cough and bronchitis (the Commission E and traditional Western herbal indication). Sore throat (the lozenge form). Chronic hepatitis B and C (the Japanese SNMC IV practice; oral preparations have a thinner evidence base). Atopic dermatitis, eczema (topical glabridin or licochalcone preparations). Mild adrenal-insufficiency support (folk and complementary practice; the pseudohyperaldosteronism is the flip-side of mild Addisonian supplementation, with the cortisol-sparing effect rationalizing the use; clinical evidence is anecdotal). Functional dyspepsia (mild). Traditional Ayurvedic indications: cough, throat irritation, gastric complaint, mental fatigue (medhya rasayana role), debility. Traditional Unani indications: cough, gastric pain, urinary irritation, harmonizing role in compound formulations. Folk and historical: snake bite (no modern evidence), wound healing.
| dosing = Whole root powder: 1 to 5 g daily, for short-course use (typically four to six weeks maximum). Decoction: 1 to 4 g of root per cup, three times daily, for short-course use. Tincture 1:5 in 45 percent alcohol: 2 to 5 mL three times daily. DGL (deglycyrrhizinated licorice): 380 to 760 mg chewed before meals three times daily (the standard modern peptic ulcer dose), indefinite duration; the principal advantage of DGL is that the pseudohyperaldosteronism dose limit does not apply. Standardized glycyrrhizin extract: dose-limited by the 100 mg/day glycyrrhizin guidance from the European SCF for habitual chronic use; short-course higher-dose use can deliver up to 200 to 400 mg glycyrrhizin daily for limited periods. Topical glabridin or licochalcone cream: per manufacturer specification, applied to affected skin twice daily. Carbenoxolone (the semisynthetic pharmaceutical derivative, available in some countries): 50 to 100 mg three times daily for peptic ulcer, with the pseudohyperaldosteronism dose limit closely monitored.
| effects =
| pharmacokinetics = Glycyrrhizin is poorly absorbed from the intestine in its intact saponin form; the principal absorption mechanism is intestinal-microbial hydrolysis to glycyrrhetinic acid, which is then absorbed and reaches the systemic circulation. Plasma glycyrrhetinic acid peaks 8 to 12 hours after oral administration of whole licorice or glycyrrhizin preparations and has an elimination half-life of approximately 8 hours; chronic dosing produces accumulation over days. Glycyrrhetinic acid is highly protein-bound in plasma (greater than 99 percent) and is metabolized via hepatic glucuronidation and sulfation, with biliary excretion and enterohepatic recycling. The 11-beta-HSD2 inhibition by glycyrrhetinic acid is competitive and reversible, with the magnitude of pseudohyperaldosteronism effect closely tracking plasma glycyrrhetinic acid concentration; the inter-individual variability in pseudohyperaldosteronism response at a given dose is substantial, with genetic variation in 11-beta-HSD2 and in the intestinal microbial conversion of glycyrrhizin to glycyrrhetinic acid contributing to the variation.

Intravenous glycyrrhizin (the Japanese SNMC formulation) bypasses the intestinal-hydrolysis step and delivers glycyrrhizin directly to the circulation, with hydrolysis to glycyrrhetinic acid then occurring in hepatic tissue and in plasma esterases; the pharmacokinetic profile is somewhat different from oral whole licorice but converges on glycyrrhetinic acid as the active species.

Deglycyrrhizinated licorice (DGL) preparations contain less than 3 percent of the glycyrrhizin of whole licorice (typically 1 to 2 mg glycyrrhizin per 380 mg DGL tablet) and accordingly produce negligible pseudohyperaldosteronism even at chronic high dose; the flavonoid and saponin fractions retained in DGL have separate absorption profiles and contribute to the mucosal-protective effect without producing the safety burden of whole licorice.
| pharmacodynamics = The principal pharmacodynamic effect of glycyrrhizin and glycyrrhetinic acid is the inhibition of 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2), the renal and colonic enzyme that normally protects the mineralocorticoid receptor from cortisol by converting cortisol to inactive cortisone in the immediate vicinity of the receptor. With 11-beta-HSD2 inhibited by glycyrrhetinic acid, local cortisol concentrations rise and cortisol (which has comparable affinity to aldosterone for the mineralocorticoid receptor and circulates at concentrations approximately one hundred times higher) binds and activates the receptor, producing functional mineralocorticoid agonism. The downstream effects are sodium retention with consequent water retention, potassium loss through the renal collecting duct, hypertension, edema, and (in severe cases) hypokalemic muscle weakness or paralysis and cardiac arrhythmia. The plasma renin and aldosterone are suppressed (the syndrome is called "pseudo-hyperaldosteronism" because the clinical picture mimics primary hyperaldosteronism while renin and aldosterone levels are low rather than elevated). The pseudohyperaldosteronism is the principal safety concern of whole licorice and the principal reason DGL exists as a preparation.

Glycyrrhetinic acid also potentiates exogenous corticosteroid effect through the same 11-beta-HSD2 inhibition mechanism and through some direct glucocorticoid receptor modulation, with clinical relevance in patients on chronic prednisone or similar corticosteroid medicines. The anti-inflammatory effect of licorice in respiratory and gastric complaint is partly attributable to this endogenous-cortisol-potentiation mechanism and partly to direct flavonoid anti-inflammatory activity. Glycyrrhizin and glycyrrhetinic acid have documented in vitro and limited in vivo antiviral activity against hepatitis B virus, hepatitis C virus, and herpes simplex virus, the empirical basis of the Japanese SNMC clinical practice. The flavonoid fraction (glabridin, licochalcone A, liquiritin) provides antioxidant activity, antimicrobial activity against several oral and gastric pathogens including ''Helicobacter pylori'', and topical anti-inflammatory effects on atopic dermatitis lesions. The saponin and polysaccharide fractions contribute to the demulcent and expectorant effects.
| interactions = <pharmaInteractions/>

The clinically significant interactions of whole Western licorice (''Glycyrrhiza glabra'' root and glycyrrhizin-containing preparations) are dominated by the pseudohyperaldosteronism mechanism and produce a cluster of medicine-class interactions that share the common feature of being amplified by licorice-induced hypokalemia or sodium retention.

'''Potassium-depleting diuretics''' (loop diuretics such as furosemide and bumetanide; thiazide diuretics such as hydrochlorothiazide and chlorthalidone): the combined hypokalemia is the principal risk, with case reports of severe hypokalemic muscle weakness and cardiac arrhythmia in patients on long-term diuretic therapy who add chronic licorice consumption. The combination is contraindicated at therapeutic-dose chronic licorice consumption; DGL avoids the interaction.

'''Cardiac glycosides''' (digoxin): licorice-induced hypokalemia increases the risk of digoxin toxicity, with case reports of arrhythmia in digoxin-treated patients on chronic licorice. The combination is contraindicated; potassium monitoring is the conservative practice if licorice consumption is unavoidable in a digoxin-treated patient; DGL avoids the interaction.

'''Corticosteroids''' (prednisone, hydrocortisone, dexamethasone, and other systemic and topical corticosteroid medicines): glycyrrhetinic acid potentiates exogenous corticosteroid effect through 11-beta-HSD2 inhibition and direct receptor modulation. The clinical effect is dose-dependent and modest at culinary licorice exposure but potentially substantial at therapeutic-dose chronic licorice with high-dose corticosteroid use; the historical clinical observation by [[wikipedia:Frans Eduard de Wied|Dutch endocrinologists]] in the 1950s that licorice extracted patients on hydrocortisone replacement therapy could reduce their hydrocortisone dose led directly to the identification of the licorice cortisol-sparing mechanism.

'''Antihypertensive medicines''' (ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, and others): the sodium-retention effect of chronic high-dose licorice opposes blood-pressure control and can produce treatment-resistant hypertension in patients on otherwise effective antihypertensive regimens. The clinical management is to reduce or eliminate chronic licorice consumption (or substitute DGL where the indication is gastric); the combination is not an absolute contraindication but the licorice intake should be a routine inquiry in any patient presenting with apparently resistant hypertension.

'''Anticoagulants''': the coumarin fraction of licorice is small and is not the 4-hydroxycoumarin warfarin class; no direct anticoagulant interaction is established. Older sources sometimes flagged a theoretical concern that has not been substantiated in case reports or pharmacokinetic studies.

'''Other interactions''': licorice modestly induces some CYP3A4 activity at high dose; the clinical effect is generally modest but can be relevant for medicines with narrow therapeutic windows and known CYP3A4 substrate dependence.

DGL (deglycyrrhizinated licorice) avoids essentially all of the above interactions and is the preparation of choice for any chronic use, particularly in patients on diuretics, digoxin, corticosteroids, or antihypertensive medicines.
| pregnancy_details = Culinary amounts of licorice (an occasional candy stick, small culinary use in baked goods or savory dishes) are considered safe in pregnancy at the same intake levels considered safe in the general adult population. Chronic high-dose licorice candy consumption in pregnancy has been associated with preterm birth in Finnish cohort studies, with a dose-response pattern that becomes clinically meaningful at the multi-gram-per-day glycyrrhizin intake range typical of heavy licorice candy consumers in northern European populations.<ref name="strandberg-2001" /> The mechanism may involve cortisol-mediated effects on the fetal hypothalamic-pituitary-adrenal axis or direct uterine effects via the mineralocorticoid pathway. Therapeutic-dose medicinal licorice and chronic high-dose supplementation should be avoided in pregnancy; DGL preparations, which have negligible glycyrrhizin content, are reasonable for short-course gastric complaint in pregnancy where indicated, although formal safety data in pregnancy is limited.
| monitoring = For patients on chronic medicinal licorice consumption (whole root or standardized glycyrrhizin preparations at more than a few hundred milligrams glycyrrhizin daily for more than two to four weeks), blood pressure monitoring and serum potassium monitoring at baseline and every two to four weeks during continued use is the conservative practice; any rise in blood pressure or fall in potassium should prompt dose reduction or substitution with DGL. For patients on diuretics, digoxin, or corticosteroids who add even short-course licorice consumption, the same monitoring applies, with a lower threshold to discontinue licorice. DGL preparations do not require monitoring beyond the routine clinical follow-up of the underlying gastric indication.
| counseling = The most important counseling distinction for licorice is the form of the preparation, particularly the distinction between whole-licorice (or any glycyrrhizin-containing preparation) and DGL (deglycyrrhizinated licorice). The two preparations are clinically distinct medicines despite originating in the same plant: whole licorice carries the pseudohyperaldosteronism risk at chronic high intake and is appropriate only for short-course use (typically four to six weeks maximum) at moderate dose; DGL has negligible glycyrrhizin, no meaningful pseudohyperaldosteronism risk, and is appropriate for indefinite chronic use for peptic ulcer or gastritis. This is analogous in clinical practice to the distinction between Ceylon and cassia cinnamon (the same plant family, two clinically relevant forms, one carrying the chronic-use safety burden and one engineered around it). Patients seeking licorice for chronic gastric or anti-ulcer use should generally use DGL; patients seeking licorice for short-course respiratory or anti-inflammatory use can reasonably use whole licorice at the European SCF guidance dose of up to 100 mg glycyrrhizin per day.

Licorice candy is a substantial source of inadvertent chronic glycyrrhizin exposure in patients who may not be in formal medicinal use. Traditional European licorice candy (the salt-licorice or sweet-licorice products of Scandinavia, the Netherlands, Germany, and the United Kingdom) typically contains 1 to 10 mg glycyrrhizin per gram of candy, and heavy consumers (multiple ounces daily) can readily exceed the 100 mg/day European SCF guidance. Patients presenting with apparently resistant hypertension, unexplained hypokalemia, or unexplained edema should be asked about licorice candy consumption as a routine part of the clinical history; the syndrome is well-documented and not infrequent in heavy candy consumers, particularly in northern European populations where licorice candy is a common confectionery item.

Patients with established hypertension, congestive heart failure, hypokalemia, renal disease, hepatic cirrhosis with ascites, or chronic corticosteroid use should avoid chronic medicinal licorice or limit themselves to DGL preparations for any therapeutic use. Patients planning elective surgery should be counseled to discontinue therapeutic-dose whole licorice supplementation two to four weeks before surgery (the duration is set by the glycyrrhetinic acid pharmacokinetic profile rather than by platelet turnover); culinary licorice and short-term licorice candy use do not require preoperative discontinuation.

Patients seeking the cortisol-sparing or mild adrenal-supportive use of licorice (a folk and complementary indication, not a primary clinical intervention) should be counseled that the effect is real but is the same mechanism that produces the pseudohyperaldosteronism syndrome at higher intake, and that the clinical management of any indication for adrenal supplementation should involve formal endocrine evaluation rather than empirical herbal supplementation.
| anecdotes =
| seealso = [[Chinese licorice]], ''[[Glycyrrhiza uralensis]]'', [[Ginger]], [[Marshmallow]], [[Slippery elm]], [[Comfrey]], [[Mullein]], [[Thyme]]
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Anti-inflammatory herbs]]
[[Category:Respiratory herbs]]
[[Category:Demulcents]]
[[Category:Western clinical herbs]]
[[Category:Ayurvedic herbs]]
[[Category:Unani herbs]]
[[Category:Anti-ulcer agents]]

Turmeric

2026-05-26T18:56:02Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| binomial = Curcuma longa L.
| family = Zingiberaceae
| common_names = turmeric (English), haldi (Hindi), haridra (Sanskrit), manjal (Tamil), pasupu (Telugu), jiang huang (Chinese, "yellow ginger"), zard chub (Persian, "yellow wood"), kurkum (Arabic; not to be confused with saffron, which is also kurkum in some Arabic usage), kunyit (Indonesian and Malay); the synonymic binomial Curcuma domestica Valeton appears in some older literature
| native_range = the Indian subcontinent, where turmeric has been cultivated for at least four thousand years and where India remains the source of approximately 80 percent of world production; cultivated also throughout southeast Asia, southern China, and the tropical Americas
| cultivars = grade-based and color-based; the "fingers" (lateral rhizome branches) are the lower-grade traded product, the "bulbs" (the central rhizome) the higher-grade; Alleppey turmeric from Kerala has the highest curcumin content (5 to 6 percent) and is the preferred grade for therapeutic supplement formulation; Madras turmeric and most Indian commodity turmeric runs 2 to 5 percent curcumin; Curcuma aromatica (yu jin in TCM), Curcuma zedoaria (e zhu in TCM), and Curcuma xanthorrhiza (Javanese turmeric) are distinct species in the same genus with overlapping but distinct uses
| parts_used = rhizome, the cured-and-dried form (the fresh rhizome is also used in Indian and southeast Asian cooking and traditional medicine); the leaves are used in some Indian cuisine but not medicinally
| cultivation = tropical herbaceous perennial; tuberous rhizome propagated vegetatively; nine to ten month growing season; rhizomes harvested at leaf senescence, boiled or steamed briefly to gelatinize the starch and inactivate the sprouting enzymes, then sun-dried and polished; the cured rhizome is what enters trade as "turmeric"
| preparations_summary = rhizome powder 1 to 4 g daily (culinary and traditional therapeutic dose); standardized curcuminoid extract 500 to 2000 mg daily (95 percent curcuminoid content typical); curcumin with piperine (''Curcuma longa'' + Piper nigrum, the bioavailability-enhanced classical combination) at 500 to 2000 mg curcumin plus 5 to 20 mg piperine; phytosome formulations (Meriva, Theracurmin, BCM-95, others) at the manufacturer-specified dose, which deliver substantially higher systemic curcumin than plain powder; tincture 1:5 in 45 percent alcohol, 2 to 4 mL three times daily; the traditional topical Lepa (paste of turmeric, sandalwood, neem, and other powders) for skin complaint; the traditional infusion in milk (haridra dugdha, "golden milk") for respiratory and warming use
| constituents_summary = curcuminoids 2 to 8 percent of dried rhizome by weight (curcumin approximately 70 percent of the curcuminoid fraction, demethoxycurcumin approximately 20 percent, bisdemethoxycurcumin approximately 10 percent); essential oil 3 to 5 percent (turmerones the principal volatile component: ar-turmerone, alpha-turmerone, beta-turmerone, with smaller amounts of zingiberene and curlone); starch 60 to 70 percent of dried rhizome (the bulk of the dry weight); polysaccharides; minor terpenoids and flavonoids
| mechanism = curcumin inhibition of nuclear factor kappa B (NF-kB) transcription, cyclooxygenase-2 (COX-2), and lipoxygenase (LOX), with downstream reduction of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) is the principal mechanistic rationale for the anti-inflammatory effects; curcumin direct radical scavenging and glutathione-system upregulation account for the antioxidant activity; turmerones have separate pharmacological activity (immunomodulatory and aromatic carminative); the bioavailability problem (free curcumin oral absorption is approximately 1 percent and what is absorbed is rapidly glucuronidated and sulfated by UGT and SULT enzymes) constrains the in vivo effect substantially relative to in vitro and animal-model findings, and accounts for the limited clinical-trial effect sizes despite extensive preclinical evidence
| pregnancy = culinary doses safe; therapeutic-dose supplementation, particularly high-bioavailability formulations, caution; traditional sources name turmeric as an emmenagogue and uterine tonic at medicinal dose
| legal = unscheduled; GRAS for culinary use; widely sold worldwide as culinary spice, traditional remedy, and dietary supplement
| interactionsummary = modest additive antiplatelet effect with antiplatelet medicines and anticoagulants at therapeutic-dose supplementation (theoretical and case-report supported; bleeding-risk caution in patients on warfarin or DOACs); modest CYP3A4 inhibition with high-bioavailability formulations or piperine-enhanced curcumin (potentially raising plasma concentrations of CYP3A4-substrate medicines); a growing case-report literature of hepatotoxicity associated with chronic high-dose curcumin supplementation, particularly with high-bioavailability formulations, represents a real safety signal at the supplement-capsule scale of use that is essentially absent at culinary scale
| intro = '''Turmeric''' is the dried, cured rhizome of ''Curcuma longa'' L., a tropical herbaceous perennial of the Zingiberaceae (the ginger family) native to the Indian subcontinent and cultivated continuously there for at least four thousand years as the principal food coloring, ritual aromatic, and anti-inflammatory medicine of the South Asian tradition. The Sanskrit name '''haridra''' (literally "yellow," from the same root as the Persian zard chub, "yellow wood") names the rhizome for the yellow color that has anchored its dual sacred-and-medicinal identity in Hindu, Buddhist, and Jain practice: turmeric paste is applied to the bride and groom in the Indian wedding [[wikipedia:Haldi ceremony|haldi]] ceremony, used as a ritual offering in temple worship, smeared on the forehead as a daily mark of auspicious blessing, and ground into the medicinal pastes (Lepa) of classical Ayurvedic external practice for thousands of years. The rhizome is documented in the Charaka Samhita and Sushruta Samhita (the foundational Ayurvedic texts compiled in the early centuries of the common era from older oral tradition) as a warming, drying, bitter, and pungent medicine indicated for indigestion, wound healing, skin disorders, blood-purification, diabetes, respiratory complaint, and inflammatory pain;<ref name="charaka-turmeric">Sharma PV (translator). ''Charaka Samhita: Text with English Translation''. Varanasi: Chaukhambha Orientalia; 1981.</ref> the bandwidth of classical indications is unusually broad even by Ayurvedic standards and matches the breadth of curcumin's in vitro pharmacology. Turmeric entered the Chinese materia medica as jiang huang ("yellow ginger") by the Tang dynasty, where it is classed as a blood-mover and qi-mover for amenorrhea, abdominal masses, and traumatic injury;<ref name="bensky-turmeric">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica, 3rd ed''. Seattle: Eastland Press; 2004.</ref> the Persian and Islamic traditions received it as zard chub and kurkum but treated it as a secondary aromatic and dyestuff rather than as a central medicinal herb. The modern Western use of turmeric dates almost entirely from the late twentieth century, when the in vitro pharmacology of curcumin (the principal yellow pigment of the rhizome) attracted research attention in anti-inflammatory, antioxidant, and anticancer pharmacology, and turmeric and its standardized curcumin extracts became one of the most widely sold dietary supplements in the United States and Europe.
| traditional_uses = The Indian subcontinent is the historical centroid of turmeric, and the depth of Indian use is unusual even by the standards of widely-traded medicinal spices. Archaeological evidence from Indus Valley sites suggests turmeric was in cultivation in the Indian subcontinent by approximately 2500 BCE,<ref name="kashyap-weber-2010">Kashyap A, Weber SA. Harappan plant use revealed by starch grains from Farmana, India. ''Antiquity'' 2010;84(326), Project Gallery. Archaeobotanical starch-grain analysis identifying turmeric, ginger, and other Zingiberaceae in Harappan-period cooking residues.</ref> and the rhizome appears in the post-Vedic literary record as haridra (the Sanskrit name) from at least the first millennium BCE. The classical Ayurvedic texts the Charaka Samhita and Sushruta Samhita document turmeric extensively: Charaka classes haridra as warming (ushna virya), drying (ruksha), bitter-and-pungent (tikta-katu rasa), kapha-vata-shamaka (pacifying the cold-and-damp and the cold-and-windy doshas), and indicates it for indigestion (agnimandya), wound healing (vrana ropana), skin disorders broadly (kushta), blood-purification (raktashodhana), diabetes mellitus (madhumeha), respiratory complaint, and inflammatory joint pain.<ref name="williamson-haridra">Williamson EM. ''Major Herbs of Ayurveda''. Edinburgh: Churchill Livingstone; 2002.</ref> Sushruta's surgical text emphasizes the topical wound application of turmeric powder for its antiseptic and granulation-promoting effect, a use that has persisted in Indian folk and clinical practice to the present and that has substantial supporting in vitro evidence for cinnamaldehyde-equivalent antimicrobial activity. Classical Ayurvedic compound formulations including turmeric are numerous: Haridra Khanda (turmeric in a herbal-mineral compound for skin disorders), Mahasudarshana Churna (turmeric among many ingredients, for fever and detoxification), Yashtimadhukadi Ghrita, and many others.

The Indian sub-tradition of turmeric in milk (haridra dugdha, or in the modern Anglophone packaging "golden milk") deserves separate notice. The traditional formulation combines warm milk with turmeric, black pepper, ginger, cardamom, and (sometimes) saffron, often sweetened with jaggery or honey; the indication is for respiratory complaint, cough, sore throat, joint pain, and general warming-and-restoration in convalescence. The formulation is culturally salient, widely used in modern Indian and diaspora households, and has been the basis of a substantial Western supplement and beverage industry over the past two decades. Pharmacokinetically, however, the systemic curcumin delivery from a cup of turmeric milk is essentially nil (the curcumin content of a teaspoon of turmeric powder is at most 200 mg, and the oral bioavailability without piperine co-administration is approximately 1 percent, yielding less than 2 mg of bioavailable curcumin); the traditional clinical effect rests on the warming-aromatic-pungent profile of the formulation and on the demulcent and protein content of the milk rather than on systemic curcumin pharmacology. This is a useful distinction for prescribers: the cultural-traditional use of turmeric in milk is real, broadly safe, and culturally significant, but it should not be confused with the bioavailability-engineered supplement use of standardized curcuminoid extract.

The Chinese tradition received turmeric as jiang huang ("yellow ginger") via Indian trade by the Tang dynasty (618 to 907 CE), where it was incorporated into the materia medica as a blood-mover (huo xue), qi-mover (xing qi), and pain reliever; the principal TCM indications are amenorrhea, dysmenorrhea with palpable abdominal masses, post-traumatic pain, and rheumatic joint pain.<ref name="bensky-jiang-huang">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica, 3rd ed''. Seattle: Eastland Press; 2004.</ref> The TCM tradition recognizes three distinct Curcuma "yellow" herbs from different species in the genus: jiang huang from C. longa (the bark-yellow rhizome, the warming blood-and-qi-mover); yu jin from C. aromatica or C. wenyujin (the heart-yellow rhizome, cooling, used for liver-qi stagnation with heat); and e zhu from C. zedoaria (the white-blue rhizome, the strongest blood-mover, used for abdominal masses). The three are distinct in clinical use within TCM despite arising from sibling species and being often confused outside the tradition.

The Islamic and Persian medical traditions received turmeric as zard chub (Persian, "yellow wood") and kurkum (Arabic, also a name shared with saffron in some Arabic usage and a recurrent source of confusion in classical pharmacological texts). Avicenna's Canon mentioned zard chub among the warming, drying, and pungent simples for digestive complaint and topical wound application, but turmeric never reached the central pharmacopoeial role in the Unani tradition that ginger or cinnamon held; turmeric in Unani practice was largely a dyestuff and secondary aromatic, with the medicinal centroid of the herb remaining firmly in South Asia.

The European reception of turmeric was minor through the early modern period. Turmeric followed the broader curry-spice trade from India to European markets but was treated chiefly as a dyestuff and culinary coloring rather than as a medicinal herb in the European pharmacopoeial tradition; the formal Western pharmacopoeial monographs of the eighteenth and nineteenth centuries acknowledged turmeric as a tinctorial commodity and only marginally as a digestive aromatic. This relative European indifference persisted until the late twentieth century, when in vitro pharmacological investigation of curcumin attracted research attention to the rhizome and turmeric began its modern transition from spice to clinical supplement.

The modern bioavailability story is the defining pharmacokinetic narrative of curcumin and is essential to interpreting the clinical-trial literature on the herb. Free oral curcumin is absorbed at approximately 1 percent of the administered dose, and what is absorbed is rapidly glucuronidated and sulfated by intestinal and hepatic UGT and SULT enzymes, so that free curcumin in plasma is essentially undetectable at typical supplement doses. The Shoba 1998 study documented that co-administration of piperine (from Piper nigrum, black pepper) inhibited the conjugation enzymes and increased curcumin systemic bioavailability approximately twentyfold in human volunteers,<ref name="shoba-1998">Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. ''Planta Medica''. 1998 May;64(4):353-356. PMID 9619120.</ref> a finding that codified the traditional Indian culinary pairing of turmeric and black pepper into a pharmacokinetic rationale and that has been the basis of most modern curcumin supplement formulations. A second generation of bioavailability-enhanced formulations (Meriva, the curcumin phospholipid phytosome complex; Theracurmin, the colloidal nanoparticle dispersion; BCM-95, the curcumin-with-essential-oils complex) increase oral bioavailability further by various carrier-system mechanisms and now constitute the majority of curcumin supplements sold in the Western market. The clinical implication is that the trial-literature effect sizes for turmeric and curcumin in inflammatory disease depend substantially on the formulation studied, and that translation from positive trial results in bioavailability-engineered formulations to the everyday consumer use of plain turmeric powder is not straightforward.

The contemporary controlled-trial literature on turmeric and curcumin for inflammatory disease is substantial and heterogeneous. The most-studied indication is osteoarthritis: head-to-head trials of curcuminoid extracts against ibuprofen and other anti-inflammatory medicines have generally found non-inferiority for symptomatic relief over short courses,<ref name="kupt-2014">Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. ''Clinical Interventions in Aging''. 2014;9:451-458. PMID 24672232.</ref> and several systematic reviews and meta-analyses have reported modest but statistically significant improvement in osteoarthritis pain scores with curcuminoid supplementation, with substantial heterogeneity attributable to formulation differences.<ref name="daily-2016">Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. ''Journal of Medicinal Food''. 2016 Aug;19(8):717-729. PMID 27533649.</ref> Ulcerative colitis maintenance with curcumin in addition to standard mesalamine therapy has been investigated in small trials with modest positive results.<ref name="hanai-2006">Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. ''Clinical Gastroenterology and Hepatology''. 2006 Dec;4(12):1502-1506. PMID 17101300.</ref> Depression adjunct trials of curcumin have produced mixed findings, with some short trials reporting non-inferiority to fluoxetine and other reports finding no significant effect.<ref name="sanmukhani-2014">Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. ''Phytotherapy Research''. 2014 Apr;28(4):579-585. PMID 23832433.</ref> Where the observational and short-trial evidence has supported indications for inflammatory and neurological disease, larger and longer randomized trials have produced more modest effect sizes, and the curcumin research field has additionally been affected by retractions of multiple prominent papers from a single academic laboratory, contributing to a more cautious modern assessment of curcumin's clinical evidence base than was current a decade ago.<ref name="retraction-watch">Retraction Watch. Database of retracted papers in curcumin / turmeric pharmacology research; ongoing coverage since 2014. Available at https://retractionwatch.com/ (search "curcumin" or "Aggarwal" for the relevant cluster of retractions in the modern curcumin literature).</ref> The interpretation for a prescriber is that curcumin's anti-inflammatory effect at clinically meaningful intake is real but modest, that bioavailability-engineered formulations are typically required to deliver clinically interesting plasma concentrations, and that any single trial should be read in the context of formulation and of the field's evolving credibility profile.

A growing case-report literature documents hepatotoxicity associated with chronic high-dose curcumin supplementation, particularly with high-bioavailability formulations and particularly in chronic supplementation extending beyond a few months. Case reports have accumulated since approximately 2018, with several published in 2020 to 2023 documenting acute hepatitis presentation in patients on multi-month high-dose curcumin or Meriva-type phytosome supplementation, generally with resolution on discontinuation.<ref name="lukefahr-2018">Lukefahr AL, McEvoy S, Alfafara C, Funk JL. Drug-induced autoimmune hepatitis associated with turmeric dietary supplement use. ''BMJ Case Reports''. 2018 Sep 10;2018:bcr-2018-224611. PMID 30206065.</ref> The NIH LiverTox database lists turmeric and curcumin as known hepatotoxicants at supplementation dose, with the bioavailability-enhanced formulations identified as the higher-risk preparations.<ref name="livertox-turmeric">National Institute of Diabetes and Digestive and Kidney Diseases. ''LiverTox: Clinical and Research Information on Drug-Induced Liver Injury'', Turmeric and Curcumin entry. Bethesda, MD: NIDDK; ongoing updates. Available at https://www.ncbi.nlm.nih.gov/books/NBK548561/</ref> The signal is real but rare in absolute terms relative to the magnitude of turmeric and curcumin supplementation worldwide; the clinical implication is that prescribers should counsel patients on chronic high-dose curcumin supplementation about the hepatotoxicity risk, monitor liver function in chronic users, and consider the dose-and-formulation choice (whether to use bioavailability-enhanced formulations or to accept lower bioavailability from plain turmeric powder) as a benefit-risk decision rather than a default. Culinary use of turmeric at the gram-per-day scale typical of Indian and southeast Asian cooking is essentially without hepatotoxicity risk.
| traditional_geography =
| botany = ''Curcuma longa'' is a tropical herbaceous perennial of the Zingiberaceae reaching 60 to 90 cm at flowering. The plant emerges annually from a tuberous rhizome, sending up large oblong leaves 30 to 50 cm long and 7 to 15 cm wide, glossy green with a prominent central midrib, arranged in a tight basal rosette. The inflorescence is a dense terminal spike of pale yellow flowers subtended by green and rosy-pink bracts (the bracts the more conspicuous floral feature). The medicinally used rhizome is the central tuberous body and its lateral branches: the central rhizome ("bulb") is rounded, 3 to 6 cm in diameter, with the lateral branches ("fingers") elongated and 1 to 2 cm in diameter, both intensely yellow-orange when cut, with a distinctive warm aromatic odor and pungent-bitter taste. Distinguished from the related Curcuma aromatica (Indian wild turmeric, the TCM yu jin) by smaller rhizome and more pungent aroma; from Curcuma zedoaria (white turmeric, the TCM e zhu) by deeper yellow rhizome color and less camphorous aroma; from ''Zingiber officinale'' (ginger, the most likely confusion in fresh-rhizome form) by deeper yellow color throughout and absence of ginger's distinctive zingerone-and-gingerol pungency. The dried-cured rhizome of commerce is hard, dense, intensely yellow, breaks with a clean crystalline fracture, and powders to the characteristic mustard-yellow color that has anchored turmeric's dual culinary-and-dye identity.
| constituents = The principal medicinally active constituents of turmeric are the '''curcuminoids''' (polyphenolic pigments of the diarylheptanoid class) and the '''essential oil''' (rich in sesquiterpene ketones called turmerones).

The curcuminoid fraction is 2 to 8 percent of dried rhizome by weight, varying by cultivar, region, and curing practice. The fraction comprises three principal compounds: '''curcumin''' (approximately 70 percent of the curcuminoid fraction, the principal pigment and the focus of essentially all modern curcumin research), '''demethoxycurcumin''' (approximately 20 percent, somewhat more bioavailable than curcumin), and '''bisdemethoxycurcumin''' (approximately 10 percent, the most stable to oxidation). Curcumin is the diferuloylmethane molecule, with two ferulic acid units bridged by a heptadienedione linker; the molecule exists in equilibrium between keto and enol tautomers and is the principal bright-yellow pigment of the rhizome. Curcumin is poorly water-soluble, sensitive to alkaline pH and light, and undergoes rapid degradation in physiological aqueous solution to ferulic acid, vanillin, and related smaller molecules; some of curcumin's observed in vitro pharmacology may be attributable to these degradation products rather than to curcumin itself.

The essential oil fraction is 3 to 5 percent of dried rhizome by weight and is dominated by '''turmerones''': ar-turmerone (the aromatic turmerone, the principal volatile component, with characteristic warm-spicy aroma), alpha-turmerone, and beta-turmerone, together with smaller amounts of zingiberene (shared with ginger), curlone, and other sesquiterpenes. The turmerones have substantially better oral bioavailability than curcumin and contribute independently to turmeric's pharmacology; the immunomodulatory and aromatic carminative effects of turmeric appear to depend more on the turmerones than on curcumin in vivo, although the modern supplement industry has focused almost entirely on curcuminoid standardization.

The non-active fractions are dominated by '''starch''' (60 to 70 percent of dried rhizome dry weight, the bulk of the rhizome carbohydrate), polysaccharides, and small amounts of protein, mineral, and minor terpenoid and flavonoid compounds.
| preparations = The traditional Indian and southeast Asian forms are the '''cured rhizome powder''' (the form of commerce, 1 to 4 g daily for culinary and traditional therapeutic use); the '''fresh rhizome''' (used in Indian and Thai cooking and in some traditional folk preparations); the '''topical Lepa''' (paste of turmeric powder with sandalwood, neem, and other powders, mixed with water or rosewater to a paste, applied externally for skin complaint); the '''haridra dugdha''' or "golden milk" (turmeric powder simmered in milk with black pepper, ginger, and sometimes cardamom and jaggery, used as a warming beverage for respiratory and inflammatory complaint).

The modern Western forms are the '''standardized curcuminoid extract''' (95 percent curcuminoid content, typically supplied as 500 mg or 1000 mg capsules, with daily doses of 500 to 2000 mg curcuminoid); the '''curcumin-piperine combination''' (curcumin extract with 5 to 20 mg added piperine from Piper nigrum, the bioavailability-enhanced classical pairing); and the '''bioavailability-enhanced proprietary formulations''' including Meriva (curcumin phospholipid phytosome complex, ~30-fold bioavailability enhancement), Theracurmin (colloidal nanoparticle dispersion, ~27-fold enhancement), BCM-95 (curcumin with turmeric essential oils, ~7-fold enhancement), and others. The proprietary formulations are the basis of most positive curcumin clinical trial results in the past decade. The '''tincture''' (1:5 in 45 percent alcohol, 2 to 4 mL three times daily) is the traditional Western herbalist's form but delivers low systemic curcumin.
| indications = Anti-inflammatory adjunct for osteoarthritis (the most-studied modern indication; modest effect; comparable to non-steroidal anti-inflammatory medicines in short-course head-to-head trials of bioavailability-enhanced formulations). Ulcerative colitis maintenance therapy in combination with standard mesalamine treatment (modest evidence base from small trials). Functional dyspepsia and indigestion (Commission E approved for this indication; the traditional digestive carminative use). Wound healing, topical (the classical Ayurvedic and folk application; modest in vitro and case-series evidence). Adjunctive for major depression (mixed trial evidence; not a primary intervention). Cardiovascular and metabolic indications (mixed observational and trial evidence, generally modest). Traditional Ayurvedic indications: skin disorders (kushta), blood-purification (raktashodhana), diabetes mellitus (madhumeha), respiratory complaint, joint pain. Traditional TCM indications: amenorrhea, dysmenorrhea with abdominal mass, post-traumatic pain, rheumatic joint pain (jiang huang). Folk indication: the warming-respiratory use in turmeric milk for cough and convalescence.
| dosing = Rhizome powder: 1 to 4 g daily, divided. Standardized curcuminoid extract (95 percent curcuminoids): 500 to 2000 mg daily, divided. Curcumin with piperine: 500 to 2000 mg curcumin plus 5 to 20 mg piperine daily, divided. Bioavailability-enhanced proprietary formulations: per manufacturer specification (typical Meriva dose 1000 to 2000 mg of the phytosome complex daily, which delivers approximately 200 to 400 mg bioavailable curcumin equivalent). Tincture 1:5 in 45 percent alcohol: 2 to 4 mL three times daily. Topical Lepa: applied to the lesion in paste form, allowed to dry, removed after 30 to 60 minutes. Turmeric milk: 1 teaspoon (approximately 2 g) turmeric powder per cup of warm milk, traditionally taken once or twice daily for cough or warming use. TCM jiang huang in decoction: 3 to 10 g daily in compound formula.
| effects =
| pharmacokinetics = Curcumin absorbed from the gastrointestinal tract at approximately 1 percent of administered oral dose; what is absorbed is rapidly conjugated by UGT (UDP-glucuronosyltransferase, especially UGT1A1) and SULT (sulfotransferase) enzymes in intestinal mucosa and liver to curcumin glucuronide and curcumin sulfate, which are the principal circulating forms; free unconjugated curcumin is essentially undetectable in plasma at typical supplemental doses without bioavailability enhancement. Curcumin glucuronide undergoes biliary excretion and enterohepatic recycling; ultimate elimination is largely fecal, with a smaller urinary fraction. Co-administration of piperine inhibits both UGT (by direct enzyme interaction and by altering membrane fluidity) and CYP3A4, producing the approximately 2000 percent increase in curcumin bioavailability documented in the Shoba 1998 trial; the practical effect is that piperine-co-administered curcumin reaches plasma concentrations in the nanomolar-to-low-micromolar range from typical supplemental doses, sufficient to engage the proposed pharmacological targets at least transiently. Phytosome (Meriva, Theracurmin) and similar carrier-system formulations achieve comparable or higher bioavailability by different mechanisms (lipid-phase partitioning bypassing some first-pass conjugation, colloidal nanoparticle absorption). The pharmacokinetic profile of the curcumin metabolites (glucuronide, sulfate) is itself pharmacologically relevant: some in vivo curcumin pharmacology may be attributable to the conjugated metabolites or to enterohepatically recycled material rather than to free curcumin in systemic circulation.

The turmerones have separate, substantially better oral pharmacokinetic profiles than curcumin, with absorption in the 10 to 30 percent range and lower first-pass conjugation; the turmerones contribute independently to turmeric's systemic pharmacology in a way that the curcumin-focused supplement industry has generally underweighted.
| pharmacodynamics = Curcumin in vitro is a broad-spectrum inhibitor of inflammatory signaling: nuclear factor kappa B (NF-kB) transcription, cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and several pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6) are downregulated by curcumin at micromolar concentrations. Curcumin also directly scavenges reactive oxygen species and upregulates glutathione system enzymes (gamma-glutamylcysteine synthetase, glutathione peroxidase, glutathione reductase), accounting for its substantial in vitro antioxidant capacity. Curcumin inhibits platelet aggregation in vitro through reduction of thromboxane A2 synthesis and direct platelet membrane effects; this is the mechanistic rationale for the additive antiplatelet interaction with anticoagulants and antiplatelet medicines. Curcumin has documented in vitro effects on tumor cell apoptosis, angiogenesis inhibition, and cell-cycle modulation that have been the basis of extensive (and substantially retracted) preclinical anticancer literature; the translation of these in vitro effects to clinically meaningful in vivo anticancer activity has not been established.

The turmerones produce immunomodulatory effects in animal models (macrophage activation, lymphocyte response modulation) that are distinct from curcumin's NF-kB inhibition; the aromatic-carminative effect of turmeric on digestive function is mediated primarily by the turmerones rather than by curcumin, and accounts for the Commission-E-approved dyspepsia indication that does not depend on systemic curcumin pharmacology.

The bioavailability constraint is the bridge between the rich in vitro pharmacology of curcumin and the modest in vivo clinical effect: in vitro effective concentrations of curcumin in the low micromolar range are difficult to achieve in plasma even with bioavailability-engineered formulations, and the systemic effects of turmeric supplementation in vivo may depend as much on the turmerone fraction and on conjugated curcumin metabolites as on free systemic curcumin.
| interactions = <pharmaInteractions/>

The clinically significant interactions of turmeric and curcumin are modest in number but include one substantive concern.

'''Antiplatelet and anticoagulant interaction.''' Curcumin inhibits platelet aggregation in vitro, and case reports document increased bleeding risk and elevated INR in patients on warfarin who add high-dose curcumin supplementation; the effect is theoretical at culinary doses, somewhat more substantial at supplementation doses, and most pronounced with bioavailability-enhanced formulations. The conservative recommendation is to avoid therapeutic-dose curcumin supplementation in patients on warfarin or DOACs without prescriber consultation, and to discontinue therapeutic-dose curcumin supplementation seven to ten days before elective surgery (parallel to the garlic and ginkgo recommendation for the same antiplatelet category). Culinary turmeric does not require preoperative discontinuation.

'''CYP3A4 modest inhibition''', particularly with piperine-enhanced curcumin or phytosome formulations, has been documented in pharmacokinetic studies; the clinical magnitude is generally modest but can be relevant for medicines with narrow therapeutic windows and known CYP3A4 substrate dependence (cyclosporine, tacrolimus, some antiretrovirals, several oncology agents). Patients on such medicines who add high-dose curcumin supplementation should monitor for the relevant pharmacokinetic interaction.

'''Hepatotoxicity at chronic high-bioavailability supplementation.''' This is the principal modern safety concern for turmeric and is distinct from any pharmacological interaction with another medicine: the risk is intrinsic to chronic high-dose curcumin exposure, particularly with bioavailability-enhanced formulations that achieve substantially higher plasma concentrations than plain turmeric powder. The signal is real, the case-report literature is growing, and the mechanistic understanding (oxidative stress, mitochondrial dysfunction, possible idiosyncratic immune component) is incomplete. The conservative recommendation for chronic supplementation users is liver function monitoring at baseline and periodically; discontinuation at any sign of hepatic dysfunction; and a low threshold to substitute plain turmeric for bioavailability-enhanced formulations or to discontinue supplementation entirely if the indication is itself marginal.
| pregnancy_details = Culinary amounts of turmeric are considered safe in pregnancy and lactation with a long historical record in essentially all turmeric-using cultures, particularly the Indian subcontinent where daily culinary intake is the norm. The traditional Ayurvedic and folk caution about turmeric in pregnancy applies to medicinal-dose use, not to culinary use: classical sources name turmeric as warming and as a mild emmenagogue at therapeutic dose, with the late-pregnancy concern being premature uterine activity. Therapeutic-dose supplementation, particularly high-bioavailability formulations and curcumin extracts, has not been formally studied in pregnancy and is best avoided; the hepatotoxicity risk and the theoretical antiplatelet effect both compound the conservative recommendation against therapeutic-dose supplementation in pregnancy.
| monitoring = For patients on warfarin or DOACs who consume turmeric at any consistent therapeutic-dose level, INR monitoring at the initiation of regular consumption and again at three to four weeks is the conservative practice; therapeutic-dose supplementation is best avoided rather than monitored in patients on warfarin. For chronic high-dose curcumin supplementation (above 1 g daily of standardized curcuminoid extract or any chronic bioavailability-enhanced formulation), liver function testing at baseline and periodically (every six to twelve months) is the conservative practice in patients with pre-existing hepatic disease or concurrent hepatotoxic medicine use; the signal of supplement-associated hepatotoxicity is substantial enough to warrant monitoring at this level of exposure regardless of additional risk factors in patients on indefinite supplementation regimens.
| counseling = Patients should be counseled that culinary turmeric (gram-per-day scale, as used in Indian, southeast Asian, and Caribbean cooking and in turmeric-milk preparations) is broadly safe, has the long historical record of Indian sub-continental use to support its safety profile, and delivers modest amounts of pharmacologically active compound through the turmerone fraction and through small amounts of cumulative curcumin metabolites. The traditional pairing of turmeric with black pepper in Indian cuisine is the culinary precedent for the modern piperine-curcumin supplement formulations and substantially enhances curcumin bioavailability.

The shift from culinary turmeric to therapeutic-dose curcumin supplementation is a meaningful change in pharmacology and risk profile. Standardized curcuminoid extracts deliver substantially more curcumin per dose than culinary use, and bioavailability-enhanced formulations (Meriva, Theracurmin, and similar) deliver substantially higher systemic curcumin concentrations than plain extracts. The clinical effect on inflammatory disease is modest at best at any of these dose levels; the hepatotoxicity risk increases with dose and bioavailability enhancement and is the principal modern safety concern for the herb.

For patients who choose curcumin supplementation for inflammatory indication: a reasonable approach is to begin with the lower end of the dose range (500 mg of standardized curcuminoid extract daily, with or without piperine), to assess clinical effect over four to eight weeks, and to discontinue if no benefit is apparent. Indefinite multi-year high-dose supplementation, particularly with bioavailability-enhanced formulations, carries the hepatotoxicity concern and warrants periodic LFT monitoring. Patients should be counseled to discontinue any curcumin supplementation immediately if they develop jaundice, dark urine, unexplained nausea, or right-upper-quadrant abdominal discomfort, and to consult their prescriber.

Turmeric powder applied topically can stain skin and clothing yellow; the cosmetic staining resolves over days to a week on skin and is generally permanent on light-colored fabric. Patients using topical turmeric paste for skin complaint should be counseled to apply at times when temporary yellow staining is acceptable and to test for cinnamaldehyde-equivalent contact dermatitis on a small area before broader application.

The traditional pregnancy caution against medicinal turmeric (as distinct from culinary use) reflects a real if modest emmenagogue effect at high dose; pregnant patients should be counseled to limit themselves to culinary doses and to avoid curcumin extract supplementation entirely in pregnancy.
| anecdotes =
| seealso = [[Ginger]], [[Cardamom]], [[Black pepper]], [[Cinnamon]], [[Ceylon cinnamon]], [[Cassia cinnamon]], [[Cloves]], [[Boswellia]], [[Garlic]]
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Anti-inflammatory herbs]]
[[Category:Digestive herbs]]
[[Category:Hepatoprotective herbs]]
[[Category:Ayurvedic herbs]]
[[Category:TCM herbs]]
[[Category:Western clinical herbs]]

Cassia cinnamon

2026-05-26T18:56:01Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| binomial = Cinnamomum cassia (L.) J.Presl
| family = Lauraceae
| common_names = Cassia cinnamon, Chinese cinnamon, cassia, gui (Chinese, the generic name), rou gui (Chinese, the bark), gui zhi (Chinese, the twig), dar-cini (Persian and Urdu, shared with Ceylon), qirfa (Arabic, shared with Ceylon); the synonymic binomial ''Cinnamomum'' aromaticum Nees appears in some older literature
| native_range = southern China and northern Vietnam (Guangxi and Guangdong provinces are the principal historical and modern production areas); cultivated widely throughout southeast Asia, with related ''Cinnamomum'' loureirii (Saigon cinnamon, Vietnam) and ''Cinnamomum'' burmannii (Indonesian cinnamon, Java and Sumatra) frequently traded under the generic "cassia" or "cinnamon" name and supplying the majority of American grocery-store cinnamon
| cultivars = grade-based: Vietnamese cassia (C. loureirii, technically a distinct species) is often the highest-cinnamaldehyde and most pungent product; Chinese cassia (''C. cassia'' proper) is the traditional TCM source; Indonesian cassia (C. burmannii, also a distinct species, also frequently sold as "cassia") is the lower-priced commodity cinnamon dominating American retail. The species distinctions matter for coumarin content (which varies among the three) and for cinnamaldehyde concentration, but the three are routinely sold interchangeably under the "cassia" or "cinnamon" name in the American market
| parts_used = inner bark (rou gui, the TCM and culinary form, the characteristic hollow tube quill); young twig (gui zhi, the TCM surface-resolving form); the leaf is less used than in ''C. verum''; root bark, camphor-rich, used historically
| cultivation = subtropical evergreen tree to 10 to 15 m at full size, maintained as coppice or semi-coppice for bark production; bark stripping is mechanically and chemically similar to the Ceylon practice but produces the characteristic single-layer thick rigid quill rather than the multi-layered brittle Ceylon scroll
| preparations_summary = bark powder 1 to 4 g daily for digestive carminative use (with the coumarin-content caveat below); bark essential oil 0.05 to 0.2 mL daily, diluted, never undiluted on skin or mucosa; rou gui (bark) 2 to 5 g per day in TCM decoction; gui zhi (twig) 3 to 10 g per day in TCM decoction; tincture 1:5 in 70 percent alcohol, 2 to 4 mL three times daily; aqueous extract for some glycemic-effect supplement formulations
| constituents_summary = cinnamaldehyde 75 to 90 percent of bark essential oil (higher than verum's 65 to 80 percent, accounting for cassia's more pungent flavor); eugenol below 1 percent of bark essential oil (contrasting with verum's 5 to 10 percent); coumarin 0.4 to 4 percent of bark dry weight (the load-bearing safety distinction; verum carries trace amounts below 0.004 percent); cinnamyl acetate, cinnamic acid and derivatives; proanthocyanidins (type A doubly-linked oligomers); MHCP (methylhydroxychalcone polymer, the proposed insulin-mimetic, identified primarily in cassia)
| mechanism = cinnamaldehyde TRPA1 ion-channel agonism produces the characteristic warming-and-pungent sensation and contributes to carminative effect through smooth-muscle modulation; cinnamaldehyde broad-spectrum antimicrobial effect via membrane disruption and thiol-disulfide exchange; MHCP enhancement of insulin-receptor autophosphorylation and downstream glycogen-synthase signaling provides the mechanistic rationale for the glycemic effect documented in type 2 diabetes trials, most of which used cassia rather than Ceylon; the coumarin fraction is metabolized hepatically via CYP2A6 with substantial individual-variable production of the 3-hydroxycoumarin minor pathway that accounts for the rare-but-real chronic-intake hepatotoxicity in heavy users
| pregnancy = culinary doses safe; therapeutic-dose supplementation, essential oil, and chronic high-coumarin intake caution
| legal = unscheduled; GRAS for culinary use; widely sold worldwide as culinary spice and as dietary supplement; this is the cinnamon dominant in the American supermarket and the principal "cinnamon" of commercial baked goods
| interactionsummary = modest hypoglycemic potentiation with insulin and oral antidiabetic medicines at therapeutic-dose supplementation (the trial evidence base is dominated by cassia); chronic high-intake coumarin hepatotoxicity is the principal clinically significant adverse-effect category for this species, distinguishing it from Ceylon and constraining the conservative chronic-supplementation dose; cinnamaldehyde contact dermatitis (common with concentrated essential oil and in spice-handling occupations); oral mucosal irritation possible at high concentrations; no clinically significant anticoagulant interaction (the cinnamon coumarin is not the 4-hydroxycoumarin warfarin class and lacks direct anticoagulant activity)
| intro = '''Cassia cinnamon''' is the dried inner bark of ''Cinnamomum cassia'' (L.) J.Presl, a subtropical evergreen tree of the Lauraceae native to southern China and northern Vietnam and one of the foundational warming herbs of traditional Chinese medicine. The species is the cinnamon of the East Asian materia medica, the principal "cinnamon" of the American supermarket and of commercial baked goods, and the higher-coumarin twin of the Ceylon cinnamon ([[Ceylon cinnamon|''Cinnamomum'' verum]]) with which it is routinely confused in commerce and clinical conversation. Cassia bark is documented in Chinese sources from the Han dynasty onward and appears in the foundational Chinese materia medica the Shennong Bencao Jing (compiled in the early centuries of the common era from older oral tradition) under the entry gui, which is the generic Chinese name for the cinnamon-family barks and twigs. The two principal TCM preparations of the bark are '''rou gui''' (the older, thick, ground-floor bark used as the chief warming-yang herb of the Chinese pharmacopoeia, indicated for kidney-yang deficiency, mingmen-fire weakness, and cold-pattern lumbar and abdominal pain) and '''gui zhi''' (the young twig used in surface-resolving formulas for early-stage external wind-cold patterns); the two are distinct in clinical use within TCM despite arising from the same plant. The cassia of Western commerce and clinical research is most often the bark, marketed under the generic "cinnamon" or "cassia" name without species discrimination from the related ''Cinnamomum'' loureirii (Saigon cinnamon, Vietnam) and ''Cinnamomum'' burmannii (Indonesian cinnamon, Java), both of which are botanically distinct species but commercially interchangeable with ''C. cassia'' in the modern global cinnamon supply. The principal safety distinction from Ceylon cinnamon is the coumarin content: cassia bark contains 0.4 to 4 percent coumarin by dry weight, against trace amounts in Ceylon, and chronic high dietary intake of cassia (heavy supplementation, large cinnamon-rich baked-goods consumption, or social-media "cinnamon challenge" levels) can exceed the European Food Safety Authority tolerable daily intake of 0.1 mg per kg body weight and produce hepatotoxicity in susceptible individuals.
| traditional_uses = The Chinese tradition is the historical centroid of cassia cinnamon. The bark and twig are documented from the Han dynasty onward and appear in the foundational Chinese materia medica the Shennong Bencao Jing (compiled in the first or second century CE from older oral tradition) under the entry gui, classed in the upper grade of medicines (the rejuvenative tonics, used long-term without harm).<ref name="yang-shennong">Yang SZ (translator). ''The Divine Farmer's Materia Medica: A Translation of the Shen Nong Ben Cao Jing''. Boulder, CO: Blue Poppy Press; 1998.</ref> The clinical use of cassia in TCM was systematized by [[wikipedia:Zhang Zhongjing|Zhang Zhongjing]] in his Shang Han Lun ("Treatise on Cold Damage Disorders") of about 220 CE, the foundational Chinese clinical text on febrile and external-pathogen disease.<ref name="shanghan-lun">Mitchell C, Ye F, Wiseman N. ''Shang Han Lun: On Cold Damage, Translation and Commentaries''. Brookline, MA: Paradigm Publications; 1999.</ref> Zhang opened the Shang Han Lun with the formula '''Gui Zhi Tang''' (cassia twig, peony root, jujube, ginger, licorice), the foundational surface-resolving formula for early-stage external wind-cold disorder, and paired it with '''Ma Huang Tang''' (ephedra, cassia twig, almond, licorice) for the warming-and-dispersing pattern; the two formulas anchor the entire TCM tradition of treating cold-pattern external invasion and remain in routine modern use.

The TCM clinical separation of '''rou gui''' (the bark) from '''gui zhi''' (the twig) is the defining preparation distinction for this herb. Rou gui is the chief warming yang herb of the Chinese materia medica: it is indicated for kidney-yang deficiency (a syndrome encompassing chronic cold extremities, low back and knee weakness, impotence, polyuria, and exhaustion), for mingmen-fire weakness (the "gate of life" digestive-fire deficiency presenting as cold abdominal pain, chronic diarrhea, and edema), and for cold-pattern menstrual disorders including amenorrhea and dysmenorrhea with clear copious discharge.<ref name="bensky-cassia">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica, 3rd ed''. Seattle: Eastland Press; 2004.</ref> Gui zhi is the surface-resolving twig: it warms the meridians, dispels wind, and is the principal ingredient of the foundational Han dynasty Shang Han Lun formulas Gui Zhi Tang and its many derivative formulas (the gui zhi family of about thirty Shang Han Lun formulas, modified for specific clinical patterns); modern Chinese herbal practice uses gui zhi as a routine ingredient in the early-stage cold-and-wind treatment of upper respiratory and musculoskeletal complaint.

The Mediterranean tradition documented cassia (Greek kasia, Hebrew qiddah) as a distinct trade good alongside true cinnamon (kinnamomon, qinnamon) from the earliest written records onward. The Hebrew Bible lists qiddah as a constituent of the holy anointing oil prescribed in Exodus thirty (alongside qinnamon, myrrh, and calamus) and as one of the trade cargoes of the merchants of Tyre in the prophecy of Ezekiel; the Hebrew distinction between the two cinnamons predates the formal botanical separation of the species by more than two thousand years. Dioscorides in book one of his De Materia Medica of about 60 CE devoted separate entries to kinnamomon and kasia, listing both as warming, digestive, and emmenagogue, but ranking kinnamomon as the more valuable.<ref name="dioscorides-cassia">Beck LY (translator). ''Pedanius Dioscorides of Anazarbus: De Materia Medica''. Hildesheim: Olms-Weidmann; 2005 (translation of c. 60 CE original).</ref> Pliny the Elder in book twelve of his Naturalis Historia gave both spices extended treatment and noted (correctly) that the Mediterranean trade in cassia was substantially larger by volume than the trade in true cinnamon, an indication that even in the Roman period the cheaper, more abundant cassia was the workhorse cinnamon of everyday commerce.<ref name="pliny-cassia">Bostock J, Riley HT (translators). Pliny the Elder: ''The Natural History''. London: Taylor and Francis; 1855.</ref>

The Islamic and Persian medical traditions documented cassia within the same Dar-Cini and qirfa entries as Ceylon cinnamon, without (initially) distinguishing the two species; the practical Unani distinction between the higher-grade darchini-yi-suluqi (Sri Lankan, Ceylon) and inferior grades implicitly distinguished cassia as the cheaper and lower-grade product. The Avicennan indications (chronic cough, asthmatic complaints, dyspepsia, vomiting, weak constitution) apply to both species; cassia in the medieval Islamic pharmacopoeia was the cheaper and more available form for routine clinical use, while Ceylon was reserved for higher-grade prescription.

The European reception of cassia was the inverse of the Ceylon trade in scale and clinical prestige. Cassia was the cheaper alternative throughout the medieval and early modern European pharmacopoeial tradition; the Continental tradition (German, French, Dutch) more often accepted cassia where the British tradition preferred Ceylon. The American market, which developed in the nineteenth century outside the British colonial trade network for Ceylon, settled on cassia as the dominant cinnamon for both culinary and clinical use, and the modern American grocery-store "cinnamon" is overwhelmingly ''C. cassia'' or one of its related species (C. loureirii, C. burmannii) rather than ''C. verum''.

The modern Western pharmacopoeial tradition recognizes cassia cinnamon (Cinnamomi cassiae cortex) separately from Ceylon, with the coumarin content as the principal safety distinction. The European Medicines Agency Committee on Herbal Medicinal Products issued a separate monograph for ''Cinnamomum cassia'' bark, with a specific coumarin-intake warning that the verum monograph does not carry.<ref name="ema-hmpc-cassia">European Medicines Agency, Committee on Herbal Medicinal Products. Community herbal monograph on ''Cinnamomum cassia'' Blume, cortex. EMA/HMPC/513617/2010 (the monograph documents are available from the EMA website).</ref> The German Federal Institute for Risk Assessment issued a 2012 statement on coumarin in cinnamon foods, noting that the EFSA tolerable daily intake of 0.1 mg coumarin per kg body weight is regularly exceeded by chronic high consumption of cassia-containing foods (heavy use of powdered cinnamon in oatmeal and baked goods, supplement use) and recommending Ceylon as the safer choice for chronic high-intake users.<ref name="bfr-coumarin">Bundesinstitut für Risikobewertung (German Federal Institute for Risk Assessment). ''Updated Health Assessment of Coumarin in Cinnamon and Other Foods''. BfR Opinion No 036/2006 (18 September 2006), with subsequent updates including the 2012 communication. Available from the BfR website.</ref> A small literature of case reports documents hepatotoxicity from chronic high-dose cassia supplementation in susceptible individuals, with onset typically over weeks to months of multi-gram daily intake and resolution on discontinuation; the reports are rare in absolute terms relative to the magnitude of cassia consumption worldwide, but the case-report literature is reproducible enough to constitute a real safety signal and is the empirical basis for the EMA and BfR coumarin warnings.<ref name="brancheau-2015">Brancheau D, Patel B, Zughaib M. Do cinnamon supplements cause acute hepatitis? ''The American Journal of Case Reports''. 2015 Apr 29;16:250-254. PMID 25923145.</ref>

The contemporary controlled-trial literature on cinnamon for type 2 diabetes is dominated by cassia rather than Ceylon, with most trial populations receiving Chinese or Indonesian cassia bark powder or extract. Meta-analyses have produced positive findings (modest reductions in fasting glucose), null findings, and intermediate findings; the most-cited recent meta-analysis (Allen 2013) reported modest improvements in fasting plasma glucose, total cholesterol, LDL, and triglycerides with cinnamon supplementation in patients with type 2 diabetes, with substantial between-study heterogeneity.<ref name="allen2013">Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. ''Annals of Family Medicine''. 2013 Sep-Oct;11(5):452-459. PMID 24019277.</ref> Where observational and short-trial evidence has supported the glycemic-effect claim, larger and more recent randomized trials have tended toward modest or null effect; the role of cassia in type 2 diabetes management is a useful adjunctive at best, not a primary intervention, and the choice between cassia and Ceylon for chronic supplementation should weigh the modestly stronger cassia evidence against cassia's coumarin hepatotoxicity concern.
| traditional_geography =
| botany = ''Cinnamomum cassia'' is a subtropical evergreen tree of the Lauraceae reaching 10 to 15 m at full size in undisturbed cultivation, maintained as coppice in commercial bark production. The leaves are opposite, oblong to elliptic, 10 to 18 cm long, with five (occasionally three) prominent palmate-pinnate veins running from the base to near the leaf apex; the five-vein pattern is one of the diagnostic distinctions from ''C. verum'', which characteristically has three (occasionally five). The bark of mature trunks is grey-brown, deeply fissured; the medicinally used bark is the harder, thicker inner bark of coppice shoots, scraped of the outer corky layer and dried to form the characteristic single-layer thick rigid quill (a hollow tube rather than the multi-layered brittle scroll of Ceylon). The bark color is darker reddish-brown than the light tan of Ceylon. The flowers are small, greenish-yellow, in lax panicles; the fruit is a small drupe 1 to 2 cm long. The young twigs (gui zhi in TCM preparation) are slender, brown, and cinnamaldehyde-aromatic. Distinguished from ''Cinnamomum verum'' in whole-stick or whole-leaf material by the five-vs-three leaf venation, the single-layer-vs-multi-layer quill structure, the darker red-brown color, and the harder rigid texture; these distinctions hold for whole material and are lost in ground powder, where chemical or spectroscopic distinction (cinnamaldehyde-eugenol-coumarin ratio profiling) is required. Distinguished from ''Cinnamomum'' loureirii (Saigon cinnamon, the related Vietnamese species often sold interchangeably) by smaller leaf size and somewhat lower cinnamaldehyde content; from ''Cinnamomum'' burmannii (Indonesian cinnamon, the principal cassia of the American grocery supply) by leaf morphology and a different terpene profile.
| constituents = The principal medicinally active constituents of cassia bark are the volatile oil (1 to 2 percent of dry bark by weight, lower than Ceylon's 3 to 4 percent) and the proanthocyanidin polyphenol fraction. The volatile oil composition is the principal pharmacognostic distinction from Ceylon: cassia bark oil contains '''cinnamaldehyde''' at 75 to 90 percent of the oil (higher than Ceylon's 65 to 80 percent, accounting for cassia's more pungent and more one-note flavor), '''eugenol''' at less than 1 percent (against Ceylon's 5 to 10 percent), and '''coumarin''' at 0.4 to 4 percent of bark dry weight (against trace amounts in Ceylon, typically below 0.004 percent).<ref name="wang2013">Wang YH, Avula B, Nanayakkara NP, Zhao J, Khan IA. Cassia cinnamon as a source of coumarin in cinnamon-flavored food and food supplements in the United States. ''Journal of Agricultural and Food Chemistry''. 2013 May 8;61(18):4470-4476. PMID 23627682.</ref> The Wang 2013 quantitative analysis of US-market cinnamon samples established the cassia-coumarin levels at 7 to 12 mg per gram of cassia powder (the higher end of the range for Chinese cassia, the lower end for Indonesian cassia), against undetectable or sub-milligram-per-gram coumarin levels in Ceylon samples; the analytical distinction is the practical fingerprint by which the two species are separated in modern quality control and the empirical basis of the chronic-intake hepatotoxicity concern.

Cassia bark oil also contains smaller amounts of cinnamyl acetate, cinnamic acid, benzaldehyde, salicylaldehyde, and trace eugenol; the overall aromatic profile is sharper and more cinnamaldehyde-dominant than Ceylon's more complex sweet-warm bouquet.

The non-volatile fraction includes '''proanthocyanidins''' (the type A doubly-linked oligomers characteristic of ''Cinnamomum'', contributing to antioxidant and astringent activity), '''MHCP''' (methylhydroxychalcone polymer, identified at higher concentrations in cassia than in Ceylon and proposed as the principal insulin-mimetic constituent), and a range of cinnamic acid derivatives.
| preparations = The traditional Chinese forms are the '''rou gui''' (the bark, used in TCM decoction at 2 to 5 g per day, with the highest grades reserved for specific tonic formulations) and '''gui zhi''' (the twig, used in TCM decoction at 3 to 10 g per day, with Gui Zhi Tang the foundational Shang Han Lun formula). The Western therapeutic forms are the '''bark powder''' (1 to 4 g daily, with the coumarin-content caveat constraining the upper limit in chronic high-intake users); the '''bark essential oil''' (steam-distilled, 0.05 to 0.2 mL daily, diluted; never undiluted on skin or mucosa, and never as a primary medicinal route in chronic use because of the concentrated coumarin and cinnamaldehyde irritation); the '''tincture''' (1:5 in 70 percent alcohol, 2 to 4 mL three times daily); and the '''aqueous extract''' (used in some glycemic-effect supplement formulations to concentrate the polyphenol and MHCP fraction while reducing the essential-oil and coumarin content).
| indications = Carminative and digestive aid for postprandial bloating, mild dyspepsia, and flatulence (the principal Commission E indication). Type 2 diabetes mellitus glycemic adjunct (the principal modern clinical indication, with most trial evidence from cassia rather than Ceylon; modest effect; not a primary intervention). TCM-specific indications: kidney-yang deficiency syndrome (rou gui), mingmen-fire weakness with cold abdominal pain or chronic diarrhea (rou gui), cold-pattern dysmenorrhea and amenorrhea (rou gui), early-stage external wind-cold disorder with chills and absent sweating (gui zhi in Gui Zhi Tang and Ma Huang Tang), warming-the-meridians for cold-pattern arthritis and musculoskeletal complaint (gui zhi). Mild antimicrobial and antifungal traditional use. Folk indications: warming for cold-pattern complaint, dysmenorrhea, and as a flavoring synergist in compound formulations.
| dosing = Bark powder: 1 to 4 g daily (the upper end constrained in chronic high-intake users by the coumarin TDI of 0.1 mg/kg/day, which a 70 kg adult exceeds at approximately 2 g of cassia powder daily). Whole bark in decoction or infusion: 0.5 to 1 g per cup, three times daily. Bark essential oil: 0.05 to 0.2 mL daily, diluted; never undiluted; not recommended for chronic high-dose internal use because of cumulative coumarin exposure. Tincture 1:5 in 70 percent alcohol: 2 to 4 mL three times daily. TCM rou gui (bark): 2 to 5 g daily in compound formula. TCM gui zhi (twig): 3 to 10 g daily in compound formula. For glycemic-effect supplementation: 1 to 6 g of cassia daily has been the typical trial range; doses above 2 g daily approach or exceed the coumarin TDI threshold for a 70 kg adult and are best limited to short-course use (weeks to a few months) rather than indefinite supplementation, or substituted with Ceylon cinnamon for the chronic-use case.
| effects =
| pharmacokinetics = Cinnamaldehyde is rapidly absorbed from the gastrointestinal tract and rapidly oxidized to cinnamic acid and then conjugated to hippuric acid (the principal urinary metabolite); elimination of the cinnamaldehyde-derived metabolites is largely complete within 24 hours of administration. Coumarin (substantial in cassia at 0.4 to 4 percent of bark dry weight) is absorbed and metabolized hepatically via CYP2A6: approximately 90 percent is converted to 7-hydroxycoumarin (a detoxification pathway, excreted in urine), and approximately 1 to 6 percent via the minor pathway to 3-hydroxycoumarin (the hepatotoxic intermediate, which can produce hepatocyte mitochondrial damage on chronic high exposure). The CYP2A6 enzyme has substantial polymorphic variation in the human population, with poor-metabolizer genotypes diverting more coumarin through the 3-hydroxycoumarin pathway and accounting for the variable individual susceptibility to chronic cassia hepatotoxicity. The pharmacokinetic distinction is the empirical basis of the EFSA tolerable daily intake of 0.1 mg coumarin per kg body weight per day, set conservatively to protect the poor-metabolizer susceptible population.
| pharmacodynamics = Cinnamaldehyde is a TRPA1 ion-channel agonist, accounting for the warming-and-pungent sensation of cassia on the tongue and gut mucosa and contributing to the carminative effect through smooth-muscle modulation and gastric motility effect. Cinnamaldehyde and the cinnamic acid derivatives produce broad-spectrum antimicrobial effect against bacteria, fungi (including Candida species), and some viruses, mediated by membrane disruption and thiol-disulfide exchange with bacterial enzymes. The proanthocyanidins produce astringent gut-mucosa stabilization. The glycemic effect of cassia has been proposed to involve MHCP enhancement of insulin-receptor autophosphorylation and downstream glycogen-synthase signaling, with cassia having higher MHCP content than Ceylon and the modern T2DM trial literature accordingly weighted toward cassia; the trial-level glycemic effect is nevertheless modest, with substantial heterogeneity between studies and a trend toward null effect in larger and more recent trials. The coumarin pharmacology of cassia is the principal pharmacodynamic distinction from Ceylon: chronic high exposure produces hepatocyte mitochondrial dysfunction in susceptible CYP2A6-polymorphic individuals via the 3-hydroxycoumarin minor metabolic pathway, the mechanistic basis of the rare-but-real cassia hepatotoxicity case reports.
| interactions = <pharmaInteractions/>

The clinically significant interactions of cassia cinnamon are dominated by the coumarin-hepatotoxicity and hypoglycemic-potentiation categories.

'''Coumarin chronic hepatotoxicity''' is the principal cassia-specific safety concern and the principal distinction from Ceylon cinnamon. Chronic dietary or supplemental cassia intake at multi-gram-per-day levels (heavy oatmeal-cinnamon consumption, large cassia-rich baked-goods intake, multi-gram-per-day cassia supplementation) regularly exceeds the EFSA tolerable daily intake of 0.1 mg coumarin per kg body weight in adults of average weight, with the higher exposures occurring among supplement users and among heavy culinary consumers. The empirical case-report literature documents rare-but-reproducible hepatotoxicity in susceptible individuals on chronic high-cassia exposure, with onset typically over weeks to months and resolution on discontinuation. The conservative recommendation for chronic supplementation is to limit cassia to short-course use (weeks to a few months) and substitute Ceylon cinnamon for indefinite or high-dose chronic use.

'''Modest hypoglycemic potentiation''' with insulin and oral antidiabetic medicines is the principal pharmacodynamic interaction; the effect is small at culinary doses, somewhat more substantial at therapeutic-dose supplementation, and the trial evidence is dominated by cassia studies.<ref name="allen2013-int">Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. ''Annals of Family Medicine''. 2013 Sep-Oct;11(5):452-459. PMID 24019277.</ref> Patients on antidiabetic regimens who add cassia supplementation should monitor for hypoglycemia, particularly during dose titration of the antidiabetic medicine.

The widely repeated concern that cinnamon (cassia or Ceylon) potentiates warfarin or other anticoagulants is mistaken about coumarin pharmacology: the coumarin of cinnamon is the parent 2H-1-benzopyran-2-one compound, not the 4-hydroxycoumarin (warfarin) class, and lacks direct anticoagulant activity. The cassia coumarin concern is hepatotoxicity at chronic high exposure, not anticoagulation. No specific anticoagulation-related preoperative discontinuation recommendation is necessary for cassia at culinary or routine supplementation doses; the hepatotoxicity concern operates on a different timescale (chronic, cumulative) and is addressed by dose-limiting rather than by perioperative discontinuation.

Contact dermatitis from cinnamaldehyde is the principal occupational concern, more common with cassia than Ceylon because of cassia's higher cinnamaldehyde concentration; this affects bakers, spice handlers, and food-industry workers more often than retail consumers.
| pregnancy_details = Culinary amounts of cassia cinnamon are considered safe in pregnancy and lactation, with a long historical record of routine use in essentially all cinnamon-using cultures. Therapeutic-dose supplementation (multi-gram daily for glycemic effect, or essential oil for any indication) and the cassia-coumarin chronic-intake concern apply in pregnancy as in the general population, with the additional consideration that fetal coumarin exposure has not been formally studied at the relevant intake levels; the conservative recommendation is to limit pregnant patients to culinary doses of cassia (or to substitute Ceylon at any chronic supplementation level) and to avoid concentrated cassia essential oil entirely in pregnancy.
| monitoring = For patients on insulin or oral antidiabetic medicines who add cassia supplementation at therapeutic dose, fasting glucose monitoring at baseline and at two to four weeks of regular supplementation is the conservative practice. For chronic high-intake cassia consumers (multi-gram daily cassia powder supplementation for indefinite duration, or comparable heavy dietary intake), liver function test monitoring at baseline and periodically (every six to twelve months) is reasonable, particularly in patients with pre-existing hepatic disease or concurrent hepatotoxic medicine use; substitution of Ceylon for cassia in chronic high-intake users is the preferable alternative to ongoing LFT surveillance.
| counseling = The most important counseling distinction for cinnamon is the species, and patients seeking cinnamon for chronic high-intake therapeutic use should generally choose Ceylon ([[Ceylon cinnamon]]) rather than cassia because of the coumarin-content difference. The cinnamon sold as a culinary spice in most American grocery stores and used in commercial baked goods is ''C. cassia'' or one of its related species (C. loureirii Saigon cinnamon, C. burmannii Indonesian cinnamon), not ''C. verum'' Ceylon cinnamon. The visual distinction between cassia and Ceylon is possible with whole sticks but lost in ground powder. Cassia is darker reddish-brown, composed of a single thick rigid layer rolled into a hollow tube, hard and resistant to crushing, with a strong, simple, pungent aroma; Ceylon is light tan, composed of many thin papery layers tightly rolled into a multi-quill scroll, brittle and easily crushed, with a delicate, complex, sweet aroma.

For patients consuming cinnamon at routine culinary levels (gram or fraction of gram per day, sprinkled on food), the coumarin exposure from cassia is unlikely to reach the tolerable daily intake threshold and species choice is not a clinical priority. For patients consuming cinnamon at therapeutic supplementation levels (multi-gram daily, particularly the powdered form in capsules) or at high dietary levels (large quantities in baked goods, daily heavy-cinnamon oatmeal, social-media "cinnamon challenge" of swallowed dry powder), the coumarin exposure from cassia can substantially exceed safe daily intake. The Ceylon species is the appropriate substitution for chronic high-intake users; cassia is the appropriate choice for short-course supplementation (weeks to a few months) and for routine culinary use where chronic exposure is moderate.

The social-media "cinnamon challenge" (swallowing a tablespoon of dry cinnamon powder) carries the acute risks of aspiration and aspiration pneumonia (dry cinnamon powder is highly aspirable and reaches the lower airways) and the cumulative-coumarin risk only with repeated practice; the acute aspiration danger is the more immediate concern. Cinnamon essential oil (either species) is concentrated and irritating; it should never be applied undiluted to skin or mucosa, and oral consumption of essential oil at more than a few drops daily can produce gastritis, oral mucositis, and (with chronic high-dose cassia oil specifically) hepatotoxicity. Cinnamon chewing-gum stomatitis is a recognized presentation of intra-oral mucosal hypersensitivity to high-concentration cinnamaldehyde, more common with cassia than Ceylon because of cassia's higher cinnamaldehyde content; presentations generally resolve on cessation. Contact dermatitis from cinnamon (especially the essential oil and especially cassia) is a regular occupational concern in spice-handling industries and culinary work.
| anecdotes =
| seealso = [[Ceylon cinnamon]], ''[[Cinnamomum verum]]'', [[Ginger]], [[Turmeric]], [[Cardamom]], [[Cloves]], [[Star anise]], [[Garlic]]
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Cardiovascular herbs]]
[[Category:Carminatives]]
[[Category:TCM herbs]]
[[Category:Western clinical herbs]]

Ceylon cinnamon

2026-05-26T18:56:00Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| binomial = Cinnamomum verum J.Presl
| family = Lauraceae
| common_names = Ceylon cinnamon, true cinnamon, kurundu (Sinhala), karuvapatta (Tamil), tvak (Sanskrit, "bark"), dalchini (Hindi), darchini (Persian and Urdu), qirfa or dar-cini (Arabic), kayu manis (Indonesian and Malay, "sweet wood"); the synonymic binomial ''Cinnamomum'' zeylanicum Blume is widely used in older botanical and pharmacopoeial literature
| native_range = Sri Lanka and the Malabar coast of southwestern India; cultivated also in the Seychelles, Madagascar, Java, Sumatra, southern India, and parts of the Caribbean
| cultivars = grade-based rather than cultivar-based: from the highest grade Alba (small, thin, tightly rolled sticks of the finest quality) through C5, C4, M5, M4, M, H1, H2 in decreasing order of stick uniformity, color, and aromatic potency; ''Cinnamomum'' loureirii (Saigon cinnamon, Vietnam) and ''Cinnamomum'' burmannii (Indonesian cinnamon, Java) are different species frequently sold under the generic "cinnamon" name in the American market, neither of them ''C. verum''
| parts_used = inner bark of coppiced young branches (the characteristic multi-layered quill scrolls or "stick" form); the leaf (Ceylon leaf essential oil is eugenol-dominant and distinct in flavor and pharmacology from the cinnamaldehyde-dominant bark oil); the root bark, camphor-rich, used historically
| cultivation = tropical lowland to mid-elevation evergreen tree to 10 to 15 m at full size but maintained as coppice in plantation production; trees are cut to stumps at two to three years and the resulting straight new shoots are harvested every 18 to 24 months for the inner bark; bark stripping is a specialized craft (the outer cork and green outer cambium are scraped away, and the inner bark separates as it dries and curls into the multi-quill scrolls)
| preparations_summary = bark powder 1 to 4 g daily (the culinary and traditional therapeutic form); bark essential oil 0.05 to 0.2 mL daily (concentrated, used dilute, never undiluted on skin or mucosa); infusion 0.5 to 1 g per cup, three times daily; tincture 1:5 in 70 percent alcohol, 2 to 4 mL three times daily; leaf essential oil (eugenol-dominant) for topical dental and flavoring use; aqueous extract for some glycemic-effect supplement formulations
| constituents_summary = cinnamaldehyde 65 to 80 percent of bark essential oil (the principal pungent and antimicrobial component); eugenol 5 to 10 percent of bark essential oil (the Ceylon-distinctive marker, contributing a clove-like aromatic note; cassia bark oil contains less than 1 percent eugenol); coumarin trace, typically below 0.004 percent of bark dry weight (contrasting sharply with cassia at 0.4 to 4 percent, the basis of the cassia hepatotoxicity concern that does not apply to Ceylon); cinnamyl acetate, cinnamyl alcohol, beta-caryophyllene, linalool, alpha-pinene; proanthocyanidins (the type A doubly-linked condensed-tannin oligomers characteristic of ''Cinnamomum''); MHCP (methylhydroxychalcone polymer, the putative insulin-mimetic, identified primarily in cassia with variable presence in verum); cinnamic acid and derivatives
| mechanism = cinnamaldehyde and eugenol produce broad-spectrum antimicrobial effect through membrane disruption and thiol-disulfide exchange with bacterial enzymes; proanthocyanidins provide astringent gut-mucosa stabilization (the basis of the mild antidiarrheal traditional use); MHCP and other cinnamon constituents have been proposed to enhance insulin-receptor autophosphorylation and downstream glycogen-synthase signaling, providing the mechanistic rationale for the modest hypoglycemic effect (the evidence base is dominated by cassia studies and the mechanism is incompletely characterized); cinnamaldehyde is a TRPA1 ion-channel agonist, accounting for the characteristic warmth-and-pungency sensation
| pregnancy = culinary doses safe; therapeutic-dose supplementation or essential oil caution
| legal = unscheduled; GRAS for culinary use; widely sold worldwide as culinary spice and as dietary supplement
| interactionsummary = modest hypoglycemic potentiation with insulin and oral antidiabetic medicines at therapeutic-dose supplementation (most trial evidence is from cassia rather than Ceylon, and the Ceylon-specific signal is weaker); no clinically significant anticoagulant interaction (the coumarin content of Ceylon is well below cassia and the cinnamon coumarin is not the 4-hydroxycoumarin warfarin class in any case); cinnamaldehyde contact dermatitis is the principal adverse-effect category, particularly with concentrated essential oil; oral mucosal irritation possible at high concentrations (cinnamon chewing-gum stomatitis is a recognized presentation)
| intro = '''Ceylon cinnamon''' is the dried inner bark of ''Cinnamomum verum'' J.Presl, a small evergreen tree of the Lauraceae native to Sri Lanka and the Malabar coast of southwestern India. The species is the original "true" cinnamon of antiquity and stands in commercial and pharmacological contrast to its better-known relative ''Cinnamomum cassia'' (Chinese cinnamon, the dominant supermarket cinnamon of the modern English-speaking world), with which it has been confused since Greek antiquity and which carries a substantially higher coumarin content and a corresponding chronic-intake hepatotoxicity concern that Ceylon cinnamon does not share. The bark has been an article of long-distance trade since the second millennium BCE, documented in Egyptian, Hebrew, Greek, Roman, Sanskrit, Arabic, and Persian sources as a costly imported spice whose botanical origin was deliberately obscured by the Arab and Sinhalese merchants who controlled the trade. [[wikipedia:Herodotus|Herodotus]], writing in the fifth century BCE in the third book of his Histories, reported that cinnamon "comes from countries unknown to us" and circulated the trade-secret legend (which he did not himself credit) that the sticks were gathered from the nests of giant birds in the cliffs of Arabia. The Hebrew Bible includes cinnamon (qinnamon) and cassia (qiddah) among the ingredients of the sacred anointing oil prescribed in Exodus thirty, alongside myrrh and calamus; lists cinnamon among the perfumes of the bridal bed in the Song of Songs; and counts it among the cargoes of the merchants of Tyre in the prophecy of Ezekiel. [[wikipedia:Pedanius Dioscorides|Dioscorides]], in book one of his De Materia Medica of about 60 CE, distinguished kinnamomon (true cinnamon, the Ceylon product) from kasia (cassia) and ranked the former among the most valued and most adulterated of all imported spices. The botanical separation of the two species was not formally settled until the eighteenth and nineteenth centuries, by which time the cinnamon trade had passed successively through Sinhalese, Portuguese, Dutch, and British control, and the term "cinnamon" had become commercially ambiguous in a way that persists to the present day.
| traditional_uses = The earliest documented use of cinnamon is in the trade goods, perfumes, and sacred preparations of the ancient Near East, where the spice arrived by sea from Sri Lanka and the southern Indian coast via the Arabian peninsula at a time when neither the Egyptian nor Hebrew civilizations had any direct contact with the Indian Ocean source. The Hebrew Bible names cinnamon (qinnamon) and cassia (qiddah) separately among the ingredients of the holy anointing oil prescribed in Exodus chapter thirty, alongside myrrh and calamus, and lists cinnamon among the perfumes of the bridal bed in the Song of Songs (chapter four, verse fourteen) and among the cargoes of the merchants of Tyre in the prophecy of Ezekiel (chapter twenty-seven). The Egyptian medical and aromatic record is fragmentary on cinnamon because the spice arrived through intermediaries who concealed its source, but cinnamon-like bark aromatics appear in the embalming and incense formulations of the New Kingdom and Late Period.<ref name="exodus-30">Hebrew Bible, Exodus 30:23-25 (the holy anointing oil); Song of Songs 4:14 (perfumes of the bridal bed); Ezekiel 27:19 (cargoes of the merchants of Tyre).</ref><ref name="miller-1969">Miller JI. ''The Spice Trade of the Roman Empire, 29 B.C. to A.D. 641''. Oxford: Clarendon Press; 1969.</ref>

The Greek tradition documented cinnamon as kinnamomon and the related but distinct cassia as kasia. [[wikipedia:Theophrastus|Theophrastus]] in his Enquiry into Plants of about 300 BCE distinguished the two and noted both as imported from "Arabia" (the geographical knowledge of the period treating the Arabian peninsula as the source rather than the Indian Ocean origin beyond it). Dioscorides in book one of his De Materia Medica of about 60 CE listed cinnamon as warming, digestive, diuretic, and emmenagogue, prescribed for chronic cough, indigestion, and bites of venomous animals; he also recorded the principal adulterants and methods of detection, an indication of how valuable the genuine product had become.<ref name="dioscorides-cinnamon">Beck LY (translator). ''Pedanius Dioscorides of Anazarbus: De Materia Medica''. Hildesheim: Olms-Weidmann; 2005 (translation of c. 60 CE original).</ref> [[wikipedia:Pliny the Elder|Pliny the Elder]] in book twelve of his Naturalis Historia (first century CE) gave the most extensive ancient account of cinnamon, devoting several chapters to the spice and its trade; he debunked the bird-nest story circulated by Herodotus as a merchant fiction, recorded the price of genuine cinnamon at fifteen hundred denarii per Roman pound during the reign of Nero (an extraordinary sum, several times the annual wage of a soldier), and reported with characteristic moralizing disapproval that Nero burnt a year's harvest of Arabian aromatics at the funeral of his wife Poppaea Sabina in 65 CE as a gesture of grief.<ref name="pliny-cinnamon">Bostock J, Riley HT (translators). Pliny the Elder: ''The Natural History''. London: Taylor and Francis; 1855.</ref> The cinnamon of Roman use crossed the eastern Mediterranean trade routes from the Indian Ocean and reached the empire at very high cost; the commodity is among those whose Indian Ocean origin Pliny and his contemporaries had begun to suspect, though the actual route remained a closely guarded trade secret.

The Islamic and Persian medical traditions documented cinnamon as qirfa (Arabic) and dar-cini (literally "Chinese wood," Persian), reflecting an Iranian-mediated trade route that named the spice by its eastern direction without (initially) distinguishing the Ceylon and Chinese species. [[wikipedia:Avicenna|Avicenna]] (Ibn Sina) in book two of his Canon of Medicine of about 1025 CE listed cinnamon as warming in the second degree, drying in the third, indicated for chronic cough, asthmatic complaints, dyspepsia, vomiting, and as a strengthener of weak constitutions; he distinguished the higher-grade darchini-yi-suluqi (the Sri Lankan product, prized for delicacy) from inferior grades, an indication that the species distinction was practically (if not botanically) understood within the Unani tradition.<ref name="avicenna-cinnamon">Gruner OC (translator). ''A Treatise on the Canon of Medicine of Avicenna, Incorporating a Translation of the First Book''. London: Luzac and Co.; 1930.</ref> Cinnamon entered the Unani tradition of South Asia by the mediation of Islamic medicine and remains a standard simple in the Unani pharmacopoeia of Pakistan and northern India to the present.

The Ayurvedic tradition documented cinnamon bark as tvak in the Charaka Samhita and Sushruta Samhita (the foundational Ayurvedic texts compiled in the early centuries of the common era), with the related leaf as tejpata (botanically ''Cinnamomum'' tamala, a distinct species, the Indian bay leaf) and the root bark as a separate aromatic.<ref name="charaka-tvak">Sharma PV (translator). ''Charaka Samhita: Text with English Translation''. Varanasi: Chaukhambha Orientalia; 1981.</ref> Tvak is classed as warming, deepana (kindling the digestive fire), pachana (digestive), and kapha-vata-shamaka (pacifying the cold-and-damp and cold-and-windy doshas), and is included in classical formulations for chronic cough (kasa), indigestion (agnimandya), polyuric sweet-urine disease (madhumeha, the classical Ayurvedic recognition of diabetes mellitus), and as a flavoring synergist in many compound preparations.<ref name="williamson-ayurveda">Williamson EM (editor). ''Major Herbs of Ayurveda''. Edinburgh: Churchill Livingstone; 2002.</ref>

The Chinese tradition uses several species of ''Cinnamomum'', but the central TCM cinnamon is ''C. cassia'' rather than ''C. verum'': cassia bark (rou gui) is the chief warming yang herb of the Chinese materia medica, and the cassia twig (gui zhi) is the surface-resolving herb of the foundational Han dynasty formula tradition. Ceylon cinnamon is not part of the formal TCM materia medica; its use in Chinese herbal pharmacy is recent and chiefly through imported and Western-influenced practice.<ref name="bensky-cinnamon">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica, 3rd ed''. Seattle: Eastland Press; 2004.</ref> The clinical implication is that "cinnamon" in TCM context almost invariably means cassia, with its characteristic high coumarin content; a patient who substitutes Ceylon for cassia in a classical formula is altering the chemistry substantively (much less coumarin, but also a somewhat different cinnamaldehyde-eugenol balance), and the substitution is reasonable in modern Western-influenced practice but is not a like-for-like exchange.

The medieval European tradition received cinnamon as the most expensive of the long-distance spice imports, with the Venetian and (later) Genoese merchants controlling the European trade and the Arab middlemen controlling the source. [[wikipedia:Hildegard von Bingen|Hildegard von Bingen]] in her Physica of the twelfth century listed cinnamon as warming and aromatic, prescribed for chronic cough, melancholy, and digestive weakness.<ref name="hildegard-physica-cinnamon">Throop PM (translator). ''Hildegard von Bingen's Physica: The Complete English Translation of Her Classic Work on Health and Healing''. Rochester, VT: Healing Arts Press; 1998 (translation of twelfth-century original).</ref> [[wikipedia:Nicholas Culpeper|Nicholas Culpeper]] in The English Physitian of 1652 wrote of cinnamon as an herb of the sun and prescribed it for chronic cough, weak digestion, and as a uterine-supporting aromatic in difficult labor; Culpeper noted that the genuine "Cinnamon of Ceylon" was hard to obtain and frequently adulterated, an observation that recurs throughout the European pharmacopoeial literature of the period.

The botanical home of Ceylon cinnamon is the wet coastal lowlands of southwestern Sri Lanka, where the species grows wild and where cultivated plantation production has been the principal export industry for five centuries. The Portuguese reached Ceylon in 1505 and within a generation had secured control of the cinnamon-producing coast through a combination of treaty with the Kingdom of Kotte and military pressure on the neighboring kingdoms. The Portuguese-Sinhalese cinnamon monopoly lasted until 1640, when the Dutch East India Company (Verenigde Oostindische Compagnie) supplanted the Portuguese and intensified plantation cultivation, introducing systematic coppice management and quality grading; the Dutch period produced the high-grade product that established Ceylon cinnamon as the international standard. The British took the colony from the Dutch in 1796 and within a generation ended the strict cinnamon monopoly that had supported the Portuguese and Dutch colonial budgets, opening Ceylon to broader colonial development and allowing cinnamon cultivation to expand to the Seychelles, Madagascar, and other tropical British possessions.<ref name="desilva-1981">de Silva KM. ''A History of Sri Lanka''. London: C. Hurst and Co.; 1981.</ref> The botanical separation of ''Cinnamomum verum'' from ''Cinnamomum cassia'' was settled in the eighteenth and nineteenth centuries against this background of colonial commerce; the species name verum (Latin "true") encodes the European pharmacopoeial preference of the period for the Ceylon product over the cheaper Chinese cassia.

The modern Western pharmacopoeial tradition recognizes cinnamon (Cinnamomi cortex) in both Ceylon and cassia forms, with most modern monographs distinguishing the two species and treating the cassia coumarin content as the principal safety consideration. The German Commission E approved cinnamon bark for loss of appetite and dyspepsia at daily doses of 2 to 4 g of bark or 0.05 to 0.2 g of essential oil, without distinguishing between species in the published monograph.<ref name="commission-e-cinnamon">Blumenthal M, Goldberg A, Brinckmann J (editors). ''Herbal Medicine: Expanded Commission E Monographs''. Newton, MA: Integrative Medicine Communications; 2000.</ref> The European Medicines Agency Committee on Herbal Medicinal Products issued separate monographs for ''Cinnamomum verum'' bark and ''Cinnamomum cassia'' bark, with the cassia monograph carrying a specific coumarin-intake warning that the verum monograph does not.<ref name="ema-cinnamon">European Medicines Agency, Committee on Herbal Medicinal Products. ''Community herbal monograph on ''Cinnamomum verum'' J. S. Presl, cortex'' and ''Community herbal monograph on ''Cinnamomum cassia'' (L.) D. Don, cortex'' (paired HMPC monographs). Available at https://www.ema.europa.eu/en/medicines/herbal.</ref> The contemporary controlled-trial literature on cinnamon for type 2 diabetes is mixed: meta-analyses have produced positive findings (modest reductions in fasting glucose), null findings, and intermediate findings, with the trial populations mostly receiving cassia or mixed/unspecified species rather than Ceylon-specific preparations.<ref name="allen-2013">Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. ''Annals of Family Medicine''. 2013 Sep-Oct;11(5):452-459. PMID 24019277.</ref> Where the observational and short-trial evidence has supported the glycemic-effect claim, larger and more recent randomized trials have tended toward modest or null effect, and the most rigorous meta-analyses note substantial between-study heterogeneity and a substantial risk-of-bias profile in the underlying literature. The Ceylon-specific glycemic-effect evidence base is sparse, and the modest clinical recommendation to consider cinnamon for diabetic glycemic adjunct rests primarily on cassia evidence; Ceylon is the safer cinnamon for chronic intake (because of the coumarin distinction) but is not the cinnamon best supported by the glycemic-effect trial literature.
| traditional_geography =
| botany = ''Cinnamomum verum'' is an evergreen tree of the Lauraceae reaching 10 to 15 m at full size in undisturbed forest but maintained as coppice bushes of 2 to 3 m in plantation production. The leaves are opposite, elliptic to ovate, 7 to 18 cm long and 3 to 10 cm wide, with three (occasionally five) prominent palmate-pinnate veins running from the base to near the leaf apex (the characteristic ''Cinnamomum'' venation pattern). Young leaves are pinkish-red, deepening to dark glossy green with maturity. The bark of mature trunks is rough, fissured, and grey-brown; the medicinally used bark is the smooth, light-tan inner bark of two-to-three-year-old coppice shoots, scraped of the outer corky layer and dried to form the multi-layered quill scrolls. The flowers are small (5 to 6 mm), greenish-yellow, in lax panicles; the fruit is a small ellipsoid drupe 1 to 2 cm long, ripening dark purple-blue, single-seeded. The whole plant is aromatic in all parts, with cinnamaldehyde dominant in the bark and eugenol dominant in the leaf, reflecting the chemotype divergence between bark oil and leaf oil that is characteristic of the species. Distinguished from ''Cinnamomum cassia'' (Chinese cinnamon, the most likely confusion in commerce) by leaf venation (three prominent veins in verum, five in cassia), by bark structure (multi-layered thin quill in verum, single-layer thick quill in cassia), and by bark color (light tan in verum, darker red-brown in cassia); these distinctions hold for whole-stick material and are lost in ground powder, where chemical or spectroscopic distinction is required.
| constituents = The principal medicinally active constituents of Ceylon cinnamon bark are the volatile oil (3 to 4 percent of dry bark by weight) and the proanthocyanidin polyphenol fraction. The volatile oil composition is the principal pharmacognostic distinction between Ceylon and the related cassia species: Ceylon bark oil contains '''cinnamaldehyde''' at 65 to 80 percent of the oil, '''eugenol''' at 5 to 10 percent, and '''coumarin''' at trace amounts (typically below 0.004 percent of bark dry weight, at the analytical detection limit in some studies), with smaller amounts of cinnamyl acetate, cinnamyl alcohol, beta-caryophyllene, linalool, and alpha-pinene. ''Cinnamomum cassia'' bark oil, by contrast, contains cinnamaldehyde at 75 to 90 percent of the oil, eugenol below 1 percent, and coumarin at 0.4 to 4 percent of bark dry weight (the basis of the chronic-intake hepatotoxicity concern that applies to cassia and not to Ceylon).<ref name="wang-2013">Wang YH, Avula B, Nanayakkara NP, Zhao J, Khan IA. Cassia cinnamon as a source of coumarin in cinnamon-flavored food and food supplements in the United States. ''Journal of Agricultural and Food Chemistry''. 2013 May 8;61(18):4470-4476. PMID 23627682.</ref> The chemotype distinction is the practical fingerprint by which the two species are distinguished in modern pharmacopoeial quality control.

The Ceylon leaf essential oil is chemotypically distinct from the bark oil: eugenol at 70 to 95 percent dominates, with cinnamaldehyde at low percentage and a different aromatic profile (clove-like rather than warm-sweet). The Ceylon leaf oil is the basis of some natural eugenol production for dental and flavoring applications.

The non-volatile fraction includes '''proanthocyanidins''', particularly the type A doubly-linked oligomers that are characteristic of ''Cinnamomum'' and that contribute to the astringent gut-mucosa effect and the antioxidant capacity of cinnamon extracts; '''cinnamic acid''' and its derivatives (cinnamyl alcohol, cinnamyl acetate, methyl cinnamate); and '''MHCP''' (methylhydroxychalcone polymer, the proposed insulin-mimetic identified primarily in cassia and variably in verum). Cinnamic acid and its derivatives are aromatic but contribute less to the characteristic warmth-and-pungency of the bark than cinnamaldehyde does.
| preparations = The traditional therapeutic forms are the '''whole bark''' (the multi-quill stick, used in decoction or infusion at 0.5 to 1 g per cup, three times daily); the '''bark powder''' (ground from whole stick, 1 to 4 g daily, in honey or warm water for digestive complaint, or sprinkled on food for the carminative effect); the '''tincture''' (1:5 in 70 percent alcohol, 2 to 4 mL three times daily, the Western herbalist's form); the '''essential oil''' from bark (steam-distilled, used at 0.05 to 0.2 mL daily, diluted in carrier oil for topical use or in capsule form internally, never undiluted on skin or mucosa given the cinnamaldehyde concentration); and the '''aqueous extract''' (used in some glycemic-effect supplement formulations to concentrate the polyphenol fraction while reducing essential-oil content). The '''leaf essential oil''' (eugenol-dominant) is used externally for dental analgesia and toothache (similar role to clove oil) and as a flavoring component. Whole sticks store well in dry conditions for years with gradual loss of volatile oil potency; ground powder loses aromatic intensity within months and is best ground at use from whole stick when therapeutic potency matters.
| indications = Carminative and digestive aid for postprandial bloating, mild dyspepsia, and flatulence (the principal Commission E and EMA HMPC indication). Mild antidiarrheal effect from the proanthocyanidins (astringent gut-mucosa stabilization). Antimicrobial use, traditionally for oral hygiene and mild upper respiratory complaint. Adjunctive for glycemic control in type 2 diabetes mellitus, with the caveat that most controlled-trial evidence is from cassia or mixed/unspecified species and Ceylon-specific evidence is sparser; the effect, where present, is modest. Folk indications: warming for cold-pattern complaint, dysmenorrhea (mild emmenagogue), and as a flavoring synergist that improves the palatability and acceptance of bitter herbal formulations. Topical leaf oil for dental analgesia and gingivitis. Not a first-line indication for any major condition; the role of cinnamon in modern Western practice is as a culinary spice with mild medicinal benefit, a Commission-E-approved digestive support, and an occasional adjunctive in diabetic supplement regimens.
| dosing = Bark powder: 1 to 4 g daily, divided. Whole bark in decoction or infusion: 0.5 to 1 g per cup, three times daily. Bark essential oil: 0.05 to 0.2 mL daily, diluted; never undiluted on skin or mucosa. Tincture 1:5 in 70 percent alcohol: 2 to 4 mL three times daily. For glycemic-effect supplementation: 1 to 6 g of cinnamon (mixed species in most trials) daily has been the typical trial range; Ceylon-specific dosing recommendations are sparse and follow the bark-powder range above. Topical leaf oil for dental use: single drop on cotton pellet, brief contact only.
| effects =
| pharmacokinetics = Cinnamaldehyde is rapidly absorbed from the gastrointestinal tract and rapidly oxidized to cinnamic acid and then conjugated to hippuric acid (the principal urinary metabolite); elimination of the cinnamaldehyde-derived metabolites is largely complete within 24 hours of administration. Eugenol is similarly rapidly absorbed and conjugated, with biliary and urinary excretion. Coumarin (in trace amounts from Ceylon, or substantial amounts from cassia) is absorbed and metabolized hepatically via CYP2A6 to 7-hydroxycoumarin and via a smaller fraction to 3-hydroxycoumarin; the chronic hepatotoxicity of cassia coumarin at high intake involves the 3-hydroxycoumarin pathway and the variable individual susceptibility of CYP-mediated metabolism, which is the basis of the rare-but-real cassia hepatotoxicity case reports. Ceylon's negligible coumarin content places it well outside the relevant exposure range at any realistic intake.
| pharmacodynamics = Cinnamaldehyde is a TRPA1 ion-channel agonist, accounting for the characteristic warming-and-pungent sensation of cinnamon on the tongue and gut mucosa and contributing to the carminative effect through smooth-muscle modulation and gastric motility effect. Cinnamaldehyde and eugenol both produce broad-spectrum antimicrobial effect against bacteria, fungi (including Candida species), and some viruses, mediated by membrane disruption and thiol-disulfide exchange with bacterial enzymes; the antifungal effect against Candida is the basis of the traditional and modern dental and oral-hygiene indication. The proanthocyanidins of cinnamon are potent in vitro antioxidants and produce astringent gut-mucosa stabilization, the mechanistic basis of the mild antidiarrheal effect. The glycemic effect of cinnamon (insofar as it is real at clinically relevant intake) has been proposed to involve MHCP enhancement of insulin-receptor autophosphorylation and downstream glycogen-synthase signaling, but the mechanistic literature is incomplete and the trial-level effect is modest; the role of cinnamon in type 2 diabetes management is a useful adjunctive at best, not a primary intervention.
| interactions = <pharmaInteractions/>

The clinically significant interactions of Ceylon cinnamon are modest in number and degree. '''Modest hypoglycemic potentiation''' with insulin and oral antidiabetic medicines is the principal pharmacodynamic interaction; the effect is small at culinary doses, somewhat more substantial at therapeutic-dose supplementation, and the trial evidence is dominated by cassia rather than Ceylon studies. Patients on antidiabetic regimens who add cinnamon supplementation should monitor for hypoglycemia, particularly during dose titration of the antidiabetic medicine.

The '''cassia-coumarin hepatotoxicity concern''' (chronic high dietary cassia intake, particularly the powdered form in baked goods, can exceed the European Food Safety Authority tolerable daily intake of 0.1 mg/kg coumarin at common American consumption levels in heavy users) does not apply to Ceylon, where the coumarin content is too low to be clinically relevant at any reasonable intake. This is the principal safety distinction between the two cinnamons and the principal reason a prescriber concerned about chronic high-intake cinnamon should specify Ceylon.

The widely repeated concern that cinnamon potentiates warfarin or other anticoagulants appears to be an extrapolation from the cassia-coumarin content combined with a misunderstanding of coumarin pharmacology: the coumarin of cinnamon is the parent 2H-1-benzopyran-2-one compound, not the 4-hydroxycoumarin (warfarin) class, and lacks direct anticoagulant activity in either species. The interaction is theoretical at best and has not been substantively documented in case reports or pharmacokinetic studies; no specific preoperative discontinuation recommendation is necessary for Ceylon cinnamon at culinary or supplementation doses.
| pregnancy_details = Culinary amounts of Ceylon cinnamon are considered safe in pregnancy and lactation, with a long historical record of routine use in essentially all cinnamon-using cultures. Therapeutic-dose supplementation (multi-gram daily for glycemic effect, or essential oil for any indication) has not been formally studied in pregnancy and is best avoided; the traditional caution about medicinal cinnamon in pregnancy derives from the emmenagogue use in late-pregnancy difficult labor (the Culpeper indication, in the European tradition) and the warming-doshic concern in Ayurveda. The Ayurvedic and Unani traditions allow culinary cinnamon throughout pregnancy and add medicinal doses postpartum for the standard postnatal warming, digestive, and lactation-supporting roles.
| monitoring = For patients on insulin or oral antidiabetic medicines who add cinnamon supplementation at therapeutic dose, fasting glucose monitoring at baseline and at two to four weeks of regular supplementation is the conservative practice; no monitoring is required for culinary use.
| counseling = The most important counseling distinction for cinnamon is the species. The cinnamon sold as a culinary spice in most American grocery stores and used in commercial baked goods is ''C. cassia'' (Chinese cinnamon, the higher-coumarin species), not ''C. verum'' (Ceylon cinnamon, the lower-coumarin species). For patients consuming cinnamon at routine culinary levels (gram or fraction of gram per day, sprinkled on food), the coumarin exposure from cassia is unlikely to reach the tolerable daily intake threshold; for patients consuming cinnamon at therapeutic supplementation levels (multi-gram daily, particularly the powdered form in capsules) or at high dietary levels (large quantities in baked goods, or the social-media "cinnamon challenge" of swallowed dry powder), the coumarin exposure from cassia can substantially exceed safe daily intake, and the Ceylon species is the appropriate choice.

The visual distinction between Ceylon and cassia is possible with whole sticks but lost in ground powder. Ceylon cinnamon is light tan in color, composed of many thin papery layers tightly rolled into a multi-quill scroll, brittle and easily crushed, with a delicate, complex, sweet aroma; cassia is darker reddish-brown, composed of a single thick rigid layer rolled into a hollow tube, hard and resistant to crushing, with a strong, simple, pungent aroma. Patients seeking Ceylon for safety reasons should buy whole sticks (most reliably labeled as "Ceylon" or "true" cinnamon at specialty grocers and Sri Lankan or Indian markets) and grind at use, or buy reputable powdered Ceylon labeled by species rather than by the generic "cinnamon" name.

Cinnamon essential oil (either species) is concentrated and irritating; it should never be applied undiluted to skin or mucosa, and oral consumption of essential oil at more than a few drops daily can produce gastritis, oral mucositis, and (with chronic high-dose cassia oil specifically) hepatotoxicity. Cinnamon chewing-gum stomatitis is a recognized presentation of intra-oral mucosal hypersensitivity to high-concentration cinnamaldehyde, generally resolving on cessation. Contact dermatitis from cinnamon, especially the essential oil and especially cassia, is a regular occupational concern in spice-handling industries and culinary work.
| anecdotes =
| seealso = [[Cassia cinnamon]], ''[[Cinnamomum cassia]]'', [[Ginger]], [[Turmeric]], [[Cardamom]], [[Cloves]], [[Garlic]]
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Cardiovascular herbs]]
[[Category:Carminatives]]
[[Category:Western clinical herbs]]
[[Category:Ayurvedic herbs]]
[[Category:Unani herbs]]

Garlic

2026-05-26T18:55:59Z

MDElliottMD: home-claude: binomial italics sweep (Mark rule 2026-05-26; body-prose only)

{{PlantMedTemplate
| binomial = Allium sativum L.
| family = Amaryllidaceae
| common_names = garlic, thum or thawm (Arabic), lashuna (Sanskrit), lehsun (Hindi), da suan (Chinese), sir (Persian), ajo (Spanish), ail (French), Knoblauch (German)
| native_range = Central Asia (the Tien Shan and Pamir mountain regions); cultivated worldwide since the Bronze Age
| cultivars = hardneck (''Allium sativum'' var. ophioscorodon) produces a flowering scape and the largest cloves but stores poorly; softneck (var. sativum) is the supermarket type, stores well, produces no scape; elephant garlic is the related Allium ampeloprasum (not true garlic); black garlic is fermented A. sativum, with substantially different (sweeter, less pungent) pharmacology
| parts_used = bulb (the clustered cloves); green scape culinary only
| cultivation = hardy bulb planted in autumn for spring harvest in temperate climates; widely cultivated worldwide
| preparations_summary = raw clove 1-4 g/day (one to four cloves); aged garlic extract 600-1200 mg/day; standardized garlic powder 600-900 mg/day (allicin yield 0.6-1.3% wt/wt); tincture 1:5 in 45% alcohol, 2-4 mL three times daily; topical poultice for fungal skin infection; garlic oil for traditional otitis externa (folk use)
| constituents_summary = alliin (S-allyl-L-cysteine sulfoxide), enzymatically converted by alliinase on crushing to allicin (the principal antimicrobial); allicin degradation products including diallyl disulfide, diallyl trisulfide, ajoene; S-allyl-L-cysteine (the principal aged garlic extract component); fructans (inulin); organoselenium compounds
| mechanism = allicin and ajoene inhibition of HMG-CoA reductase (modest lipid-lowering); endothelial nitric oxide synthase activation and hydrogen sulfide release (modest blood-pressure-lowering, vasodilation); inhibition of platelet aggregation via thromboxane A2 reduction; broad-spectrum antimicrobial via allicin thiol-disulfide exchange with bacterial enzymes; CYP3A4 induction (the major clinical interaction substrate)
| pregnancy = dietary amounts safe; therapeutic doses of standardized extract caution
| legal = unscheduled; GRAS for culinary use; sold worldwide as dietary supplement
| interactionsummary = clinically significant bleeding risk with warfarin, direct oral anticoagulants, and antiplatelet agents; CYP3A4 induction reduces saquinavir, ritonavir, cyclosporine, and tacrolimus plasma concentrations; preoperative discontinuation 7-10 days before elective surgery is the standard recommendation
| intro = '''Garlic''' is the bulb of ''Allium sativum'' L., a perennial bulbous member of the Amaryllidaceae cultivated for at least five thousand years and used continuously as both food and medicine from the Bronze Age to the present. The species epithet sativum is the Latin agricultural suffix meaning "cultivated," reflecting that no wild ancestor of true garlic survives; the plant is thought to derive from Allium longicuspis of the Central Asian Tien Shan and Pamir mountains and to have been carried west along the Silk Road and south into the Indian subcontinent before recorded history. Herodotus, writing in the fifth century BCE about the construction of the Great Pyramid at Giza some two thousand years before his own time, reported that the cost of "radishes, onions, and garlic" issued as daily rations to the workmen was inscribed at the pyramid's base at sixteen hundred talents of silver. The Egyptian medical papyrus known as the Codex Ebers, composed around 1550 BCE during the reign of Amenhotep I, prescribes garlic for twenty-two distinct complaints including headache, parasites, weakness, and the bites of vermin. The continuous documented clinical use of garlic across Mediterranean, Islamic, Ayurvedic, Chinese, and modern Western traditions is rivalled in the materia medica only by opium, wine, and the date palm.
| traditional_uses = The Egyptian record is the earliest sustained one. The Codex Ebers of approximately 1550 BCE includes garlic in formulations for headache, fatigue, parasites, hypertension (in the form of a recognised disease called "the disease of weariness in the chest"), and the bites of the asp.<ref name="ebers-garlic">Bryan CP (translator). ''The Papyrus Ebers''. London: Geoffrey Bles; 1930.</ref> The pyramid workers' garlic ration recorded by Herodotus is corroborated by the discovery of clay garlic models in Tutankhamun's tomb and by mummified garlic cloves preserved in the dry climate of Egyptian burials. The Greek tradition adopted garlic as both food and medicine; [[wikipedia:Hippocrates|Hippocrates]] in the fifth century BCE prescribed it for respiratory complaints, parasites, fatigue, and digestive disorders, and [[wikipedia:Pedanius Dioscorides|Dioscorides]] in book two of his De Materia Medica catalogued its use for cough, intestinal worms, snake bite, and the suppression of menstruation.<ref name="dioscorides-garlic">Beck LY (translator). ''Pedanius Dioscorides of Anazarbus: De Materia Medica''. Hildesheim: Olms-Weidmann; 2005 (translation of c. 60 CE original).</ref> Olympic athletes consumed garlic before competition for its reputed strengthening effect; Greek soldiers carried it on campaign.

The Roman tradition continued and expanded the Greek inheritance. [[wikipedia:Pliny the Elder|Pliny the Elder]] in book twenty of his Naturalis Historia (first century CE) lists sixty-one separate medicinal applications of garlic, the most of any single plant in his materia medica.<ref name="pliny">Bostock J, Riley HT (translators). Pliny the Elder: ''The Natural History''. London: Taylor and Francis; 1855.</ref> Roman soldiers consumed garlic for strength and protection against the diseases of camp life; the plant followed the legions into every province of the empire, naturalizing in soils across Europe and North Africa. The Mediterranean culinary and medicinal use of garlic has continued unbroken from this period to the present.

The Islamic tradition documented garlic as thum or thawm, with a characteristic ambivalence preserved in the hadith literature: medicinal use is encouraged for many indications, but the strong odor on the breath disqualifies a user from attending the mosque immediately after eating raw cloves. The classical Islamic medical tradition codified this practical distinction by recommending cooked or roasted preparations where breath-odor mattered and reserving raw garlic for therapeutic use.<ref name="bukhari-garlic">Sahih al-Bukhari, Book 65 (Food), Hadiths 362-364, variant narrations on garlic and onion consumption before mosque attendance, attributed to Jabir ibn Abd Allah and Ibn Umar.</ref> [[wikipedia:Avicenna|Avicenna]] in book two of his Canon of Medicine (early eleventh century) lists garlic for respiratory complaints, gastrointestinal parasites, snake and scorpion bite, joint pain, and as a strengthener of weak constitutions.<ref name="avicenna-garlic">Gruner OC (translator). ''A Treatise on the Canon of Medicine of Avicenna, Incorporating a Translation of the First Book''. London: Luzac and Co.; 1930.</ref> The Persian tradition (sir in Farsi) elaborated the same applications and added the cardiovascular indication: the use of garlic for "thickened blood" and chest pain is consistent across the medieval Persian medical texts.

The Ayurvedic tradition documented garlic as lashuna in the Charaka Samhita and Sushruta Samhita (the foundational Ayurvedic texts compiled in the early centuries of the common era).<ref name="charaka-garlic">Sharma PV (translator). ''Charaka Samhita: Text with English Translation, Vol. II''. Varanasi: Chaukhambha Orientalia; 1981.</ref> The plant is classed as rasayana (rejuvenative), with the unusual property of containing five of the six classical Ayurvedic tastes (all except sour) and the corresponding multi-dosha activity. Charaka prescribes garlic for vata disorders generally (the cold-and-dry imbalance), for hridroga (heart disease), for udara (abdominal swelling), and for chronic respiratory complaints; the same text contraindicates large doses for pitta-predominant or summer-season use. The Indian culinary tradition treats garlic as both food and medicine, and the religious-dietary objection to garlic in some Vaishnava and Jain communities (on the grounds of its rajasic-tamasic character disturbing the meditative mind) is the inverse-image of the Ayurvedic clinical endorsement: same characterization, different valence.

The Chinese tradition adopted garlic as da suan and treats it as a warming, pungent food-medicine that disperses cold, kills worms, and resolves toxin (jie du). The plant is not part of the formal materia medica of the major TCM classics in the way ''Glycyrrhiza uralensis'' or ''Zingiber officinale'' are, but it appears across the folk tradition and in modern Chinese herbal pharmacopoeias as a treatment for cold-pattern abdominal pain, parasites, and the early stages of cold-type respiratory infection.<ref name="bensky-garlic">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica, 3rd ed''. Seattle: Eastland Press; 2004.</ref>

The medieval European tradition continued the Mediterranean inheritance through monastic and folk medicine. [[wikipedia:Hildegard von Bingen|Hildegard von Bingen]] in her Physica of the twelfth century lists garlic for cough, hoarseness, and the "viscous humors" of the chest, with the unusual practical recommendation to consume it raw because cooking diminished its medicinal effect.<ref name="hildegard-physica">Throop PM (translator). ''Hildegard von Bingen's Physica: The Complete English Translation of Her Classic Work on Health and Healing''. Rochester, VT: Healing Arts Press; 1998 (translation of twelfth-century original).</ref> [[wikipedia:Nicholas Culpeper|Nicholas Culpeper]] in The English Physitian of 1652 wrote that garlic "hath a special virtue against all cold diseases" and prescribed it for cough, expectoration, and as an anthelmintic. The plague-prophylactic legend of the Four Thieves Vinegar, said to have originated during the Marseille plague of 1720 with a group of grave-robbers whose garlic-infused vinegar protected them from infection, sits between folklore and history; the recipe (garlic, sage, rosemary, lavender, thyme, mint, wormwood in vinegar) is preserved in pharmacopoeias of the period as Vinaigre des Quatre Voleurs, and a related formulation was sold in French pharmacies into the twentieth century.

The early twentieth century saw a return of garlic to formal Western medical use during the First World War, when the British Royal Army Medical Corps used garlic juice as a wound antiseptic for the treatment of trench infections in the absence of effective antibiotic alternatives; the historical reports note substantially reduced post-surgical sepsis with garlic-soaked dressings.<ref name="cavallito-garlic">Cavallito CJ, Bailey JH. Allicin, the antibacterial principle of ''Allium sativum''. I. Isolation, physical properties and antibacterial action. ''Journal of the American Chemical Society''. 1944;66(11):1950-1951.</ref> The isolation of allicin by Cavallito and Bailey at the Sterling-Winthrop Research Institute in 1944 placed garlic's antimicrobial action on a chemical footing and opened the modern phase of garlic pharmacology.

The contemporary controlled-trial literature has substantially supported the cardiovascular indications. Meta-analyses of randomized blood-pressure trials show a modest but consistent reduction in systolic and diastolic blood pressure with garlic preparations standardized for allicin yield, with the largest effect in hypertensive patients;<ref name="ried2013">Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. ''Nutrition Reviews''. 2013;71(5):282-299. PMID 23590705.</ref><ref name="ried2008">Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. ''BMC Cardiovascular Disorders''. 2008;8:13. PMID 18554422.</ref> the Stevinson meta-analysis of garlic for hypercholesterolemia found a modest LDL-lowering effect, though more recent trials with higher methodological rigor have produced equivocal results.<ref name="stevinson">Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. ''Annals of Internal Medicine''. 2000;133(6):420-429. PMID 10975959.</ref> The Lissiman 2014 Cochrane review of garlic for the common cold found one small trial supportive of a preventive effect, with insufficient data for therapeutic effect on established colds.<ref name="lissiman2014">Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. ''Cochrane Database of Systematic Reviews''. 2014;(11):CD006206. PMID 25386977.</ref> Observational studies in high-allium-consumption populations (the Iowa Women's Health Study, the Shandong Province cancer cohort) have shown reduced rates of gastric and colorectal cancer with frequent garlic consumption,<ref name="steinmetz1994">Steinmetz KA, Kushi LH, Bostick RM, Folsom AR, Potter JD. Vegetables, fruit, and colon cancer in the Iowa Women's Health Study. ''American Journal of Epidemiology''. 1994 Jan 1;139(1):1-15. PMID 8296768.</ref><ref name="fleischauer2000">Fleischauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. ''The American Journal of Clinical Nutrition''. 2000 Oct;72(4):1047-1052. PMID 11010950.</ref> though randomized prevention trials have not yet established a definitive causal effect: the fifteen-year follow-up of the Shandong garlic intervention trial found no significant reduction in gastric cancer incidence or mortality with garlic supplementation, despite the strong observational signal.<ref name="ma2012">Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of ''Helicobacter pylori'', garlic, and vitamin treatments on gastric cancer incidence and mortality. ''Journal of the National Cancer Institute''. 2012 Mar 21;104(6):488-492. PMID 22271764.</ref>

The modern antimicrobial use of garlic has shifted from the historical broad antiseptic role to specific indications. Allicin has documented in vitro activity against ''Helicobacter pylori'', Candida species, methicillin-resistant ''Staphylococcus aureus'', and several other clinically significant pathogens, but the oral bioavailability of allicin is essentially zero (it is metabolized in the gut and on first pass to other thiosulfinates); the in vivo antimicrobial effect of oral garlic depends on aged-garlic-extract components and on the polysulfide degradation products of allicin rather than on allicin itself.<ref name="lawson2001">Lawson LD, Wang ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. ''Journal of Agricultural and Food Chemistry''. 2001 May;49(5):2592-2599. PMID 11368641.</ref> Topical and inhalation formulations preserve more of the original allicin and have correspondingly larger antimicrobial effect.
| traditional_geography =
| botany = ''Allium sativum'' is a perennial bulbous plant reaching 30 to 90 cm at flowering. The bulb is the medicinal organ, composed of four to twenty individual cloves enclosed in a papery white or purple-tinged outer sheath. The leaves are flat, grass-like, and concentrated at the base; the flowering scape (in hardneck cultivars only) rises in midsummer bearing an umbel of small pink or white flowers that rarely set viable seed (garlic is propagated almost entirely vegetatively from cloves, with the consequence that all garlic of a given cultivar is essentially a clonal lineage). Distinguished from the wild allium relatives by the large compound bulb composed of multiple discrete cloves, from elephant garlic (Allium ampeloprasum, a different species with one to six much larger cloves and a milder flavor) by the smaller clove size and stronger pungency, and from onion (Allium cepa) by the compound rather than single-bulb structure.
| constituents = The sulfur-containing secondary metabolites are the principal medicinally active components of garlic, and their chemistry is uniquely complex because the active constituents are generated only on tissue damage. The intact clove contains '''alliin''' (S-allyl-L-cysteine sulfoxide), a stable, odorless, water-soluble amino acid derivative, stored in the cytoplasm of the clove cells; in a separate cellular compartment the enzyme '''alliinase''' is sequestered, ready to act on alliin only when crushing, cutting, or chewing breaks the cellular membranes and brings the two together. Within seconds of tissue damage alliinase converts alliin to '''allicin''' (diallyl thiosulfinate), the principal antimicrobial and the source of garlic's characteristic odor. Allicin is itself unstable; over minutes to hours it decomposes to '''diallyl disulfide''', '''diallyl trisulfide''', '''ajoene''', and several vinyldithiins, each with its own pharmacology. The clinical implication is that the form and processing of garlic determine which sulfur compounds reach the patient: raw crushed garlic delivers transient allicin, dried garlic powder delivers a slower-release allicin (provided alliinase is preserved by enteric coating, which is the basis of the standardized garlic powder preparation), and aged garlic extract delivers very little allicin but substantial quantities of the stable, water-soluble '''S-allyl-L-cysteine''' produced by the long fermentation process.

The non-sulfur fraction includes '''fructans''' (predominantly inulin, contributing the prebiotic and mild laxative effect at high doses), organoselenium compounds (selenium uptake by garlic is substantially greater than for most cultivated plants, and selenium-enriched garlic is marketed for cancer chemoprevention research), saponins, phenolics, and trace alkaloids.
| preparations = Multiple preparation forms are in current use, each delivering a different sulfur-compound profile: the '''raw clove''' (one to four cloves daily, chewed or finely crushed and added to food shortly before consumption) delivers transient high-dose allicin; the '''standardized garlic powder''' tablet or capsule (typically 600 to 900 mg daily of dried garlic standardized to 0.6 to 1.3 percent allicin yield, enteric-coated to preserve alliinase) is the form most used in cardiovascular clinical trials; '''aged garlic extract''' (600 to 1200 mg daily of the extract produced by twenty-month aging in dilute alcohol) delivers S-allyl-L-cysteine and is the preparation with the most evidence for cardiovascular and immunomodulatory indications; '''garlic oil''' (the steam-distilled essential oil, rich in diallyl disulfide and ajoene) is used at 5 to 10 mg daily; '''tincture''' (1:5 in 45 percent alcohol, 2 to 4 mL three times daily) is the traditional Western herbalist's form. Topical preparations include the '''poultice''' (crushed clove applied directly to fungal skin lesions, with caution against burns on prolonged contact) and the traditional '''garlic oil''' (cloves macerated in olive oil) for folk treatment of otitis externa.
| indications = Mild hypertension (adjunctive to or in place of pharmaceutical antihypertensive medicine in early or borderline cases). Modest hypercholesterolemia (adjunctive; not a replacement for statins in established cardiovascular disease). Atherosclerosis prevention (the observational and modest-trial evidence base). Common cold prevention (Cochrane-supported, single trial). Gastrointestinal parasites (the historical anthelmintic indication; modern evidence chiefly in vitro). ''Helicobacter pylori'' adjunctive treatment. Mild upper respiratory infection. Tinea pedis and onychomycosis (topical and oral). Diabetes mellitus type 2 (adjunctive; modest glycemic effect). Folk indications: otitis externa (garlic oil), insect bite, snake bite (historical, no modern evidence).
| dosing = Raw clove: 1 to 4 g daily (one medium clove is approximately 3 g). Standardized garlic powder: 600 to 900 mg daily, enteric-coated, providing approximately 5 to 12 mg allicin yield. Aged garlic extract: 600 to 1200 mg daily for cardiovascular indication, up to 7200 mg daily in some research protocols. Garlic oil: 5 to 10 mg daily. Tincture 1:5 in 45% alcohol: 2 to 4 mL three times daily. Topical poultice: applied to the lesion for 10 to 20 minutes, removed before burn develops on healthy skin.
| effects =
| pharmacokinetics = Allicin is rapidly absorbed but extensively metabolized on first pass to diallyl sulfide, diallyl disulfide, and other thiosulfinate degradation products; intact allicin reaches the systemic circulation in negligible quantities after oral administration. The sulfur-compound metabolites are excreted partly via the lungs (the basis of the persistent garlic breath after consumption, which can continue for 24 to 48 hours) and partly via the urine and skin. S-allyl-L-cysteine is the principal stable garlic-derived compound reaching systemic circulation after aged garlic extract; it has a half-life of approximately 10 hours and reaches steady-state concentrations after several days of regular dosing.
| pharmacodynamics = Allicin and ajoene inhibit HMG-CoA reductase in vitro, providing the proposed mechanism for the modest LDL-lowering effect of garlic supplementation. Allicin releases hydrogen sulfide (H2S) on reaction with vascular endothelial thiols, contributing to vasodilation and the modest blood-pressure-lowering effect. Allicin inhibits platelet aggregation through reduction of thromboxane A2 synthesis and through direct thiol-disulfide exchange with platelet membrane proteins; this is the mechanistic basis of the bleeding-risk interaction profile. The broad-spectrum antimicrobial effect of allicin is mediated by thiol-disulfide exchange with bacterial enzymes (most notably the cysteine-containing enzymes of central metabolism), producing a mechanism distinct from that of all major antibiotic classes and accounting for activity against multi-resistant organisms. CYP3A4 induction by aged garlic extract and high-dose standardized preparations is the basis of the clinical interactions with calcineurin inhibitors and antiretroviral protease inhibitors.
| interactions = <pharmaInteractions/>

The clinically significant interactions of garlic are dominated by the bleeding-risk and CYP3A4-induction categories. The bleeding risk of garlic combined with warfarin is documented in multiple case reports of supratherapeutic INR and bleeding events;<ref name="garlic-warfarin">Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. ''American Journal of Health-System Pharmacy''. 2000;57(13):1221-1227. PMID 10902065.</ref> the recommendation is to avoid therapeutic-dose garlic supplementation in warfarin-treated patients, with culinary doses typically considered safe. The same caution applies to the direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran), with the additional consideration that the DOAC plasma concentrations may be subject to CYP3A4 induction (apixaban, rivaroxaban) or P-glycoprotein induction (dabigatran, edoxaban) by garlic compounds; the combined effect is unpredictable and the conservative recommendation is to avoid the combination. Antiplatelet medicine (aspirin, clopidogrel, prasugrel, ticagrelor) combined with therapeutic-dose garlic produces additive antiplatelet effect; the clinical consequence is increased bleeding risk, particularly perioperative or in patients with thrombocytopenia or other bleeding diatheses.

CYP3A4 induction by garlic is the basis of the documented interactions with the HIV protease inhibitors (saquinavir, ritonavir), with the calcineurin inhibitors used in transplant medicine (cyclosporine, tacrolimus), and with several other CYP3A4 substrates with narrow therapeutic windows. Reductions of 30 to 50 percent in plasma saquinavir concentrations have been reported with concurrent garlic supplementation, with the clinical risk of antiretroviral failure and emergence of resistance.<ref name="garlic-saquinavir">Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. ''Clinical Infectious Diseases''. 2002;34(2):234-238. PMID 11740713.</ref> Similar magnitude reductions in cyclosporine plasma concentrations have been observed; the combination is contraindicated in transplant patients.

The preoperative discontinuation recommendation is seven to ten days before elective surgery for therapeutic-dose garlic supplementation, on the basis of the antiplatelet effect duration and platelet turnover; culinary use does not require preoperative discontinuation.
| pregnancy_details = Dietary amounts of garlic are considered safe in pregnancy and lactation, with a long historical record of routine pregnancy consumption in essentially all garlic-using cultures. The flavor of garlic transfers to amniotic fluid and breast milk, and infants exposed to garlic in utero or via maternal lactation show distinct flavor preferences for garlic-containing foods after weaning; some clinical reports note prolonged breastfeeding sessions on days of maternal garlic consumption, with mixed acceptance from mothers. Therapeutic doses of standardized garlic preparations have not been formally studied in pregnancy; the conservative recommendation is to limit pregnant patients to culinary doses, particularly in the third trimester where the antiplatelet effect could theoretically increase peripartum bleeding risk.
| monitoring = For patients on warfarin who choose to consume garlic at culinary doses, INR monitoring at the initiation of regular consumption and again at three to four weeks is the conservative practice; therapeutic-dose supplementation is best avoided rather than monitored. For transplant patients on calcineurin inhibitors, plasma-level monitoring at any change in garlic intake (initiation, discontinuation, or substantial change in quantity) is recommended.
| counseling = Patients should be counseled that culinary use of garlic is safe for almost all patients (with the exceptions of those with established Allium allergy, severe Alliaceae cross-reactivity, or active gastrointestinal ulceration where the irritant effect of raw garlic may delay healing). The breath and body odor produced by garlic consumption derives from sulfur metabolites excreted via the lungs and skin and can persist for 24 to 48 hours; chewing parsley, mint, or anise after consumption modestly reduces the breath effect but does not affect the systemic odor. Raw garlic applied directly to skin can produce contact burns, particularly in occluded or prolonged-contact applications; the traditional topical poultice should be limited to 10 to 20 minutes of contact and inspected at intervals. Improperly preserved garlic-in-oil at room temperature is a documented source of Clostridium botulinum growth, with several documented cases of botulism from home-prepared garlic-in-oil; commercially prepared products are acidified or refrigerated to prevent this, and home preparation should follow the same controls. Patients planning elective surgery should be counseled to discontinue therapeutic-dose garlic supplementation seven to ten days before surgery.
| anecdotes =
| seealso = [[Onion]], [[Leek]], [[Ginger]], [[Turmeric]], [[Cayenne]], [[Hawthorn]], [[Ginkgo]]
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Cardiovascular herbs]]
[[Category:Antimicrobial herbs]]
[[Category:Anti-inflammatory herbs]]
[[Category:Ayurvedic herbs]]
[[Category:TCM herbs]]
[[Category:Unani herbs]]
[[Category:Western clinical herbs]]

Heart's delight

2026-05-26T17:27:27Z

MDElliottMD: home-claude: redirect to Lemon balm

#REDIRECT [[Lemon balm]]

Bee balm

2026-05-26T17:27:26Z

MDElliottMD: home-claude: redirect to Lemon balm

#REDIRECT [[Lemon balm]]

Melissa (herb)

2026-05-26T17:27:26Z

MDElliottMD: home-claude: redirect to Lemon balm

#REDIRECT [[Lemon balm]]

Balm

2026-05-26T17:27:26Z

MDElliottMD: home-claude: redirect to Lemon balm

#REDIRECT [[Lemon balm]]

Melissa officinalis

2026-05-26T17:27:25Z

MDElliottMD: home-claude: redirect to Lemon balm

#REDIRECT [[Lemon balm]]

Lemon balm

2026-05-26T17:27:18Z

MDElliottMD: home-claude: Lemon balm (Melissa officinalis) herb #8; PMIDs verified; Q1 Wolbling 1994 PMID 23195812; Q3 EMA/HMPC/196745/2012

{{PlantMedTemplate
| name = Lemon balm
| binomial = Melissa officinalis
| family = Lamiaceae
| native_range = Southern Europe, western Asia, and northern Africa; naturalized through temperate Europe, the Americas, and Australasia. Wild populations occur on roadsides, hedgerows, disturbed ground, and the margins of woodland, particularly on calcareous soils. Widely cultivated as a garden and medicinal herb throughout the temperate world.
| plant_part = Aerial parts (leaves and flowering tops), harvested just before full flowering when volatile oil content peaks; occasionally the essential oil distilled from fresh herb.
| image =
| intro = Melissa officinalis L. -- lemon balm, balm, melissa -- is a perennial herb of the mint family whose Greek name means bee, a record of the insects that congregate on its small white flowers and make from them a honey prized in antiquity. It has been called "the elixir of life" by Paracelsus and "sovereign for the brain" by John Evelyn; its unbroken reputation across two thousand years of Western and Islamic medicine is for lifting the heart, clearing the head, and settling the gut. The same compounds responsible for its sharp lemon scent -- the polyphenolic fraction concentrated in its leaves -- have turned out to be active against herpes simplex virus in controlled trials, giving it a specific antiviral credential unlike any other common nervine herb.

| history = The genus name carries the oldest story. In Greek myth, Melissa was a bee-priestess of the mountain goddess Cybele; she fed the infant Zeus on honey when his father Kronos sought to devour him, and was afterward transformed into a bee. Theophrastus in the fourth century BCE noted that beekeepers rubbed hive entrances with melissa leaves to keep their colonies from straying -- a practice that survives in modern beekeeping -- and the plant's association with bees, honey, and the sweetness of life runs through every tradition that has known it.{{citation needed}}

Dioscorides, writing in the first century of the common era, described melissa as useful for treating scorpion stings, dog bites, and the spasms of nervous origin; he recorded it as an infusion for "those who suffer from melancholy," establishing the herb's neurological reputation at the foundational level of European botanical medicine.{{citation needed}} The Romans cultivated it widely, and it passed from Roman gardens into the monastery.

Hildegard of Bingen in the twelfth century listed balm among the plants of the monastic garden that addressed the spiritual ailments she called melancholia; Paracelsus in the sixteenth century, temperamentally given to extreme claims, called it "the elixir of life" -- "among all the herbs none is better for the heart."{{citation needed}} John Gerard's Herball of 1597 recommended it for "driving away melancholly and heaviness of mind" and for "warming and comforting the heart."{{citation needed}}

The most enduring and delightful preparation in lemon balm's history was not a medicine in the modern sense but a spirit: Carmelite water (eau des Carmes), developed by the Carmelite nuns in Paris in the fourteenth century from lemon balm, lemon peel, nutmeg, coriander, angelica root, and cloves in high-proof spirits. It circulated as a tonic for the heart, a remedy against fainting and melancholy, and a general cordial; Charles V of France was reputed to drink it daily.{{citation needed}} The preparation survives commercially today under the Boyer label in France, continuous from the 17th century, and may be the longest-lived packaged medicinal preparation in Western Europe.

John Evelyn, the English diarist and gardener, wrote in the late seventeenth century: "Balm is sovereign for the brain, strengthening the memory and powerfully chasing away melancholy."{{citation needed}} The modern dimension was added not by herbalists but by laboratory pharmacologists. In 1994, the German physician and researcher Rainer Wölbling published the first rigorously controlled clinical trial of a standardized lemon balm cream -- subsequently commercialized as Lomaherpan -- applied to cold sores caused by herpes simplex virus.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from Melissa officinalis." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref> The trial demonstrated that what herbalists had used empirically for mouth sores for centuries worked through a specific mechanism -- rosmarinic acid and other polyphenols blocking herpes virus attachment to host cells -- that remains among the most mechanistically coherent antiviral findings in phytomedicine.

| taxonomy = Melissa officinalis L. is placed in tribe Mentheae, family Lamiaceae, the sole widely used species in the genus Melissa. The genus name derives from the Greek melissa (bee); the species epithet officinalis (of the dispensary) is shared with hundreds of medicinal plants and indicates long-standing apothecary use. No infraspecific taxa carry commercial or medicinal significance.

L. officinalis is a vigorous, branching perennial growing to 1.5 m (5 ft), with deeply veined, toothed bright-green leaves that release a sharp lemon scent when crushed -- a quality immediately distinguishing it from mint (Mentha) and other Lamiaceae in the garden. The lemon scent derives principally from citronellal, a compound also responsible for the scent of lemongrass (Cymbopogon citratus) and lemon eucalyptus (Corymbia citriodora), reflecting convergent volatile chemistry across plant families rather than close botanical relationship.

The small white flowers, tinged pink or lilac, appear in dense axillary clusters from early summer onward; they are rich in nectar and unusually attractive to honeybees. In the garden lemon balm self-seeds freely and becomes naturalized with ease; it is one of the least demanding of the Lamiaceae in cultivation, tolerating partial shade, poor soils, and neglect.

The medicinal parts are the aerial parts -- leaves and flowering tops -- harvested just before full flowering when volatile oil content is highest. Post-flowering leaves are coarser in flavor and lower in volatile oil. The essential oil is produced commercially but is one of the most expensive in herbal commerce: approximately 3,000 to 5,000 kg of fresh leaf is required to produce 1 kg of oil, reflecting the low volatile oil yield (typically under 0.2 percent of fresh weight) and the labor-intensive harvest involved. The essential oil is rarely indicated in clinical practice and is used primarily in aromatherapy.

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lemon balm belongs to the nervine class of Western herbal medicine -- herbs with a primary action on the nervous system -- and is distinguished within that class by its particular gentleness: it is among the most pediatric-appropriate nervines in the Western tradition, given to colicky infants, anxious children, and restless adolescents alongside adults, without dose adjustment anxieties. This record of safe pediatric use across centuries is itself a kind of pharmacovigilance.

The principal traditional indications map closely onto the modern clinical evidence: anxiety and nervous agitation, insomnia with a restless or worried mind, palpitations from nervous origin (the "racing heart" that has no structural cardiac cause), nervous indigestion, colic and flatulence with an anxiety or tension component, and headache related to tension or nervous overload. The Carmelite water tradition adds a specifically cardiac tonifying dimension -- the heart-gladdening claim -- that aligns with both the nervous-palpitation indication and the mood-lifting effects documented in Kennedy's controlled trials two centuries later.

Secondary traditional indications include the antiviral use -- cold sores, oral herpes, used as topical fresh leaf or strong infusion -- which predates any knowledge of herpesvirus and reflects accurate empirical observation, and a diaphoretic use in febrile illness that made lemon balm standard in European childhood fever management.

'''Islamic medicine (Unani)'''

Lemon balm appears in Islamic-Galenic medicine as Turunjan (ترنجان) and, in some North African traditions, as Badharuj -- though this Arabic identifier is also applied by some sources to sweet basil (Ocimum basilicum), creating a minor source-identification ambiguity.{{citation needed}} Ibn Sina's Canon of Medicine praises it in terms that no other classical herbalist surpassed: lemon balm "causeth the heart and mind to become merry, exhilarateth the mind, settleth digestion, and is good against melancholy and the spleen." The Canon identifies it as a warming, drying herb good for cold temperaments, for cardiac palpitations, and for the "sadness and grief" that Ibn Sina associated with obstruction of the vital spirit.{{citation needed}}

'''Ayurvedic medicine'''

Lemon balm is not a primary plant of the classical Ayurvedic pharmacopoeia -- its native range does not extend to the Indian subcontinent -- but it has been incorporated into contemporary Ayurvedic and integrative practice in Europe and North America where it overlaps with herbs of similar action. It is occasionally classified by contemporary Ayurvedic practitioners as a tridoshic nervine suitable for vata-type anxiety and pitta-type irritability.{{citation needed}}

| pharmacology = '''Volatile oil and polyphenolic constituents'''

The essential oil of M. officinalis is dominated by citral -- a mixture of the geometric isomers geranial and neral -- which accounts for the plant's characteristic lemon scent, along with citronellal, linalool, and caryophyllene oxide.{{citation needed}} The volatile oil fraction, however, is present in much lower concentration than in most other medicinal Lamiaceae (under 0.2 percent of fresh weight), and its contribution to the therapeutic actions of whole-plant preparations may be secondary to the non-volatile polyphenolic fraction.

Rosmarinic acid and related caffeic acid derivatives -- the principal polyphenolic compounds in lemon balm -- are the dominant pharmacologically active fraction for antiviral activity. Rosmarinic acid and the tannin fraction interfere with viral attachment to host cells by binding to glycoproteins on the herpes simplex virus (HSV) envelope, preventing the virus from docking with cell-surface receptors; this mechanism has been demonstrated in cell-culture models and correlates with the clinical efficacy of topical Melissa preparations in herpes labialis.{{citation needed}}

The flavonoids (luteolin, apigenin) and triterpenes (ursolic and oleanolic acids) contribute anti-inflammatory and anxiolytic properties; apigenin in particular has affinity for the benzodiazepine receptor site of the GABA-A receptor, and this GABA-A interaction is the proposed basis for lemon balm's anxiolytic and mild sedative activity -- the same general mechanism as valerian, passionflower, and lavender, reflecting convergent pharmacology across unrelated plant families.{{citation needed}}

The anti-thyroid mechanism is distinct from both of the above: aqueous extracts of Melissa officinalis inhibit binding of thyroid-stimulating hormone (TSH) and Graves' immunoglobulins to TSH receptors in vitro, reducing thyroid stimulation. The mechanism is thought to involve the polyphenolic fraction competitively occupying the TSH receptor or blocking immunoglobulin binding sites.

| clinical_evidence = '''Antiviral: herpes simplex (topical)'''

The strongest and most specific clinical evidence for lemon balm is topical and antiviral. The German physician Rainer Wölbling conducted the first placebo-controlled trial of a standardized Melissa cream on recurrent cold sores in 1994, demonstrating significant reduction in lesion size, healing time, and symptom severity with a 1 percent dried Melissa extract cream applied four times daily.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from Melissa officinalis." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref>

Koytchev and colleagues (1999) confirmed and extended these findings in a larger placebo-controlled trial of the Lomaherpan-equivalent preparation (Lo-701, a 70:1 Melissa dry extract cream) applied four times daily to active cold sore lesions. The treated group showed significantly faster healing, smaller lesion area at day two, and reduced pain compared with placebo; the authors noted particularly strong benefit in patients treated at first symptom appearance (the prodrome or early vesicle stage) before full lesion development.<ref name="koytchev1999">Koytchev R, Alken RG, Dundarov S. "Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis." Phytomedicine. 1999;6(4):225-230. PMID 10589440.</ref>

The commercial preparation Lomaherpan (standardized 1 percent Melissa officinalis extract cream; Lomapharm, Germany) continues to be used and studied on this basis; it is the reference preparation for the EMA's traditional use opinion on Melissa for cold sores.

The evidence is specific to topical application: lemon balm polyphenols must be in direct contact with the HSV-infected tissue to exert their envelope-binding antiviral effect. Internal lemon balm preparations (infusion, tincture) have not been evaluated in placebo-controlled trials for recurrent herpes; the antiviral claim should not be extended to oral preparations without direct supporting evidence.

'''Mood and cognitive modulation (oral preparations)'''

Kennedy and colleagues conducted a series of dose-finding studies in healthy volunteers that provide the clearest pharmacological picture of oral lemon balm's cognitive and mood effects. In a 2002 crossover study, single doses of a standardized Melissa officinalis extract (300 mg, 600 mg, or 900 mg) produced dose-dependent improvements in calmness ratings and speed of mathematical processing on validated psychometric batteries; notably, the highest dose (900 mg) reduced calmness ratings relative to placebo, suggesting an inverted-U dose-effect relationship -- a feature consistent with the GABA-A modulation mechanism and commonly observed with GABAergic agents.<ref name="kennedy2002">Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. "Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm)." Pharmacology Biochemistry and Behavior. 2002;72(4):953-964. PMID 12062586.</ref>

A 2003 companion study found significant improvements in mood and cognitive performance following single oral doses, with dose-dependent effects on the speed of memory and spatial working memory tasks.<ref name="kennedy2003">Kennedy DO, Wake G, Savelev S, et al. "Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human pharmacological models." Neuropsychopharmacology. 2003;28(10):1871-1881. PMID 12888775.</ref>

In a 2006 study, Kennedy and colleagues evaluated a standardized combination of Melissa officinalis and Valeriana officinalis (valerian) extract under laboratory-induced stress conditions. The combination produced significant reductions in anxiety ratings during a multi-tasking battery, reductions in self-rated stress and alertness, and mood improvements relative to placebo; the effects were consistent with additive or synergistic action of the two plant extracts' respective mechanisms.<ref name="kennedy2006">Kennedy DO, Little W, Haskell CF, Scholey AB. "Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress." Phytotherapy Research. 2006;20(2):96-102. PMID 16444660.</ref>

These studies establish a real but modest anxiolytic and cognitive-modulating effect of oral lemon balm that is consistent with the GABA-A mechanism. Effect sizes are smaller than those seen with oral Silexan for generalized anxiety disorder; the evidence base is sufficient for mild-to-moderate situational anxiety but has not been evaluated against prescription anxiolytics in the manner of the Silexan trials.

'''Anti-thyroid activity (in vitro and limited clinical data)'''

Auf'mkolk and colleagues (1985) demonstrated in an in vitro receptor-binding assay that aqueous extracts of Melissa officinalis (and several other plants) inhibit the binding of thyroid-stimulating hormone and Graves' immunoglobulins to TSH receptors, reducing adenylate cyclase stimulation.<ref name="aufmkolk1985">Auf'mkolk M, Ingbar JC, Kubota K, Amir SM, Ingbar SH. "Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and the biological activity of Graves' immunoglobulins." Endocrinology. 1985;116(5):1687-1693. PMID 2985357.</ref> This finding has been used as the pharmacological rationale for combining lemon balm with bugleweed (Lycopus europaeus) as an adjunctive herbal support in mild hyperthyroidism and Graves' disease; controlled clinical trials evaluating this combination for clinical outcomes in hyperthyroid patients are limited in number and quality.{{citation needed}}

'''Pediatric use'''

The use of lemon balm for sleep disturbance and nervousness in children is supported by tradition, basic safety data, and a limited clinical literature that includes combination preparations (valerian plus lemon balm).{{citation needed}} No serious adverse effects attributable to lemon balm have been reported in pediatric use at traditional doses.

| preparations = Infusion (tea): 2 to 4 g dried leaf and flowering tops per cup of hot water, covered while steeping (10 to 15 minutes) to retain the volatile oil fraction; the covering step is not cosmetic -- the volatile constituents are pharmacologically active and evaporate readily. Taken three times daily for daytime use or before sleep for insomnia.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation for internal use; 2 to 6 ml per dose, three times daily.

Standardized dry extract: solid extract standardized to rosmarinic acid content (typically 3 to 5 percent), usually in capsule form; the preparation form used in the Kennedy cognitive-modulation studies (300 to 900 mg per dose).

Topical cream: 1 percent standardized Melissa dry extract (Lomaherpan; equivalent commercial preparations) applied topically to cold sore lesions at first symptom; the antiviral evidence is specific to topical preparations with defined rosmarinic acid content.

Essential oil: rarely used therapeutically; primarily aromatherapy; expensive and frequently adulterated with lemongrass (Cymbopogon citratus) or lemon-scented verbena (Aloysia citrodora) oil; if used, always diluted in carrier oil.

Combination preparations: Melissa plus Valeriana officinalis (valerian) is the most common commercial combination, targeting sleep and mild anxiety; this combination has the best clinical evidence base (Kennedy 2006) for lemon balm's anxiolytic and sleep-promoting effects.

| dosing = '''Internal preparations'''

Infusion: 2 to 4 g dried leaf per cup, three times daily and before bed. Acute use for nervous agitation or palpitations: a strong cup (double strength, 4 g covered, 15-minute steep) taken as needed.

Tincture (1:5 in 45 percent ethanol): 2 to 6 ml per dose, three times daily. Children: no established dose adjustment in traditional use; standard practice has been to reduce proportionally by body weight or to use a weaker preparation (diluted infusion), noting the absence of observed adverse effects in pediatric use at herbal practice doses.

Standardized extract: 300 to 600 mg per dose (consistent with Kennedy's effective dose range); 900 mg per dose has been associated with reduced calmness in Kennedy's studies and should be avoided as a starting dose.

For cold sore prevention with oral preparations: no clinical evidence base; oral lemon balm does not substitute for topical treatment and no internal anti-HSV dose has been evaluated.

Combination preparations (Melissa plus valerian): follow manufacturer dosing; typically one to two capsules or 5 to 10 ml liquid combination tincture at bedtime for sleep.

'''Recreational dose ladder'''

Lemon balm has no established recreational dose structure. Its sedative-anxiolytic effect at therapeutic doses is among the gentlest in the nervine class -- substantially milder than valerian, kava, or cannabis -- and dose escalation beyond the Kennedy effective range (300 to 600 mg standardized extract) produces diminishing benefit rather than progressive relaxation, as the 900 mg dose in Kennedy's studies reduced, rather than increased, calmness. No ethnobotanical or contemporary self-dosing literature documents recreational use of lemon balm in any form; the ceiling of effect at accessible doses is simply too low and too undramatic to attract recreational interest. No tiered dose ladder is warranted.

| pharmacokinetics = The pharmacokinetics of lemon balm's active constituents have not been characterized to the same degree as those of pharmaceutical preparations. Rosmarinic acid, the principal polyphenolic constituent, is absorbed from the gastrointestinal tract and undergoes conjugation and hydroxylation by intestinal microbiota and hepatic enzymes; plasma levels peak approximately 30 to 60 minutes after ingestion.{{citation needed}} The apigenin and luteolin flavonoids have been more extensively characterized in other botanical contexts and show oral bioavailability dependent on gut microbiome composition.

| interactions = Central nervous system depressants: additive effect expected with sedatives, anxiolytics, alcohol, and sedating herbal medicines (valerian, hops, passionflower, kava); lemon balm's own sedative effect is mild, but the interaction is pharmacologically consistent and clinically relevant when adding lemon balm to a regimen that includes prescription sedatives or anxiolytics. Therapeutic use with benzodiazepines should be mentioned to the prescriber.

Thyroid preparations: theoretical antagonism with levothyroxine and other thyroid hormone replacement if lemon balm's anti-TSH-receptor activity translates to clinical reduction of thyroid function; this is relevant primarily at high chronic doses in patients with hypothyroidism or those on replacement thyroid therapy. At standard infusion doses, the interaction is theoretical rather than documented; in practice, standard tea use is unlikely to produce clinically significant thyroid antagonism.

| interactionsummary = Additive CNS sedation with sedatives and anxiolytics. Theoretical thyroid hormone antagonism at high doses in hypothyroid patients.

| safety = Lemon balm has an outstanding safety record across two thousand years of use in children and adults. No serious adverse events have been reported in clinical trials, case reports, or systematic reviews at standard therapeutic doses. It is among the herbs most consistently identified as safe for children in the traditional and contemporary herbal literature.

Hypothyroidism: the anti-thyroid mechanism identified by Auf'mkolk (1985) in vitro has led to a theoretical caution for chronic high-dose oral use in patients with established hypothyroidism or those on thyroid hormone replacement. Standard infusion use (2 to 4 g dried herb three times daily) has not produced clinical hypothyroidism in case reports; the caution is precautionary at current doses. Patients with established hypothyroidism on levothyroxine who wish to use lemon balm chronically should have thyroid function monitored.

Pregnancy: lemon balm is used traditionally during pregnancy and lactation as a calming herb, and is one of the nervines most commonly recommended for perinatal anxiety in traditional midwifery practice. No clinical trial data in pregnancy exists. Consensus in contemporary herbal practice is that standard infusion doses are likely safe; concentrated extracts and high-dose standardized preparations have not been evaluated and should be used conservatively in pregnancy.

Allergic reactions to lemon balm are rare; contact dermatitis has been reported with the essential oil and less commonly with topical fresh plant preparations.

| monitoring = No routine monitoring required for standard-dose internal use in healthy adults. Patients with hypothyroidism or on thyroid hormone replacement using chronic lemon balm preparations: thyroid-stimulating hormone at baseline and after two to three months of regular use. Patients adding lemon balm to benzodiazepine or sedative regimens: monitor for excess sedation, particularly at treatment initiation.

| counseling = The distinction between oral and topical applications is important to convey clearly. Oral lemon balm (infusion, tincture, extract) is indicated for anxiety, nervous insomnia, palpitations, and nervous digestive symptoms; the clinical evidence for these indications is consistent but modest. Topical Lomaherpan-equivalent cream (1 percent standardized Melissa extract) is the form with the specific antiviral evidence for cold sores, applied at first sign of prodrome; oral lemon balm should not be presented as a substitute for the topical application in herpes management.

Patients with recurrent cold sores benefit most from topical treatment begun at prodrome (tingling, burning, or itching before vesicle formation) rather than after full blister development; early application is the message from Koytchev (1999) and consistent with the mechanism of attachment inhibition working best before viral invasion is complete.

Patients using lemon balm for anxiety who are not experiencing adequate response at standard infusion doses may benefit from a standardized extract at the 300 to 600 mg range, or from a Melissa plus valerian combination product (which has the best clinical evidence for the combined anxiolytic-sleep indication). If anxiety is more than mild to moderate, a clinical assessment for generalized anxiety disorder, for which Silexan (oral lavender oil) has substantially stronger evidence, is appropriate.

| regulatory = '''Germany and European Union'''

German Commission E: lemon balm (Melissenblätter) approved for nervous sleep disorders and functional gastrointestinal complaints; covers dried herb preparations (infusion, tincture) based on traditional use and the clinical evidence base.

EMA HMPC: positive opinion for traditional use of Melissa officinalis leaf for relief of mild symptoms of stress and to aid sleep; also for traditional use of standardized topical preparations for symptomatic treatment of cold sores (Herpes labialis). One HMPC monograph (EMA/HMPC/196745/2012) covers both the internal nervine/sleep indication and the topical herpes simplex indication.<ref name="ema-hmpc-melissa">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Melissa officinalis L., folium. EMA/HMPC/196745/2012. First published: 5 August 2013. https://www.ema.europa.eu/en/medicines/herbal/melissae-folium.</ref>

'''United States'''

Melissa officinalis: GRAS (generally recognized as safe) as a food flavoring; sold as a dietary supplement under DSHEA without FDA evaluation of efficacy claims. No approved drug indication.

'''United Kingdom'''

MHRA traditional herbal registration: Melissa officinalis preparations registered for traditional use for mild anxiety and sleep disturbance, and for topical application to cold sores; the topical Lomaherpan-equivalent preparations are registered separately.

| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Western clinical herbs]]

Phencyclidine

2026-05-26T17:25:48Z

MDElliottMD: home-claude: add dosing field + Erowid PCP block (MedTemplate parity with Ketamine)

Phencyclidine (PCP), chemically 1-(1-phenylcyclohexyl)piperidine, is a synthetic [[:Category:Dissociatives|dissociative]] [[NMDA receptor]] antagonist first synthesized in 1956 by Victor Maddox at the [[Parke-Davis]] Research Laboratories in Detroit, Michigan, during a systematic screening program for new general anesthetics.<ref name="maddox-1965">Maddox VH, Godefroi EF, Parcell RF. The synthesis of phencyclidine and other 1-arylcyclohexylamines. ''Journal of Medicinal Chemistry'' 1965;8:230-235.{{citation needed}}</ref><ref name="domino-2010">Domino EF. History and pharmacology of PCP and PCP-related analogs. ''Journal of Psychoactive Drugs'' 2010;42(3):223-226.{{citation needed}}</ref> It is the prototype of the [[:Category:Arylcyclohexylamines|arylcyclohexylamine]] class, the chemical family that includes [[Ketamine]], [[Methoxetamine]], and the modern research-chemical analogs (3-MeO-PCP, 4-MeO-PCP).

Parke-Davis marketed phencyclidine briefly as '''Sernyl''' for human surgical anesthesia from 1963, then withdrew it from human use in 1965 after consistent reports of severe emergence reactions, prolonged psychosis, and a clinical presentation that anesthesiologists found unmanageable.<ref name="greifenstein-1958">Greifenstein FE, DeVault M, Yoshitake J, Gajewski JE. A study of a 1-aryl cyclohexylamine for anesthesia. ''Anesthesia and Analgesia'' 1958;37:283-294.{{citation needed}}</ref><ref name="domino-2010" /> Veterinary use as '''Sernylan''' (large animal anesthesia, particularly for primates) persisted until 1978. By that point, phencyclidine had become a notorious street substance under the names '''angel dust''', '''dust''', '''sherm''', '''wet''', and (misleadingly) '''embalming fluid''', and the United States Drug Enforcement Administration had moved it from [[USLegal:DEA Schedule III|Schedule III]] (its original 1970 placement) to [[USLegal:DEA Schedule II|Schedule II]].<ref name="dea-scheduling">United States Drug Enforcement Administration. Schedules of Controlled Substances: Rescheduling of Phencyclidine. ''Federal Register'' 1978;43:34134.{{citation needed}}</ref>

Phencyclidine has no current medical indication anywhere in the world. Its enduring importance is scientific. The binding site within the NMDA receptor channel pore is still called "the PCP site". Krystal, Javitt and others established in the 1990s that NMDA antagonism in healthy volunteers reproduces both the positive AND the negative symptoms of [[Schizophrenia]] more faithfully than any [[Psychostimulant]] model, which underpins the [[Glutamate hypothesis of schizophrenia|glutamate hypothesis of schizophrenia]] and the entire generation of NMDA-targeted therapeutic candidates that followed.<ref name="krystal-1994">Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. ''Archives of General Psychiatry'' 1994;51(3):199-214.{{citation needed}}</ref><ref name="javitt-zukin-1991">Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. ''American Journal of Psychiatry'' 1991;148(10):1301-1308.{{citation needed}}</ref> Ketamine's reframing as a rapid-acting antidepressant and the approval of dextromethorphan-bupropion ([[Auvelity]]) are downstream of work that began with phencyclidine.

{{MedTemplate
| generic = Phencyclidine
| brand = Sernyl (human, withdrawn 1965); Sernylan (veterinary, withdrawn 1978)
| structure =
| classes = [[:Category:Dissociatives|Dissociative]], [[:Category:NMDA_receptor_antagonists|NMDA receptor antagonist]], [[:Category:Sigma-1_receptor_agonists|Sigma-1 receptor agonist]], [[:Category:Arylcyclohexylamines|Arylcyclohexylamine]], [[:Category:Anesthetics|Anesthetic (historical)]]
| uses = <vote slug="phencyclidine-historical-anesthesia-use">Historical: dissociative surgical anesthesia (withdrawn 1965)</vote>, <vote slug="phencyclidine-research-tool-use">Research tool: NMDA receptor pharmacology and the glutamate hypothesis of schizophrenia</vote>
| starting_dose = No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl).
| preparations = Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets.
| fda_max = N/A (no current medical indication)
| pill_id =
| routes = Oral, IV, IM, smoked, insufflated
| onset = Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min
| duration = 4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours
| halflife = Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range<ref name="cook-1982">Cook CE, Brine DR, Jeffcoat AR, et al. Phencyclidine disposition after intravenous and oral doses. ''Clinical Pharmacology and Therapeutics'' 1982;31(5):625-634.{{citation needed}}</ref>
| bioavailability = ~72% oral; ~85% smoked<ref name="cook-1982" />
| pregnancy = Limited human data; case series describe neurobehavioral effects in exposed neonates. No medical indication exists; recreational use in pregnancy is associated with maternal hypertensive emergency and possible developmental sequelae.{{citation needed}}
| legal = [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.<ref name="dea-scheduling" />
| mechanism = <vote slug="phencyclidine-mech-claim">Phencyclidine is a non-competitive open-channel blocker of the NMDA glutamate receptor, binding to a site within the channel pore (the "PCP site", named for this medicine) that is accessible only when the channel is open; the resulting use-dependent block produces dissociation, anesthesia, and the broad cognitive disruption characteristic of NMDA antagonism.</vote> Secondary activity at sigma-1 receptors (agonist), the dopamine transporter (weak inhibition), and nicotinic acetylcholine receptors (antagonist) shapes the distinctive clinical profile compared with the cleaner profile of ketamine.<ref name="anis-1983">Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. ''British Journal of Pharmacology'' 1983;79(2):565-575.{{citation needed}}</ref> Metabolized by [[CYP3A4]] and [[CYP2B6]]; the parent compound is the principal active species.
| dosing =
<titration slug="erowid-dose-oral" author="erowid-claude"
title="Oral dose ladder (Erowid)">
Erowid's dosage documentation for oral PCP<ref name="erowid-pcp-dose">
Erowid. PCP Dosage. Erowid.org.
https://www.erowid.org/chemicals/pcp/pcp_dose.shtml.
Accessed 2026-05-26.</ref> reports the following tiers (threshold
and heavy not characterized):

* '''Light:''' 3-5 mg
* '''Common:''' 5-10 mg
* '''Strong:''' 10+ mg

Duration approximately 4 to 6 hours with aftereffects up to 24 hours.
Timing not specified by Erowid. PCP is frequently applied to plant
material (cannabis or tobacco) and smoked; specific dose tiers for
smoked administration are not documented by Erowid.
</titration>
}}

== History ==

=== Synthesis and first human anesthetic trials, 1956-1962 ===

The arylcyclohexylamine scaffold emerged at Parke-Davis in the mid-1950s as part of a search for analgesics and anesthetics free of the respiratory depression and circulatory instability of the [[:Category:Opioid_receptor_agonists|opioids]] and [[:Category:Barbiturates|barbiturates]] then in routine surgical use. Victor Maddox, working in the medicinal-chemistry group, synthesized phencyclidine in 1956; his colleague Graham Chen described its remarkable animal pharmacology over the next two years, including the unusual combination of profound analgesia and anesthesia without significant cardiovascular or respiratory depression, but with a state that did not look like ordinary sleep.<ref name="maddox-1965" /><ref name="chen-1959">Chen G, Ensor CR, Russell D, Bohner B. The pharmacology of 1-(1-phenylcyclohexyl)piperidine HCl. ''Journal of Pharmacology and Experimental Therapeutics'' 1959;127:241-250.{{citation needed}}</ref>

The first human anesthetic trial, by Frederick Greifenstein and colleagues at Wayne State University in 1958, reported what they called "a profound analgesia with a peculiar mental state".<ref name="greifenstein-1958" /> Patients appeared awake but disconnected: eyes open, sometimes tracking, but unresponsive to surgical stimulus and afterward amnestic. Edward Domino, who would become the field's chief historian, joined the project in the late 1950s and coined the term '''dissociative anesthesia''' to describe the state, distinguishing it from both classical general anesthesia and from the twilight sedation produced by sedative-hypnotics.<ref name="domino-2010" />

=== Sernyl approval and the emergence problem, 1963-1965 ===

The US Food and Drug Administration approved phencyclidine for human surgical anesthesia in 1963, marketed by Parke-Davis as '''Sernyl'''. The initial enthusiasm was real: Sernyl produced surgical anesthesia with preserved airway reflexes, preserved cardiovascular tone, and no respiratory depression, in patients whose comorbidities made conventional general anesthesia hazardous. Anesthesiologists who used it described it as a near-ideal agent intraoperatively.

The problem was emergence. In the first published series of any size, 10 to 30% of patients emerged from Sernyl anesthesia with severe agitation, frank hallucinations, paranoid delusions, and a psychosis that in some cases persisted for days to weeks after a single anesthetic dose.<ref name="greifenstein-1958" /><ref name="domino-2010" /> Surgical recovery rooms became unmanageable. Reports accumulated of patients who recovered from anesthesia, were discharged, and presented to psychiatric emergency rooms in florid psychotic states a week later. Parke-Davis withdrew the human indication in 1965, four years after FDA approval, and refocused the program on a structural analog that the chemist Calvin Stevens had synthesized in 1962 and that produced shorter, less intense, and more medically manageable dissociation: '''ketamine'''.<ref name="domino-2010" /> The decision to push ketamine and shelve phencyclidine for human medicine was, in retrospect, prescient: ketamine remains in routine clinical use globally six decades later.

=== Veterinary Sernylan and recreational emergence, 1967-1978 ===

Phencyclidine continued in veterinary use as '''Sernylan''' for nearly a decade and a half after the human withdrawal, principally for large-animal and non-human-primate anesthesia where the preserved cardiovascular tone outweighed the emergence concerns that ended the human program. Sernylan was withdrawn in 1978.

Recreational use of phencyclidine emerged in San Francisco in 1967, where it appeared briefly as a tablet sold under the name "the PeaCePill"; the experience was widely reported as unpleasant, and phencyclidine nearly disappeared from the West Coast scene within a year.<ref name="domino-2010" /> It returned in the early 1970s in a different form: as a powder, frequently smoked after being sprinkled on cannabis or parsley, or "dipped" into a solvent and applied to cigarettes ("wet", "fry", "sherm" - the last from the Sherman brand of cigarettes commonly used as the substrate). Liquid forms were sometimes sold or described as '''embalming fluid'''; some samples genuinely contained formaldehyde as a solvent for phencyclidine, while other samples sold under the name were formaldehyde alone with no phencyclidine, an interchangeability that confused both users and clinicians.<ref name="holland-1998">Holland JA, Nelson L, Ravikumar PR, Elwood WN. Embalming fluid-soaked marijuana: new high or new guise for PCP? ''Journal of Psychoactive Drugs'' 1998;30(2):215-219.{{citation needed}}</ref>

By the mid-1970s, urban emergency departments in the eastern United States were seeing enough acute phencyclidine intoxication to make it a routine differential in any agitated, hypertensive, dissociated patient of unclear etiology. The DEA rescheduled phencyclidine from [[USLegal:DEA Schedule III|Schedule III]] to [[USLegal:DEA Schedule II|Schedule II]] in 1978, citing the public-health burden of the dipped-cigarette epidemic.<ref name="dea-scheduling" />

=== The 1980s media moral panic ===

The 1980s brought the cultural moment that still shapes American lay perception of phencyclidine: a series of news and law-enforcement narratives in which intoxicated users displayed apparently superhuman strength, indifference to injury, and resistance to physical restraint. The accounts were exaggerated in their cinematic details but had a real toxicologic basis. The combination of profound dissociation, analgesia, motor disinhibition, and adrenergic surge can produce behavior in which a user breaks bones, dislocates joints, or sustains serious injury without subjectively perceiving it, and can produce muscular performance unconstrained by the normal sensory feedback that limits exertion. Cases of self-injury, of fractures discovered in custody after a phencyclidine-intoxicated arrestee was restrained, and of post-arrest [[Rhabdomyolysis]] are documented in the toxicology literature of the period.<ref name="mccarron-1981">McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. ''Annals of Emergency Medicine'' 1981;10(5):237-242.{{citation needed}}</ref> The mythology layered on top of these real phenomena was substantially overstated; the underlying pharmacology was not invented.

=== Scientific exploitation begins, 1979-1994 ===

In parallel with the recreational epidemic, basic researchers were using phencyclidine to dissect a question that conventional pharmacology had not been able to answer: which receptor system, when disrupted, produces something that looks like [[Schizophrenia]]? The dominant model in the 1970s was the dopamine hypothesis, based on the neuroleptic activity of D2 antagonists and the psychotogenic activity of [[Amphetamine]] and other [[:Category:Psychostimulants|psychostimulants]]. The psychostimulant model reproduced positive symptoms (delusions, hallucinations, paranoia) but failed to reproduce negative symptoms (affective flattening, alogia, avolition) or the cognitive deficits.

Nick Anis, Susan Berry, Nigel Burton and David Lodge at the University of Bristol showed in 1983 that phencyclidine and ketamine selectively reduce excitation of central neurones by N-methyl-D-aspartate, identifying for the first time that the molecular target of dissociative anesthesia is the NMDA glutamate receptor.<ref name="anis-1983" /> Daniel Javitt and Stephen Zukin at the Albert Einstein College of Medicine consolidated the clinical implications in their 1991 review, articulating the '''NMDA hypofunction hypothesis of schizophrenia''': that phencyclidine reproduces the full symptom complex of schizophrenia (positive, negative, AND cognitive) better than any other pharmacologic model precisely because it blocks NMDA-mediated glutamate signaling, and that endogenous NMDA hypofunction may underlie the disorder.<ref name="javitt-zukin-1991" /> John Krystal and colleagues at Yale tested this directly in 1994 by administering subanesthetic ketamine to healthy volunteers, who developed transient positive-symptom-like perceptual disturbances and (importantly) the cognitive and negative-symptom-like features that the psychostimulant model could not produce.<ref name="krystal-1994" />

This work redirected schizophrenia neuroscience for the next generation and made phencyclidine, even after its medical withdrawal and its descent into the street, one of the most scientifically productive molecules of the late twentieth century.

== Pharmacology ==

=== Receptor activity ===

Phencyclidine's principal action is non-competitive open-channel block of the [[NMDA receptor]]. The NMDA receptor is a glutamate-gated cation channel essential for excitatory synaptic transmission, synaptic plasticity, and learning. Phencyclidine binds at a site deep within the channel pore (the '''PCP site''') that is sterically accessible only when the channel has been opened by glutamate binding and membrane depolarization; this gives the block its '''use-dependence''', meaning that more-active synapses experience disproportionately greater inhibition.<ref name="anis-1983" /> The PCP site is shared by [[Ketamine]], [[Dextromethorphan]], [[Memantine]], [[Methoxetamine]], and the experimental tool compound MK-801 (dizocilpine), although the binding affinities and the kinetics of unblock vary widely across the class and account for much of the difference in their clinical profiles.

Secondary activity contributes to the distinctive phencyclidine clinical syndrome:

* '''Sigma-1 receptor''' agonism, shared in part with dextromethorphan and methoxetamine. The sigma-1 receptor is a chaperone protein at the endoplasmic reticulum-mitochondria interface; its role in psychotomimetic effects is incompletely characterized but plausibly contributes to the prolonged psychosis that phencyclidine produces and ketamine generally does not.{{citation needed}}
* '''Dopamine transporter''' inhibition, weak. Contributes modestly to the adrenergic and reinforcing dimensions of the experience.
* '''Nicotinic acetylcholine receptor''' antagonism. May contribute to autonomic disturbance.

The two pharmacologic features that most distinguish phencyclidine from ketamine clinically are (a) substantially longer NMDA-receptor unblock kinetics, producing a longer duration of action, and (b) the sigma-1 component, contributing to a more sustained and less medically tolerable post-acute psychiatric tail.

=== Pharmacokinetics ===

Phencyclidine is a highly lipophilic weak base (pKa ~8.5). It is rapidly absorbed by all routes, with smoked bioavailability ~85% and oral bioavailability ~72%.<ref name="cook-1982" /> Distribution is wide, with substantial deposition into adipose tissue and into the brain (brain concentrations several-fold higher than plasma). The volume of distribution is correspondingly large (~6 L/kg).

The elimination half-life is highly variable (reported range 7-46 hours, mean ~21 h) and prolonged compared with ketamine. The lipophilic deposition behaves as a slow-release reservoir, and re-release from fat is one mechanism for the prolonged and sometimes biphasic clinical course that phencyclidine produces. Metabolism is hepatic, predominantly by [[CYP3A4]] and [[CYP2B6]], producing inactive hydroxylated metabolites that are renally excreted. The parent compound is the principal active species; urinary acidification accelerates renal elimination of the parent (because more of the weak-base parent is ion-trapped in acidic urine), although this is no longer recommended in management because of the [[Rhabdomyolysis]] risk that acidic urine compounds.

== Acute effects and clinical presentation ==

Phencyclidine intoxication produces a syndrome that is recognizable once seen but that mimics, at different points along its dose-response curve, several other emergency-medicine presentations. The full syndrome includes:

* '''Dissociation''': a sense of being separated from one's body, from the environment, or from the experience of meaning. At low doses, dreamy and disinhibited; at higher doses, the dissociation becomes complete and the user is unresponsive to environmental cues.
* '''Anesthesia and analgesia''': profound. Self-injury without subjective pain is the toxicologic basis of the "superhuman strength" mythology.
* '''Vertical nystagmus''': the most clinically distinctive sign. Phencyclidine produces nystagmus in all three planes (vertical, horizontal, rotary), but vertical nystagmus in particular narrows the differential strongly toward dissociative intoxication.
* '''Adrenergic surge''': tachycardia, hypertension, mydriasis, diaphoresis.
* '''Motor disturbance''': ataxia at low doses; muscle rigidity, catatonia, and dystonic posturing at higher doses; opisthotonic posturing and seizures at toxic doses.
* '''Hyperthermia''': frequently overlooked, sometimes fatal; the agitated, hypermetabolic, often-restrained patient can reach core temperatures of 41-42 C.
* '''Hyperreflexia and hyperacusis''': useful in distinguishing phencyclidine from anticholinergic delirium (in which reflexes are normal or depressed) and from sympathomimetic intoxication (in which dissociation is absent).

The clinical course is typically 4 to 8 hours for acute behavioral effects, with a recovery period of 24 to 48 hours during which cognitive, perceptual, and affective abnormalities can wax and wane unpredictably as phencyclidine re-releases from adipose stores.

== Toxicology and emergency management ==

The acute toxicology of phencyclidine intoxication centers on five complications, each potentially fatal:

# '''Hypertensive emergency''' with end-organ damage (intracranial hemorrhage, aortic dissection).
# '''Hyperthermia''' progressing to rhabdomyolysis and acute kidney injury.
# '''Rhabdomyolysis''' from sustained muscular hyperactivity, often compounded by physical restraint and by acidic environments (urine acidification, lactic acidosis from prolonged seizure or exertion).
# '''Seizures''', from focal twitching at intermediate doses to status epilepticus at toxic doses.
# '''Traumatic injury''' sustained while dissociated and analgesic, frequently undetected until imaging in the ED.

Management is supportive and follows several principles:<ref name="mccarron-1981" />

* '''Quiet, dim, low-stimulation environment''' wherever feasible. External stimulation worsens agitation and worsens hyperthermia.
* '''Benzodiazepines''' as first-line for agitation, seizure, hypertension, and hyperthermia. Lorazepam or diazepam IV, titrated to effect; very high cumulative doses may be required.
* '''[[:Category:Neuroleptics|Neuroleptics]] are generally avoided''' in acute phencyclidine intoxication. They lower seizure threshold, worsen hyperthermia by impairing thermoregulation, do not address the underlying NMDA-mediated state, and have not demonstrated benefit over benzodiazepines.
* '''Aggressive IV hydration''' to maintain urine output and protect renal function in the setting of rhabdomyolysis.
* '''Active cooling''' for hyperthermia.
* '''Urinary acidification is no longer recommended'''. Once routine, it was abandoned because the acceleration of renal phencyclidine elimination is small relative to the worsening of rhabdomyolysis-induced renal injury.
* '''Differential diagnosis''' must include sympathomimetic intoxication ([[Methamphetamine]], [[Cocaine]], [[Cathinone|synthetic cathinones]]), anticholinergic delirium, [[Serotonin syndrome]], [[Neuroleptic malignant syndrome]], and acute primary psychosis. Vertical nystagmus, dissociation, and hyperreflexia together favor phencyclidine.

== Psychiatric effects and the NMDA model of schizophrenia ==

Phencyclidine reliably produces psychosis. Three patterns are distinguished clinically:

* '''Acute phencyclidine psychosis''': during and shortly after acute intoxication, lasting hours. Hallucinations, delusions, severe disturbance of self-experience. Resolves with the acute pharmacologic effect.
* '''Prolonged phencyclidine psychosis''': persistent psychosis for days to several weeks following a single intoxication episode. Sometimes responsive to neuroleptics; often runs its course regardless. Whether it represents a pharmacologic tail (lipophilic re-release) or an unmasking of latent vulnerability is debated.
* '''Chronic phencyclidine-associated schizophreniform disorder''': among heavy chronic users, a syndrome closely indistinguishable from chronic schizophrenia that may persist even after sustained abstinence.

This clinical phenomenology is the empirical basis of the '''NMDA hypofunction model of schizophrenia''', the alternative to the dopamine model that has dominated schizophrenia neuroscience since the 1990s.<ref name="javitt-zukin-1991" /><ref name="krystal-1994" /> The NMDA model accounts for features the dopamine model cannot: the negative symptoms (affective flattening, alogia, social withdrawal), the cognitive deficits (working memory, executive function), and the resistance of these features to D2-antagonist treatment. It also generates testable therapeutic predictions, several of which (glycine-site agonists, mGluR2/3 agonists, glycine transporter inhibitors) have been pursued through clinical development with mixed results.

The same receptor pharmacology underlies [[Ketamine]]'s breakthrough as a rapid-acting antidepressant.<ref name="berman-2000">Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. ''Biological Psychiatry'' 2000;47(4):351-354.{{citation needed}}</ref><ref name="zarate-2006">Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. ''Archives of General Psychiatry'' 2006;63(8):856-864.{{citation needed}}</ref> The 2022 FDA approval of dextromethorphan-bupropion ([[Auvelity]]), an NMDA antagonist combined with a CYP2D6 inhibitor to extend its half-life, is a direct clinical descendant of the line of research that began when Greifenstein and Domino first noticed that something strange was happening to Sernyl patients in the recovery room.

== Recreational use and street forms ==

Phencyclidine has moved through several distinct recreational eras, each shaped by formulation and route:

* '''Tablet era (1967-early 1970s)''': the original "PeaCePill" in San Francisco. Oral phencyclidine produces a slower, more dose-uncertain experience that users generally rated as unpleasant. The tablet form did not establish a sustained market.
* '''Dipped-cigarette era (mid-1970s to 1980s)''': liquid phencyclidine, often dissolved in ether, formaldehyde, or other solvents, applied to a cigarette or cannabis joint and smoked. Names: '''wet''', '''fry''', '''sherm''' (after Sherman brand cigarettes used as the substrate), '''dipper'''. Pharmacokinetically more controllable than oral dosing; the smoked route allows the user to titrate dose by puff. This was the formulation that drove the urban epidemic and the rescheduling.
* '''Powder era (overlapping)''': '''angel dust''' as a white-to-off-white powder, sometimes snorted, sometimes added to cannabis, sometimes sold as something else (mescaline, THC, or LSD analogs, all of which it is not pharmacologically resemble).
* '''Embalming-fluid confusion''': some street samples genuinely contained formaldehyde as a solvent for phencyclidine; other samples sold as "embalming fluid" or "wet" were formaldehyde or PCP-free dipping solutions with no phencyclidine content. Users could not reliably know which they were getting; clinicians presented with intoxicated patients could not reliably know either.<ref name="holland-1998" />

Current US recreational phencyclidine use is at low ebb relative to its 1980s peak. The dissociative scene has shifted toward [[Ketamine]] (medical diversion and clandestine synthesis), toward the structural analogs '''3-MeO-PCP''' and '''4-MeO-PCP''' in the research-chemical market, and historically toward '''[[Methoxetamine]]''' (MXE), which was widely available 2010-2013 before being scheduled in most jurisdictions.

== Analogs and the modern dissociative scene ==

The arylcyclohexylamine scaffold is generative. Several phencyclidine analogs have appeared as research chemicals since 2008, including:

* '''3-MeO-PCP''' (3-methoxyphencyclidine): longer-acting and reportedly more selectively psychotomimetic than the parent. Scheduled in many jurisdictions.
* '''4-MeO-PCP''' (4-methoxyphencyclidine): less potent and shorter-acting; sometimes available where 3-MeO-PCP is scheduled.
* '''PCEEA, PCMEA, PCMPA''': minor variations on the piperidine substituent.
* '''[[Methoxetamine]]''' (MXE): a ketamine analog with longer duration and a more pronounced psychotomimetic profile, sometimes described as bridging the ketamine-phencyclidine gap. scheduled in the UK in 2012 under a temporary class order; scheduled internationally.
* '''Deschloroketamine''', '''2-FDCK''', and other ketamine analogs occupy adjacent space in the modern dissociative market.

The pharmacology of these analogs is incompletely characterized and routinely mischaracterized in the marketplace; pre-purchase claims about potency, duration, and toxicity often diverge from what users report in case reports and forum experience.

== Scientific and clinical legacy ==

Phencyclidine is the rare withdrawn medicine whose post-withdrawal scientific value substantially exceeded its therapeutic value. The lines of work it opened:

* Identification of the NMDA receptor as a discrete pharmacologic target, and discovery of the PCP site as a probe of receptor activation state.<ref name="anis-1983" />
* The [[Glutamate hypothesis of schizophrenia|glutamate hypothesis]] and the NMDA hypofunction model.<ref name="javitt-zukin-1991" /><ref name="krystal-1994" />
* The [[Ketamine]] antidepressant program, beginning in 2000 with Robert Berman and colleagues at Yale and culminating in the 2019 approval of esketamine ([[Esketamine|Spravato]]) for treatment-resistant depression.<ref name="berman-2000" /><ref name="zarate-2006" />
* The [[Auvelity|dextromethorphan-bupropion]] approval (2022) for major depressive disorder, extending NMDA-targeted treatment beyond ketamine.
* A generation of glutamatergic schizophrenia therapeutic candidates (rapastinel, bitopertin, pomaglumetad), most of which failed in late-phase development, but which would not have been pursued at all without the phencyclidine-derived model.

== See also ==

* [[Ketamine]] - the structural analog that succeeded clinically where phencyclidine failed
* [[Methoxetamine]] - a research-chemical-era analog
* [[Dextromethorphan]] - clinically used NMDA antagonist with shared mechanism
* [[Memantine]] - NMDA antagonist with low-affinity, fast-off kinetics permitting therapeutic use in dementia
* [[Auvelity]] - dextromethorphan-bupropion, clinical descendant of the NMDA antidepressant program
* [[Esketamine]] (Spravato) - the FDA-approved enantiomer of ketamine for treatment-resistant depression
* [[NMDA receptor]] - the molecular target

== References ==
<references />

[[Category:Pharmaceutical]]
[[Category:Dissociatives]]
[[Category:Arylcyclohexylamines]]
[[Category:NMDA receptor antagonists]]
[[Category:Sigma-1 receptor agonists]]
[[Category:Anesthetics]]
[[Category:Schedule II controlled substances]]

Dextromethorphan

2026-05-26T17:24:07Z

MDElliottMD: home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean)

{{MedTemplate
| generic = Dextromethorphan
| brand = DXM
| structure =
| classes = Dissociative
| mechanism = NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor
| uses =
| starting_dose =
| preparations =
| fda_max =
| routes =
| onset =
| duration =
| halflife =
| bioavailability =
| pregnancy =
| legal =
| intro =
| pharmacokinetics =
| pharmacodynamics =
| indications =
| dosing =
<titration slug="erowid-dose-oral" author="erowid-claude"
title="Oral dose ladder (Erowid, HBr salt)">
Erowid's dosage documentation for oral dextromethorphan hydrobromide<ref
name="erowid-dxm-dose">Erowid. DXM Dosage. Erowid.org.
https://www.erowid.org/chemicals/dxm/dxm_dose.shtml.
Accessed 2026-05-26.</ref> reports the following tiers:

* '''Light:''' 100-200 mg
* '''Common:''' 200-400 mg
* '''Strong:''' 300-600 mg
* '''Heavy:''' 600-1,500 mg

Threshold not characterized. Duration 4 to 8 hours for standard HBr
formulations; 6 to 12 hours for extended-release polistirex
formulations. Erowid notes that doses are affected significantly by
body weight and recommends conservative starting amounts. A critical
harm note: many OTC formulations containing DXM also include
acetaminophen, chlorpheniramine maleate (CPM), guaifenesin, or other
active ingredients that become dangerous at the doses required for
psychoactive DXM effects; use of single-ingredient preparations is
essential for harm reduction.
</titration>
| effects =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring =
| counseling =
| anecdotes =
| seealso =
| references =
}}

[[Category:Psychedelics]]
[[Category:Dissociatives]]
[[Category:Morphinans]]
[[Category:Dissociative Anesthetics]]
[[Category:NMDA receptor antagonists]]

Methoxetamine

2026-05-26T17:24:06Z

MDElliottMD: home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean)

{{MedTemplate
| generic = Methoxetamine
| brand =
| structure =
| classes = Research material, Dissociative
| mechanism = NMDA antagonist; SERT inhibitor; sigma-1 agonist
| uses =
| starting_dose =
| preparations =
| fda_max =
| routes =
| onset =
| duration =
| halflife =
| bioavailability =
| pregnancy =
| legal =
| intro =
| pharmacokinetics =
| pharmacodynamics =
| indications =
| dosing =
<titration slug="erowid-dose-multi-route" author="erowid-claude"
title="Multi-route dose ladders (Erowid, very tentative)">
Erowid's dosage documentation for methoxetamine (MXE)<ref
name="erowid-mxe-dose">Erowid. Methoxetamine Dosage. Erowid.org.
https://www.erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml.
Accessed 2026-05-26.</ref> is marked "very tentative" throughout and
notes that "doses reported by different users vary by a large amount."

'''Insufflated:'''
* Threshold: 5-20 mg; Light: 10-50 mg; Common: 20-60 mg; Strong: 25-100+ mg

'''Oral:'''
* Threshold: 8-20 mg; Light: 10-30 mg; Common: 40-60 mg; Strong: 50-100+ mg

'''Sublingual/buccal:'''
* Threshold: 5-10 mg; Light: 8-25 mg; Common: 15-50 mg; Strong: 40-100+ mg

'''Intramuscular:'''
* Threshold: 3-8 mg; Light: 5-20 mg; Common: 15-30 mg; Strong: 20-80+ mg

Timing data are not provided by Erowid. The wide variability between
users (some report strong effects at 50 mg; others minimal at the
same dose) and Erowid's tentative qualifier should be reflected in
any presentation.
</titration>
| effects =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring =
| counseling =
| anecdotes =
| seealso =
| references =
}}

[[Category:Research chemicals]]
[[Category:Arylcyclohexylamines]]
[[Category:Dissociatives]]
[[Category:Dissociative Anesthetics]]
[[Category:NMDA receptor antagonists]]

Ketamine

2026-05-26T17:24:05Z

MDElliottMD: home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean)

{{MedTemplate
| generic = ketamine
| brand = ketalar
| structure = Ketamine.svg
| class = Dissociative, Anesthetic, Antidepressant
| mechanism = NMDA-receptor antagonism
| uses =
| formula =
| mass =
| cas =
| atc =
| routes =
| onset =
| duration =
| halflife =
| bioavailability =
| pregnancy =
| legal =
| intro =
| pharmacology =
| pharmacokinetics =
| indications =
| dosing =
<titration slug="erowid-dose-insufflated" author="erowid-claude"
title="Insufflated dose ladder (Erowid)">
Erowid's dosage documentation for insufflated ketamine<ref
name="erowid-ketamine-dose">Erowid. Ketamine Dosage. Erowid.org.
https://www.erowid.org/chemicals/ketamine/ketamine_dose.shtml.
Accessed 2026-05-26.</ref> reports the following tiers:

* '''Threshold:''' 10-15 mg
* '''Light:''' 15-30 mg
* '''Common:''' 30-75 mg
* '''Strong:''' 60-125 mg
* '''K-hole:''' 100-250 mg

Onset 5 to 15 minutes; duration 45 to 60 minutes with aftereffects
1 to 3 hours. The "K-hole" -- a state of profound dissociation and
anesthesia-adjacent experience -- is a recognized category in ketamine
harm-reduction literature, distinct from the "strong" tier in
character as well as magnitude.
</titration>

<titration slug="erowid-dose-oral" author="erowid-claude"
title="Oral dose ladder (Erowid)">
Oral tiers reported by Erowid:<ref name="erowid-ketamine-dose"/>

* '''Threshold:''' 40-50 mg
* '''Light:''' 50-100 mg
* '''Common:''' 75-300 mg
* '''Strong:''' 200-450 mg
* '''K-hole:''' 500+ mg

Onset 5 to 20 minutes depending on stomach contents; duration
approximately 90 minutes with aftereffects 4 to 8 hours. Oral doses
are substantially higher than insufflated for equivalent effect.
</titration>

<titration slug="erowid-dose-im" author="erowid-claude"
title="Intramuscular dose ladder (Erowid)">
IM tiers reported by Erowid:<ref name="erowid-ketamine-dose"/>

* '''Threshold:''' 10-15 mg
* '''Light:''' 15-30 mg
* '''Common:''' 25-50 mg
* '''Strong:''' 40-100 mg
* '''K-hole:''' 60-125 mg
* '''Anesthetic:''' 100-200 mg

Onset 1 to 5 minutes; duration 30 to 60 minutes with aftereffects
2 to 4 hours. Erowid also notes IV anesthetic dosing at 1-4.5 mg/kg
body weight.
</titration>
| effects =
| adverse =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring =
| counseling =
| anecdotes =
| seealso =
| references =
}}
[[Category:Arylcyclohexylamines]]
[[Category:Dissociative Anesthetics]]
[[Category:General (IV) Anesthetics]]
[[Category:Anesthetics]]
[[Category:NMDA receptor antagonists]]

Lavandula vera

2026-05-26T16:17:57Z

MDElliottMD: home-claude: redirect to Lavender

#REDIRECT [[Lavender]]

Lavandula officinalis

2026-05-26T16:17:57Z

MDElliottMD: home-claude: redirect to Lavender

#REDIRECT [[Lavender]]